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PREFACE 
In this thesis a number of pharmacokinetic investigations in man are 
described. The compounds that were administered are antipyretic and anti-
inflammatory analgesics. Within this widely used class of drugs it appeared 
possible to find a combination of practical and theoretical interest. 
For all drugs studied the pharmacokinetic results are discussed on basis 
of the separate processes that constitute the overall kinetic pattern. The 
thesis is divided into three main sections: 
— the first section contains a general introduction into the field as well as 
some methods that were used throughout the investigations 
— in the second section linear pharmacokinetics are discussed. For most 
of the drugs in this study the kinetic behaviour can be described 
adequately on basis of simple models. Attention is paid to the 
mechanisms by which the drugs are eliminated from the body. The 
renal clearance is discussed in some detail, although this quantitatively 
is of minor importance 
— the third section is devoted to non-linear pharmacokinetics. Methods 
are proposed to calculate the relevant parameters in case of capacity-
limited elimination. The significance of non-linear pharmacokinetic 
behaviour of drugs is discussed, also when these drugs are administered 
in a chronic dosage regimen, with special reference to salicylates. 
This thesis gives the answer to some questions, but much more questions 
arise from it. A lot of intriguing problems obtruded upon us during the 
investigations and one of the major results of our study is the fact that 
background information is supplied for a lot of forthcoming research. 
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GLOSSARY 
t time after administration of a drug (min or hr) 
D dose of drug administered (e.g. mg) 
F fraction of the administered dose, that reaches the general circula­
tion intact (biological availability) 
С concentration of drug (mg/1), usually in plasma; if the con­
centration in another compartment is referred to, this is indicated 
with an appropriate suffix 
Cpi plasma concentration at any time during a dosage interval in a 
plateau situation 
Cpi average plateau concentration in plasma 
V volume of distribution, assuming a one-compartment pharma­
cokinetic model; in case of more compartments a suffix denotes 
which compartment is referred to (e.g. 1) 
VA
a
 halflife of absorption, assuming a first-order absorption process 
(min or hr) 
r
a
 time constant of absorption, assuming a first-order absorption 
process (min or hr) 
t'/igi halflife of elimination, assuming a one-compartment model with 
first-order elimination (min or hr) 
7
el time constant of elimination, assuming a one-compartment model 
with first-order elimination. Sometimes т
е
\ is referred to as the 
mean turnover time (min or hr) 
τ a time constant corresponding with one or another phase in a 
pharmacokinetic model; a suffix refers to the phase in question 
(hr of min) 
к a rate constant (hr-1 or min"1 ); к = -
τ 
A a pre-exponential factor in pharmacokinetic equations; in one-
compartment models with oral administration 
л FD Tel 
v T
el-Ta 
and with i.v. administration A = т^  
10 
t 0 lag-time, representing the time after oral administration during 
which (practically) no absorption takes place 
Veci total body clearance function (l/hr or ml/min) including linear as 
well as non-linear elimination pathways 
код the total body clearance constant when only linear mechanisms 
of elimination prevail (l/hr or ml/min) 
kç m metabolic clearance constant; that part of код that occurs by 
one of more metabolic pathways (l/hr or ml/min) 
kQT renal clearance constant, that part of код that occurs by renal 
excretion (l/hr or ml/min) 
kca 'clearance constant' of absorption (l/hr of ml/min) 
j ^ rate of disappearance of the drug (e.g. mg/hr) 
f¡ blood flow through the intestine (l/hr or ml/min) 
fj blood flow through the liver (l/hr of ml/min) 
Код (apparent) Michaelis-Menten constant of an enzymatic mecha­
nism of drug elimination (mg/1) (dissociation constant) 
Kj (apparent) Michaelis-Menten constant for a tubular secretion 
process, fully analogous to Код 
Kj (apparent) Michaelis-Menten constant for an inhibitor of drug 
elimination 
Q
m
 metabolic capacity of an enzyme system (e.g. mg/hr), analogous 
to Vjnax when only one enzyme (homogeneously distributed) is 
involved 
TM the transport maximum of a tubular secretion mechanism, having 
the same meaning for the secretory process as Q
m
 has for a 
metabolic pathway 
f the fraction of the total body clearance that occurs via a poten­
tially saturable pathway 
AUC area under the plasma curve, when plasma concentration data are 
plotted on a linear scale 
At dosage interval, when a drug is administered repeatedly (hr or 
min) 
pK
a
 — log Kg, where Kg is the acid dissociation constant 
TPC true partition coefficient; the partition coefficient of the union­
ized species between an organic solvent and aqueous medium 
APC apparent partition coefficient (pH-dependent) 
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SECTION I 
INTRODUCTION 

CHAPTER 1 GENERAL INTRODUCTION 
ANTIPYRETIC AND ANTIINFLAMMATORY ANALGESICS 
All substances belonging to this class of drugs are synthetic compounds, 
derived from the prototypes salicylic acid, phenazone and acetanilide. These 
prototypes were made in the 19th century, in the search for effective 
substitutes for quinine. Antipyretic action was the first effect aimed at, but 
all compounds appeared to have some analgesic effect, which made them 
useful for the treatment of less severe types of pain. They are not suffi-
ciently active for the treatment of severe pain, so that as a rule they 
cannot replace narcotic analgesics. One might divide the drugs under con-
sideration in two main groups: 
minor analgesics for general use (e.g. paracetamol, phenacetin, glafenine 
and to some extent acetylsalicylic acid) and 
minor analgesics with pronounced antiinflammatory effect (but very low 
analgesic effect when no inflammatory condition prevails, e.g. most sali-
cylates, arylacetic acid derivatives). 
Some of the general analgesics are available without prescription and it 
needs not to be said that these should meet strong requirements concern-
ing their safety. Apart from the nature of the active substance also the 
pharmaceutical formulation may be of extreme importance in the respect 
(see for instance acetylsalicylic acid, chapter 16). 
The newer developments, during the last two decades, are especially in 
the field of the drugs with more specific antiinflammatory action. A lot of 
arylacetic acid derivatives have been synthesized and tested. Some of these 
are discussed in chapters 5—9. In another context we reviewed the prac-
tical aspects of therapy with antipyretic and antiinflammatory analgesics 
as well as some current hypotheses concerning their mechanisms of action 
(van Ginneken, 1975; van Ginneken and van Rossum, 1975). The main 
mechanisms by which these drugs are supposed to exert their pharmaco-
logical effect are briefly indicated in the following paragraph. 
ANALGESIC, ANTIINFLAMMATORY AND ANTIPYRETIC EFFECT 
Contrary to the narcotic analgesics, which have an effect directly on the 
central nervous system thereby altering the appreciation and the evalua-
tion of the pain stimulus, the non-narcotic analgesics appear to have a 
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peripheral site of action (Lim et al., 1964). Apparently they are com-
petitive antagonists of bradykinin (and possibly other plasma-kinins) 
which is a potent stimulant of pain chemoreccptors. Bradykinin seems to 
be responsible for the pain stimulus experienced in several conditions (also 
in the acute inflammatory reaction) but has a variety of other effects as 
well and appears to be a major mediator of acute inflammation (Rocha e 
Silva and Lerne, 1972; Rocha e Silva, 1973; Rocha e Silva, 1974; Maling et 
al., 1974). The apparent relationship between the analgesic and anti-
inflammatory effect became still more significant by the discovery that 
several prostaglandins, known as mediators of inflammatory reactions, had 
a sensitizing effect on pain receptors, even in concentrations at which 
these prostaglandins have no pain producing activity themselves (Ferreira, 
1972). The minor analgesics are inhibitors of the prostaglandin synthesis 
and it is especially this effect that seems to be essential for the production 
of analgesia (Ferreira et al., 1973; Moneada et al., 1975). Several other 
aspects of inflammatory disorders are mediated or potentiated by prosta-
glandins as well and the inhibition of prostaglandin synthetase by non-
steroid antiinflammatory drugs is very well documented and correlates 
reasonably with the antiinflammatory potency of the drugs (Ferreira et al., 
1971; Vane, 1971; Flower et al., 1972; Vane, 1972; Vane, 1973; Greaves 
and McDonald-Gibson, 1973; Williams and Morley, 1973; Moneada et al., 
1973; Flower, 1974; Flower and Vane, 1974; Newcombe et al., 1974; 
Debyetal., 1975). 
Evidence has been reported that also the antipyretic activity of the 
drugs, which probably occurs at a central site of action, is explained by 
inhibition of the prostaglandin synthesis (Flower and Vane, 1972). Several 
other mechanisms have been proposed as determinants for antiinflamma-
tory activity (see for instance a short review by Paulus and Whitehouse, 
1973). Antiinflammatory drugs have been reported to stabilize the 
membrane of lysosomes, thereby preventing or diminishing the release of 
lysosomal enzymes from several types of leucocytes, which are involved in 
inflammation. Although this matter has been extensively studied during 
the last years, it seems that no unambiguous statement can be made up to 
now, in view of many conflicting data (Paulus and Whitehouse, 1973; de 
Duvc et al., 1974). However, since several lysosomal enzymes are inhibited 
also directly by antiinflammatory agents, it seems likely that a decrease of 
the destructive activity of these enzymes is involved in the mechanism of 
action (e.g. Ignarro, 1972; Saeed and Warren, 1973; Douwcs, 1974; 
Wojtecka-Lukasik and Dancewitz, 1974; Ringrosc et al., 1975; Nakanishi 
and Goto, 1975). Finally, it should be mentioned that inflammation may 
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be regarded as an immunologically related reaction and that all known 
mediators can be incorporated m a unifying concept for inflammation on 
basis of immunological mechanisms (Willoughby and Di Rosa, 1971, 
Zvaifler, 1973, Vogt, 1974, Dannenberg, 1975). 
As a matter of fact several immunological events appear to be influenced 
directly by antunflammatory drugs (see references cited above and Brown 
and Mackey, 1968, Di Rosa et al., 1972, Opelz and Terasaki, 1973, 
Aisenberg, 1974, Whaley et al., 1975, Crout et al., 1975). 
BASIC STEPS IN DRUG ACTION 
In general drugs may exert their pharmacological action in two different 
ways. First of all some drugs have an effect by virtue of their overall 
physicocherracal characteristics (e g osmotic diuretics, antacids). Usually 
these are only effective in rather high concentration, since they need to 
bring about changes in the organism by just being present. The situation is 
totally different with the large majority of drugs, that give a specific effect 
originating from the interaction between the drug and some part of the 
organism for which it has a special affinity. The receptive substance 
(receptor) can only seldom be adequately defined but has been recognized 
long ago and provided a useful working hypothesis for molecular pharma-
cology (see e g. Anens, 1964). Drug-receptor interactions can fruitfully be 
described by the law of mass action Many pharmacologists have directed 
their attention to the processes occurring between the administration of a 
drug and the observation of its pharmacological effect Most of the ex-
perimental work has been done on isolated organ preparations of vanous 
origin. The reason for this restriction is obvious in view of the long, largely 
obscure way from administration of a drug to an intact organism to the 
ultimately observed effect After drug administration one first has to con-
sider the processes of absorption, distribution and elimination of the drug 
and the factors that may modify these processes Part of the drug reaches 
the biophase or receptor compartment where actual interaction between 
drug and receptor takes place. Only a small fraction of the administered 
dose will participate in this interaction, while the rest does not react but 
merely establishes the concentration gradients needed for the achievement 
of a high enough concentration in the biophase for the effect aimed at. 
Clearly a much lower dose would suffice if it were administered in or near 
to the receptor compartment. The least known steps in drug action are 
those between drug-receptor interaction and effect the stimulus-effect 
relationship Real progress in the analysis of these steps can only be made 
17 
after integration of pharmacological, physiological and biochemical con-
cepts and data. In an Utopian situation pharmacology would be able to 
predict for a certain dose of a certain drug not only the nature and the 
intensity of its effect, but also how fast and how long it would act. 
Unfortunately we are still far removed from this ideal and therefore the 
whole area has been divided into the separate study of the basis steps of 
drug action by the various subdisciplines (pharmacokinetics, biochemical 
pharmacology, molecular pharmacology, neuropharmacology etc.). Never-
theless some general remarks can be made on basis of our current 
knowledge. There is a lot of evidence available that the actual drug-
receptor interaction takes place in seconds or less (for a discusssion on this 
matter see van Ginneken, 1976). This means that the process of drug-
receptor interaction is very fast as compared with the pharmacokinetic 
processes of absorption, distribution and elimination, which usually have 
time scales of hours or at least minutes. Furthermore pharmacokinetics is 
highly significant in that the concentration of the drug in the biophase is 
somehow related to the plasma concentration, even though the relation-
ship may be very complicated, especially by factors such as specific reten-
tion of drug in target tissue, pH differences between plasma and biophase, 
protein binding etc. In any case the drug-receptor interaction is expected 
to be a reflection of the pharmacokinetics of the drug rather than deter-
mined primarily by its reaction rate constants. There may be some excep-
tions, for instance some steroid hormones with very low dissociation rate 
constants of the drug-receptor complex, leading to specific retention of 
the active complex. However, when the plasma concentration can be 
followed long enough, also such a retention phenomenon will be reflected 
in the plasma curve as a final phase with a long halflife. On basis of these 
considerations one might expect the time course of the pharmacological 
effect of a drug to be conformable to that of its plasma level. Whereas the 
plasma concentration usually is a logarithmic function of time, the effect 
might be rather a linear function of time, since typical dose-response 
curves show a logarithmic dependence of effect on concentration over 
substantial dose ranges (see e.g. van Rossum and van Koppen, 1969). It 
should be noted that this simple relationship can only be found as long as 
the effectuation of the drug-receptor complex is fast with respect to the 
pharmacokinetic events, and as long as the effect is not irreversible or only 
slowly reversible. 
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THE PRESENT INVESTIGATIONS 
In recent years a lot of investigations have been devoted to the mechanism 
of action of antiinflammatory analgesics (as indicated above). Very little is 
known, however, concerning the time course of the effects. As a matter of 
fact the analgesic activity is often difficult to evaluate quantitatively since 
relief of pain by these rather weak drugs is determined to a large degree by 
subjective, individual factors which mask more objective parameters. 
Nevertheless it seems that for several of the drugs a simple relationship 
between analgesia produced and plasma levels exists. Examples of this will 
be discussed in some of the following chapters. This implies that pharma-
cokinetic data are valuable for establishing dosage regimens which may 
provide effective plasma levels for periods as long as desired. In acute 
situations relief of pain should be obtained as soon as possible. Therefore 
also the pharmaceutical formulation of an analgesic can be very important 
since it determines the rate of absorption of the specific drug. The relev-
ance of pharmacokinetic studies with regard to those aspects of analgesic 
therapy is obvious. As far as antiinflammatory action is concerned matters 
may be more complicated in view of the multiplicity of mechanisms in-
volved. Competitive interactions may be supposed to fade away when the 
drug is disappearing, but more complex interactions are prevailing in anti-
inflammatory action. For instance, inhibition of a normally occurring 
process, like the prostaglandin-synthesis, may have a prolonged effect 
depending upon the turnover-time of the system. Further there may be a 
complex relationship between the concentration of drug in plasma and at 
the site of action. Part of the antiinflammatory activity will be located 
primarily in leucocytes (stabilization of lysosomal membranes, enzyme 
inhibition, inhibition of lymphocyte transformation). Therefore the con-
centration of the drugs in the leucocytes will be extremely important and 
this may be much higher and much more slowly decreasing than the con-
centration in plasma. Such a phenomenon has been described for colchicine 
(Wallace and Ertel, 1970) and there is much evidence that several drugs 
with a carboxylic acid function are selectively taken up by leucocytes 
(Loh and Wilson, 1970, 1971, 1975). At the moment we are planning 
investigations into the possibility of uptake mechanisms in leucocytes with 
high affinity for non-steroid antiinflammatory acids. When a compartment 
with a prolonged retention of the drugs under consideration exists indeed, 
this implies that the time course of the effect maybe different from the 
time cours of the plasma curve. In principle, such a compartment will be 
reflected in the plasma curve, but it is doubtful whether it can be detected 
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in view of the relatively small amounts of drug involved. As a rule therapy 
with antiinflammatories is guided by clinical symptoms. Several drugs that 
will be described in the following chapters exhibit highly fluctuating 
plasma levels in usual dosage regimens. It is a question if these regimens are 
optimal. One possibility is that the levels at the various sites of action are 
more constant by retention phenomena as discussed above. Another 
possibility is that the effect as such reaches a steady level (despite the 
variable plasma concentration) by long turnover-times of the systems that 
are influenced. In any case detailed study of the profile of the plasma 
curve is a first step to the interpretation and evaluation of dosage regimens. 
With the aid of this information it is possible to adapt regimens for obtain-
ing higher or lower blood levels and to influence the rate at which such 
levels are approached. Furthermore the pharmacokinetic parameters can 
contribute to the establishment of dosage regimens that provide blood 
levels, that are at any time lower than the toxic and higher than the 
subtherapeutic levels. This is extremely important for instance for sali-
cylates, where the therapeutic concentration is close to the toxic range. 
Understanding of the mechanisms of the clearance process makes it 
possible to find out effective measures for treatment of intoxication and 
also to adjust dosage regimens in case of liver or kidney disturbances (if 
necessary). The investigations described in this thesis were planned on 
basis of these general considerations. They have been undertaken from a 
fundamental pharmacokinetic point of view, but whenever it is relevant, 
attention is paid to the practical consequences of the findings. 
The main point of the present thesis is the interpretation of the pharma-
cokinetic results in terms of the basic processes that determine the kinetic 
behaviour of drugs in the body. Special attention is paid to the deviations 
from normal pharmacokinetic models, such as occur for instance with 
salicylate. 
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CHAPTER 2 GENERAL MATERIALS AND METHODS 
The pharmacokinetic analyses described in this thesis are based on measure-
ment of the concentrations of the various drugs in plasma and urine of 
human volunteers. In this chapter the general procedures are outlined. 
Details on the way of administration of the drugs and the subjects involved 
are given in each chapter separately. The subjects were unrestricted as to 
movement or position. Smoking and water consumption were permitted 
during the whole course of the trials. 
MATERIALS 
Ibuprofen, ibufenac as wel as 4-n-butylphenylacetic acid were kindly 
supplied by Boots Pure Drug Company, Nottingham, England; alclofenac 
by Continental Pharma, Brussels, Belgium; flufenamic acid and mefenamic 
acid by Parke-Davis, Bornem, Belgium; 4-isopropylaminophenazone by Byk 
Nederland, Zwanenburg, The Netherlands and 4-methylaminophenazone 
by Hoechst, Frankfurt, GFR. 
Phenazone, 4-isopropylphenazone, 4-dimethylaminophenazone, para-
cetamol, phenacetin and sodium salicylate were obtained from OPG, 
Utrecht, The Netherlands. 
All materials used for packing of gas chromatographic columns were 
obtained from Applied Science Lab., State College, Pa., USA. 
The silylating reagent BSTFA (N,0,bis(trimethylsilyl)trifluoroaceta-
mide) was obtained from Pierce, Rockford, Illinois, USA. 
Two different types of /3-glucuronidase were used (Suc d'Helix Pomatia, 
Industrie Biologique de France, Gennevilliers, France; and bovine liver 
glucuronidase, Sigma, St. Louis, Missouri, USA). 
All other reagents and solvents were of analytical-reagent grade (Merck, 
Darmstadt, GFR or Baker, Deventer, The Netherlands). 
SAMPUNG PROCEDURE 
At regular times after drug administration blood samples are taken from a 
fore arm vein (about 5 ml). The blood samples were centrifuged, plasma 
was stored in a deep freezer (-20oC) until assay and the erythrocytes were 
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mostly discarded. In some experiments also the erythrocytes were analys­
ed for their drug content, after they had been homogenized by ultrasoni-
fication. For a period of at least 30 hrs after drug intake samples were 
collected of every aliquot of urine voided. For that purpose the urine was 
voided in a calibrated cylinder (500 ml), the time and the total volume of 
the urine was registered, samples were poured into 50 ml bottles, and the 
rest was discarded. The accuracy of the volume measurement of course is 
dependent upon the total volume, but the relative error usually will be less 
than 5%. The pH of the urine was measured as soon as possible and the 
samples were stored in a refrigerator, when they could be analysed within 
a few days and otherwise in a deep freezer. 
GAS CHROMATOGRAPHIC ANALYSIS 
Extraction procedure 
For the gas chromatographic methods employed it is necessary to extract 
the drugs from the biological sample with the aid of a suitable organic 
solvent. In case of GC analysis always an internal standard (10—20 μg) was 
added before extraction. When the drug to be extracted was an acid the 
sample was acidified with 1-3 ml of 3NHC1, when it was a base the 
sample was alkalinized with 1 ml IN or 0,2 ml 5N NaOH. The general 
procedure was as follows: To the plasma (1 ml) or urine (0.2-5 ml, 
depending upon the concentration of the drug) in a 40 ml conical tube 
were added: 10-20 μξ of an internal standard (if possible in aqueous 
solution, otherwise in a small volume of ethanol) and the extraction 
solvent. Then the aqueous layer was acidified or alkalinized or buffered. 
After mechanical shaking for 20 minutes and centrifugation (if necessary) 
the organic solvent was transferred to another conical tube and evaporated 
to dryness with a gentle stream of dry filtered air. When no formation of 
derivatives was necessary the residu was dissolved in 25-100 μΐ of absolute 
ethanol, about 5 μ\ of which was injected into the gas Chromatograph. 
When the substance had to be derivatized for gas chromatography the 
residu was dissolved in freshly distilled ether and carefully transferred into 
a reacti-vial (Pierce). 
Formation of derivatives 
After slow evaporation of the ether from the reacti-vial, 20-25 μΐ BSTFA 
was added and the contents were thoroughly mixed on a whirlmixer. 
Trimethylsilylation appeared to be practically instantaneous and in any 
case complete within 1 hr. The silylated products remained stable for at 
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least two days, when stored in a dosed reacti-vial. In practice the deriv­
atives (3—5 μΐ) were injected into the gas Chromatograph after standing at 
room temperature for about 3 hrs. In two cases other derivatives than 
trimethylsilylated were made, viz. paracetamol and mefenamic acid. Para­
cetamol was acetylated with acetic anhydride according to the procedure 
described in detail by Prescott (1971). Mefenamic acid was mostly sily-
lated but in a few cases we prepared the methylester with the aid of 
trimethylanilinium hydroxide. Trimethylanilinium hydroxide was 
prepared according to the method of Brochmann-Hanssen and Оке (1969) 
and was used as a solution (0.1 M) in methanol. The methylation with 
trimethylanilinium hydroxide takes place after injection in the gas Chroma­
tograph in the flash-heater so there is no need for prior incubation. In 
practice about 1 μΐ of the methylating solution was taken up in a micro-
syringe together with 5 μΐ of the solution obtained by adding 20—50 μ\ 
methanol to the residu of the plasma or urine extraction. This mixture was 
directly injected into the gas Chromatograph. 
Gas chromatography 
A Hewlett-Packard, Model 402 gas Chromatograph equipped with flame 
ionization detector was used. The column (glass) with a length of 1.80 m 
and an internal diameter of 3 mm was packed with 3%OV—17 or 
3.8% UCW-98 on Gaschrom-Q 60-80 or 80-100 mesh. The gas chroma­
tographic conditions were: nitrogen (carrier gas) flow 20 ml/min, 
hydrogen flow 30 ml/min and air flow 150 ml/min. These values are in­
dicative; for every specific analysis they were optimalized. The temper­
ature of the oven was adjusted to obtain reasonably short retention times 
of the compounds eluting from the column, without losing sufficient 
separation of the peaks. The temperature of the oven was adjusted to 
obtain reasonably short retention times of the compounds eluting from 
the column, without losing sufficient separation of the peaks. The temper­
atures of the flash-heater and of the detector were taken about 50oC and 
60oC respectively above the temperature of the oven. The specificity of 
the analysis was checked by comparison with a lot of blanc urine or 
plasma samples. Only when in .the concentration range studied no inter­
ference with peaks originating from endogenous compounds was observed, 
the procedure was considered adequate. Calibration graphs were con­
structed by adding variable, known amounts of the drug under investiga­
tion together with 10-20μg of the appropriate internal standard to blanc 
plasma or blanc urine, treating these samples as described above and plot­
ting the peak area ratio of the drug and its internal standard in the result-
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TABLE 2.1 
Extraction and gas chromatographic conditions employed m the investigations 
Substance 
alclofenac 
benzoic acid 
ibufenac 
Ibuprofen 
mefenamic acid 
mefenarmc acid 
Phenazone 
4-isopropylphenazone 
4-aminophenazone 
4-methylaminophenazone 
4-dimethylaminophenazone 
4-isopropylammophenazone 
paracetamol 
phenacetin 
Extraction1 
A, toluene 
A*, ether 
A, hexane 
A, hexane 
A, CHCI, 
A, CHCI, 
B, CHCI j 
B, CHCI, 
B, CHCI, 
B, CHCI, 
B, CHCI, 
B, CHCI, 
Bu8*, CHCI, 
Bu8, ethylacetate 
Denv.' 
sil. 
su. 
SÚ 
SÚ. 
SÚ 
me. 
-
-
-
-
-
-
ас. 
-
GC* 
UCW 
OV 
ov 
OV 
ov 
SE 
OV 
ov 
ov 
ov 
ov 
ov 
ov 
ov 
98, 
17, 
17, 
17, 
17; 
30, 
17, 
17, 
17, 
17, 
17, 
17, 
17, 
17, 
170oC 
100° С 
160oC 
160°C 
200°C 
220oC 
180°C 
180° С 
180oC 
180oC 
180° С 
180° С 
180° С 
180°С 
Internal standard 
3,4 -diiïiethoxybenzoic acid 
4-methylbenzoic acid 
4-n-butylphenylacetic acid 
4-n-butylphenylacetic acid 
4-(N-benzylamino)-benzoic acid 
4-(N-benzylammo)-benzoic acid 
phenacetin 
phenuamme 
4-dimethylaminophenazone 
phenacetin 
phenacetin 
4-dimethylaminophenazone 
phenacetm 
Phenazone 
1. A = acidified, В = alkalinized, Bu8 = buffered (pH 8),an asterisk indicates that the aqueous phase was saturated with NaCl in order to 
enhance extraction efficiency. 
2. Derivatives tnmethylsilyl (sil.), methyl (me ) or acetyl (ac ). 
3. Gas chromatographic column (3% OV 17 or 3 8% UCW 98 or 2% SE 30 on Gaschrom. Q). Also the temperature of the oven is indicated. 
ing chromatogram against the amount of drug added. In most cases the 
ratio of the peak heights could be used instead of the ratio of the peak 
areas, since both the relative retention times and the ratio of the peak 
heights of drug and internal standard appeared to be constant over a wide 
range of chromatographic conditions. Therefore as a rule it was sufficient 
to measure peak height ratios instead of the more elaborate surface area 
determination. 
Table 2.1 shows the relevant details concerning preparation of the 
samples and gas chromatography of the drugs studied. 
DISCUSSION 
Extraction 
Several of the drugs studied are known to be strongly bound to plasma 
proteins, especially the arylacetic acid derivatives. Therefore, we had to 
determine whether the method described measures total plasma concentra-
tion, including the fraction that is protein bound or only free plasma 
concentration. Although the latter possibility could be excluded a priori, a 
possible influence of the presence of proteins in the extraction mixture 
was investigated by parallel extractions from purely aqueous medium, with 
the standard added before and after protein denaturation. No interference 
by plasma proteins was observed in the methods employed. The extraction 
from plasma was practically the same as from aqueous solution. As 
expected on basis of the high distribution coefficients (see chapter 3) 
extraction was essentially complete, the recovery being 95% or more. The 
same efficiency was found for urine extraction. The internal standards, 
that were used, were selected on basis of similarity of physicochemical 
character to the drug under investigation and on basis of their relative 
retention time in the gas Chromatograph with respect to the drug. A 
primary requirement was of course that it did not coincide with endogen-
ous compounds in the gas chromatogram; further a retention time not 
too far from that of the drug was required (in practice the difference of 
the retention times did not exceed a factor 2). Especially in case of acidic 
compounds that were derivatized for gas chromatography a lot of peaks 
originating from plasma or urine were observed. Care was taken to avoid 
interference. Sometimes this required long waiting periods to have all 
endogenous compounds eluted from the column. Alkaline extracts were 
much 'cleaner' in this respect. When derivatives had to be made for gas 
chromatography, we judged it essential that the standard was suited to the 
same derivatization procedure, in order to be a real internal standard. The 
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use of such internal standards has the enormous advantage that a lot of 
quantitative pipetting is made superfluous and that calibration is very easy. 
Formation of derivatives 
Although some special columns have been described in literature for the 
direct gas chromatography of carboxylic acids we were unable to obtain 
quantitative results with the drugs of our study on such columns. Very 
good results were obtained by silylation and subsequent gas chromato­
graphy. Several very efficient silylating reagents are available. 
In our study we used only BSTFA, since this combines powerful donor 
capacity with high volatility. Also its reaction products are very volatile, so 
that even at the lowest temperature at which the gas Chromatograph was 
operated (100°C) all waste products eluted from the column together with 
unreacted BSTFA. Further BSTFA (Hke several other trimethylsilyl-
donors) is an excellent solvent for a variety of organic compounds, 
especially after silylation. In our studies it appeared unnecessary to use 
any other solvent. With the exception of paracetamol (see below) no 
catalyst was used for silylation. The trimethylsilyl derivatives were formed 
practically instantaneously and were stable for several days, provided that 
the special reacti-vials (Pierce) were used. As a matter of fact in our 
experience the use of such vials was essential for the whole procedure since 
both BSTFA and the silylated compounds are sensitive to moisture. 
Special measures such as working under nitrogen were not taken, since this 
appeared to be unnecessary in view of the small volume of the reacti-vials 
and the large excess of silylating reagent used. Due care was taken to avoid 
contamination of the BSTFA, the quality of which was checked at regular 
times with the aid of standard solutions of drug and internal standard. 
The acetylation of paracetamol was performed with acetic anhydride 
(30 μΐ) and pyridine (15 μΐ) (Prescott, 1971). The mixture was kept at 
450C for 20 min after which the reaction was virtually complete. This 
procedure, however, yielded results that suffered sometimes from bad 
reproducibility. Relative errors as high as 30% were sometimes met in the 
determinations. Therefore, several parallel measurements were done to 
obtain a reliable estimate of the error involved in the individual concentra­
tion values. These errors were taken into account in the subsequent com-
puterfitting procedures. In our present investigations we obtain much 
better results with a silylation procedure modified after Prescott (1970) 
and Thomas and Coldwell (1972). This procedure, consisting of silylation 
with BSTFA and pyridine (as a catalyst) at 60oC for about 1 hr, yields 
very reproducible and accurate results. 
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Mefenamic acid in some experiments was present only in very low con­
centrations. In these cases it appeared impossible to obtain reliable data 
with the use of the normal silylation procedure and the flame ionization 
detector. Since a nitrogen detector made a more sensitive analysis method 
possible, we adapted the procedure for that purpose. Silylating reagents 
are not useful for working with a nitrogen detector because of the high 
risk of contamination of the detector and therefore we used methylderiva­
tives in those cases. Esterification of the carboxyl group was easily per­
formed with the aid of trimethylanilium hydroxide according to Broch-
mann-Hanssen and Оке (1969). 
Calibration graphs 
In all cases linear calibration graphs were obtained for amounts of drug up 
to 25 fig at least; for the acids up to 50 ¿ig. It need not be said that in any 
case the magnitude of the sample was adapted to the concentration range 
over which the calibration graph was constructed. Nearly always plasma 
samples of 1 ml could be used. Urine samples sometimes were much 
smaller (especially in case of alclofenac and 4-aminophenazone) and 
occasionally larger. The calibration graphs were calculated according to the 
least squares method. The standard deviation of the concentration 
measurements was calculated and appeared to be about 2% for the ary-
lacetic acids, with the exception of mefenamic acid (< 10%) and for the 
other compounds, except paracetamol (see above), 5% or less. As a rule 
the standard deviation increased when very low concentrations 
(< 2 Mg/ml) were measured, which was only seldom done, however. The 
limit of detection was always below 1 μg per sample. 
Alternative procedures 
In literature two alternative extraction and derivatization procedures for 
gas chromatographic determination of Ibuprofen have been described. One 
implies extraction by passing acidified plasma through a column of 
Amberlite XAD-2 resin and subsequent esterification with diazomethane 
(Mills et al., 1973). The other consists of extraction of acidified samples 
with benzene and methylation with Ι,Γ-carbonyldiimidazole and triethyl-
amine in methanol (Kaiser and Van Giessen, 1974). We prefer our method, 
which is derived from a procedure described by Nash et al. (1971), because 
of its safety, simplicity and ease of handling. 
Roncucci et al. (1971) published a method for gas chromatographic 
determination of alclofenac and its metabolites. They perform extraction 
with methyl isobutyl ketone, whereas we prefer toluene, which is more 
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volatile, so that it can be evaporated more easily. Further they employ a 
mixture of hexamethyldisilazane and trimethylchlorosilane in dioxane as a 
silylating reagent. In our experience BSTFA is very satisfactory and 
generally applicable for silylation of a variety of compounds. 
Extraction procedures for pyrazolone derivatives have been described by 
Brodie and Axelrod (1949, 1950), who also gave colorimetrie methods for 
quantitative determination in biological material. Gas chromatographic 
analyses of phenazone (e.g. Prescott et al., 1973) and 4-dimethylamino-
phenazone (e.g. Windorfer et al., 1973; Vesell et al., 1975) have been 
published. Our extraction and gas chromatographic analysis is similar to 
these and is generally applicable for a large variety of alkaline drugs. 
SPECTROPHOTOFLUOROMETRIC ANALYSIS 
For two compounds a sepectrophotofluorometric analysis was used. In 
fluorometry it is essential to ascertain the concentration range in which 
the sample to be analysed is lying, since the fluorescence is not unambig-
uous. As is well-known, at high concentration of the fluorescent compount 
the relative fluorescence yield diminishes by a quenching phenomenon, so 
that a calibration graph has the form of a bell-shaped curve. A certain 
fluorescence may correspond with a concentration above or below the top 
of the curve. Therefore, the samples were diluted if necessary to check the 
validity of the readings. The wave lengths of activation and emission were 
adjusted before every measurement and standard solutions for calibrating 
purposes were repeatedly examined during each period of measuring. For 
all measurements an Aminco Bowman spectrophotofluorometer was used. 
Salicylic acid 
The fluorometric determination of salicylate has been the subject of 
several papers (e.g. Saltzman, 1948; Chirigos and Udenfriend, 1959; Potter 
and Guy, 1964; Harris and Riegelman, 1967; Rowland and Riegelman, 
1967; Lever and Powell, 1973). The method we used is similar to the one 
described by Harris and Riegelman and by Rowland and Riegelman and 
involves the following steps: plasma or urine (usually 0.5-1 ml) is 
acidified with 0.5 ml IN H2SO4 after adding 10 ml ether (plasma) or 5 ml 
carbontetrachloride (urine), which have been saturared with water. The 
mixture is mechanically shaken for 20 min and then centrifuged. 1 ml of 
the ether layer (or 0.5 ml of the carbontetrachloride layer) is reextracted 
with 5 ml phosphate buffer of pH 7.1, by shaking for 20 min. After 
centrifugation the ether layer is aspirated and residual ether is removed by 
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blowing dry filtered air through the buffer solution. In case of extraction 
with carbontetrachloride the fluorescence of the buffer solution can be 
read directly after centrifugation (activation wave-length 308 nm, emission 
wave-length 412 nm). The procedure yields an average recovery of 97 
± 3%. linear calibration curves can be obtained over a concentration range 
up to about 100 mg/1 plasma or urine and even over much wider ranges by 
appropriate dilution of the samples. The method is very sensitive, but due 
to the presence of some fluorescent material in blanc samples accurate 
readings cannot be done at concentrations below 0.5 mg/1 plasma or urine. 
Flufenamic acid 
Our efforts to obtain a reliable gas chromatographic procedure for the 
assay of flufenamic acid in plasma and urine were unsuccesful because of 
interfering peaks from blanc plasma. Therefore, we used the fluorometric 
method of Hattori et al. (1970) with some minor modifications. This 
method is based on the finding that flufenamic acid gives a strongly 
fluorescent complex with aluminium chloride in ethanol. Briefly the 
following steps are involved. Extraction of flufenamic acid from the 
acidified sample is performed with 10 ml ethylacetate. After mechanical 
shaking for 20 min the mixture is centrifuged and 2 ml of the ethylacetate-
layer is slowly evaporated at 40oC by a gentle stream of dry, filtered air. 
The residu is reconstituted in 4 ml of absolute ethanol and then 0.1 ml of 
a solution of 0.5% aluminium chloride in absolute ethanol is added. The 
fluorescence of the resulting solution at a wave-length of 450 nm is read 
(activation wave-length 360 nm). The recovery of flufenamic acid in this 
procedure is essentially complete. The standard deviation of the determi­
nations is 1—5% (increasing with decreasing flufenamic acid concentra­
tion). Calibration curves are linear up to at least 10 μg of flufenamic acid 
added per ml plasma. The sensitivity is high, in alcoholic solution a concen­
tration of 0.01 mg/1 can easily be measured. The measurement of flufena­
mic acid in biological samples, however, is limited by the presence of blanc 
'flufenamic acid levels' of about 0.1 mg/1. 
OTHER GENERAL METHODS 
All other methods are given in the text whenever it is relevant, except for 
the tollowing: 
Glucuronidase treatment of urine samples. 
In several studies we determined not only the free drug excreted in 
urine, but also the amount excreted as glucuronide. For this purpose 
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5000—10.000 units of ß-glucuronidase were added per ml of adequately 
buffered urine (depending upon the pH optimum of the glucuronidase 
employed). In all cases splitting of the glucuronides was virtually complete 
after standing at room temperature for about 15hrs (overnight). The 
samples were analysed further as described above. By comparing the drug 
content after glucuronidase treatment with that measured directly, the 
amount of drug excreted as glucuronide was determined. 
ANALYSIS OF PLASMA CURVES. 
The plasma concentration data were fitted* by computer according to an 
open one-compartment model with oral administration. In this way 
optimal estimates for the various pharmacokinetic constants were 
obtained. Usually visual inspection of the fitted curve as compared to the 
experimental data convinced us of a very good adaptation to the model 
which assumes first-order absorption as well as first-order elimination. In 
other words the simple one-compartment model with first-order rates 
appeared to be highly acceptable for description of the experimental 
situation. However, in some instances, the computer program was not able 
to fit the data in an acceptable way to the linear one-compartment model. 
In these cases we suspect non-linear absorption to occur. Obviously then 
the curves cannot be described by a sum of two simple exponential terms. 
In such cases the computer, being unaware of the model mistakes, can 
make enormous errors also in the elimination phase, although that always 
appears to be first order, except of course in those cases where a better 
approximation (capacity-limited kinetics as for salicylic acid and 4-amino-
phenazone) is available. However, when absorption was not first order 
while elimination was, the time constant for elimination was determined 
by manual linear regression of the data from the logarithmic phase. The 
points in the absorption phase cannot easily be adapted to another model, 
since a general mathematical description of processes that cause deviations 
from first-order absorption is in most cases impossible. The main processes 
responsible are: 
1. rate limiting dissolution of the drug in the gastrointestinal tract. This 
can also apply to drugs given in solution since the acidic drugs we deal 
with can be expected to precipitate in the stomach contents. 
2. disturbances by the presence of food etc. in the gastrointestinal system. 
Obviously then the access of the drug to the absorbing mucosa can be 
* Non-linear regression program FARMFIT, in use at the Computer Centre of the 
University of Nijmegen. 
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hindered. 
3. rate limiting processes in the transport mechanisms through the absorb-
ing membranes. 
4. reversible absorption, which means that the membrane passage can go 
in two directions, so that pseudo steady-states can be achieved in the 
absorption phase. 
5. another point of interest is the occurrence of a so-called lagtime. This 
means that there may be a certain period after administration of the 
drug, during which no absorption takes place at all or during which the 
absorption is at least very much slower than first order. It is very 
common that before a process appears to follow first-order kinetics an 
induction period takes place during which possible pre-requirements 
can be fulfilled. For instance, in the case of gastrointestinal absorption 
one can imagine that first a concentration gradient towards the vascular 
system should be established before the rate becomes first order. 
In practice it would be difficult to discriminate between the various 
possibilities, especially since usually only a few data points are available in 
the absorption phase. Therefore, we decided not to try to characterize 
these deviations further. 
Only as far as the lagtime is concerned our standard mathematical 
analysis by the computer program Farmfit offers the opportunity to 
decide in an objective manner whether we get a significant improvement 
by allowing a lagtime to occur or not. In practice any curve is analysed by 
Farmfit in two ways: one with and one without a lagtime. When by 
introducing the lagtime a significant decrease in the chi-square value is 
achieved we assume that the parameters obtained this way are the best 
estimate, if there is no or a too small decrease in the chi-square value we 
can safely neglect the possibüity of a lagtime. In the tables of parameters 
we usually did not list lagtimes since there is no way in which they can be 
interpreted in a quantative manner. The general mathematical description 
of the plasma concentration С in a single compartment system with oral 
administration and first-order kinetics is given by the following equation: 
c = A[e-(t-t0)/re l_e-(t-t0)/,a] 
(cf chapter 4, eq. 4.16) 
where 
k FD
 r
el A = 77-
v
 '"el-'-a 
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The computer program Fannfit now gives the best fitting values for r
e
j r
a
, 
t 0 (if a lagtime is allowed to occur) and A, together with the errors in 
these parameten. When no lagtime is regarded it is obvious that the error 
in the intercept A will be in the same order of magnitude as the error in r
e
i. 
When, however, a lagtime is introduced also the uncertainty in this para­
meter will contribute to the error in A and usually this contribution is 
much larger because only a few data points are available in the absorption 
phase and because the absorption process not seldom deviates from first-
Order kinetics. Furthermore one can imagine that when the absorption 
phase is allowed to be characterized by two parameters (lagtime and the 
time constant for absorption т
а
) there appears a strong negative correlation 
between these two parameters if not enough data are available. This cor­
relation is of course of a purely mathematical nature: physiologically and 
pharmacokinetically lagtime and absorption time constant are fully 
independent parameters. However, it can increase the uncertainty in the 
parameters to a large extent. Moreover, in the computer program the 
parameters are regarded as normally distributed. This is obviously a wrong 
approximation. It is easy to see that both for the lagtime and for r
a
 the 
distribution of values to be expected is very asymmetric. In cases where 
the computer provides errors in the parameters which are unlikely large, 
we attributed this to the following factors: 
1. too few data in the absorption phase 
2. asymmetric distribution of expectation-values 
3. unallowed extrapolation: in the program the errors are determined by 
making small changes in the best fitting values and by extrapolation of 
the deviations obtained from optimal fit. 
4. mathematical correlation between estimated parameters: the un­
certainty in the parameters of course will increase when they show a 
strong correlation. This as a matter of fact is a common complication. 
Quite often the number of data is not very large with respect to the 
number of parameters to be fitted (for instance 10 : 4) and the curves 
exhibit too little characteristics (usually only an ascending and a 
descending limb on basis of two exponentials) to distinguish the para­
meters clearly enough. As a result of this a mathematical correlation 
may arise between the various parameters, not only between r
a
 and A, as 
we discussed in some detail, but also in the other combinations of 
parameters. 
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CHAPTER 3 DRUG PARTITIONING 
INTRODUCTION 
According to common theories in pharmacology the passage of drugs 
through membranes is restricted to the drug in its unionized form. 
Although there is no direct evidence for confirming this hypothesis, it 
appears a useful assumption in many experimental studies concerning 
passive diffusion of drugs through biological membranes. Of course, this 
assumption is unjustified when active, carrier-mediated transport processes 
are concerned and when the possibility of ion-pair formation has to be 
regarded. In pharmacokinetics the concept especially applies to the 
processes of drug absorption and renal drug excretion. Totally in line with 
the hypothesis are, for instance, the observations that renal excretion of 
amphetamines is diminished by high urinary pH (Vree, 1973) while that of 
acids (for instance salicylate) is highly enhanced under these circumstances 
(see e.g. chapter 16). This pH-partition concept has led to an equation like 
the one of Henderson — Hasselbalch. This equation, however, can easily 
lead to misunderstandings, since actually partitioning is determined not 
only by the concentration of unionized species, so by the pH of the 
medium and the pKa of the drug, but also by the intrinsic lipophilicity of 
the drug (the lipophilicity of the unionized forms, as reflected in the true 
partition coefficient TPC, the partition coefficient of the drug in its union-
ized form). It is well-known that proton transfer is an extremely fast 
reaction (Eigen, 1963). This implies that ionization equilibria are very 
stable in the sense that disturbances in the equilibrium concentrations of 
the reactants are compensated practically instantaneously. Dealing with 
membrane passage it is obvious that even though the concentration of the 
unionized molecular species may be very small a substantial amount can 
penetrate the barrier, provided that its lipophilicity is high. In other words, 
the unfavourable ionization conditons are compensated by high 
lipophilicity. pH partitioning as reflected in Henderson — Hasselbalch's 
equation of course remains important, since that governs the diffusion 
gradients in both directions through the membrane. Drawing conclusions 
from the predictions of the equilibrium concentrations at both sides of the 
membrane is, however, questionable since obviously in drug absorption 
and renal excretion one is not dealing with equilibrium situations, but the 
rate of penetration is the crucial determinant. This rate can be approached 
by investigating the degree of partitioning of a certain drug between 
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watery buffers of various pH and an organic solvent. The partition coeffi­
cients obtained in such extraction systems indicate how important 
penetration through the membrane into a constantly moving and refresh­
ing medium will be. This is in fact the most simple system for combining 
the effects of рКз and partition coefficient on drug distribution (cf. also 
Wagner and Sedman, 1973). In this chapter a method will be discussed for 
determining the true partition coefficient of a drug, when its pK
a
 is 
known, of its pKa, when the TPC is known, or even of both pK
a
 and TPC 
when very accurate partitioning measurements are performed at many 
different pH values so that the data can be fitted by computer to a model 
with the two independent variable parameters. 
Our interest is especially in the field of non-steroidal antiinflammatory 
agents and therefore the substances discussed are all members of this class 
of drugs. Several of these are aromatic carboxylic acids. Direct measure­
ment of the TPC of these compounds by using a very acidic aqueous phase 
where ionization is negligible is usually difficult and very inaccurate 
because of the low solubility of the substances in an acidic medium and 
because of the rather high TPC. We prefer to use a method which is 
certainly more laborious, but the results of which are far more significant. 
In an appendix to this chapter some data are given concerning the parti­
tioning of phenazone derivatives, that are relevant for the discussion in 
chapter 10. 
THEORY 
In aqueous environment the following ionization equilibrium is established 
for acids 
H A ^ A - + H + (3,1) 
The degree of ionization is dependent upon the dissociation constant of 
the acid K
a
 according to 
^ ιϊά] ( 3 · 2 ) 
After rearrangement: 
[HA]
 =
 [H*] 1 1 (3.3) 
[HA1 + [A-] [H+]+K
a
 Ka , . .ηΡΗ-pKa 
[Н+] 1 + ш 
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where pH = - log[H+] and pK
a
 = - log K
a 
When ук introduce partitioning between the aqueous medium and an 
equal volume of organic solvent, we can define the extraction ratio in 
equilibrium situations, E, as: 
E Cprg _
 c
org/cw
 =
 APC ^ 3 4 ) 
w ^org org' w +ArC 
where С
ог
„ = total concentration in the organic phase 
C
w
 = total concentration in the aqueous phase 
APC = apparent partition coefficient (pH dependent) 
Assuming that only unionized molecules are extracted in the organic phase 
we obtain under equilibrium conditions: 
E= ^ - j T (3.5) 
1 + 1 0 p H - p K a + T p c 
In case of alkaline substances in an analogous way it can be derived that 
E = IPC £j6) 
l+10pKa~pH+TPC 
By measuring E at various pH values we can calculate the TPC and/or the 
pKa by means of a non-linear curve fitting program (such as Farmfit), 
which supplies the optimal estimates of the parameters. In our experience 
it is difficult to fit on basis of the two parameters simultaneously, since 
then the uncertainty in both of them usually is very high. In general, 
however, the method should be used for determining TPC for drugs whose 
pKa is measured in an independent way. When the pKa is kept fixed at the 
known value, the TPC can be determined very accurately. When the TPC is 
not too large, for instance about 10, which means that E maximally will be 
about 0.9, then of course the computer program gives quite accurate 
estimates for both pK^ and TPC. Graphical estimation of the TPC is very 
easy by measuring the pH at which E = 0.5 (50% of the total amount of 
drug is in the organic phase) since then: 
pHo.5 = pKa + log(TPC-l) (3.7) 
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Obviously this equation is only meaningful when TPC > 1 (otherwise of 
course E would always be smaller than 0.5). This, however, is practically 
always the case. When bases are considered instead of acids one would 
obtain: 
pHo.5 = P K a - l o g ( T P C - 1 ) ( 3 · 8 ) 
It should be noticea that the TPC which is introduced in this analysis may 
have only a limited significance from a thermodynamic point of view. As is 
well-known carboxylic acids can form dimers in organic solvents. In such a 
case a thorough analysis of the partitioning would require incorporation of 
the dimerization equilibrium into the equations described here. The true 
thermodynamic partition coefficient is the ratio of the concentration of 
unionized monomer in the organic phase over that in the aqueous phase 
and will be lower than the TPC we estimated, since only part of the 
substance in the organic phase is present as monomer (depending upon the 
equilibrium constant of dimerization). 
MATERIALS AND METHODS 
Ibuprofen and ibufenac were obtained from Boots Ltd., Nottingham, 
England. Alclofenac was obtained from Continental Pharma, Brussels, 
Belgium. Flufenamic acid and mefenamic acid were obtained from Parke 
Davis, Bornem, Belgium. All other reagents were Merck p.a. or Baker 
analyzed reagent grade Buffer solutions from pH 2 to 9 were prepared 
according to Mcllvaine (citric acid/phosphate) or Teorell and Stenhagen 
(citrate/phosphate/borate). Stock solutions of drugs were made in the 
organic solvents in a concentration of 2 mg/ml. Partitioning systems were 
composed of one milliliter drug solution combined with 9 ml of pure 
organic solvent (saturated with buffer) and 10 ml of aqueous buffer 
solution (saturated with organic solvent) of different pH in closed reaction 
vials. The solutions were thoroughly mixed in a shaking machine for about 
half an hour and thereafter equilibrated. EquiUbrium was reached usually 
in about two hours, as it appeared from measurements after various equili-
bration times. After equilibration the pH of the aqueous phase was 
measured again (in cases that the pH of the buffer solution prepared 
differed from that after equilibration the latter of course was used for the 
calculations). 0.2 ml of the organic phase was pipetted, internal standard 
was added, silylation and GC analysis was performed as described before 
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(chapter 2). Then the concentration in the organic layer and the extractior: 
ratio could be calculated. As far as the organic solvents are concerned, we 
used hexane (Merck p.a.) or chloroform. The chloroform used was either 
chloroform Merck p.a. (indicated CHCI3 in table 3.1) or freshly distilled 
chloroform (CHCI3,
 d i s t ) . 
RESULTS AND DISCUSSION 
The values for the extraction ratio at the various different pH values were 
fitted according to equation 3.5, mostly with a fixed pK
a
 value but in 
some cases also with both pK
a
 and TPC variable. The results of this 
analysis are summarized in table 3.1 and some illustrating examples are 
given in figure 3.1. It should be noted that all partition data at the dif­
ferent pH values were given a weight factor on basis of the standard error 
in the mean of several determinations. Table 3.1 clearly shows that par-
TABLE3.1 
pK. and true partition coefficients of some antiinflammatory acids 
Substance 
alclofenac 
ibuprofen 
ibufcnac 
flufcnamic acid 
mefenamic acid 
flufenamic acid* 
mefenamic acid* 
рк
а 
4.60 
4.40 
4.10 
3.90 
4.20 
3.70 
(± 200%) 
4.20 
(± 120%) 
TPC (± SE) 
77.7 
11.0 
38.1 
1170 
11.1 
270 
22330 
56180 
36000 
56000 
± 3% 
± 10% 
± 10% 
± 10% 
± 1 3 % 
± 1 2 % 
± 7% 
± 4% 
t 300% 
± 100% 
Organic solvent 
C H C I 3 ) d i s t 
CHCI3 
hexane 
CHOI, 
hexane 
CHOI, 
CHCl3,dist 
C H C I 3 i d i s t 
С Н С 1
з , dist 
C H C l , , d i s , 
•fitted on both pKa and TPC; errors are very large by strong mathematical 
correlation between pKa and TPC. 
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tition coefficients are highly dependent upon the organic phase used. This 
is obvious as far as different solvents are concerned but also the quality 
and the purity of the solvents is rather critical. This is especially important 
in case of chloroform to which always about 0.7% of ethanol is added to 
avoid phosgene formation. 
f ract ion unionized 
fraction in CH C l j 
Mefenamic ocid 
CH СІЗ dist 
4 6 θ 10 2 
Rgure 3.1 
Distribution of flufenamic acid.and mefenamic acid between freshly distilled chloro­
form and aqueous buffers of different pH. Also the fraction of the acids that is 
unionized at the various pH values is plotted. Note the shift of the extraction curve 
with respect to the ionization curve. 
In fig. 3.1 also the degree of ionization at the various pH values is given 
in the form of an ionization curve. Obviously in most instances even in 
case of practically complete ionization a high extraction ratio is obtained. 
This indicates a compensation effect of lipophilicity on the unfavourable 
ionization degree. In an analogous way it might be explained that most of 
the non-steroidal antiinflammatory acids are for the largest part reabsorb­
ed from tubular urine even when the urinary pH is some units above their 
pK
a
 value. For instance, excretion of salicylic acid (pK
a
 =3) in urine is 
negligible at urinary pH of S although at this pH 99% of the salicylate is in 
the ionized form. That this very low excretion is due to tubular reabsorp­
tion indeed can be deduced from the fact that by increasing urinary pH to 
7 a hundredfold-enhancement of renal clearance results. An analogous 
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phenomenon can be expected to occur in case of alkaline drugs that are 
sufficiently lipophilic in nature. It seems therefore no optimal approach to 
predict the amount of tubular reabsorption of drugs solely on basis of 
their pKa as compared to the pH of the urine. It might be of advantage to 
use for these purposes the pHg 5 as defined in eq. 3.7, since this is an easily 
interpretable parameter combining both ionization and partition effects. 
Like any other parameter describing partitioning this pHQ.5 is dependent 
on the organic solvent used and only values that have been determined in 
exactly the same system can be compared. 
APPENDIX 
PHENAZONE DERIVATIVES 
In view of the variability of the estimates of partition coefficients with 
varying quality of the organic solvent used for extraction, we determined 
the distribution of the phenazone derivatives used in our study all together 
under identical circumstances instead of taking data from various sources 
in literature. 
MATERIALS AND METHODS 
For the pnenazone derivatives see chapter 2. The chloroform used was one 
and the same lot of chloroform Merck p.a. A phosphate buffer of pH 7.4 
was prepared according to S^rensen. Partitioning systems were the same 
as described before in this chapter. Quantitative analysis was done by 
injecting the same volume of the organic layer before and after extraction 
with buffer solution into the gas Chromatograph (see chapter 2). These 
injections were performed repeatedly in order to obtain reliable results. 
The extraction ratio was calculated and from that the apparent partition 
coefficient at pH 7.4. 
RESULTS AND DISCUSSION 
The values obtained, together with their standard deviation are given in 
table 3.2. All partition experiments were done at least 6 times and each 
sample was injected 10-12 times. The partition coefficient of 4-isopropyl-
phenazone could not be determined by the method applied since the 
addition of the phosphate buffer had no significant effect on the concen-
tration in the organic layer. By using systems with volumes of phosphate 
buffer 2, 4, 6 and 8 times as high as the volume of the organic layer and by 
43 
extrapolating the partition ratios obtained to the situation of equal 
volumes, the partition coefficient could be roughly estimated at 150 
(±30). 
TABLE 3.2 
Apparent partition coefficient (chloroform-aqueous buffer, pH 7.4) of some Phena-
zone derivatives. 
Substance AÏCTA ± S D (n = 6) 
Phenazone 19.4 ±5.1 
4-isopropy phenazone >50 
4-ammophenazone 12.7 ± 0.8 
4-methylaimnophenazone 6.7 ±1.4 
4-dimcthylaminophenazone 13.4 ±3.1 
4-isopropylaminophenazone 8.8 ±1.3 
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SECTION II 
LINEAR PHARMACOKINETICS 

CHAPTER 4 LINEAR PHARMACOKINETICS 
INTRODUCTION 
The absorption and elimination of drugs usually is supposed to be gover­
ned by first-order nrocesses. This means that all rate processes can be 
described by linear differential equations which as a rule can easily be inte­
grated. Sometimes, however, deviations from this first-order behaviour are 
encountered and then one is dealing with non-linear pharmacokinetics. For 
some cases of non-linear pharmacokinetic behaviour a reasonable formal 
mathematical description is possible. Examples are the so-called capacity 
limited elimination (when the enzyme system, responsible for elimination 
by metabolism, can become saturated), active tubular secretion and/or 
active tubular reabsorption in the kidney and binding of drug to serum 
proteins (when binding is strong enough to become the rate limiting step 
in drug elimination or distribution). Some aspects of non-linear pharmaco­
kinetics are discussed in more detail in section III. Here we confine our­
selves to a broad outline of linear pharmacokinetics as far as it is relevant 
for understanding the data and the analysis presented in section II. More 
specific ascpects will be discussed in the following chapters, whenever they 
are important for understanding and describing the experimental data. 
Concerning the elementary basis and significance several reviews and text­
books are available (e.g. Dost, 1953; Rescigno and Segre, 1961; van Ros-
sum, 1971 ; Wagner, 1971 ; Notari, 1975; Gibaldi and Ferner, 1975). In this 
chapter some new derivations and theoretical results are included. 
CLEARANCE 
The most fundamental concept in pharmacokinetics is the clearance, the 
sum of the processes by which a drug is removed from the body. The 
parameter to characterize the clearance process can be called the clearance 
function, Узд. Usually 'clearance' refers to removal of the drug from the 
body compartment in which the drug concentration is followed, so in 
general one should express this by speaking of plasma clearance (when 
plasma concentrations are measured) or blood clearance (when concen­
tration in whole blood is measured). Unless explicitly stated otherwise, by 
clearance we mean the plasma clearance. 
The clearance function вд may be very complex, but when it can be 
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properly defined the rate of elimination of a drug is simply related to the 
plasma concentration at any moment: 
f = - V c e l - C (4.1) 
where Q is the amount of (unchanged) drug in the body compartment, 
from which elimination occurs, at any time t; 
С is the plasma concentration at any t; 
У Cel h*8 ^ е dimension of 1/hr or ml/min. 
Since in this chapter we will confine the discussion to linear kinetics we 
can define the clearance function as a clearance constant kçe\. So: 
5?-=-ксе1-С (4-2) 
The clearance constant код can in an abstract sense be regarded as the 
volume that is fully cleared from drug per unit of time. 
On basis of this equation we can define the amount of drug eliminated at a 
certain time after administration, Q
e
]
 t as: 
t 
Qel,t = l4:el /" С dt (4.3) 
Ultimately, when t approaches «> or at least is large with respect to the 
slowest elimination process involved, the whole dose (D) administered will 
be eliminated; in formula: 
D= keel ƒ Cdt (4-4) 
The integral in the right side of equation 4.4 of course is nothing else than 
the area under the curve (AUC) of the plasma concentration plotted versus 
time on a linear scale. 
k C e l ~ <4·5) 
This implies that the clearance constant in principle can be calculated after 
graphical determination of the AUC from t=0 to t=°. This may, however, 
be very difficult especially when the profile of the plasma curve is depen-
dent upon various processes with a highly different rate, which implies 
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that the decay at low plasma concentrations cannot be predicted accura-
tely and that large mistakes may be made in the estimation. How large 
these mistakes can be, will become more clear from the following parts of 
this chapter. A general problem is furthermore that in case of oral admini-
stration one cannot be sure that the whole dose has reached the circu-
lation, so that D, which is of course the dose that has come into the body, 
is not known exactly. The main advantage of the use of eq. 4.5 for calcu-
lating the clearance constant is that it is to some degree a model-indepen-
dent procedure which is valid as long as linear kinetics prevail. Of course 
the clearance function will not be a constant anymore, but a dose-depen-
dent parameter when non-linear processes are responsible for (part of) the 
elimination of the drug. 
VOLUME OF DISTRIBUTION 
When a drug is administered it will always have to come first in the blood 
before it can be transported to wherever its action is needed. Of course 
there are some exceptions: desinfectants, antacids and some other gas-
trointestinal drugs can exert their effect without passing through the 
bloodstream and such a passage should even be avoided in many cases. 
Furthermore, there are some drugs like local anaesthetics that can be 
applied directly to the site of action and sometimes even other drugs are 
given systemically to insure localization of the drug whose effect is 
primarily required. There are, however, only a few types of drugs that can 
be administered so near to the site of action that they need not to be 
distributed by the blood. For the large majority of drugs administration is 
always, directly or indirectly, to the bloodstream from where distribution, 
including transport to the site of action, and elimination occurs. So the 
fact that in practice only blood is accessible as a real body tissue for 
regular drug concentration measurements is not a disastrous limitation 
since the blood as the primary transport system of the body gets in con-
tact with all other tissues and will equilibrate more or less rapidly with all 
of them. The rate of equilibration between the various tissues with respect 
to their drug content of course will be determined not only by their degree 
of perfusion and their volumes but also by the physicochemical characte-
ristics of the drug. 
In pharmacokinetics the body is assumed to be composed of one or 
more compartments. The drug concentration within such a compartment 
may be inhomogeneously distributed over the various tissue and water 
components, but a requirement is that within the compartment a concen-
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tration equilibrium exists which is established very fast with respect to 
transfer in and out the compartment (in other words: equilibrium may not 
be disturbed by interaction with other compartments). As we will see the 
number of compartments needed in a certain model to describe concen­
tration data adequately is highly dependent on the accuracy and the 
sensitivity of the assay method. Obviously the central compartment (and 
often the only one) is that compartment which is constantly in equili­
brium with the blood. This compartment has a certain apparent volume 
which can be delinea as that volume over which the amount of drug 
present in it should be distributed if the concentration all over the com­
partment would equal the plasma concentration. When more compartments 
are present eacn 01 these wui nave such an apparent volume. 
Sometimes the volume of distribution of a drug can be interpreted as the 
volume of a real body compartment, for instance plasma, extracellular, 
water or total body water (about 3 1, about 12 1 and 30-40 1 respec­
tively). Some drugs can even be used f от assessment of the volume of total 
body water, e.g. phenazone and some of its derivatives. Mostly, however, 
the distribution volumes encountered are composites of these, what one 
night call elementary volumes, and often the distribution volume is much 
larger by accumulation in one or another tissue. 
ONE-COMPARTMENT MODEL 
In many cases pharmacokinetic analysis on basis of only one compartment 
is sufficient. The rate of elimination of a drug from the body as a single 
compartment is very simple: 
f - = - k C e l - C (4.2) 
This equation can easily be integrated after dividing both sides by the 
apparent volume V and after establishing the boundary conditions 
g-^-c «<> 
^Cel The factor -γ— has the dimension of hr (or min"1) and is a rate con­
stant. This rate constant к is used extensively in literature as the basic 
pharmacokinetic parameter (This, however, seems no optimal approach 
from an educational and conceptual point of view). We often use a time 
constant: 
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ν 
к kCel 
T
e
j = - = — — (dimension hr or min) (4.7) 
This time constant again has the advantage of being easily interpretable, 
it is the time in which the whole volume has passed through the 
eliminating organ(s) once. Furthermore, it is analogous to the halflife tH
e
i 
which in practice is the most commonly used parameter and which is also 
a time constant. 
SINGLE COMPARTMENT, INTRAVENOUS ADMINISTRATION 
When the dose D is administered i.v. the boundary condition for eq. 4.6 is 
(t=0; С = 5 ) and integration yields the well-known formula: 
I^Çel
 t 
c - B . - v . B . - * . . . B . - t f r * . 
φ - " * " (4.8) 
From this we also see the relation between tVigj and T
e
j 
-t/T
e
i -t/t^ei 
e = 2 
or 
t^e! = r
e l In 2 (4.9) 
SINGLE COMPARTMENT, ORAL ADMINISTRATION 
When the drug is administered orally (or s.c, i.m., i.p. etc.) eq. 4.2 
becomes more complicated, since it must contain also an absorption term. 
Then a so-called zero'th compartment is introduced (usually the gastroin­
testinal tract), with a (apparent) volume VQ, containing an amount Qo 
with concentration Co (KJO/VQ). Absorption is supposed to occur via a 
first-order process governed by the same kind of parameters as the elimi­
nation process, but with a suffix 'a' attached to the symbols instead of the 
suffix 'el'. Such a model can be pictured as: 
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D-» 
Qo 
Vo 
Co 
kCa 
Qi 
V, 
C, 
-»kCel (4.10) 
The model is fully characterized by two differential equations with the 
appropriate boundary conditions: 
dQo 
d f - — kCaco [t=0;Qo=D] (4.11) 
^
1
=
 +
 kcaC0-kceiC1 dt [tFOjQi^J] (4.12) 
Division by Vo and Vi respectively leads to: 
dÇa 
dt 
О
 т
я 
[ t = 0 ; C o = ^ ] 
о 
(4.13) 
dÇi _ кса _ ^Çel 
dt " , ^ " , c , [t=0;Ci=0] (4.14) 
These simultaneous equations can be integrated very easily. For instance 
eq. 4.13 can be integrated directly since it is a simple homogeneous first-
order differential equation; the result can be substituted in eq. 4.14 which 
in turn then becomes a first order differential equation (inhomogeneous). 
In general the solution of a set of simultaneous linear differential 
equations is easily performed by use of Laplace transformation. Inte-
gration of eq. 4.13 and eq. 4.14 yields: 
с =5-c , - V i 
T
el 
-t/T, 
r
el- r a 
el -t/η, (4.15) 
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Equation 4.15 is still not totally conect and two other parameters have to 
be introduced in order to make it generally applicable. 
1. The biological availability, F. 
When a drug is introduced into the gastrointestinal tract it is possible that 
only part of the dose is absorbed, the rest being excreted unchanged in the 
faeces. Also it is possible that the drug is absorbed completely, but is meta-
bolized partly at its first passage through the liver before it can reach 
the general circulation (first-pass effect). For, as is well-known, all 
substances absorbed from the gastrointestinal tract are collected in the 
portal vein and go through the liver before being distributed over the 
body. Still another possibility is that part of the drug is metabolized in the 
intestine by the microflora before absorption can take place. AU these 
factors can diminish the dose administered effectively and so' 
equation 4.15 will have to be corrected for these phenomena. This usually 
is accomplished by multiplying the dose D in equation 4.15 with a 
factor F, the biological availability. F or the biological availability can be 
defined as that fraction of the dose given that reaches the general circu-
lation intact. In case of intravenous administration F will equal unity. 
2. The lag-time, to 
Another effect that has to be accounted for is the lag-time (t0). This 
lag-time can be interpreted as the time after oral administration during 
wiuch absorption does not yet take place. In a physiological sense its 
meaning will not always be clearcut. The best approach probably is to 
regard the lag-time as a purely operational parameter used for fitting 
absorption data to a first-order model. When, for instance, a solid dosage 
form is applied one can imagine that before absorption can follow first 
order kinetics the drug must dissolve and a concentration gradient between 
gastrointestinal tract and blood must be established. The same can happen 
when a drug is given in solution but precipitates in the stomach (for 
instance to be expected with acidic compounds). 
It will take some time (the induction period) before a steady state is 
achieved. During the induction period some absorption takes place 
already, but at a very low rate. This implies also that sometimes a measu-
rable plasma concentration can be reached during the lag-time. So in this 
sense the lag-time is used to correct for deviations from first-order 
absorption. On the other hand it is conceivable that the presence of food 
in some cases can retard the diffusion of the drug to the absorbing mucosa 
in the gastrointestinal tract. Then it will take some time before absorption 
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can take place anywav. 
Furthermore most drugs will be absorbed primarily from the small 
intestine, because of the large absorbing surface and not from the stomach, 
where they come first after ingestion. Although our volunteers usually 
were fasting overnight before drug administration the passage time through 
the stomach might be dependent upon the dosage form and on the pH of 
the stomach contents. 
All these factors together are accounted for by the lag-time. We will not 
do any effort to interprete this lag-time in detail, since we use it as a 
purely operational parameter which serves to cover irregularities in the 
absorption process. 
Introduction of these two additional factors in eq. 4.1 S leads to: 
d = 5P Tel 
v i ^ - ' ' a 
- ( t - to ) /T e l - ( t - t 0 ) / T a 
e — e (4.16) 
Two remarks have to be made now: 
Firstly, this equation of course is not valid when t < t0, then Ci ^) . 
Secondly, it is obvious that from this equation (so after oral administra-
tion) Vi (and kçgi) can never be determined absolutely, but only the 
relative values Vi/F (and kçei/F). The absolute values can only be 
calculated when one can be sure that the whole dose administered has 
entered the general circulation (as with i.v. administration). The time con-
stants (and the rate constants) of course are independent of the biological 
availability and can be determined always accurately, provided that 
enough data points are available. 
Equation 4.15 does not apply to the case that т
л
 = т
е
\. Then it can 
easily be derived that: 
r - £Р -L „ -t/r 
^ " V , r e (4.17) 
0"=Tel =Ta) 
So instead of a bi-exponential function we get a mixed linear and mono-
exponential function of time. The profile of the plasma curve, however, is 
quite similar to a bi-exponential one. Fig. 4.1 shows an illustrative example 
where experimental data are analysed according to both equations and 
figure 4.2 gives a theoretical example. In practice, when using a computer 
program for fitting procedures, one should realize that eq. 4.17 might be a 
better alternative when r
a
 and r
e
| appear to be nearly equal or when 
abnormal values for the kinetic parameters are obtained. 
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Figure 4.1 
Regression analysis of experimental data according to 
equations 4.17 ¡resulting in ra = Te¡ = 1.48 hr) and 
4.16 {resulting in т
а
 = 0.6 hr and Te¡ = 2.2 hr). 
Although the parameters differ substantially, the 
experimental data are reasonably fitted by both curves. 
1Л 
1Л 
plasma concentration (mg/l;log scale) -
10O-
Figure 4.2 
Simulated plasma curves for an oral dose of 500 mg 
of a hypothetical drug (V » 6 I, r
e
/ = 150 min) where 
the time constant of absorption т
а
 increases and 
ultimately equals T
e
j. 
MULTICOMPARTMENT MODELS 
So far the discussion has been restricted to cases where the one-compart-
ment model may be applied. In fact this implies a rapid distribution over 
all tissues where the drug can penetrate. This is not seldom the case; 
especially drugs with a small volume of distribution as caused for instance 
by strong binding to plasma proteins or by inability to penetrate cells (so 
that only the extracellular fluid constitutes the distribution volume) will 
often follow single-compartment kinetics. Also drugs that distribute easily 
over the total body water often fulfil this criterion. Many drugs exhibit a 
biphasic plasma concentration curve after i.v. administration and a 
monophasic curve after oral administration. The reason for this is 
undoubtedly that after i.v. administration there is a small but measurable 
period during which distribution from a central compartment (blood 
and highly perfused tissues) towards another compartment takes place. 
Provided that this distribution process is more rapid than the absorption 
process the phenomenon will not show up after oral administration. 
Sometimes also oral administration data cannot be sufficiently be 
described by one-compartment models. Then one or even more deeper 
compartments have to be assumed. The first and central compartment as a 
rule consists of the blood and highly vascularised tissues (liver, kidney, 
lung, heart and sometimes brain). This is the compartment in which the 
concentration measurements are performed and from which elimination is 
supposed to occur. Another compartment can be regarded as the less 
perfused tissues (fat for instance), tissues where specific uptake of drug 
takes place or tissues where drug penetration is hindered by some kind of 
banier (brain, placenta). Whether more than one compartment would be 
discovered or not depends primarily upon the amount of drug involved 
and the rates of exchange. The influence on the plasma concentration 
curve will be very clear when a large amount of drug leaves the central 
compartment to penetrate in another compartment, but will be negligible 
when only a small amount of drug is concerned. It is also conceivable that 
when the exchange of drug is fast, compartments might easily be over-
looked whereas they can be detected when the rate of exchange is low. 
When several different compartments show about the same rate of 
exchange with the central compartment they will not show up as different 
entities, but they will combine to one. Only rarely more than two com-
partments will be needed to characterize the kinetic behaviour of drugs in 
the body. An important factor in this respect obviously is also the 
accuracy and the sensitivity of the assay method. 
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Multicompartment models usually are regarded as a central compart-
ment, from which the elimination processes take place and one or more 
peripheral compartments which are all in exchange with the central 
compartment but not with each other. Of course various different types of 
models are conceivable. For instance, it might be possible that elimination 
takes place from a peripheral compartment rather than from the central 
one, and one can think of models where peripheral compartments are 
connected directly to other peripheral compartments and only indirectly to 
the central compartment. 
MATHEMATICAL ANALYSIS OF MULTICOMPARTMENT MODELS 
As long as linear (first-order) kinetics prevail all multicompartment phar-
macokinetic models can be described by a set of simultaneous linear diffe-
rential equations, which can always be solved. 
We will outline the general approach for models, in which the drug is 
administered directly or indirectly to a central compartment 1 which is in 
exchange with n-1 other compartiments, numbered 2 . . .n. These other 
compartments are not connected among each other and elimination occurs 
exclusively from the central compartment. The analysis is based on the 
general approach as described for instance by Rescigno and Segre (1961) 
and is not restricted to this specific type of pharmacokinetic models, but 
since this type seems to be the most fruitful instrument in 
pharmacokinetic practice we will take it as an example. The model under 
consideration usually is referred to as a mamillary model. 
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L INTRAVENOUS ADMINISTRATION 
In case of i.V. administration the model is described by the following set of differen­
tial equations: 
dQ, n n 
S r = - k C e l c . - Σ k.jC, + Σ kj.Cj I t^ jQ^D] 
o l
 i=2 i= 2 
dQ 1 _ 
7 — — KJJC, — ^лС, 
dt " k , iCi ~ к " C i [t=0; Q, = . . = 0 ^ . . .Q h =oj 
d Q n
_ 
¿ p - k i n C , - Ь
ш
С
п (4.18) 
Q| = the amount of drug in the ith compartment 
k,i and kj, are parameters in term of clearance constants (with dimension l/hr or 
ml/min) governing transport in and out the various compartments. 
Cj = the concentration of drug in the ith compartment 
When we now introduce the volumes of the various compartments (Vj) and apply 
Laplace transformation we obtain the following set of equations in which x¡ is the 
Laplace transform of C¡ and s is the Laplace number. 
D keel n k . i " Iti, 
1 γ
ι 1=2 ν ι ι=2 ν ι 
Κ · - Κ-· 
s x
' ~
x
' - ^
x
' 
".i 
k
. n 
« η "
 v 
58 n 
Xi 
Xi 
k i . 
k
n. 
(4.19) 
Upon rearrangement the following set results: 
η к, 
Чі D 4:β1 
( s +
—
 +
Л y - ) X t - . \ v " X i = v v i 1=2 v i i=2 v i s 
k
. i «4. 
- vT x- + ( s + v : ) x i = 0 
— x 1 + ( s + — ) x n = 0 
v
n
 v
n 
(4.20) 
The solution of this set of linear equations is given by the following general equation 
obtained after application of Cramers rule: 
"i Δ ·1 i+1 
D/V, Δ l " (4.21) 
where Δ is the determinant of the set of equations and Δ,^  the determinant which is 
obtained from Δ by deleting the fust row and the ith column. 
bCel n Ki 
s+ + Σ — 
V. 1=2 V . 
k.) 
k. 
hi 
v, 
• • * 
• · · —-
"•Пі 
vT 
s + 
s + 
"m 
(4.22) 
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This determinant can be developed m powers of s leading to: 
Δ = s n + H . s 1 1 - 1 + Η
ΐ 8
η
-
2
 + H n - l s + H n ( 4 . 2 3 ) 
where Hj denotes the sum of all minors with rank ι of the determinant obtained from 
Δ by deleting all s terms, that have the same diagonal elements as that determinant 
itself. For instance. 
H, =-
'Cel η к 
+ Σ 
V, 1=2 V 
η k i . 
+ Σ 
1=2 V . 
η Г/кСеІ " к ' Л к і > к
а 1
 η к
і . к,.
 η к11 
+ —— Σ —— + -^- Σ г — + 
. 1=3 і . ι=4 V, 
+ . . + 
41-1,1 
vT 
Til ^IJ^Jl 
(4.24) 
The determinants Δ,, are represented by the following general equation. 
Kl--
s + 
κ31 
Kl, 
' 1 + 1 
s + 
s + 
Ki + ι.» 
V l + . 
s + 
k
n. 
(4.25 
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By developing this determinant to the ith row it can easily be deduced that 
Δ , . ^ - Ι ) 1 ^ £ i - (s + £ i ) . . . . (s + ^ i - H s + ^ A i i ) 
> » V l - ι V i + i 
(s + ^nj) 
V
n
 (4.26) 
So the general solution for x, takes the form 
4,= v ' v l Li v ' - ' v l + ι v n 
η „ n-1 ,. n-2 
s +Hls + H 2 s + + H n _ l S + H n 
(4 27) 
It should be noted that 2 < ι < n, so x, has to be defined separately, but the deter­
minant Δ, , is a very simple one and obviously 
b·. ?:-£>»•$·· <·ν' "•£' 
χ, = -
Δ
 s" + H.s" 1 + H,s n 2 + + H
n
 _ , + H
n 
(4 28) 
One can see that Xj is simply related to x, 
kii/V, 
K l l 
X l
" ¡Γ" χ ι (4 29) 
·*$ 
In order to obtain the solution of the model in terms of Cj we need the antitransform 
of the functions x.. These can also be given in general equations The denominator of 
the equations for all X] terms is the same. In the mamillary type of models this 
denominator can always be factonzed, so 
s
n
 + H 1 s
n _ 1
 + H
n
_ 1 s + H n = ( s + — ) ( s + — ) ( s + — ) . 
Ti тг Τι 
. . . ( s + — ) (4.30) 
η 
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г, 
(The reason for indicating the roots with— will become obvious from the following). 
T i 
It is clear from this equation that the rj's are functions of all the elementary k¡ and Vi 
values in the model, as these are comprised in the coefficients H¡. 
As far as the numerator of equation 4.28 is concerned: 
for x, this can be written as 
- (s n _ 1 +X l a s n - 2 + + \ i S 1 + + 4 i i - i * + W (4·31) 
' ι 
where every λ, is a function of all terms —— 
v i 
31 · 31 · 41 · · · · · · · · · 111 
and λ,
 n
 = (4.32) 
ν,ν, v
n 
and for Xj 
5- -iL (sn 2 + Х;, s" 3 + + *α*+ + 4 η - . « + λίη) 
1
 ' (4.33) 
^З 1 ^ з ι к і 1 
where λ: is a function of the terms —— , — — etc. (except —— ) 
з
 v
» i 
kjjkj, . . . . ( k j - , , ) (kj + i,i)· · -Цц 
and λ ΐ
η
= W· 3 4) 
V.V, V j . , Vi
 + 1 Vn 
So 
4 = - ^ 
— ί,η-Ι , , n-2 i „ . 
V, l + λ 4 5 + λ ι ί ί + 4 n - . s + \ n > 
(s + —) (s + — ) (s + — ) + (s + —) 
T
«
 T i T i τ 
η 
(4.35) 
D k i i n-2 n-3 
V ; v ~ ( s + X i 3 S + N j ^ + + 4 n - . s + N n > 
Xi = — — 
(s + —)(s + — ) (s + — ) (s + — ) 
r> r ' rj T n 
(4.36) 
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The antitiansforms of these equations are given by 
--I 
1 ,n-l (- — ) + \ l a ( - — ) 
τ , τ . τ . T, 
1
 4n-2 
+ λ, 
•η
 e
_ t / T l + 
+ (n-1) similar terms obtained by cyclic permutation of τ, r
n 
(4.37) 
and analogously 
_ D k> ι (- - )
n
-
2
 + λ,, (- - Г 3 + . . . .A- (- - )JH ,+ λ 
( L . L ï f L . L , . 
L T » r i Ta T i 
.(i-i-, 
, n
 e- t / T ·
 + 
> + (n-1 ) similar terms obtained by cyclic permutation of τ, 
(4.38) 
Generally 
^'¿ \ e -Ur, (4 39) 
Now it is clear that every concentration in every compartment is dependent on the 
same set of tune constants, r, τ
η
, whereas only the coefficients A differ. 
Both the time constants and the coefficients are functions of all elementary model 
parameters (the k's and Vs). The number of exponentials is equal to the number of 
compartments. Q 
Further it is obvious that when 1=0, C, = -
" i 
η D 
Μ
 ί ι
Α 4 = ^ (4.40) 
and that 0 = 0 when t=0 
Σ Α.. = 0 ( ι * 1) 
M TI 
(4.41) 
63 
[I ORAL ADMINISTRATION 
When the drug is not directly applied into the blood, but to a site from which 
absorption takes place and when this absorption can be regarded as a first-order 
process, this can formally be accounted for by introducing a zeroth compartment 
from which the drug is irreversibly transported to the first (central) compartment. So 
the set of differential equations 4.18 is extended with 
^ = - k C a C 0 ( t = 0 , Q o = D ) 
dO η η 
¿ ρ = "Ca C° - kCel C ' - ^ k . ι C · + ^ k i . C i ( t = 0 · Q ' = 0 ) 
(4 42) 
the rest being equal to scheme 4.18. (It should be noted that the decay of the 
concentration in the zeroth compartment can be derived directly to be 
C 0 = e
 T a
. We will outline the calculation of C, - C
n
) 
v
o 
Upon Laplace transformation the problem again is reduced to calculating the deter­
minant of the new set of linear equations (which we call Δ 0 ) and the Δι derived 
from it. The relationship between these determinants and those described in the 
foregoing paragraph can easily be derived and is as follows. 
Δ» = (s + — ) Δ (4.43) 
^Са 
and Δ 0 , , = - — Δ,, (4 44) 
» ι 
so 4 , = 
5-Δ» 
ν, " 
Δ" 
D kCa 
ka 
D 
v i r a 
1 
(4.45) 
(s + — ) Δ (s + — ) Δ 
V„ τ, a 
V 
where т
а
 = = time constant for absorption 
kCa 
When we express C, after oral administration analogously to eq. 4 39 we get 
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C^A. e t / T a + Σ Ar. e t / T J (4.46) 
ι io
 я 1 V 
The time constants т. are functions of all elementary pharmacokinetic parameters. 
Vo 
Only т
а
 is simply — , so the only elementary, model-independent time constant. kCa 
For an η-compartment system equation 4.46 has n+1 exponential terms. Further it 
is obvious that when t=0, €, = 0 (i > 1). 
SoA,,, + S i Ajj =0 (4.47) 
The equations 4.18 to 4.47 provide a complete description of mamillary multicom-
partment models. The general formulation used allows any number of compartments 
to be inserted. The main difficulty is the factorization of equation 4.30. When more 
than two compartments are involved, often numerical methods will be required for 
this factorization. 
CLEARANCE IN MULTICOMPARTMENT KINETICS 
Since we defined the clearance constant in linear pharmacokinetics as 
к С е 1 = - ^ (4.4) 
/ С , dt 
we can easily express the clearance as a function of time constants and 
coefficients (in a mamillary model) 
kCel'-J (4.48) 
In case of oral administration D should be replaced by FD 
This relationship is very useful for calculating the clearance constant, since 
the A's and T'S can all be graphically determined by the well-known 
method of residuals or can be fitted by a computer program on basis of 
the plasma concentrations measured as a funciion of time. The equation of 
course is valid after both oral and i.v. administration. Eq. 4.48 shows that 
mistakes can be made in the determination of the clearance constant when 
not all compartments have been detected. The seriousness of the errors 
made depends upon the magnitude of the products AJTJ of the A's and T'S 
that have been overlooked. 
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DISTRIBUTION VOLUME IN MULTICOMPARTMENT MODELS 
In multicompartment models of course every compartment has its own 
(apparent) volume of distribution. Except for the central compartment, 
however, these volumes cannot be determined. In case of i.v. administra­
tion it follows simply from eq. 4.40 
D D 
V l =
 5 ^ ( 4 · 4 9 ) 
where Ci о is the (extrapolated) drug concentration at time t=0 
It can easily be derived that the intercepts after oral administration 
A, :
 o r a
i are simply related to those after i.v. administration: 
Aij,oral = ~ i_ i_ Aij,i.v. = — Aij,i.v. ( 4 · 5 0 ) 
Obviously, after oral administration in multicompartment kinetics the 
volume of the central compartment may be calculated from 
л/ FD 
V, (4.51) 
η τ a. 
j=l Tj 
(note that A i 0 is excluded from the sum in the denominator) 
In multicompartment kinetics the height of the plasma concentration is 
determined by the dose, the way it is administered, the volumes of all 
compartments and the rate of exchange between the central and peripheral 
compartments. These last two factors, the real pharmacokinetic deter­
minants, are reflected in the total apparent volume of distribution, Vf. 
This volume can be visualized as that volume needed to contain the total 
amount of drug homogeneously distributed with a concentration equal to 
the plasma concentration in a multicompartment model where full distribu­
tion-equilibrium between the various compartments exists. The total 
volume of distribution Vf can be formulated as a function of Vi and the 
time or rate constants of distribution. Suppose at a certain time the total 
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amount of drug in the compartments 1 η together to be Q and the 
amount in the ith compartment to be Q¡. When now distribution equili-
brium is established this implies for mamillary models: 
dQi _ 
j t - knCi - к ; , C ¡ - 0 ( 2 < i < n ) 
and 
dCh η η 
τ — = - Σ к
и
 С, + Σ Ц, С ^ О dt i=2 i=2 
From eq. 4.52 follows that 
СІ = Г — Cx so Qi = 
Ki Vi 
ki, 
C, 
(4.52) 
(4.53) 
(4.54) 
Now 
Q = V1C1 + Σ^ Qi i=2 
η к i 
r
 . Q 
η к ; 
ν. η +y. - υ 
Vi 
Vi 
c, 
Q_ 
Vf 
(4.55) 
(4.56) 
which means 
V f =V 1 ( 1 + Σ -£-!•) 
i=2 Kii 
η к.і і (4.57) 
It can be shown that after i.v. administration eq. 4.57 can be formulated as: 
Vf = JzL »j 'J [§л^ (4.58) 
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An analogous expression can be deduced for Vf after oral administration 
by the use of eq. 4.50 
F D | AJJ ( T j ' - T a T j ) 
Vf,oral = T V ; ( 4 · 5 9 ) 
Д
 Aij i T J- T a)j 
From the equations 4.48 to 4.59 it is obvious that determination of the 
total clearance and of V! and Vf can always easily be accomplished, 
provided that the plasma concentration is followed long enough. As stated 
before serious errors may be made when one or more phases in the plasma 
curve are overlooked. 
RENAL EXCRETION 
The excretion of drugs in urine is governed by four different processes: 
a. glomerular filtration: in the glomeruli part of the blood flowing 
through the kidneys is ultrafiltrated (about 125 ml filtrate per minute) 
b. passive backdiffusion: nearly all the water of the glomerular filtrate is 
(partly actively) reabsorbed in the renal tubuli, so that only about 
1 ml/min of urine results. Also filtered drug molecules can be passively 
reabsorbed during the passage of the primary urine through the tubuli. 
This passive backdiffusion is of course pH dependent, since only union­
ized drug molecules can be expected to penetrate through the tubular 
wall back into the blood. 
с tubular secretion: some drugs are excreted from the capillaries surround­
ing the renal tubuli into the primary urine by an active process (tubular 
secretion) analogously to some endogenous 'waste' substances. This 
process is limited by a certain fixed maximum transport value and 
susceptible to competition by various compounds secreted by the same 
mechanism. 
d. active tubular reabsorption: some drugs are actively reabsorbed from 
the primary urine into the capillaries around the renal tubuli; also this 
process is analogous to that for endogenous substances (e.g. glucose). 
Like tubular secretion this active reabsorption is saturable and suscept­
ible to competition phenomena. 
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The two last (active) processes are principally non-linear in nature, only at 
relatively low drug concentrations (low as compared to the dissociation 
constants between drug and transport mechanisms) the clearance and 
reabsorption by these processes can be represented by constant, concentra-
tion-independent parameters. A more detailed discussion of this matter is 
given in following chapters. The first two processes (glomerular filtration 
and passive tubular backdiffusion) in practice can often be summed up to 
one linear renal clearance constant kç r , since urinary concentrations have 
the advantage of being measurable over a relatively long period in case the 
drug is excreted m urine to a substantial degree. In such a long period 
fluctuations in urinary pH and urine flow, which may have pronounced 
influence on the value of the renal clearance constant, usually will average 
out. A factor that might be of extreme importance in renal excretion of 
drugs is binding to plasma proteins. Whether or not protein binding will 
retard renal excretion is primarily determined by the magnitude of the 
dissociation rate constant of the drug-protein complex, since this will 
indicate whether the dissociation of the drug from the protein can become 
the rate limiting step in the excretion process (Rodrigues de Miranda, 
1975). 
As long as linear pharmacokinetics prevail it is obvious that the rate ot 
excretion of a drug in urine is given by: 
dQr 
τ — = kçr Cp (Cp = plasma concentration) (4.60) 
which means that the renal excretion rate as a function of time is a pure 
reflection of the profile of the plasma concentration curve. Therefore it is 
possible to obtain time constants for elimination from renal excretion data. 
Distribution volumes and clearance constants of course cannot be calcu-
lated on basis of renal excretion measurements alone. Also the cumulative 
amount of drug excreted in urine after oral dosage is a measure for the 
relative bioavailability. However, great care has to be taken in interpreting 
renal excretion measurements in a quantitative way and it is advisable to 
draw conclusions only when conditions are standardized as far as possible: 
constant urine production by waterloading and constant urinary pH by 
administration of e.g. sodium bicarbonate or ammonium chloride. The 
renal clearance constant can be obtained from the quotient of the renal 
excretion rate over a certain period and the average plasma concentration 
over that period (according to eq. 4.60). On the other hand it can be 
determined by measuring the total body clearance kçej and the total 
amount of drug excreted unchanged in urine Qr t o t on basis of the foUow-
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ing obvious equation: 
^ І = S î M (4.61) 
kCel D 
It should be noticed that this equation is also valid in case of oral admini-
stration, when the biological availability is principally unknown. 
CHRONIC ADMINISTRATION 
As long as linear pharmacokinetics prevail there exists a simple relationship 
between equations for the plasma concentration after the first dose and 
for the plasma concentration after multiple doses. This relation can easily 
be derived in the following way. 
The plasma concentration after the first dose, Cj (1) is given by 
C l ( 1 ) = Σ Ai e _ t / 7 i (4.39) 
v /
 i=0 
When we denote the dosage interval with At the plasma concentration at 
the end of the first interval is: 
η - Δ ί / τ · 
C i ( A t ) = ¿ ) Aj e » (4.62) 
At t=At the second dose is given and from then the plasma concentration 
obviously is described by 
η — Λί/τ· — tir-
С і ( 2 ) = М А і е + А і ) е (4·6 3) 
' 1=0 
It should be noted that t represents here the time elapsed after the last 
dose (so not from the start of medication). Analogously the plasma con­
centration after the third dose is given by 
ο,ο,φν-
2
*""^-^^-"" (4.64) 
When we switch over to a general formulation, the plasma concentration 
after the jth dose is: 
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C l ( j ) = i | ) ( A i e - Ö - 1 ) A ^ + A i e - Ö - 2 ) ^ i + 
+ Α 0 ε _ ί / Τ ί (4.65) 
The preexponential factor (between the brackets) is a geometric series, 
that can be summed up accordingly 
C l ( D . ! i = i ^ L A l . ^ ' <«,) 
Ш
 i=0
 l_e-àtlTi 
(Once again it is stressed that t is the time afther the jth dose) 
Eq. 4.66 is very similar to eq. 4.39, the only difference being that the 
coefficients A¡ are multiplied by a factor depending on the number of 
dosages j , the dosage interval At and the time constant т[. This factor will 
always be larger than or equal to 1 and will increase with decreasing Δι/τ}. 
In practice this means that phases with a long time constant become more 
prominent after multiple dosing. It is conceivable that 'deeper' compart­
ments that cannot be detected after a single dose, because of the low 
concentrations associated with it, come into a measureable range after 
chronic administration, since then deeper compartments are gradually 
filled up (van Rossum, 1971). The correctness of a model based on single 
dose experiments therefore can best be verified by measuring plasma decay 
curves after chronic administration. The increase in the factors A¡ of 
course is not unlimited; after a certain number of doses a plateau is 
reached and the plasma concentration will not increase further. From 
eq. 4.66 it can be seen that this plateau situation is reached when jAt > T[. 
When large differences exist between the various time constants T¡ it is 
possible that pseudo plateau situations are reached. The real plateau is 
reached when jAt is very large as compared to the largest time constant 
involved. Then the following equation holds true: 
C
' ( P l ) = ! o -At / r ; A i e ~ t / T i ( 4 · 6 7 ) 
1 - е 
Once this plateau level has been reached, the profile of the plasma curve 
over the following intervals of course is the same and the average value of 
the plateau concentration is given by a very simple equation: 
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ι /·Δί 
C l ( p i ) = S
o
y C l(pi)d t 
i . fàt £ ___! Ai e -^і dt = i - Σ M 
(4.68) 
By substituting eq. 4.48 we obtain: 
c.(pi)=k¿r or ei(P«"k^i" ( 4 · 6 9 ) 
So in linear pharmacokinetics the height of the average plasma plateau level 
is directly proportional to the dose per interval and inversely proportional 
to the total body clearance constant and the dosage interval. Eq. 4.69 may 
also be used for determining the relative bioavailability of various dosage 
forms after oral administration, since the average plateau concentration 
after chronic administration is directly proportional to the biological avail-
ability F. Further under standardized conditions also the average renal 
excretion rate during the plateau situation could be used as a measure for 
this relative bioavailability since it is directly proportional to the average 
plasma concentration. 
Finally, it may be noted that apart from the averageplateau concentra-
tion, the average concentration during any interval can be calculated 
analogously 
_ γ At j η Air, 
CHRONIC ADMINISTRATION IN THE ONE-COMPARTMENT MODEL 
Of special importance for some of the experiments described in chapters 5 
and 8 is the chronic oral administration in a one-compartment model. In 
this case eq. 4.66 can be written as 
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C lG) = 
FD 
V, 
rel 
г
еГ 
1 - е 
1-е 
-jAt/T
e
i 
-t/rel. 
1 - e 
1 - е 
-jAt/Ta 
-At/T. 
- t / T . (4.71) 
With regard to this equation the following remarks can be made: 
1. No accumulation of drug will occur at all when the dosage interval At is 
large as compared to the time constants for absorption and elimination, 
т
а
 and т
е
\. Since usually т
е
і is larger than т
а
 and since in a one 
compartment system r
e
i = 1.44 t'/icj, one might use the common 
formulation that appreciable drug accumulation can only be expected 
when the dosage interval is smaller than the halflife of the drug. 
2. It is interesting to note that in chronic oral administration not only the 
peak height of the plasma curves during the successive intervals in­
creases until a certain maximum is reached, but that also the time at 
which the successive peaks are attained ( t
m a x
) changes. This can 
generally be derived by differentiating the equation for CiQ) to the 
time t . This differential quotient is equal to 0 for t = t
m a x 
X Р
С
ЧІ)1 
dt 
FD »"el 
*тах * ! rel ~~ r a 
1 i _ e - J ^ r e l _ t 
7
el
 1 _ e -
A t / T
e l 
1 i - e - J A t / r a 
max /rel + 
- t max< 
ra
 l _ 9 - A t / r , 
This leads to the following expression for t 
/rel (4.72) 
Га
7
 el 
t m a x , j = —
a 
in ^ 1 + In ÍL 
(1 
max,j 
-
j A t / T a ) ( l - e -At/reK 
-
Л і / Т а ) ( 1 _ е - І Д * / т е 1 ) 
(4.73) 
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Clearly t
m a x
 has a limiting value when jAt > т
а
 and j At >T
e
j 
T
a
T
el . Tel (1 - e ~ j A t / 7 e l ) 
W ( H
m
) = — in ^ ( i _ e _ A t / T a ) ' (4-74) 
From inspection of these equations it can be seen that during chronic 
administration t
m a x
 gradually decreases until a certain minimum. In 
practice, however, this effect might only be measured in extreme cases 
since usually variations in the time constant for absorption will mask 
the phenomenon. The peak concentration in any interval of course can 
be calculated by substituting the value of t
n i a x : according to eq. 4.73 
in the equation 4.71. It may be noted that this analysis clearly shows 
that the formulas given by Wagner (1971) on page 293 of his textbook 
are incorrect. 
3. In the plateau situation (when jAt > the largest time constant), equa­
tion 4.71 obviously reduces to 
FD '"el 
Ci(pl) = V. rel· 
-Δί/τ, e 
l - e - A t / T e l 
-t/Ta" 
"t/rel. 
(4.75) 
1 - e 
The average value of Ci during an interval in this situation is 
1 / · Δ ί F I ^ e l FD 
С
ЧРІ)=ДГ0./ c'(pi)dt=Aïvr = Z n ^ (4 ·7 6> 
(Note that this result is equal to the general equation 4.69) 
4. The equations presented obviously are not valid when т
а
 = т
е
\=т 
In that case it is easy to show that the equation for the plasma concen­
tration after j dosages is given by 
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r -
F D
 Г ΔΙ e +2ΔΙ e +. 
, . . + (j-l)Ate-Ö-1)At/ r
 + ( 1 + β - Δ ί / Γ + 
+ e-
2 A t /
' + -Ье-О-
1 )^)^^ -t/r (4.77) 
The second seríes in this equation again is a normal geometric one and 
the first is somewhat different but can be summed up as follows: 
Δ
ί β
-
Δ ΐ / Τ
 + - K J - D A t e - G -
1
^ ^ 
( l + e - A t / T +
 + e-fr-l)At/r\ 
d /1-е -jAt/r 
di V l - e - A t / V 
τ 
( l - e - A t / 7 ) 2 
So the plasma concentration after the jth dose can be represented by 
(4.78) 
r
 F D Ate-^-iAte-^+O-QAte-ÍMW
 | 
( l - e - A t / 7 ) 2 
1-е -jAt/r 
1-е -Δί/τ 
t 
-t/T (4.79) 
For the plateau situation we now obtain the following equation: 
-Δί/τ 
r -
 F D 
с,(рі)- Гт 
Ate 
+ 
1 
(1-.-^)» l-e-A t / r 
e
 t / T
 (4.80) 
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The average plasma concentration during an interval in the plateau situation 
can easily be shown to be 
— 1 f FD 
c,(pi) = KÍ J c ,(pi)dt=Än^r 
which is equal to the result of equation 4.69. 
Figure 4.3 shows a theoretical example of the accumulation profile that 
can be expected on basis of equation 4.79. The curve is obtained by 
computer simulation. The validity of equation 4.79 was checked by 
some other simulations according to equation 4.71, in which values for 
r a and rei were inserted that differed only 0.5—1% from each other. 
Ilie curves obtained then were practically indiscernable from the one 
given in figure 4.3 
plasma cone (mg/l:log scale) 
500-
300 
ZOO-
TOO-
50-
30-
20· 
Ю -
1
 • 1 • • 1 • 1 ' i - 1 
2O0 40O 6 0 0 8 0 0 1000 
time ( mm) 
Figure 4.3 
Simulation of the accumulation of a hypothetical substance according to equation 
4.79 (V =61, τ 0 = Tei = 150 min, U = 50 min, D = 500 mg). The curve for a 
substance with the same parameters, but τ
α
 = 149, simulated according to equation 
4.71 is practically the same. See text for further explanation. 
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CHAPTER 5 PHARMACOKINETICS OF IBUPROFEN IN MAN 
INTRODUCTION 
Ibuprofen (2(4-isobutylphenyl) propionic acid)* is a member of a large 
series of substituted arylacetic acids, which possess analgesic antipyretic 
and anti-inflammatory activity. A variety of pharmacological test systems 
have been utilized to show the effectiveness of Ibuprofen in animals 
(Adams et al., 1969; Adams et al., 1970). The spectrum of activity of 
Ibuprofen in these tests appeared to be comparable with that of acetyl-
salicylic acid. Toxicological studies in several animal species revealed no 
serious acute or chronic toxicity (Adams et al., 1969; Adams et al., 1970). 
Although the drug was shown to have ulcerogenic activity it was estab-
lished that this was a systemic rather than a local effect and that it was 
related to the plasma concentration. Extrapolation to the human situation 
led to the prediction that the risk of gastrointestinal irritation, which is in 
fact present in all known antiinflammatory drugs, would be relatively 
small. This has been confirmed in clinical practice. Therapy with Ibuprofen 
up to now has been accompanied by only a low incidence of side-effects. 
Daily doses up to 1200 mg (in divided portions) appear to be free of 
serious side-effects (Huskisson et al., 1971). The value of Ibuprofen in the 
treatment of rheumatic disorders has been established in numerous clinical 
trials (Dick-Smith, 1969; Huskisson et al., 1971). The analgesic and anti-
inflammatory effects may be somewhat less than those of aspirin in the 
usual dosage, but the tolerance usually is better. The antipyretic effect of 
Ibuprofen seems to be quite strong, which makes Ibuprofen even suitable 
for use as a specific antipyretic agent. A recent study concerning primarily 
the analgesic efficacy of Ibuprofen indicates that Ibuprofen in episiotomy 
pain is a useful substitute for acetylsalicylic acid (Bloomfield et al., 1974). 
The main metabolites of Ibuprofen in man are devoid of pharmalogical 
activity (Adams et al., 1970). In view of the fact that there is a clear 
correlation between the antiinflammatory activity and the dose admin-
istered or the plasma concentration at certain times in rat (Kaiser and 
Glenn, 1974) a pharmacokinetic characterization of the drug in man seems 
most useful, since one might expect such a correlation in man too. Adams 
et al. (1970) and Mills et al. (1973) presented some data concerning the 
fate of ibuprofen in man. Their results indicate a short halflife and there-
* Brufen®, reg. trademark Boots Pure Drug Company, Nottingham, UK 
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fore a minimal risk of accumulation in dosage regimens of 3 or 4 times 
daily. Elimination appeared to proceed practically exclusively by forma-
tion of metabolites, which in turn are rapidly excreted, about 60% in 
urine, the rest probably in bile. More systematic measurements of the 
plasma concentrations after a single oral dose of Ibuprofen suggested a 
halflife of about 2 hr in man (Kaiser and Van Giessen, 1974). 
The present studies were undertaken to provide a full pharmacokinetic 
analysis of Ibuprofen in man, including computerfit of plasma concentra-
tion data to the appropriate models and calculation of the relevant para-
meters. Attention has been paid to some biopharmaceutic aspects and to 
the profile of the plasma concentration curve on repetitive administration. 
Further the mechanisms of renal clearance involved were analysed in 
detail. 
MATERIALS AND METHODS 
Drugs 
Ibuprofen (4-isobutylphenylpropionic acid) was kindly supplied by Boots 
Pure Drug Company, Nottingham, UK. Brufen® tablets, containing 
200 mg of ibuprofcn, were commercially obtained from O.P.G., Utrecht, 
The Netherlands. 
Drug administration 
Three different dosage forms of Ibuprofen were employed: Tablets as they 
are marketed in the Netherlands (Brufen® tablets) containing 200 mg 
Ibuprofen; gelatme capsules containing 200 mg Ibuprofen pure substance 
and solutions, freshly prepared by dissolving 400 mg Ibuprofen in 3 ml of 
10%NaHCO3 solution and diluting with water to 200 ml. Tablets and 
capsules were taken together with about 200 ml of water. 
The volunteers participating in the study were all young, healthy 
students who did not receive any other medication during and for a period 
of at least two weeks prior to the trials. None of them had ever suffered 
from liver of kidney function disturbances. The subjects fasted overnight 
prior to the ingestion of the drug at 9.00 a.m. and for an additional 3 hrs 
after drug intake. At regular times after drug administration 7 to 10 blood 
samples of about 5 ml were taken from a fore arm vein and collected in 
heparinized tubes. For at least 30 hrs from the time of drug intake all 
volunteers collected samples of every aliquot of urine they voided, after 
recording the time and the total volume of production. The various 
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volunteers who participated twice or thrice in this study had at least a 
one-week interval between two experiments. One subject took two 
Brufen® tablets three times daily (at 1.00, 9.00 and 17.00 hrs exactly) for 
a period of 14 days. In this experiment samples were taken throughout the 
period, frequently after the first and the last dose and in the period in 
between two or three samples every other day. The blood samples were 
centrifuged, plasma was stored in a deepfreeze (—20° C) until assay. The 
erythrocytes were mostly discarded. Only in some experiments also the 
erythrocytes were analysed for their Ibuprofen content. 
Preparation of samples and gaschromatographic analysis 
As described in chapter 2. 
Protein binding 
The binding of Ibuprofen to albumin was determined by equilibrium dia-
lysis in the apparatus described by Rodrigues de Miranda (1975). In the 
protein compartment a solution of 2.8% bovine serum albumin in 
phosphate buffer pH 7.4 with 0.9% NaCl added was present. The other 
compartment contained Ibuprofen in concentrations ranging from 20 to 
75 mg/1 in an equal volume of the same solvent. Dialysis was performed at 
370C for 20 hrs. During this equilibration process no change in protein 
concentration occurred. After 20 hrs equilibrium was reached as was con-
firmed by pilot experiments in which Ibuprofen was added alternatively to 
the protein free and to the other compartment. Ibuprofen analysis at both 
sides of the membrance was performed as described in chapter 2. 
RESULTS AND DISCUSSION 
The profile of the plasma curve 
Ibuprofen is rapidly absorbed and its concentration in plasma thereafter 
declines to negligible levels within 10 hrs after administration of the three 
dosage forms to the healthy volunteers in this study. Some typical 
examples of plasmacurves together with renal excretion data are given in 
fig. 5.1. The profile of the plasma curves can satisfactorily be described 
according to the open one compartment model (cf. chapter 4). With the 
aid of the computer program Farmfit the plasma concentration data were 
fitted to the appropriate equation: 
C = A ( e " t / T e l - e ~ t / T a ) (5.1) 
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Figure 5.1 
Plasma curves and renal excretion after oral administration of Ibuprofen (400 mg). 
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where А = -г7 (5.2) 
v
 »ei.-rai 
Table 5.1 shows a compilation of the kinetic parameters obtained by this 
fitting procedure. It should be emphasized that the distribution volume, V, 
and the clearance constant, kçei, cannot be determined in absolute terms 
after oral administration, since the biological availability, F, is not known. 
Therefore at least part of the variability in the values estimated for the 
volume of distribution and for the clearance constant will be due to 
differences in F. 
TABLE 5.1 
Pharmacokinetic parameters for Ibuprofen after oral administration (D= 400 mg). 
Subject1 
JE 
LH 
VR 
WS 
JA 
DB 
GB 
BK 
HL 
TS 
AA 
JB 
JB4 
JE 
JH 
LH 
JHo 
MR 
VR 
WS 
(23,91,186) 
(23,66,176) 
(20,67,180) 
(22,78,187) 
(22,70,181) 
(20,80,185) 
(20,65,178) 
(25,60,173) 
(23,76,183) 
(20,67,180) 
(23,81,184) 
(23,67,176) 
(23,91,186) 
(25,57,174) 
(23,66,176) 
(22,75,189) 
(21,54,167) 
(20,67,180) 
(22,78,187) 
V/F 
(1) 
SOLUTION1 
6.1 
6.0 
4.8 
6.2 
CAPSULE' 
7.6 
8.6 
9.2 
5.7 
6.4 
8.3 
TABLET 
4.6 
8.6 
5.7 
11.0 
7.0 
7.4 
8.9 
7.1 
8.1 
11,5 
"Cel/F 
(ml/min) 
39 
41 
31 
37 
49 
53 
54 
38 
36 
53 
36 
51 
35 
72 
46 
49 
51 
46 
52 
70 
T e l 
(min) 
156 
146 
158 
166 
156 
160 
170 
153 
178 
155 
126 
167 
162 
152 
153 
151 
174 
155 
163 
172 
tJ4 
(min) 
108 
101 
110 
115 
108 
111 
118 
106 
124 
108 
87 
116 
112 
105 
107 
105 
121 
108 
113 
119 
т
й 
(min) 
0.7 
2.3 
1.1 
0.4 
8.9 
15.3 
5.1 
2.7 
6.1 
4.7 
46 
75 
30 
88 
29 
57 
16 
10 
12 
26 
1. Numbers in parentheses represent age (yr), bodyweight (kg) and height (cm); all 
subjects are male, 
2. Relative error in 7 
except MR. 
• - is high; upper limit is about 3 min. 
3. These data are taken from the study of chapter 7. 
4. Parameters determined after chronic administration (400 mg 3 dd for 2 \ veeks). 
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Absorption rate 
For all 3 dosage forms absorption was a rapid process, although in case of 
the commercial tablets in a few cases an unusually long time constant for 
absorption was observed. These seem to be exceptions, however, caused by 
individual factors rather than by the drug formulation. Although all curves 
were analysed for the possible occurrence of a lagtime, introduction of this 
additional parameter did not give any significant improvement of the fit in 
most cases. Only when commercial tablets were administered, in 3 out of 
10 participants (AA, WS, JB) a lagtime varying from 10 to 20 minutes 
appeared to be desirable in the sense that a better fit resulted with this 
additional parameter. 
The absorption rate seems to be dependent on the pharmaceutical 
formulation. The average time constants for absorption of tablet, capsule 
and solution are in the order of 20, 5 and 1 minutes respectively. These 
differences certainly are not unexpected. Since a drug has to be dissolved 
before it can be absorbed it is quite understandable that administration of 
the drug in solution warrants the highest absorption rate. The advantage of 
gelatin capsules over the commercial tablets might be that the capsules 
release the drug more easily in a finely dispersed form, resulting in a higher 
dissolution rate of the drug in the gastrointestinal fluid. From a practical 
point of view, however, also ease of storage and dispensing of the drug 
formulation should be considered. Taking these factors into account we 
therefore tend to conclude that differences in absorption rate do not 
justify preference of capsules or solutions over tablets especially since even 
for tablets plasma levels near to maximal are reached as a rule within 
30 minutes. 
Elimination rate 
The rate of elimination of ibuprofen from plasma is quite high. The half-
life (ttë), which is a significant parameter in this respect, varies roughly 
from 1.5 to 2 hrs. The halflife is determined by two fundamental pharma-
cokinetic parameters: the volume of distribution representing the volume 
over which the drug can be imagined to be distributed on basis of the 
measured plasma concentration and the clearance constant which is a 
measure for the efficiency of the clearing organs (liver and kidney especial-
ly) in eliminating the particular drug from the body. 
Volume of distribution and biological availability 
As was stated before after oral administration the volume of distribution 
cannot be determined absolutely, since the biological availability is essen-
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tially unknown. Therefore in table 5.1 the quotient V/F is given, which 
obviously can be calculated according to: 
This implies that the real volume distribution, V, may be smaller than this 
value, since the biological availability by definition is maximally equal to 
unity. It also implies that when various formulations are administered to 
the same volunteer the lowest estimation of V/F is the best approximation 
of the actual volume of distribution, since it corresponds with the highest 
biological availability. The differences found in the values V/F for the 
volunteers WS, JE, VR and LH after administration of tablets and solution 
can easily be explained by assuming the biological availability of the tablet 
form to be lower than that of the solution. The ratio Ftab]et : Fsolution 
should be 0.54; 0,55; 0.59 and 0.81 for the four volunteers respectively. 
Additional evidence in favour of this assumption lies in the fact that the 
time constant for elimination is not significantly different after tablets and 
solution and that the distribution volume or the clearance constant hardly 
could change so much in a few weeks time without other noticeable signs. 
Furthermore, when the experiments were repeated after several months 
roughly the same differences in height of the plasma levels were encounter-
ed. Capsules seem to be comparable with tablets in this respect. In con-
clusion, our data suggest that the biological availability of the tablet (and 
capsule) form is quite variable, being comparable to that of solutions in 
some cases, but definitely lower in other cases. 
It should be borne in mind that the volunteers in this study were fasting 
overnight prior to drug ingestion; this together with the fact that they 
were all young and healthy restricts of course generalization of the con-
clusions. 
The availability of the solution most probably will be nearly complete; 
the actual volume of distribution according to the open one-compartment 
model therefore seems to be in the order of 5 to 7 liters (0.06 to 
0.08 liters per kilogram bodyweight), since still smaller volumes would be 
very unusual. Roughly this estimation coincides with the blood volume. 
However, since we know that the concentration of Ibuprofen in the 
erythrocytes is much lower than in plasma and that the drug in plasma is 
highly protein bound (see below) it is reasonable to think of blood, extra-
cellular and possibly also intracellular water as the phases over which 
Ibuprofen is distributed. That the pharmacokinetic distribution volume is 
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only about 50% of the volume of the extracellular fluid is then directly 
related to the strong protein binding, causing disproportionately high 
plasma levels. 
Oearance 
Since the clearance constant код equals the quotient ν/τ6] it is obvious 
that the estimation of this parameter is also dependent on the biological 
availability. The same discussion as given above for the distribution volume 
therefore can be applied to the clearance constant. When the values for the 
relative clearance constants k^çj/F for the subjects who took both tablets 
and solution are corrected for the differences in F, as argued above, it 
appears that the clearance constant is independent of drug formulation. 
Another result of course would be hardly feasible. Taking these considera-
tions into account, the best estimate for the value of the clearance constant 
is in the range of 30 to 50 ml/min. The clearance of Ibuprofen occurs 
almost exclusively by metabolic transformation. The contribution of renal 
excretion is negligible for all practical purposes (see below). Since we are 
dealing with plasma clearance and since the blood cells contain only minor 
amounts of drug we can compare the clearance constant with the plasma-
flow through the liver, which is approximately 750 ml/min. Assuming that 
the metabolism predominantly takes place in the liver, one might calculate 
that in the liver only about 4—7% of the drug is extracted from the plasma 
passing through. This does not seem to be a very efficient process and a 
retarding effect by the strong binding to albumin in the plasma is very well 
possible. Also the very low renal clearance may be caused by this binding, 
but on the other hand substantial reabsorption may be an important factor 
here. The fact that the protein binding seems to inhibit renal excretion to 
a much higher degree than metabolic conversion might be due to differ-
ences in the average transit times. The hepatic transit time can be expected 
to be longer than the renal cortical transit time, so the dissociation of the 
drug-protein complex will be more easily rate limiting in the kidney than 
in the liver. Evidence in favour of this assumption is obtained by compar-
ing the bloodflow through the kidneys and the liver per equal amount of 
tissue. For the kidneys this is as high as 400 ml/min per 100 ml of tissue, 
whereas for the liver a value of about 40 ml/min per 100 ml of tissue is 
found, so a factor 10 lower (Mapleson, 1963). Furthermore the vascular 
system becomes quite diffuse in the liver, thereby allowing even protein 
bound drug to leave the blood vessels. 
The low metabolic clearance constant implies that no significant first 
pass effect can occur, although the rate of elimination of the drug from 
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plasma is rather high (see abo chapters 8 and 10B). The fact that despite 
the low clearance constant a high elimination rate is found is a direct 
consequence of the small apparent volume of distribution, to which the 
rate of elimination is inversely proportional. 
Renal excretion 
The relevant renal excretion data are summarized in table S.2. Obviously 
only a negligible amount of drug is excreted unchanged by the kidney 
whereas a more substantial amount is found in urine in the form of its 
glucuronide. Some examples of the urinary excretion rate both for free 
and for glucuronidated Ibuprofen are given in figures S.l and 5.2. Al-
though the renal excretion of unchanged Ibuprofen is practically negligible 
the renal clearance appeared to be a highly interesting process. This is 
demonstrated in fig. 5.3 where the renal excretion rate is plotted as a 
function of the average plasma concentration over the period of excretion. 
TABLE 5.2 
Cumulative renal excretion in %of dose (Qr%) of unchanged Ibuprofen and ibupiofen-
glucuronide after oral administration of Ibuprofen (I>=400 mg). 
Subj. 
AA 
JB 
JE 
JH 
LH 
JHo 
VR 
WS 
JA 
DB 
GB 
BK 
HL 
TS 
Qr% 
(unch.) 
TABLET 
0.71 
0.35 
0.81 
0.55 
0.64 
0.27 
1.39 
150 
CAPSULE 
0.83 
1.45 
0.35 
0.80 
2.06 
0.43 
Qr% 
(gluc.) 
19.25 
7.65 
_ 
12.80 
— 
_ 
— 
" 
13.90 
8.85 
10.00 
9.25 
16.20 
10.90 
— not determined. 
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Figure 5.2 
Renal excretion of free andglucuronidated Ibuprofen in a volunteer who received 
400 mg Ibuprofen (capsule). Note the much larger excretion of the glucuronide. 
The profile of these graphs suggests at least two mechanisms governing 
Ibuprofen excretion, viz. glomerular filtration and tubular secretion. If 
only glomerular filtration would occur the plots in fig. 5.3 should be 
straight lines passing through the origin. The profile that is found 
experimentally is in accordance with the superposition of tubular secretion 
upon glomerular filtration. Tubular secretion usually is an active process, 
which is saturated when the supply of substrate exceeds certain limits. The 
simultaneous occurrence of glomerular filtration and tubular secretion can 
be formulated as follows: 
dQr 
dt 
where 
M 
k c r C P + K T + C , 
Τ
 τ ν
- ρ 
(5.4) 
- ^
1
 = rate of urinary excretion (e.g. in ^g/min) 
dt 
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T M = 
Ky = 
с
р
 = 
clearance constant for glomerular filtration (combined with 
passive reabsorption; e.g. in ml/min) 
tubular transport maximum = the amount of drug that can 
be secreted maximally per unit of time (e.g. in μg/min) 
Michaelis Menten constant for the drug with respect to the 
secretion mechanism (e.g. in /ig/ml or mg/1) 
plasma concentration 
The two processes can be differentiated as exemplified in the figure. One 
makes use of the fact that tubular secretion becomes saturated at high 
plasma levels where Cp » Kj. Then the renal excretion rate is given by: 
d Q I _ , 
d t -
 k Cr C p + T M (5-5) 
renal ексгеіюп rote (идДпт) 
18 
subject JE 
2 0 3 0 «3 5 0 
plasmo coocentrtition (ид/ті ) 
Figure 5.3 
Renal excretion rate of ibuprofen as a function of the average plasma concentration 
over each interval. Note the non-linear curves, indicating the occurrence of tubular 
secretion. The graphs can be analysed as discussed in the text and give an impression 
of the relative contribution of filtration (GF) and tubular secretion (TS) to the 
overall excretion. The plasma concentration at half-maximal tubular secretion 
represents the Michaelis-Menten constant of the secretion mechanism (Kj). 
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so that the excretion rate at high plasma levels becomes a linear function 
of the plasma concentration. The straight line is shifted with respect to the 
origin by the amount Тод. So a line through the origin parallel to the final 
straight part of the excretion curve represents the linear part of renal 
excretion (filtration). By subtracting this line from the experimental curve 
the process of tubular secretion is found. Kj is equal to the plasma con­
centration at which the tubular secretion rate is half-maximal and can be 
found experimentally by interpolation. Obviously also Тэд is easily 
accessible (figure 5.3). Unfortunately the values found for these para­
meters (Kj = 2-4 mg/1 and Ход = 2-4 Mg/min) are purely operational, 
since one cannot be sure which plasma concentration is meant with Cp in 
equations 5.4 and 5.5. We derived the parameters for the case that Cp is 
the total plasma concentration, comprising both free and protein-bound 
drug. This, however, is a questionable assumption, since protein binding 
certainly will retard the rate of tubular secretion (Rodrigues de Miranda, 
1975). The degree of this effect will be dependent on the rate of dissocia­
tion of the drug-protein complex. The same holds true in fact for the 
glomerular filtration process. Taking into account that in the concen­
tration range studied about 99% of the drug in plasma is protein bound we 
can conclude that the estimated value for the clearance constant for 
glomerular filtration may be even a factor 100 too low, when no dissocia­
tion of the drug from the protein occurs at all during the process of 
filtration. The actual clearance constant will be somewhere in between and 
cannot be calculated on basis of the present data alone. 
The fact that strong indications for tubular secretion of Ibuprofen are 
found is not surprising. Despopoulos (1965) summarized molecular charac­
teristics required for tubular secretion. One of these is the occurrence of a 
free, ionized carboxyl group as it is present in Ibuprofen. However, the 
secretory mechanism has only a low capacity for ibuprofen and is easily 
saturated. This may be caused by the fact that other prerequisites are 
lacking, for instance an amino function which seems to enhance tubular 
secretion strongly. As far as the influence of protein binding is concerned 
it should be realized that such binding counteracts the appearance of 
tubular secretion. Characteristic for the binding is the fact that at low drug 
concentrations the fraction of bound drug is relatively higher, so the 
amount of drug directly available for excretion or secretion is relatively 
smaller than at high levels. This implies that at low plasma concentrations 
the renal excretion rate is decreased by protein binding below the 
theoretical level that would be obtained in the absence of protein binding. 
Such an effect is opposite to the one measured, so one may conclude that 
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on basis of free drug concentrations the appearance of tubular secretion 
would be more pronounced. 
Since only very minor amounts of Ibuprofen are excreted in urine un­
changed, there will be no need for dosage adjustment in renal function 
impairment. Furthermore, competition by other drugs for the tubular 
secretion mechanism can never be significant in that quantitatively only 
negligible amounts of Ibuprofen are involved in this process. On the other 
hand, Ibuprofen might give rise to substantial inhibition of tubular 
secretion of other drugs that are secreted by the same mechanism to a 
higher amount, since the degree of inhibition is primarily determined by 
the ratio of the plasma concentration over its K j value. That up to now no 
serious interactions in this respect are reported may be caused by the fact 
that such drugs are rare or even not existing. 
Metabolites in urine 
Table 5.2 shows that approximately 10-20% of the dose administered is 
excreted in urine as ibuprofen-glucuronide. See also fig. 5.2. The occur­
rence of this ester-type glucuronide is not unexpected since conjugation to 
renal excretion ratedig/rnin.-log scale)-
10-
0.1-
0.01 
h г"1 
LJ 
subj.W.S. 
5 10 
t ime ( hr) 
Figure 5.4 
Renal excretion of two presumable metabolites of Ibuprofen. Mass spectrometric 
analysis of the compounds indicated a structural similarity to Ibuprofen and suggest­
ed oxidation of the isobutyl group. 
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glucuronic acid is a common metabolic pathway for carboxylic acids. Gas-
chromatograms of urine extracts obtained usually contain two other peaks 
with retention times about 3 and 6 times that of Ibuprofen. The increase 
and subsequent decrease of the height of these peaks was reminiscent of 
what could be expected for metabolites of Ibuprofen (fig. 5.4). Mass 
spectra obtained from silylated urine extracts in the GCMS LKB 9000 were 
in accordance with the structure of the two urinary metabolites as 
proposed by Adams et al. (1967). Roughly estimated the total amount of 
these metabolites excreted was about 1—2% of the dose, but it cannot be 
excluded that more substantial amounts are excreted as glucuronide. As 
far as the large remaining part of the dose, not accounted for, is concerned 
one may think of biliary excretion as a major pathway of elimination, 
especially for metaboUtes. Indications for this can be found in literature 
(Adams et al., 1970; MUls et al., 1973). 
Protein binding 
Under the circumstances as described and in the concentration range 
applied (20—75 mg/1) the binding of Ibuprofen to bovine serum albumin 
appeared to be more than 98%. At plasma concentrations below 20 mg/l 
the theoretical binding percentage is even higher. On the basis of our data 
we estimated the association constant of the drug-protein complex Kass to 
be in the order of 105—106 1/mol. This agrees reasonably with the value of 
105 1/mol that Mills et al. (1973) found for the association of Ibuprofen to 
human plasma. In practice these binding data imply that at usual (thera-
peutic) concentrations the drug in plasma is nearly completely protein 
bound (binding percentage more than 98%). As discussed above this high 
protein binding probably will contribute to the small volume of distribu-
tion and to the relatively small renal and metabolic clearance. The com-
bination of high plasma levels (caused by small distribution volume) and 
the high degree of binding to plasma proteins might be expected to give 
rise to serious interactions with other drugs at the level of protein binding. 
Up to now, however, no data are available in this respect, nor have serious 
clinical consequences been reported. 
Erythrocytes 
Figure 5.5 shows for two volunteers the concentration of Ibuprofen in the 
erythrocytes as compared to the plasma levels. The concentration in ery-
throcytes appears to be slightly less than 10% of that in plasma, but 
equilibrium seems to be established rapidly, since the Unes are reasonably 
parallel, so the ratio is constant. Several factors might contribute to the 
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finding that erythrocyte concentrations are so much lower than plasma 
concentrations. First of all there is a difference in pH: the pH of plasma is 
7.4 whereas that of erythrocyte cystosol is 7.25. The pK
a
 of Ibuprofen is 
4.4 as we determined by differential Potentiometrie titration similar to the 
method of Janssen et al. (1970). This pH difference accounts for about 
30% lower concentrations in erythrocytes than in plasma. The second and 
important factor is the possible difference in protein binding: Ibuprofen is 
highly bound to plasma protein, but probably much less to cellular 
proteins although no exact data are available. Finally, there is a source of 
error in the experimental method. After centrifugation erythrocytes 
remain somewhat contaminated with plasma. When this contamination 
would mount up to for instance 10%, the only justified conclusion would 
be that erythrocytes contain not more than negligible amounts of Ibu­
profen, since the levels found would be due to contamination with plasma. 
This last situation cannot be excluded in the light of the experimental 
procedures. 
concentration (mg/ljlog scale) 
ibuprof en 
, 400 mg oral 
• plasma 
Δ erythrocytes 
200 400 600 200 ' 400 ' 6 0 0 
time (min) 
Hgwe 5.5 
Concentration of Ibuprofen in erythrocytes as compared with the concentration in 
plasma. Note the parallel course, which indicates rapid equilibration. 
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Repeated administration 
Mills et al. (1973) presented evidence that neither Ibuprofen itself nor its 
known metabolites had a tendency to accumulate in plasma in man (and in 
several animal species) after repetitive administration during 14 days. For 
Ibuprofen this is not surprising in view of its short halflife (1.5—2 hrs) with 
respect to the usual dosage interval (8 hrs). As was shown in chapter 4 the 
average steady state plasma concentration after chronic administration is 
given by: 
с = - ^ -
p
 AtkC e l 
Inserting the values found for Ibuprofen in this study one can calculate 
that the average steady state concentration in a dosage regimen of 400 mg 
thrice daily is about 20 mg/1, which is hardly above the average concentra­
tion after a single 400 mg dose. This also implies that such dosage regimens 
are subject to very pronounced fluctuations in the plasma concentration. 
plasma cone. (mg/l; log scale 
100 
104 16Θ 176 216 224 264 272 336 344 
time (hrs) 
Figure 5.6 
Plasma concentration during repeated administration (400 mg, 3 dd) of Ibuprofen. 
Practically no accumulation occurs and the plasma level is very fluctuating. The curve 
is generated on basis of the parameters obtained after a single dose and gives a 
reasonable adaptation to the experimental data. 
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All of these predictions are confirmed experimentally as exemplified in 
figure 5.6 where the plasma concentration during chronic administration 
to a volunteer in a regimen of 400 mg thrice daily (every 8 hrs) is given. 
Although the profile is exactly as expected, which also confirms that the 
open one-compartment model yields an adequate description of Ibuprofen 
kinetics, serious questions remain open for discussion. For instance, the 
question of how it is possible that these fluctuating plasma levels can lead 
to apparently satisfactory pharmacological effects. One possible explana-
tion for the discrepancy between plasma levels and presumed effect is that 
only temporarily high levels are needed to regulate one or another disturb-
ed process, which then automatically remains in order for a longer period 
of time. Another possibility would be that the plasma concentration is not 
a good reflection of the effective drug concentration at the site of action. 
One might think for instance of concentration of Ibuprofen in leucocytes 
or in the synovial fluid as a better guide for the efficiency of the drug, 
since these compartments probably are more directly connected with the 
site of action of the drug. 
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CHAPTER 6 PHARMACOKINETICS OF IBUPROFEN 
OPTICAL ISOMERS IN MAN 
INTRODUCTION 
In the preceeding chapter the pharmacokinetics of Ibuprofen in man have 
been discussed. Since Ibuprofen contains an asymmetric carbon atom, the 
question arose if there exists a difference in pharmacological activity and 
pharmacokinetic behaviour between the two optical isomers. As far as the 
activity is concerned, it is quite common that there exists a difference 
between optical isomers (see for instance Rodrigues de Miranda, 1975). 
Also in the field of antiinflammatory phenylacetic acid derivatives, 
analogous to Ibuprofen, it has been found that the dextro-isomers are 
often much more potent than the levo-isomers (Shen, 1967). However, in 
case of Ibuprofen, Adams et al. (1967) reported that no difference exists 
in the antiinflammatory potency of the two isomers in the guinea pig 
ultraviolet erythema test. Interestingly they also found that the principal 
urinary metabolites of racemic Ibuprofen in man were dextrorotatory. 
These facts might indicate an isomerisation step from the levo- to the 
dextro-isomer of Ibuprofen in vivo. Support for this idea is given by the 
observation that after administration of the pure levo-isomer the urinary 
metabolites were dextrorotatory, although to a lesser extent than after the 
dextro-isomer itself indicating that only incomplete inversion takes place 
(Mills et al., 1973). Finally, after completion of our study, Van Giesen and 
Kaiser (1975) published a method for differential measurement of the 
optical isomers of Ibuprofen in plasma or urine. Applying this method to 
the analysis of plasma samples after administration of the racemic mixture 
they found the levo-enantiomer to disappear substantially more rapidly 
from plasma than the dextro-isomer. As a matter of fact on the basis of 
these observations, one would expect a biphasic elimination of racemic 
Ibuprofen. In our previous study, however, we did not find any indication 
for that. Therefore we decided to follow the plasma concentration and 
renal excretion after administration of the pure dextro- and levo-enantio-
mers as well as the racemic Ibuprofen in the same volunteers, in order to 
see whether the pharmacokinetics of the individual isomers sum up to the 
monoexponential decay found for the racemate. 
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MATERIALS AND METHODS 
Drugs, reagents, preparation of urine and blood samples, glucuronidase 
treatment, gaschromatography were the same as described in chapters 2 
and 5, except for the following additions. 
1(—)—1-phenylethylamine and d(+)—1-phenylethylamine were obtained 
from Aldrich, Milwaukee, Wisconsin, USA. 
A gift of reference amounts of the d- and 1-isomers of Ibuprofen from 
Boots Pure Drug Company (Nottingham, England) is gratefully acknowl­
edged. 
Resolution of Ibuprofen 
To a solution of racemic Ibuprofen in hot acetone an equimolar amount of 
1(—)—l-phenylethylamine in acetone was added (cf. Adams et al., 1967). 
The precipitating phenylethylammonium salt was collected in four about 
equal fractions. The first fraction of the salt was recrystallized twice from 
acetone. A melting point of 160—1620C was obtained. The salt was dis­
solved in HCl 2N and this solution was extracted with n-hexane. After 
crystallization the resulting Ibuprofen (mp 49.5—50.5) appeared to be 
sufficiently pure dextro-isomer with a specific rotation [a]?? =53.6° (in 
ethanol). From the third and fourth fraction, which were of course already 
enriched with l(-)-isomer, Ibuprofen was isolated. This was dissolved in 
hot acetone and mixed with an equimolar amount of d(+)—1-phenylethyl­
amine in acetone. Again the precipitate was collected in four fractions. 
Hie first fraction was crystallized from acetone, then from toluene and 
finally from chloroform. The resulting melting point was 149—1510C. 
From this salt Ibuprofen was isolated and then crystallized from petroleum 
ether. The specific rotation of this Ibuprofen fraction (mp 50—510C) in 
ethanol was [α]ΐΐ = —55.5°, indicating sufficiently pure levo-isomer. 
The overall yield in this resolution procedure was about 8% for both 
isomers, calculated on basis of total amount of racemic starting material. 
Drug administration 
Four volunteers participated in this study. At the first day of the series of 
experiments they received 200 mg of racemic Ibuprofen; one week later 
two of them received 200 mg of the dextro-isomer and the other two 
200 mg og the levo-isomer; after another week each volunteer got 200 mg of 
the other isomer and two weeks later all of them ingested a control dose of 
200 mg of the racemate. In the last experiment only 5 blood samples were 
drawn in order to confirm that the volunteers showed the same pharma-
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coki net ic pattern as m the first experiment. In the other experiments 
10 blood samples were taken over a period of 9 hrs after drug administra­
tion. The conditions were the same as described in chapter S. 
The dosage form in all cases was the same and consisted of 200 mg 
Ibuprofen (or ibuprofen-isomer) dissolved in 3 ml КаНСОз 10% solution, 
diluted with water to 200 ml. 
RESULTS AND DISCUSSION 
The pharmacokinetic parameters obtained are summarized in table 6.1 and 
figure 6.1 shows as an example for one of the volunteers the plasma levels 
and the urinary excretion data after ingestion of racemic, dextro- and 
TABLE 6.1 
Pharmacokinetic parameters after oral administration of Ibuprofen isomers (D=200 mg). 
Subject' 
JE 
* 
(24,90,186) 
(24,66,176) 
(21,69,180) 
(23,79,187) 
isomer 
+ 
-
+ 
С 
+ 
-
± 
С 
+ 
-
± 
с 
+ 
-
± 
с 
Vf/F 
(1) 
6.3 
5.5 
5.9 
7.7 
4.1 
5.6 
6.3 
4.5 
5.0 
8.7 
5.7 
7.0 
W f Tel (mi/min) (min) 
45 
30 
37 
51 
26 
37 
55 
24 
33 
55 
37 
45 
140 
180 
160 
150 
160 
151 
115 
186 
152 
159 
153 
156 
t% 
(min) 
97 
125 
111 
106 
104 
HI 
105 
109 
80 
129 
106 
110 
110 
106 
108 
101 
-a' 
(min) 
0.4 
0.6 
0.5 
0.4 
0.5 
0.5 
0.4 
0.6 
0.1 
0.6 
0.5 
0.4 
LH 
VR 
WS 
1. Numbers in parentheses represent age (yi), bodyweight (kg) and height (cm); all 
subjects are male. 
2. The relative error in т
л
 in high; upper limit about 3 min. 
3. " С refers to a control experiment where only halflife of the racemate was mea­
sured. 
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Figure 6.1 
Plasma curves of ibuprofen and cumulative renal excretion of Ibuprofen and its 
glucuronide after oral administration of the separate isomers and of the racemate. 
levorotatory ibuprofen. The data reveal some interesting differences in the 
pharmacokinetic behaviour of the enantiomers. In any case, the elimina­
tion halflife of the dextro-isomer tends to be smaller than that of the 
levo-isomer, whereas the halflife of racemic mixture has a value in 
between. The differences, however, are only in 2 of the volunteers 
significant. The theoretical plasma profile for the racemate, as expected on 
basis of the average of the separate curves for the enantiomers, is in close 
agreement with the experimental results. In principle the elimination of 
the racemate proceeds in a biphasic way, which is not detected experimen­
tally because of the relatively small difference in elimination rate of the 
optical isomers. More pronounced differences are encountered in the 
values for V/F and keel/*7 a s ^ е У a r e f?7611 i n t a ^ e ^^ · ^ n e "^ßht 
expect some random variation to occur in these parameters since all drug 
formulations have been given orally. However, the variations are not 
arbitrary, but systematic differences occur. In any one of the volunteers 
the dextro-isomer exhibits a larger apparent volume of distribution and a 
larger clearance constant than the levo-isomer. As should be expected 
when dealing with real, fundamental differences in these parameters, 
the values for the racemic ibuprofen are about the average of the 
values for the enantiomers separately. This evidently suggests that 
the measured differences are not caused by variable biological avail-
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ability but are due to differences in the intrinsic pharmacokinetic 
behaviour of the substances. It may be noted, furthermore, that 
absorption from the drug solution applied was extremely rapid and started 
without delay. The estimated time constants for absorption are in all cases 
smaller than 0.6 minutes and no lag-time occurs. Provided that the absorp-
tion can be regarded as a linear process, this implies that absorption is 
completed within a few minutes. In that case it does not make sense that 
the bioavailability of the dosage form would not be about unity. But even 
when absorption is not a linear process, which means that r a would only 
be an operational parameter, it still can hardly be imagined that, in the 
very short time interval involved, substantial differences in the absorbed 
fraction would be found. Especially since the three substances concerned 
have exactly the same overall physicochemical properties, are dispensed in 
the same formulation and to the same volunteers on an empty stomach. 
Accepting the significance of the differences measured it remains difficult 
to offer a straightforward explanation. Optical isomers can only be 
expected to behave differently from each other as long as three-points-
interactions are involved (cf. Rodrigues de Miranda, 1975), but certainly 
not when general physicochemical characteristics are concerned, like acid 
or base strength, lipophilicity etc. Now the volume of distribution of a 
drug is regarded as primarily determined by its pKa, its lipophilicity and 
by possible affinities for cell or tissue compartments. As argued before 
(chapter 5) it is very unlikely that Ibuprofen would cumulate in one or 
another tissue to a substantial amount, since most of the drug is present in 
plasma. A factor which definitely will play a role in the smallness of the 
volume is the high degree of protein binding. Small differences in affinity 
between the stereoisomers might not easily be detected but nevertheless be 
sufficient for explaining the differences in apparent volume of distribution 
(and to some extent also in total body clearance, cf. Van Ginneken and 
van Rossum, 1975). If stereoselectivity in the protein binding of Ibuprofen 
would occur one should expect the racemate to behave as a mixture of 
two compounds. This is not found experimentally (Mills et al., 1973). 
Furthermore, Perrin (1973) demonstrated that the binding of fenoprofen, 
a drug closely related to ibuprofen, to human serum albumin is not stereo-
specific, but is mainly the result of hydrophobic interactions and hydrogen 
bonding of the carbonyl group. In a study on the pharmacokinetics of 
hexobarbital isomers Breimer (1974) also did not find significantly 
different protein binding percentages for the optical isomers. In general, 
binding to plasma proteins seems to be not stereospecific and extra-
polating we assume that here no explanation for the different kinetic 
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behaviour of the ibuprofen ¡somen can be found. 
On the other hand enzymatic transformation as a rule is stereoselective, 
so the differences found in the clearance constant are not unexpected. 
Then another phenomenon might be relevant for discussion, viz. a first 
pass effect, leading to different amounts of drug that reach the general 
circulation intact after oral administration. This possibility can be elimin-
ated because of convincing arguments. For, the magnitude of the first-pass 
effect depends upon the ratio of hepatic drug clearance and blood (or 
plasma) flow through the liver. Since for the ibuprofen isomers the clear-
ance constants are in the order of 30—SO ml/min, which is very small with 
regard to hepatic plasma flow (about 750 ml/min) one can conclude that 
none of the isomers will be cleared substantially during its fírst pass 
through the liver. 
Another point of interest is the amount of ibuprofen excreted by the 
kidney after ingestion of any of the isomers. From the data in table 6.2 it 
becomes evident that ibuprofen excretion after the dextro-isomer is some-
what larger than after the levo-isomer. This is in agreement with the 
observation of Van Giessen and Kaiser (1975) that after administration of 
racemic ibuprofen most of the ibuprofen excreted is dextrorotatory. The 
excretion of ibuprofen-glucoronide is somewhat higher after the dextro-
TABLE6.2 
Cumulative renal excretion of ibuprofen and ibuprofen-glucuionide after oral admini-
stration of ibuprofen isomers (Qr%= percentage of dose). 
isomer 
+ 
± 
+ 
± 
+ 
± 
+ 
± 
Qr% (unch.) 
1.42 
0.88 
1.33 
2.12 
1.34 
3.30 
3.11 
1.04 
3.65 
4.28 
1.87 
2.37 
Qr% (glue.) 
10.0 
4.3 
8.1 
8.8 
2.2 
10.1 
11.7 
4.4 
14.3 
17.0 
6.5 
13.2 
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isomer than the levo-isomer. The observed differences are, however, only 
of minor importance and can in no way account for the overall pharma-
cokinetic differences encountered. 
In this discussion up to now we neglected one additional phenomenon, 
which, as it will turn out, can yield the clue of the solution of our 
problem, viz. the possibility of isomerization. Adams et al. (1967) found 
that the urinary metabolites of racemic Ibuprofen in man were dextro-
rotatory and Mills et al. (1973) confirmed this finding, even after 
administration of levo-ibuprofen. A third important observation in this 
respect was done by Van Giessen and Kaiser (1975) who measured plasma 
levels of both isomers of Ibuprofen separately after administration of the 
racemic mixture in man. The levo-enantiomer appeared to disappear from 
plasma much more rapidly that the dextro-enantiomer. Interestingly this 
seems contradictory to our data, which indicate a slightly faster elimina-
tion of Ibuprofen after ingestion of the dextro- than after the levo-isomer. 
In combination with the differences in distribution volume we measured, 
this evidently suggests that stereoselective elimination alone can never 
satisfactorily explain the observations. On the other hand all data are in 
entire agreement when isomeric inversion is assumed to take place. Based 
upon the analysis of the simplest model including isomeric inversion as 
given in the appendix some numerical examples are simulated in figure 6.2. 
Concentration data at hourly intervals are generated for total Ibuprofen 
after i.v. injection of the dextro- and levo-isomer and of the racemic 
mixture. Although the theoretical curves are principally biexponential, so 
that no straight lines can be expected in a semilogarithmic plot, it will in 
an experimental situation with a limited number of points always be 
possible to obtain a reasonably fitting straight line. Such lines are drawn in 
the figure. It is obvious that differences in the intercepts on the concentra-
tion axis exist, although the same distribution volume for both isomers 
was taken for simulation. This implies that also after oral administration 
different apparent volumes of distribution will be estimated for different 
isomers and that the apparent volume of distribution of the racemic 
mixture, which has an intermediate value, can be expected to approximate 
the actual volume quite well in most cases. Furthermore, it becomes clear 
from these simulations that the above mentioned paradox concerning the 
elimination rate of the two isomers can easily be accounted for. It is suffi-
cient to assume that the high rate of disappearance, that Van Giessen and 
Kaiser (1975) found for the levo-isomer is primaraly determined by in-
version to the dextro-isomer and not at all or only for a small part by real 
elimination. When this inversion clearance is higher than the elimination 
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τα cone (mg/ljog scale) 
6 8 10 2 4 6 8 10 
time (hours) 
Figure 6.2 
Theoretical plasma curves after intravenous administration of 400 mg of the separate 
isomers or the racemate of a hypothetical drug. The volume of distribution is 61 for 
both isomers. The curves are simulated on basis of the equations given in the appen­
dix and represent the total concentration of the drug (both isomers). The upper, 
middle and lower curve correspond to administration of isomer 2, racemate and 
isomer 1 respectively. The parameters used for simulation are: кс
е
ц = 2, kcel2 
= 0.2, Kj2 = k2i = 1,5 (curve a); kcell = 2, kcel2 = l·5· k12 = !· k21 = 0.5 (curve 
b): kCel 1 = 2 ' kCel2 = 0.2, к¡2 = О, А^ = 3 (curve с); kCe¡] = 2, kCe[2 = 1.5, λ;2 
= 0, к2] = 3 (curve d). Every к has the dimension of l/hr. 
It should be noted that the isomeric conversion leads to differences in the apparent 
volumes of distribution and that the elimination of the total amount of drug may 
proceed more slowly after administration of the isomer with the highest sum of 
isomerization and elimination clearance (curves с and d). 
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clearance of the dextro-isomer itself, then the elimination of total Ibuprofen 
will be faster after the dextro-isomer than after the levo-isomer. 
In conclusion we may state that our data strongly support the idea, 
already expressed in the literature, that the elimination of Ibuprofen 
enantiomers involves inversion of levo- to dextro-ibuprofen, whereas the 
opposite inversion does not take place, or at most to a very minor extent. 
NOTE added in proof: 
After completion of this chapter further evidence in favour of the isomeric inversion 
as discussed in the text was given by Adams et al. (J. Pharm. Pharmacol. 28, 256, 
1976) on basis of the difference between the pharmacological activities in vitro and 
in vivo and by Kaiser et al. (J. Pharm. Sci. 65, 269, 1976) on basis of measurement of 
the enantiomeric composition of drug-related materials excreted in human urine. 
APPENDIX 
The most simple pharmacokinetic model allowing interconversion of two 
stereo-isomers can be depicted as follows: 
I, 
кц | k21 
ί. 
kCeli 
kCel2 
(6.1) 
where li and I2 designate the respective isomers, k^ and kji the 'isomeri-
zation clearance constant' (with the dimension of volume per time) and 
''Celi а ш * kçe] the elimination clearance constant (also in volume per 
time). We assume the volume of distribution of both isomers to be the 
same. For the sake of simplicity we restrict this description to i.v. 
adminstration and then the model is governed by the following set of two 
simultaneous differential equations (where Ci and C2 represent the con-
centrations of the respective isomers in this single compartment, the 
volume of which is given by V): 
dÇ1= kj, 
dt V 
ЦГеІ. + к 12 
С, (6.2) 
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dÇa 
dt V с, -
kCel, + k « (6.3) 
The boundary conditions for these equations are dependent upon the 
isomer administered : 
for li : (t=0; Ci = - and C2=0) 
Ь :(t=0;C,=0andC 2 =^) 
equimolar mixture of li and Ij (racemate): 
(t=0;C, = C 2 = ^ r ) 
In this way the system is fully defined and both concentrations can be 
expressed as a function of time by integrating equation 6.2 and 6.3. 
Since in the context of our discussion only the sum of concentrations of 
the two isomers is relevant we here only present the result for this sum 
Ci + Сг- Then we obtain: 
1. after i.v. administration of I| 
ЦГеІа
 +
 k i î + k » 
0 = 0, +C2 = 
- a 
b-a 
kçel, + ki2 + k2i b 
V L b-a 
2. after i.v. administration of I2 
at 
,-bt 
C = Ci +C 2 = 
D 
V 
kiel, + к ч + k2i 
V 
I b-a 
— a 
-at 
(6.4) 
D 
V 
kCel, + k l l + k 2 1 
V 
L b-a 
"— D 
-bt (6.5) 
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3. after i.v. administration of the racemic mixture (It + Ь ) 
c = c , + C 2 = ^ 
kCel, + kCel, + 2k12 + 2k21 
2V 
L b-a 
— a 
.-at 
D 
V 
kCel, + kCel, + 2ki2 + 2k21 
2V 
L b-a 
- b 
e -
 b t
 (6.6) 
The rate constants (reciprocal time constants) in these equations are 
defined by: 
a)b = %(p±Vp^r4q) (6.7) 
where 
P = 
kÇelt + kCel2 + к ч + кді 
q= 
kCelt'tCeU + k C e l i k « + k C e l
a
k
n 
(6.8) 
(6.9) 
REFERENCES 
Adams, S.S., E.E. Cliffe, B. Lessel and J.S. Nicholson, / Pharm. Sci 56, 1686 
(1967). 
Breimer, D.D., Pharmacokinetics of hypnotic drugs, Ph.D. thesis, Nijmegen (1974). 
Mills, R.F.N., S.S. Adams, E.E. Cliffe, W. Dickinson and J.S. Nicholson, Xenobiotica 
5,589(1973). 
Perrin, J.H., J. Pharm. Pharmacol 25, 208 (1973). 
Rodrigues de Miranda, J.F., Specificity in drug-protein interaction, Ph.D. thesis, 
Nijmegen (1975). 
Shen, T.Y., Chem. Eng. News 45,10 (1967). 
Van Giessen, G.J. and D.G. Kaiser, /. Pharm. Sci 64, 798 (1975). 
Van Ginneken, C.A.M. and J.M. van Rossum, Pharm. Weekblad 110,1253 (1975). 
107 

CHAPTER 7 COMPARISON OF THE PHARMACOKINETICS 
OF IBUPROFEN AND IBUFENAC IN MAN 
INTRODUCTION 
Among the enormous series of phenylacetic acid derivatives, synthetized 
and tested for antiinflammatory properties during the last 15 years, there 
are two compounds which interested us especially from a pharmacokinetic 
point of view, viz. ibufenac (4-isobutylphenylacetic acid) and its alpha-
methyl analog Ibuprofen (2(4-isobutylphenyl) propionic acid). Both these 
compounds exhibit substantial antiinflammatory, analgesic and antipyretic 
activity, Ibuprofen being more active than ibufenac in a set of conven-
tional animal models (ibufenac: Adams et al., 1963; Ibuprofen: Adams et 
al., 1967). Since long term use of ibufenac occasionally caused jaundice 
(Buckler and Adams, 1968) the compound was abandoned and all the 
attention was directed towards its alpha-methyl derivative Ibuprofen, 
which apparently lacked this side-effect. It is interesting to note that the 
higher incidence of side-effects for ibufenac, as compared to Ibuprofen, 
apparently can be related to differences in tissue distribution. Studies with 
C14-labelled drugs in rat and dog revealed much higher concentrations for 
ibufenac than tor Ibuprofen in liver, kidney, adrenal, fat and several other 
tissues after chronic administration in the same dosage during 2-4 weeks 
(Adams et al., 1970). However, taking into account the higher plasma 
concentration of ibufenac at the moment of examination, it seems that the 
data hardly reveal significant differences in tissue/plasma ratio's between 
ibufenac and Ibuprofen, that have to be explained by preferential uptake 
of ibufenac. Although it is virtually impossible to determine tissue concen-
trations in man we judged it worthwhile to undertake a comparative study 
of the pharmacokinetics of Ibuprofen and ibufenac in order to see if 
differences in volume of distribution and elimination rate could contribute 
to the differences in toxicity. 
MATERIALS AND METHODS 
The drugs and reagents were the same as described in chapters 2 and 5, 
except for the following addition: ibufenac was obtained from Boots Pure 
Drug Company (Nottingham, England), for which we express our 
gratitude. 
Preparation of samples, gaschromatography and glucuronidase treatment 
of urine samples for both Ibuprofen and ibufenac were identical to the 
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methods described in chapter 2. Under the circumstances described 
Ibuprofen and ibufenac have exactly the same retention time, so that they 
cannot be measured separately when present in the same sample. 
Drug administration 
Eight volunteers participated in this study. All of them were young and 
healthy males, who did not receive any other medication during and for a 
period ot at least two weeks prior to the experiments. They were fasting 
overnight prior to drug administration and tor at least 2.5 hrs thereafter. 
Every volunteer received both Ibuprofen and ibufenac at a biweekly inter-
val. Both drugs were administered in a dose of 400 mg in the form of soft 
gelatine capsules, containing 200 mg of pure drug substance. They were 
taken together with about 200 ml of water. 
RESULTS AND DISCUSSION 
The pharmacokinetic parameters obtained are summarized in table 7.1. An 
illustrative example of the plasma and renal excretion data is given in 
fig. 7.1. All parameters are based upon computerized analysis according to 
the open one-compartment model which yields an adequate description of 
the experimental findings. In the following these parameters are discussed 
in terms of the elementary processes involved. 
Absorption 
As a rule ibufenac appears to be absorbed much more slowly than Ibu-
profen. Ibufenac absorption is also more irregular. The reason of this 
observation is not self-evident, although differences in lipophilicity may 
have something to do with it. As shown in chapter 3 Ibuprofen is more 
lipophilic than ibufenac, which might give rise to a faster penetration 
through the mucosa of the gastrointestinal tract. The somewhat lower 
acidity of Ibuprofen (pKa = 4.4) as compared to ibufenac (pKa = 4.1; 
Skidmore and Whitehouse, 1967) might enhance the permeation 
difference, although only to a minor extent. According to generally 
accepted theories gastrointestinal absorption of organic acids is increasing 
with increasing lipophilicity (provided that low watersolubility does not 
become a limiting factor) and with increasing pKa, since only the union-
ized acid readily crosses the membraneous barriers of the gastrointestinal 
tract (Schanker et al., 1957, 1958, 1959; Hogben et al., 1957, 1959). It is 
questionable, however, whether the relatively small differences in physico-
chemical properties of the two drugs under consideration can be solely 
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TABLE 7.1 
Comparative pharmacokinetic parameters for ibuprofen and ibufenac after oral admi-
nistration (D=400 mg; capsule). 
Subject' 
JA 
DB 
GB 
BK 
HL 
TS 
(22,70.181) 
(20,80,185) 
(20,65,178) 
(25,60,173) 
(23,76,183) 
(20,67,180) 
Drug 
ibuprofen 
ibufenac 
ibuprofen 
ibufenac 
ibuprofen 
ibufenac 
ibuprofen 
ibufenac 
ibuprofen 
ibufenac 
ibuprofen 
ibufenac 
V/F 
(1) 
7.6 
11.5 
8.6 
22.7 
9.2 
12.8 
5.7 
12.3 
6.4 
10.7 
8.3 
12.8 
"Cel/F (ml/min) 
49 
54 
53 
110 
54 
85 
38 
68 
36 
36 
53 
130 
ra tK 
(min) (min) 
156 
213 
160 
210 
170 
151 
153 
182 
178 
299 
155 
102 
108 
148 
111 
146 
118 
104 
106 
126 
124 
207 
108 
71 
Ta (min) 
9 
183 
15 
90 
5 
24 
3 
88 
6 
31 
5 
102 
1. Numbers in parentheses represent age (yr), bodyweight (kg) and height (cm); all 
subjects are male. 
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Figure 7.1 
Plasma curves and renal excretion of Ibuprofen and ibufenac after oral administration 
(400 mg, capsule) to the same volunteer. 
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responsible for the different absorption characteristics. A contributing 
factor might also be the binding to plasma proteins. It is conceivable that 
by strong protein binding in plasma the concentration gradient of free, 
diffusable drug from the lumen towards the vascular system surrounding 
the gastrointestinal tract is kept high. This phenomenon obviously can 
enhance the absorption process, which is assumed to be governed by 
passive diffusion. Now Ibuprofen is known to be almost completely bound 
to plasma proteins at usual concentrations whereas exact data are un-
fortunately not available for ibufenac. However, on the basis of the lower 
lipid solubility of ibufenac it seems possible that also its protein binding 
will be lower than that of Ibuprofen. 
With regard to the mechanism of the absorption one last remark should 
be made. An increasing number of reports is recently appearing in liter-
ature which suggest that the common theories on passive diffusion as the 
main determinant of the absorption process, are open to question again. 
For several substances it is known that active processes are involved in 
absorption (Levy and Jusko, 1966; Rivier, 1973; Giorgi, 1970; Gibaldi and 
Grundhofer, 1972; Lauterbach, 1975;Csáky, 1975). 
If this would be the case also for Ibuprofen and ibufenac, then the 
differences in absorption rate could be primarily attributed to differences 
in the affinity for and the capacity of the carrier mechanism involved. But 
as long as no direct evidence in favour of a carrier mediated absorption is 
provided, these considerations remain purely speculative. 
Volume of distribution 
Since the drugs in this study are administered orally the distribution 
volume cannot be determined in absolute terms, but only relatively to the 
biological availability. Table 7.1 shows the best possible estimates for the 
ratio V/F for both Ibuprofen and ibufenac. The data strongly indicate a 
larger apparent volume of distribution for ibufenac than for ibuprofen. 
This is in accordance with the studies of Adams et al. (1970) who found 
that ibufenac in animals reached much higher tissue levels than ibuprofen. 
On the other hand it is contrary to what might be expected on the basis of 
lipid solubility. Again (as in the discussion above) differences in protein 
binding might be the crucial determinant. 
Some variation in the estimates of V/F will also be caused by differences 
in biological availability. The more irregular and less rapid absorption of 
ibufenac as compared to ibuprofen might result in a relatively smaller 
amount absorbed. 
However, as the data in table 7.1 show, there is no correlation between the 
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time constant for absorption and the estimated value for V/F after ibufenac 
administration. 
Accepting the supposition that ibufenac actually has a larger volume of 
distribution than Ibuprofen, it remains questionable whether this is signif-
icant in the sense that it might be related to different tissue distribution. 
Although there are some indications for higher tissue levels of ibufenac 
than of ibuprofen, we therefore tend to conclude that the observed 
toxicity of ibufenac is a specific effect, which is not or only to a minor 
extent exhibited by ibuprofen. 
Elimination 
Since the predominant symptom of toxicity of ibufenac was the occur-
rence of jaundice, one might speculate that ibufenac affects the metabolic 
system in the liver. Then also ibutenac itself might be eliminated at a slow 
rate as compared to ibuprofen, or at least exhibit an irregular elimination 
pattern. However, although the rate of elimination of ibufenac in most 
cases indeed was found to be lower than that of ibuprofen, in some of the 
volunteers the opposite was true. The best measure for the efficiency of 
the clearing organs with respect to a certain drug is not the time constant 
or the rate constant for elimination, but rather the clearance constant. 
Since the clearance constant for ibufenac tends to be even higher than that 
of ibuprofen (although we only can compare the relative values kçej/F) 
and since the clearance is practically confined to hepatic metabolism, there 
is no indication at all for impaired hepatic function with respect to ibu-
fenac. The presupposition of irregular elimination was confirmed by 
preliminary experiments with ibufenac. Already in our ibuprofen studies 
we noticed that in a few cases a small oscillation occurred in the elimina-
tion phase. This oscillatory behaviour was interesting to note, but not of 
practical importance, since the amplitude of ihe oscillation was low and in 
no way a hindrance to optimal determination of the slope of the semi-
logarithmic plasma decay curve. This situation altered in the first ibufenac 
experiments, where the incidental oscillations took the form of real drops 
in the plasma curve (cf. figure 7.2). It became evident that a drop in the 
plasma curve (indicating a temporarily enhanced elimination) only 
occurred after the volunteers involved had taken a quite heavy dinner. 
When only a light lunch was taken no significant oscillation was noticed. It 
is an attractive hypothesis therefore to attribute these phenomena to an 
enterohepatic circulation of the drug or at least to an enhanced biliary 
excretion. For, it is conceivable that increase in bile secretion (under the 
influence of fatty food components) promotes biliary excretion of the 
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Figure 7.2 
Plasma curve as obtained after oral administration ofibufenac in a pilot experiment. 
Note the drop in the curve, which coincides with dinner. See text for further explana-
tion. 
drug or its metabolites (e.g. glucuronide), which afterwards may be re-
absorbed from the intestine. When such an effect becomes very pronounc-
ed, it should be realized that the area under the plasma curve, which 
FD 
normally is equal to , will be seriously overestimated. An entero-
^Cel 
hepatic circulation of ibuproten has been suggested in animal experiments 
by Mills et al (1973). We obtained evidence that in man the phenomenon is 
much more signiticant tor ibutenac. This implies that, depending upon the 
composition of the diet, the elimination of ibufenac may be seriously 
retarded and in consequence toxicity eventually increased. 
Renal excretion 
As a rule unchanged ibufenac is excreted in a lower percentage than Ibu-
profen. Since only very minor amounts appear in urine unchanged this 
observation is only of academic interest, without practical consequences. 
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TABLE 7.2 
Cumulative renal excretion of unchanged and glucuronidated drug after oral admini-
stration of ibuprofen and ibufenac (D=400 mg; capsule) (Qr%= % of dose). 
Drug 
ibuprofen 
ibufenac 
ibuprofen 
ibufenac 
ibuprofen 
ibufenac 
ibuprofen 
ibufenac 
ibuprofen 
ibufenac 
ibuprofen 
ibufenac 
Qr% 
(unch.) 
0.83 
0.88 
1.45 
0.75 
0.35 
0.45 
0.80 
0.23 
2.06 
0.55 
0.43 
0.28 
Qr% 
(glue.) 
13.90 
1.00 
8.85 
6.25 
10.00 
3.55 
9.25 
4.80 
16.20 
2.70 
10.90 
4.75 
It was intriguing to find that, contrary to ibuprofen, ibufenac did not 
appear to be subject to tubular secretion mechanisms. Actually an 
opposite behaviour was found, for the renal clearance constant of ibufenac 
tended to increase with increasing plasma concentration. A typical 
example is given in figure 7.3, where for the same volunteer the renal 
excretion rate is plotted as a function of the average plasma concentration. 
Ibuprofen exhibits the usual pattern of combined filtration and secretion 
(cf. chapter 5) but ibufenac excretion seems to be inhibited at low plasma 
concentration. One way of explaining this phenomenon is to assume that 
ibufenac is actively reabsorbed from tubular urine, which can result in a 
clearance lower than the degree of filtration. Perhaps more likely ibu-
fenac's excretion in urine is limited by binding to plasma proteins. It seems 
hardly plausible that the rather non-specific mechanism, that accomplishes 
tubular secretion of ibuprofen, would not affect ibufenac. On the other 
hand it is quite conceivable that the mechanism would be less efficient 
with respect to ibufenac. In that case it is possible that the protein binding 
conceals all signs of the secretion process and that a curve as depicted in 
figure 7.3 results (Rodrigues de Miranda, 1975). 
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Figure 7.3 
Renal excretion rate as a function of the average plasma concentration over the 
excretion interval for Ibuprofen and ibufenac in the same volunteer Whereas Ibu-
profen shows clear signs of a tubular secretion, the opposite ¡s true for ibufenac See 
text for further explanation 
Turning to the data on renal excretion of the glucuromdes we observe 
that after equal doses less ibufenac than Ibuprofen is excreted in unne in 
the form of its glucuromde. It is, however, an unallowed extrapolation to 
consider the amount of glucuromde in the unne as a reflection of the 
capacity of the organism to perform the conjugation reaction Since biliary 
excretion will be an important pathway of elimination at least of ibufenac 
and probably also for Ibuprofen, one must assume that major fractions of 
glucuromde are excreted in bile. After splitting by the intestinal flora part 
of the drug may be reabsorbed (enterohepatic circulation). So, obviously a 
difference in the rate of renal excretion of the glucuromde should not be 
asenbed a priori to a difference in the rate of glucuromde formation. 
117 
REFERENCES 
Adams, S.S., E.E. Cliffe, В. Lessei and J.S. Nicholson, Nature 200, 271 (1963). 
Adams, S.S., E.E. Cliffe, B. Lessei and J.S. Nicholson, J. Pharm. Sei 56, 1686 
(1967). 
Adams, S.S., R.G. Bough, E.E. Cliffe, W. Dickinson, В. Lessei, K.F. McCullough, 
R.F.N. Mills, J.S. Nicholson and G.A.H. Williams, Rheumatol. Phys. Med. SuppL 9 
(1970). 
BucUer, J.W. and S.S. Adams, Med. Proc. 14, 574 (1968). 
Csáky, T.Z., Arzneim. Forsch. 25, 464 (1975). 
Gibaldi, M. and B. Giundhofer, Proc. Soa Exp. Biol. Med. 141, 564 (1972). 
Giorgi, G., Pharmacol. Res. Comm. 2, 285 (1970). 
Hogben, C.A.M., L.S. Schanker, D.J. Tocco and B.B. Brodie, /. Pharmacol exp. Ther. 
120, 540 (1957). 
Hogben, C.A.M., D.J. Tocco, B.B. Brodie and L.S. Schanker, /. Pharmacol, exp. Ther. 
125, 275 (1959). 
Lauterbach, F., Arzneim. Forsch. 25, 479 (19751. 
Levy, G. and W.J. Jusko, J. Pharm. Sci 55,1443 (1966). 
Milb, R.F.N., S.S. Adams, E.E. Cliffe, W. Dickinson and J.S. Nicholson, Xenobiotica 
3, 589 (1973). 
Rivier, D.A., Experientia 29,1443 (1973). 
Rodrigues de Miranda, J.F., Specificity in drug-protein interaction, Ph.D. thesis, 
Nijmegen (1975) and personal communication (1975). 
Schanker, L.S., P.A. Shore, B.B. Biodie and C.A.M. Hogben, J. Pharmacol exp. Ther. 
120, 528 (1957). 
Schanker, L.S., D.J. Tocco, B.B. Brodie and C.A.M. Hogben, J. Pharmacol exp. Ther. 
123, 81 (1958). 
Schanker, L.S., / Pharmacol exp. Ther. 126, 283 (1959). 
Skidmore, LF. and M.W. Whitehouse, Biochem. Pharmacol 16, Til (1967). 
118 
CHAPTER 8 PHARMACOKINETICS OF ALCLOFENAC IN 
MAN 
INTRODUCTION 
Among the series of arylacetic acid derivatives, used in the therapy of 
inflammatory disorders, alclofenac* (4-allyloxy-3-chlorophenylacetic acid) 
attracts the attention because it combines the usual antiinflammatory and 
antipyretic effectiveness with a more general analgetic action. In this sense 
the pattern of pharmacological activity seems to be comparable to that of 
acetylsalicylic acid. In a clinical double-blind study alclofenac (500 mg) 
was more effective than codeine (30 mg) and about as potent as penta-
zocine (50 mg) in the treatment of chronic pain (Staquet et al., 1971). The 
analgesic effect appears to be directly related to the plasma levels (Roncucci 
et al., 1971). Lambelin et al. (197Q) reported that in hyperthermic rabbits 
alclofenac is 45 times more active than acetylsalicylic acid. Although in 
this respect no systematic clinical studies have been done up to now alclo-
fenac can be expected to be of value as antipyretic agent. As far as the 
antiinflammatory effect is concerned alclofenac has been compared to 
various other drugs in the treatment of rheumatic diseases (Fellmann, 
1971; van Hoek, 1970; Aylward, 1973, 1975; Pavelka et al., 1973; Klemm 
et al., 1971). Alclofenac was found equipotent or sometimes superior to 
the other drugs studied (ibuprofen, indomethacin, phenylbutazone) and 
often better tolerated. Apart from slight gastrointestinal complaints and 
incidental allergic skin reaction no significant side-effects were reported. 
Billings et al. (1974), however, reported three cases of a hypersensitivity 
vasculitis which disappeared after withdrawal of alclofenac. 
Extensive studies on the metabolic pattern of alclofenac in several 
animal species, including man, have been reported (Roncucci et al., 1970, 
1971, 1972). Appreciable interspecies differences were noted but in all 
cases practically the whole dose absorbed was excreted in urine, partly as 
unchanged alclofenac, partly as metabolites. In man about 70% of the dose 
was excreted in urine as alclofenac or alclofenac glucuronide and another 
20% in the form of two other metabolites (3-chloro-4-hydroxyphenyl-
acetic acid and 3-chloro—4-dihydroxypropyloxyphenylacetic acid). Also 
some data on the pharmacokinetics of radiolabelled alclofenac in patients 
with various disorders were published (Roncucci et al., 1971), as well as a 
most interesting discussion on dosage regimens for chronic therapy with 
* Mirvan®, reg. trademark Continental Pharma, Brussels, Belgium. 
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alclofenac (Strolin-Benedetti et al., 1973). 
The present investigations were undertaken in connexion with a com-
parative study on the pharmacokinetics of various antiinflammatory anal-
gesics. Our purpose was to look after relationships of kinetic behaviour 
with physicochemical characteristics and to collect data for planning 
rational dosage regimens. 
MATERIALS AND METHODS 
Drugs 
Alclofenac pure substance for reference purposes was obtained from Con-
tinental Pharma, Brussels, Belgium, which is gratefully acknowledged. 
Mirvan® tablets and suppositories (containing 500 resp. 600 mg of alclo-
fenac) were commercially obtained as they are marketed in the Nether-
lands. 
Preparation of samples and gaschromatographic analysis 
As described in chapter 2. 
Drug administration 
The ten volunteers participating in this study were all young, healthy 
males, who did not receive any other medication during and for a period 
of at least 4 weeks prior to the experiments. None of them has ever 
suffered from liver or kidney function impairment. They were fasting 
overnight prior to and for at least 3 hrs after drug intake (at nine o'clock 
in the morning). All volunteers received an oral dose of 500 mg alclofenac 
in the form of commercially available tablets (Mirvan®). Four of them also 
took a rectal dose of 600 mg alclofenac in the form of a Mirvan® supposi-
tory. Two of the volunteers ingested an oral dose of 1000 mg (two 
tablets). Oral doses were always taken together with about 100 ml of 
water. In all single dose experiments about 10 blood samples were taken 
from the forearm vein at regular times after drug intake and all urine 
samples were collected separately for a period of at least 30 hrs. One 
volunteer took alclofenac chronically for two weeks in a dosage regimen of 
one tablet three times daily (at 1.00, 9.00 and 17.00 hrs). Blood samples 
were collected frequently during the first dosage interval and after the last 
dose and an additional two or three every other day over the whole period 
of drug administration. 
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RESULTS AND DISCUSSION 
Some representative examples of the plasma levels and urinary excretion 
of unchanged drug after oral and rectal administration of alclofenac are 
given in figures 8.1, 8.2 and 8.3. Table 8.1 summarizes the relevant 
pharmacokinetic parameters as obtained by computerfit (non-linear regres-
sion program Farmfit) according to the open one compartment model (see 
chapter 4). Already on visual inspection of the experimental data it was 
obvious that this pharmacokinetic model would provide a very satisfactory 
description of alclofenac pharmacokinetics. This was evidently confirmed 
by the computer analysis as can be seen from the figures. The drawn lines 
actually are the curves obtained by the computerized regression analysis 
and they match the measured points excellently. 
TABLE 8.1 
Pharmacokinetic parameters after oral and rectal administration of alclofenac. 
Subject1 
AA 
AAa 
JB 
MB 
JE 
JH 
LH 
PK 
WM 
DZ 
MB 
PK 
AA 
JB 
WM 
DZ 
(24,80,184) 
(23,67,176) 
(24,80,186) 
(24,91,186) 
(25,57,174) 
(24,66,176) 
(19,76,187) 
(22,72,185) 
(22,60,175) 
(24,80,186) 
(19,76,187) 
(24,80,184) 
(23,67,176) 
(22,72,185) 
(22,60,175) 
V/F 
(D 
ORAL, 
6.2 
9.0 
5.6 
8.9 
7.5 
4.3 
5.1 
7.1 
6.1 
10.0 
ORAL, 
16.2 
16.7 
W F 
(ml/min) 
Tel 
(min) 
500 mg (tablet) 
37 
53 
38 
38 
44 
41 
45 
49 
40 
69 
166 
170 
147 
235 
171 
104 
114 
145 
152 
146 
1000 mg (2 tablets) 
70 
107 
231 
156 
RECTAL, 600 mg (supp.) 
9.5 
9.5 
7.8 
9.6 
67 
47 
48 
68 
143 
202 
163 
141 
rii 
(min) 
115 
118 
102 
163 
119 
72 
79 
101 
106 
101 
160 
108 
100 
140 
113 
98 
Ta 
(min) 
40 
1 
145 
10 
17 
83 
36 
18 
27 
2 
11 
18 
31 
22 
28 
33 
1. Numbers in parentheses represent age (yr), bodyweight (kg) and height (cm) respec-
tively; all subjects are male. 
2. Parameters determined after chronic administration (500 mg 3 dd) for 2 weeks. 
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alclofenac 
subject A A 
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• 600 mg rectal 
subject DZ 
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10 
/ 
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1000 mg 
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100 300 500 
time (mm) 
10 20 30 
time (hrs) Figure 8.2 
Plasma curves and cumulative renal excretion after administration of alclofenac in 
doses of 500 and 1000 mg to the same subject. See text for further explanation. 
Figure 8.1 
Plasma curves of alclofenac after oral and rectal administration to the same subject. 
Absorption rate 
When administered on an empty stomach the absorption of alclofenac 
tablets is a fairly rapid process. The time constant for absorption, based 
upon the assumption of a unidirectional first-order process, usually does 
not exceed 40 minutes and is much shorter in several cases. This indicates 
that the maximum plasma level will be obtained within about 2 hrs after 
oral administration of the tablets to fasting subjects. In our study the 
average time constant for absorption is definitely smaller than the average 
value of 110 minutes found by Roncucci et al. (1971) (cf. Strolin-
Benedetti et al., 1973). Two factors may be primarily responsible: firstly, 
they employed a different drug formulation (soft gelatine capsules) and 
secondly, their subjects were non-fasting patients. Since from our prelimin-
are investigations we got the impression that the absorption was not retard-
ed at all by a light breakfast, we tend to believe that here a real biopharma-
ceutical difference is concerned and that alclofenac absorption from 
commercial tablets occurs more rapidly than from gelatin capsules. The 
fact that two of our volunteers show an unusually slow absorption, most 
probably has to be attributed to unknown, individual factors not 
representing a drug- or formulation-characteristic. This is the more so since 
one of them (JB) after rectal administration absorbed the drug at a normal 
high rate. 
Also from suppositories alclofenac is quite rapidly absorbed with a rate 
in the same range as found for the tablets. 
Witn regard to the onset of the absorpiion process our data indicate no 
appreciable delay after oral or rectal administration. The regression 
analysis did not improve when the possibility of a lag-time was incor-
porated. Therefore we conclude that absorption starts immediately after 
administration. This conclusion should, however, be restricted to our 
experimental setting where the drug is administered to fasting volunteers. 
It is quite possible that the presence of a substantial amount of food in the 
gastrointestinal tract will give rise to a limiting step before normal first 
order absorption can occur (cf. also chapter 4). On the other hand, as 
stated above, the final rate of absorption does not seem to be very 
sensitive to such factors. With respect to the rapid onset of absorption an 
exception has to be mentioned, viz. the 1000 mg doses in the two sub-
jects MB and PK where optimal fit required a lag time of 43 and 31 min 
respectively. Although this observation may be reminiscent of dose 
dependent pharmacokinetics, we have no evidence that such dose depen-
dence actually exists. On the contrary, the profile of the plasma curve 
after the high dose fits well into the normal one compartment model with 
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first-order absorption and elimination. Moreover, data by Roncucci et al. 
(1971) are in flat contradiction with non-linear kinetics. Therefore our 
observation may be a mere coincidence that should be investigated in more 
detail before definite statements can be made. There are, however, still 
other remarkable aspects involved in this matter as will be discussed below. 
Elimination rate 
Alclofenac is rapidly eliminated from the body. The halflives we measured 
varied roughly from 1.5 to 2.5 hrs. The rate of elimination is independent 
of the dose and the pharmaceutical formulation of the drug, in so far as in 
our study no significant differences were found in this respect. The short 
halflife implies that it will be very difficult to obtain a constant plateau 
concentration of alclofenac, which might be desirable for optimal therapy 
in chronic inflammatory disorders. On the other hand, it diminishes the 
risk of accumulation to toxic levels. This can certainly be of advantage 
when alclofenac is used as a general analgesic agent, since then the drug 
can be taken frequently for a short period of time. Of course, one has to 
take into account that the range of halflives of alclofenac for the whole 
population will be wider than what we found in our limited and homo-
geneous group of volunteers. An indication in favour of this expectation 
can be found in the literature (Strolin-Benedetti et al., 1973, reporting 
values of 2.5 to 5.5 hrs in an inhomogeneous group of 5 elderly patients). 
Assuming that effective analgesia with alclofenac requires plasma levels 
of about 10 mg/1 (Roncucci et al., 1971) one may expect that in our study 
therapeutic blood levels lasted for 3—5 hrs, starting within 20 min after 
oral or rectal administration. Antiinflammatory effects of course cannot 
easily be quantified, improvement of clinical symptoms should guide long 
term therapy. 
Volume of distribution and biological availability 
Since we are dealing with oral and rectal administration our analysis does 
not yield exact values of the volume of distribution (and of the clearance 
constant) since we cannot know a priori which fraction of the dose 
administered actually has been absorbed. Therefore it is inevitable to 
combine the discussion of the fundamental parameters (Vand kçei) with 
consideration of the biological availability (F). The total urinary and faecal 
excretion of radioactivity after administration ot alclofenac-14C suggests 
that large differences in the biological availability may occur (Roncucci et 
al., 1971). In some cases Roncucci got practically complete recovery in 
urine, in some other cases large amounts appeared in the faeces. The most 
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logical explanation is that in the latter cases the absorption has been far 
from complete, since all patients had normal renal and hepatic function. 
Because our estimated values for the volume of distribution in fact 
represent the ratio V/F we may assume that at least part of the variations 
in these estimates results from differences in the fraction absorbed (F). 
This implies that the tabulated individual values actually represent the 
upper limit for the volume of distribution of alclofenac in a one-compart-
ment model. Obviously then the volume of distribution is very small 
(5 to 7 1, cf. also the discussion on Ibuprofen in chapter 5). Most probably 
binding to plasma proteins is a factor contributing to the small distribution 
volume. Although exact data are not available, preliminary data suggest 
that alclofenac is extensively bound to human plasma proteins, but 
definitely less than for instance Ibuprofen. On the other hand alclofenac is 
less lipophilic than Ibuprofen, so that it will have more difficulties in 
passing through biological membranes. The combination of these factors 
seems to result in comparable distribution volumes for alclofenac and 
Ibuprofen. 
Assuming that the real volume of distribution is exclusively determined 
by the physicochemical characteristics of the drug and not by its dose and 
formulation, we can estimate the relative biological availability of different 
drug formulations by comparing the ratios V/F calculated after administer-
ing the dosage forms. In case of alclofenac this comparison leads to the 
conclusion that the biological availability of the suppository in three of 
our volunteers is lower than that of the tablet, the ratio;;—"^-being 0.65; 
Ftabl. 
0.59 and 0.78 for the subjects AA, JB and WM respectively. In one case 
the ratio is about unity (1.04 for subject DZ), but in this case also the oral 
dose seems to be only partially absorbed. So there is some indication that 
the bioavailability of the suppository is a little lower than that of the 
tablet, but the availability of the tablet is fluctuating also. Since further-
more the suppository contains a higher dose (600 mg instead of 500 mg) 
there will be no need at all for adapting the dosage regimen when tablets 
and suppositories are administered alternately. Also for single dose situa-
tions the two forms are equally effective. 
A few remarks should be made concerning the 1000 mg doses, in these 
cases a strikingly high estimate of V/F resulted. Together with the unusual 
lag-time mentioned above, this may be due to an irregular absorption 
process. It can easily be derived that in our analysis a too high apparent 
value for the volume of distribution would be obtained when for instance 
the so-called lag-time were a period during which absorption does take 
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place in fact but with a rate lower than in the ultimate first-order phase. 
The shorter the halflife of the drug the more pronounced this pheno-
menon will be. Taking into account these considerations a rough estimate 
of the error made in our analysis indicates that it might amount to some 
50% overestimation of the distribution volume. This of course would bring 
the values for V/F more in line with the normal range found for the 
500 mg dose. In general this example points to a weak side in pharma-
cokinetic analysis: when the absorption process is not purely first order 
and unidirectional large errors may be encountered in the calculation of 
the volume of distribution (and the clearance constant). In such cases due 
reserve should be practised in the presentation of the results. 
Clearance 
Also the clearance constant cannot be determined in absolute terms after 
oral administration, only the ratio kçej relative to F can be given 
(table 8.1). Referring to the factors discussed above we may give for 
the expectation-values of the clearance constant the range kçei = 
30-50 ml/min. This range is comparable to Ibuprofen (chapter 5) and 
obviously no first-pass effect can be expected since the overall clearance 
constant is very small with respect to hepatic plasmaflow. Furthermore in 
case of alclofenac usually less than 80% of the total clearance occurs by 
metabolism, the rest being urinary excretion. Excretion into the faeces is 
not an important pathway since in man practically the whole dose appears 
in urine, partly in the form of metabolites (Roncucci et al., 1970,1971). 
It should be noted that the clearance constant for alclofenac is quite low, 
indicating an inefficient extraction in the clearing organs. As was argued 
before for Ibuprofen (chapter 5), protein binding may be a limiting factor. 
The hepatic clearance may also be hindered somewhat by the fact that 
alclofenac is not as lipophilic as a drug like Ibuprofen is, so that it probably 
cannot penetrate into the liver cells as easily as Ibuprofen. On the other 
hand this might be accompanied by a higher watersolubility which can be 
in favour of urinary excretion by glomerular filtration, because passive 
backdiffusion from primary urine is less likely to occur. 
Renal excretion 
Alclofenac is excreted in urine unchanged in very variable amounts. The 
variations are much larger than could be explained on basis of differences 
in the fraction of the dose that has been absorbed. As table 8.2 shows 
none of our volunteers excreted less than 10% of the dose unchanged 
whereas the other extreme amounts to not less than 50%. The percentages 
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TABLE 8.2 
Cumulative renal excretion of alclofenac as %of dose (Q
r
%). 
Subject' 
AA, о 
0 
г 
JB, о 
г 
MB, о 
0 
JE, о 
( 500) 
(1000) 
Q
r
% 
14 
16 
12 
14 
10 
36 
13 
31 
Subject1 
JH, 
LH, 
PK, 
WM, 
DZ, 
0 
о 
о ( 500) 
о (1000) 
о 
г 
0 
г 
Q
r
% 
35 
31 
40 
12 
48 
20 
50 
20 
1. " о " and "г" refer to oral or rectal administration. 
cumul renal excretion C/o of dose) 
tablet 
(urine flow 2.77 ml/mm) 
alclofenac 
subj. D.Z. 
30 35 
t ime ( h r s ) 
Figure 8.3 
Cumulative renal excretion of alclofenac after oral or rectal administration to the 
same volunteer whose plasma curves are represented in figure 8.1. The renal clearance 
is related to the urine flow. See text for further explanation. 
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are in no way correlated to the estimates of V/F, so apart from the fact 
that they are too variable to be caused by changes in F they fluctuate fully 
independently of it. Since renal excretion of unchanged drug is a major 
pathway of elimination for alclofenac, it is worthwhile to examine the 
factors that may influence this excretion, in more detail. When dealing 
with ionizable compounds one has to consider of course the influence of 
urinary pH on the net excretion. As argued before (chapter 3) it is not 
enough to reckon with the degree of ionization of the drug in urine but 
also its lipophilicity plays an important role. Even drugs that are ionized in 
urine for more than 99% can be reabsorbed substantially when their lipo-
philicity is very high. Alclofenac has a pKa of about 4.6, which implies 
that at the urinary pH values we measured in our volunteers (pH > 5.5) 
usually more than 90% of the drug in urine is ionized. Now the lipo-
philicity of alclofenac is certainly not high enough to compensate fully for 
this high degree of ionization (see chapter 3), so that we may expect that 
passive backdiffusion will not prevent substantial renal excretion. In man 
the glomerular filtration rate is about 125 ml/min. The renal clearance 
constant for alclofenac in our study is definitely much lower and never 
exceeds 35 ml/min. In other words: the renal clearance is far below the 
maximally attainable value, even when no tubular secretion occurs at all. 
In this context one should regard the binding to plasma proteins as a 
predominant factor and backdiffusion as a cooperative mechanism. As 
long as this backdiffusion is independent of urinary pH and only governed 
by the concentration of the drug in the glomerular filtrate and the result-
ing tubular urine, it offers no special problems from a pharmacokinetic 
point of view. For, in such a situation the only consequence is that filtra-
tion and backdiffusion together sum up to an effective renal clearance 
constant, lower than the original filtration rate, but highly significant for 
practical purposes. This situation seems to prevail in case of alclofenac. 
Although in all individuals the pH of the urine samples collected was 
rather variable (5.5—7.2) we were unable to detect related fluctuations in 
the renal excretion rate. As argued above this is not very surprising on the 
basis of physicochemical properties of alclofenac. On the other hand it was 
intriguing to note that the same individual on different occasions showed 
large differences in the cumulative amount of drug excreted unchanged. 
Interestingly this appeared to be connected with the total volume of urine 
produced over the excretion period. For the volunteers that participated 
twice in this study, table 8.3 shows the percentage of the dose excreted 
unchanged (Qr %) together with the average urine flow (in ml/min) and 
the upper limit of the overall clearance constant (kçej/F) over the total 
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excretion period (about 30 hrs). Since we are dealing with variable bio-
availability the last column contains the value for kç r , the renal clearance 
constant, which is independent of F because it can be calculated from the 
product of Q and kçei/F, where Qr is related to the total dose administer-
ed and as a matter of fact represents F.Qr. Obviously these data suggest a 
positive correlation between the amount excreted unchanged and the urine 
flow. It should be noted that the renal clearance constant in any case is 
much higher than the urine flow, although much lower than the rate of 
glomerular filtration (see above). This phenomenon is highly interesting 
since it indicates that during the passage of the glomerular filtrate from the 
glomerulus through the tubuli and the collecting tubes to the ureter no full 
equilibrium exists between the primary urine and the surrounding blood-
vessels. For if this were the case the ultimate renal clearance constant 
should approach the urine flow rate more closely. On the other hand some 
reabsorption (backdiffusion) must occur since otherwise the renal 
clearance would be independent of the urine flow, but only dependent on 
the efficiency of the glomerular filtration. 
TABLE 8.3 
Renal excretion data of alclofenac for volunteers who participated twice in this study. 
Subject1 
AA, 
JB, 
MB, 
PK, 
WM, 
DZ, 
о 
I 
О 
г 
О 
О 
О 
О 
О 
г 
О 
г 
( 500) 
(1000) 
( 500) 
(1000) 
Q
r
% 
14 
16 
12 
14 
10 
36 
13 
40 
12 
48 
20 
50 
20 
urine-flow 
(ml/min) 
0.60 
0.91 
0.56 
0.47 
1.36 
2.40 
0.70 
2.00 
1.07 
2.46 
2.00 
2.77 
1.07 
kcel/F 
(ml/min) 
37 
53 
67 
38 
47 
38 
70 
49 
107 
40 
48 
69 
68 
kCr 
(ml/min) 
5.2 
8.5 
8.0 
5.3 
4.7 
13.7 
9.1 
19.6 
12.8 
19.2 
9.6 
34.5 
13.6 
1. "o" and "r" refer to oral or rectal administration. 
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With regard to the influence of urine flow on the efficiency of the renal 
excretion we wondered if this might be a general phenomenon that also 
would be deieciable when daia from several subjects together were com-
pared. Some indications that this extrapolation is allowed indeed, can be 
derived from figure 8.4. Taking all excretion data from our study together 
we plotted the percentage of drug excreted against the urine flow. The 
same type of graph was constructed for the urinary clearance constant. A 
tendency to positive correlation is certainly present and mathematical 
analysis yielded highly significant correlation coefficients (see legend to 
figure 8.4). The dependence of renal clearance of a drug on the urinary 
flow rate is a possible phenomenon that should be considered in pharma-
cokinetic studies on basis of renal excretion data. Usually not enough 
attention is paid to this possibility (Fülgraff, 1972). 
Or (% of dose) Kcr ( m l / m m ) 
average urine flow (ml /mm) 
Hgure 8.4 
Correlation between the amount ofaklofenac excreted unchanged, Qr (and the renal 
dearance constant k(y) and the average urine flow over the period in which substan-
tial excretion occurred. The drawn lines are the result of the regression analysis. Since 
the intercepts did not differ significantly from O, also regression lines through the 
origin were calculated (dotted). 
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The next point of interest obviously is the question whether also a relation 
can be found between the urine flow (and consequently the renal ex­
cretion rate) and the total rate of elimination. Since urinary excretion can 
play a major role in the elimination process one might presume that 
factors decreasing the rate of urinary excretion generally will decrease the 
overall rate of elimination as well. Contrary to what we expected, this is 
not found at all. No straightforward relation between these rates could be 
demonstrated. Strangely enough, one gets the impression that low urinary 
excretion is effectively counterbalanced by high metabolism. This is quite 
an unusual observation but it is substantiated by the finding that the rate 
of urinary excretion of alclofenac glucuronide increases when that of free 
unchanged compound decreases. Table 8.4 shows the excretion percen­
tages of both unchanged and glucuronidated alclofenac for those experi­
ments in which we performed glucuronidase treatment of the urine 
samples. When one takes the variations in bioavailability into account, 
there appears a striking constancy of the sum of the amounts of free ana 
glucuronidated drug excreted. For the moment it is impossible to offer a 
satisfactory explanation for this phenomenon. One might speculate about 
the possibility of conjugation in the kidney, such as described for benzoic 
acid, salicylic acid and p-aminobenzoic acid in animals (Suk Han Wan and 
Riegelman, 1972a, b; Suk Han Wan et al., 1972). Alternatively one might 
think of the possibility of splitting of substantial amounts of previously 
formed glucuronide by glucuronidases in the kidney. Our data, however, 
TABLE 8.4 
Cumulative renal excretion of unchanged and glucuronidated alclofenac after oral and 
rectal administration. 
Subject 
AA, о 
r 
JB, о 
r 
WM, о 
r 
DZ, о 
r 
(unch.) 
14 
12 
14 
10 
48 
•20 
50 
20 
Q
r
% 
(glue.) 
68 
40 
26 
20 
14 
36 
18 
42 
Tota: 
82 
52 
40 
30 
62 
56 
68 
62 
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renal excretion rate (яэ/тіп) 
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/ 
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/ 
10 15 5 10 15 20 
average plasma cone (Aig/ml ) 
Figure 8.5 
Renal excretion rate of diclofenac as a function of the plasma concentration. A linear 
relationship prevails. See text for further explanation. 
do not allow any furtner conclusions in this respect and for a more 
thorough analysis animal experiments will probably be indispensable. 
Up to now we implicitly assumed that the renal excretion of alclofenac 
is governed by linear processes. The argumentation presented might 
become disputable when substantial amounts of alclofenac would be 
excreted in urine by a tubular secretion mechanism. As was shown before 
(chapter 5) evidence concerning the mechanisms of renal excretion can be 
obtained by studying the excretion rate as a function of the average 
plasma concentration over the excretion interval. In case of alclofenac the 
renal excretion rate appears to be a linear function of the plasma concen­
tration, indicating that only linear processes (presumably filtration and 
some passive backdiffusion) contribute significantly to the overall 
excretion (see fig. 8.5). This means that the assumption expressed above 
for all practical purposes is justified. However, it should be realized that 
these data do not fully exclude the presence of a tubular secretion 
mechanism. The renal excretion rate in case of combined filtration and 
secretion can be represented by 
^ r _ ,
v
i , TM 
dt " l k C r + K T + C p ) c p (8.1) 
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Explanation of the symbols is given already in chapters. This equation 
shows that as long as Cp<4 Kj a purely linear function results, viz. 
dQ, , T M 
5 Г = ( к с г + Е 7 > с Р (8·2> 
Of course this rate is experimentally indiscernable from filtration alone. In 
view of the wide range of plasma concentrations involved, this situation 
would only prevail when the drug would have an extremely low affinity 
for the transport mechanism. In that case the ratio Tj^ j/Kj probably 
would be so small that it may be omitted for all practical purposes. An 
alternative explanation might be the effective inhibition of the secretion 
by plasma protein binding. Although we cannot rule out this possiblity, 
the fact that the protein binding of alclofenac is extensive but labile seems 
to give evidence against it. So, it is quite unlikely that the situation as 
defined by equation 8.2 prevails. There is, however, another way in which 
a tubular secretion process might be concealed in the overall pictures as 
given in figure 8.5. At this stage of the discussion reference to our Ibu­
profen study (chapter 5) is pertinent. In case of Ibuprofen we found clear 
indications for tubular secretion. The transport maximum was very low, 
but also the linear part of the renal clearance was quantitatively very small. 
Alclofenac has a carboxylic acid group in common with Ibuprofen. This is 
one of the prerequisites for tubular secretion, but when other factors (like 
an amino function) are lacking, the secretion mechanism appears to have 
only limited capacity. In this respect there seems no need for assuming 
differences between alclofenac and Ibuprofen, but there is another very 
important difference: the linear part of the renal clearance of alclofenac is 
much higher that that of Ibuprofen. This may cause that a possible secre­
tion mechanism vanishes into a quantitatively much larger filtration. As a 
consequence the actual situation would best be described by the other 
extreme of equation 8.1, prevailing when С > Kj: 
dQ
r
 , 
^ = k C r C p + T M (8.3) 
Also this equation predicts a linear relationship between renal excretion 
rate and plasma concentration, but the straight line fitting this relationship 
will not pass through the origin. The fact that the regression lines as 
depicted in figure 8.5 often cross the dQ
r
/dt-axis above the origin may be 
meaningful, but the difference between the actual intercepts and the origin 
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cannot be made statistically significant on basis of our data alone. Never­
theless we may conclude that for alclofenac tubular secretion, if present, 
has only a very limited capacity (less than S μ§/πΰη). 
Chronic administration 
The short halflife of alclofenac excludes the possibility of accumulation in 
a dosage regimen of one dose three times daily. An advantage of this is 
that dangerously high levels will not easily be reached, but a disadvantage 
may be that it will be impossible to obtain a steady level of the drug in 
plasma. For the moment it is not known wnether fluctuations in the 
plasma level affect the therapeutic effectiveness of antiinflammatory drugs 
adversely or not, but it is hardly conceivable that it would not be of 
advantage to have a real steady state as far as drug concentration in plasma 
is concerned. One of the volunteers participating in this study took one 
Mirvan® tablet thrice daily for two weeks. The result of the measurements 
of the plasma concentration during this period is shown in fig. 8.6. 
plasma cone, (mg/l-,log scale)-
100-
alclofenac 
5 0 0 mg 3 d d 
sub). A A 
104 16Θ 176 216 224 264 272 336 344 
time (hrs) 
Figure 8.6 
Plasma concentration during repeated administration (500mg, 3dd) of alclofenac. 
The curve is simulated on basis of the parameters obtained after a single dose. The 
plasma levels are very fluctuating and no accumulation occurs. 
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Obviously very large fluctuations and practically no accumulation occur. 
The rate of elimination at the end of the two weeks period is exactly the 
same as at the start of the experiment. No variations in renal excretion, 
other than caused by the factors discussed above, were seen. The curves 
drawn in the figure are simulated by computer on basis of constant 
pharmacokinetic behaviour and constant biological availability. The theore-
tical curve matches the experimental data reasonably well, but the picture 
is somewhat flattering since the time axis is relatively short, so that devia-
tions are not clearly visible. Closer examination suggests that appreciable 
variations in bioavailability and absorption rate occur. In view of the 
reasonably fitting overall picture, however, we tend to assume that it will 
be possible to design directives for optimal individual dosage regimens. A 
first approach in this direction can be found in the paper by Strolin-
Benedetti et al. (1973). 
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CHAPTER 9 PHARMACOKINETICS OF FLUFENAMIC AND 
MEFENAMIC ACID IN MAN 
INTRODUCTION 
Rufenamic acid*, N—(3-trifluoromethylphenyl)anthraniIic acid, and 
mefenamic acid**, N—(2,3-dimethylphenyl)anthranilic acid, are represen-
tatives of a large group of N-phenylanthranilic acid derivatives (fenamates) 
that have been synthesized and tested for antiinflammatory activity. These 
two fenamates appear to have some analgesic and antipyretic effect, but 
especially their antiinflammatory effectiveness has drawn the attention. 
Numerous references concerning this matter may be found in a monograph 
edited by Hume Kendall (1967), in which results of experimental labora-
tory studies as well as clinical trials are reported. The antiinflammatory 
effect of mefenamic acid is claimed to be equivalent or slightly superior to 
acetylsalicylic acid, whereas flufenamic acid seems to be 2-3 times as potent. 
Several types of side-effects may occur during therapy with fenamates. As 
for all antiinflammatory drugs gastro-intestinal disturbances occur. Head-
ache and skin rashes are occasionally met. Also some blood disorders and 
liver function disturbances have been reported in association with the use 
of fenamates (for a review of the side-effects, see Prescott, 1972). In the 
Netherlands mefenamic acid is marketed, flufenamic acid is not. 
The present study was undertaken in order to obtain more insight into 
the pharmacokinetic behaviour of the two fenamates in man. From a 
theoretical point of view the drugs were especially interesting because of 
their extremely low water solubility, which should be expected to cause 
difficulties in the absorption process. From a more practical point of view 
possible implications of a suspected enterohepatic circulation on the 
profile of the plasma curve were interesting. 
PHARMACOKINETICS 
Little information on the pharmacokinetics of flufenamic and mefenamic 
acid in man can be found in literature. Only in a paper by Glazko (1967) 
some plasma levels in man after oral intake of these fenamates are given. 
Although the data clearly deviate from one-compartment kinetics, it seems 
that the major part of the plasma decay curve is monophasic. Only when 
* Ailef®, reg. trademark Parke-Davis 
** Ponstan®, reg. trademark Parke-Davis 
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very low concentrations are reached the elimination rate appears to slow 
down, suggesting that at least two compartments are involved. From the 
data of Glazko we estimate the relevant halflives for elimination roughly at 
2—3 his for flufenamic acid and somewhat lower for mefenamic acid. The 
most predominant features of the kinetics of the fenamates seem to be a 
strong protein binding and an extensive biliary excretion and reabsorption 
(enterohepatic circulation) as evidenced by animal experiments (Glazko, 
1%7). 
MATERIALS AND METHODS 
Drugs 
Rufenamic acid and mefenamic acid in a pure form were obtained from 
Parke-Davis Bomem, Belgium, which is gratefully acknowledged. Mefenamic 
acid tablets (Ponstan®) were commercially obtained as they are marketed 
in the Netherlands. 
Drug administration 
Flufenamic acid was administered to 8 young, healthy, male volunteers in 
the form of soft gelatin capsules containing 200 mg of pure substance. The 
subjects were fasting overnight prior to the drug ingestion and for an 
additional 3 hrs thereafter and took the capsule with 100 ml of water. 
Mefenamic acid was first administered to 8 young, healthy, male volun-
teers who had fasted overnight and remained without food for an addi-
tional 3 hrs after drug intake. In view of the low plasma levels obtained we 
judged it worthwhile to repeat the experiment with the same volunteers 
after they had taken breakfast. Six of the eight volunteers from the first 
part of the study were able to participate in this experiment. The subjects 
were instructed to have breakfast (in the English way) 0.5 to 1 hr before 
drug administration, but the breakfast was not standardized. The drug was 
administered in a 1 g dose (4 tablets Ponstan®) together with about 
100 ml of water. 
Preparation of samples, fluorometric analysis of flufenamic acid and gas 
chromatographic analysis of mefenamic acid were as described in 
chapter 2. 
RESULTS 
Flufenamic acid 
Figure 9.1 shows the individual plasma curves obtained. The data are 
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pio: isma concentration ( mg / l ) 
f lufenamic acid 
200 mg orai 
24 25 26 27 
time (hrs) Figure 9.1 
Individuai plasma curves after oral administration of flufenamic acid (capsule, 
200 mg). The concentration is plotted on a linear scale. It was impossible to obtain a 
reasonable fit to normal pharmacokinetic models. See text for further explanation. 
plotted on a linear scale, since apparently they do not obey simple 
pharmacokinetics. No acceptable computerfit could be obtained, neither 
on basis of a one-compartment model nor on basis of a two-compartment 
model. Maximal plasma levels are obtained usually in about 1.5 hre, but in 
two subjects (PK and MB) this took much longer times. The peak heights 
show a large interindividual variation. This might be the result of differ-
ences in biological availability. In table 9.1 some indicative parameters are 
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TABLE 9.1 
Some parameters for flufenamic acid plasma curves (D=200 mg, capsule) 
Subject1 
DB 
JBr 
MBr 
HH 
BK 
PK 
FR 
DZi 
t * 
max 
(min) 
90 
90 
290 
80 
50 
170 
90 
90 
С
 2 
'-max 
(mg/1) 
5.9 
20.2 
10.5 
8.5 
10.6 
5.4 
15.4 
13.0 
AUC 
(mg. hr/1) 
25.1 
43.8 
54.4 
39.7 
37.9 
35.1 
44.3 
38.6 
(ml/min) 
133 
76 
61 
84 
88 
95 
75 
86 
1. All volunteers are male, age 20-26 yr, bodyweight 60-80 kg. 
'max 
peak. 
2' 'max a n c ' Cmax refer to the time and the concentration of the measured plasma 
listed and also the area under the curve is given. This area has graphically 
been determined from the linear plot of the plasma concentration versus 
time. From the last measured concentration point the residual area (to 
infinity) has been estimated according to the following obvious relation­
ship. 
AUCQ.« = AUCo_t· + ƒ С dt (9.1) 
where AUC = area under the linear plasma curve = / С dt 
С = plasma concentration 
t = time 
and the suffixes denote the time range over which the area is estimated. 
Under the assumption that from t' the decay of the plasma concentration 
is governed by a single time constant т
е
і, equation 9.1 simplifies to: 
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A U C Q ^ = Auc0_t. + q · те1 (9.2) 
where Cf· = plasma concentration at time t' 
This equation, known as Dost's law of corresponding areas (Dost, 1968), 
allows (under the condition mentioned) estimation of the AUC, which has 
a clear pharmacokinetic meaning as long as linear kinetics prevail, viz. 
AUC= г ^ - ( 9 · 3 ) 
(cf. chapter 4) 
For our analysis we assumed that the ultimate slope of the semilogarithmic 
plasma curve corresponded to r
e
i . Of course large mistakes can be 
made in this estimation, but since the major part of the plasma curve was 
graphically determined, we may expect the relative error introduced in the 
total area by possibly wrong estimates of r
e
i not to exceed some 10% 
(even under the most unfavourable circumstances). From the AUC we 
calculated the values of kçe | /F, which turn out to be in the range of 
60—130 ml/min. Although these are only rough estimates and although 
the biological availability F is unknown, it appears that the total body 
clearance of flufenamic acid is low. Especially in view of the fact that the 
estimated values may be still too high when absorption is incomplete, we 
may assume the clearance constant for flufenamic acid to be in the same 
order of magnitude as found for Ibuprofen and alclofenac. Presumably also 
the volume of distribution is low. It is impossible to calculate a steady 
state volume on basis of our data, but the relatively high plasma levels 
found in several cases, suggest that at least the volume of the central 
compartment will not exceed some 15 1 and maybe much smaller. In view 
of the strong protein binding reported by Glazko (1967) this is not surpris-
ing. The small distribution volume also explains the initially rapid decrease 
of the plasma level, despite the low total body clearance. As far as renal 
excretion of unchanged drug is concerned, we were unable to find more 
than traces of flufenamic acid in urine. 
Mefenamic acid 
The pharmacokinetic pattern of mefenamic acid is similar to that of 
flufenamic acid in that it is irregular and cannot be analysed according to 
simple compartment models. Also its renal excretion is negligible. When 
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taken after an overnight fast the drug gives remarkably low plasma levels. 
Since we considered it possible that the absorption would improve when 
the gastro-intestinal motility was enhanced, we administered the drug to 
the same volunteers 0.5—1 hr after they had taken breakfast. The results 
are exemplified in figure 9.2 and some parameters for each individual are 
listed in table 9.2. The area under the curve again was calculated as out-
lined in the foregoing paragraph. It may be noted that the AUC is much 
smaller for mefenamic acid than for flufenamic acid when the dose ratio 
(1000 : 200) is taken into account. From equation 9.3 it can be seen that 
two factors may cause such a difference: a larger kçei and/or a smaller F. 
plasmo concentration (mg/l) -
'time (h&J 
Figure 9.2 
Some typical examples of plasma curves after oral administration of mefenamic acid 
(1000 mg, 4 tablets Ponstan®). The same remarks as for figure 9.1 can be made. Note 
that much higher levels were obtained when the subjects had breakfasted than when 
they were fasting. See text for discussion of this phenomenon. 
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TABLE 9.2 
Indicative parameters foi mefenamic acid (1 g) administered to fasting ( 0 or not fas­
ting (n) subjects. 
Subject1 
DB f 
η 
JBo f 
η 
BK f 
η 
PK f 
η * 
TS f 
η 
RSo f 
η 
HH f 
FR f 
*тах 
(mg/1) 
270 
180 
270 
260 
260 
265 
110 
115; 265 
260 
170 
60 
180 
195 
195 
^max 
(mg/1) 
3.0 
5.9 
4.2 
12.8 
4.8 
10.3 
3.7 
9.2; 10.3 
14.1 
17.3 
8.3 
25.1 
14.0 
5.3 
AUG 
(mg.hr/1) 
18.2 
46.7 
28.7 
56.5 
24.1 
34.6 
23.1 
49.4 
48.6 
62.7 
29.1 
75.4 
38.6 
26.9 
kcel/F 
(ml/min) 
920 
360 
580 
295 
690 
480 
720 
340 
345 
265 
575 
220 
430 
620 
1. All volunteers are male, age 20-26 yr, bodyweight 60-80 kg. 
Ζ t
m a x
 and C
m a x
 refer to the flme and the concentration of the measured plasma 
peak. 
* plasma curve with two peaks. 
On basis of our data it is impossible to discriminate between these two 
possibilities. Nevertheless, in view of the variability of the area under the 
mefenamic acid curve we assume that the biological availability of this 
drug from the tablets usually is low. As far as the clearance constant is 
concerned we would expect values in the same order of magnitude as for 
flufenamic acid, since also mefenamic acid is strongly protein bound 
(Glazko, 1967; Terada et al., 1974) and since also its initial rate of elimina­
tion is comparable with that of flufenamic acid. Therefore, it seems that 
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differences in the clearance constant can hardly be large enough to explain 
the striking differences between the AUC's of the two fenamates. Most 
likely, the difference is caused primarily by differences in F. 
DISCUSSION 
The pharmacokinetic pattern of the fenamates is very irregular as com-
pared to the other arylacetic acid derivatives studied. We assume that this 
is related to the rather extreme physicochemical properties of these drugs. 
Both drugs are only very slightly water soluble, but there is quite a 
difference between the two. Whereas the solubility of flufenamic acid in an 
aqueous buffer of pH 6 is about 0.1 mg/ml, the solubility of mefenamic 
acid in the same solvent is not more than 0.004 mg/ml (Winder, 1967). It 
is very well conceivable that such a low water solubility is a limiting factor 
in the process of absorption from the gastro-intestinal tract. In this respect 
flufenamic acid has somewhat more favourable properties. The irregular 
absorption of the fenamates probably is directly related to the low solubil-
ity. Also the fact that our data suggest that flufenamic is much better 
absorbed than mefenamic acid, is compatible with these physicochemical 
characteristics. One might argue that this comparison is not fair since we 
administered flufenamic acid in capsules and mefenamic acid in the form 
of commercial tablets. In preliminary trials, however, we used a suspension 
of crushed tablet material. In these trials the absorption appeared to be 
even worse than in case of intact tablets. So it seems that the tablet 
formulation is not a deteriorating factor in this respect. Obviously also 
the elimination behaviour of the two fenamates is very irregular. Most prob-
ably this is caused by an enterohepatic circulation. In animal experiments 
Glazko (1967) found strong indications that the fenamates are excreted 
into bile and then partly reabsorbed from the intestine. In our investiga-
tions we observed in several cases that the plasma level of mefenamic acid 
24 hrs after administration was higher than the level at 10 hrs after intake. 
This phenomenon, which was never seen for flufenamic acid, suggests a 
enterohepatic circulation in man indeed. Another explanation seems 
hardly possible. It should be noticed that this implies that the estimated 
area under the curve may be flattering in the sense that part of the drug in 
the body contributes twice to the total area: first directly after absorption 
and then again after biliary excretion and reabsorption. To avoid over-
estimation of the AUC as far as possible we extrapolated the area from 
t = 10 hrs, without taking into account the higher plasma levels after 
24 hrs. Nevertheless, it cannot be excluded that already during the first 10 
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hrs enterohepatic circulation takes place to such a degree that it increases the 
AUG substantially The improvement of mefenamic acid absorption by the 
presence of food in the gastro-intestmal tract may be related to an increase 
of the bile flow. It is very well conceivable that the bile can emulsify the 
drug, thereby making it more suitable for absorption. A similar pheno-
menon has been reported for dipyridamole (Persantm®) by Mellinger and 
Bohorfoush (1966). These authors concluded that the plasma level of dipy-
ridamole during chrome administration exhibits more fluctuations by the 
intake of food than by the mtake of a new dose We suppose that m case 
of chronic administration of mefenamic acid the same effects will be 
observed There is another possibility that should be considered in case of 
drugs with very low water solubility and high lipophilicity, viz. absorption 
via the lymphatic system. In order to investigate this possibility, more 
specific (animal) experiments such as described by Kdian (1973) are 
needed. 
Of the drugs discussed in this chapter only one (mefenamic acid) is 
marketed in the Netherlands, and it is that very drug that exhibits very 
pronounced absorption difficulties. Flufenamic acid appears to yield usual-
ly rather high plasma levels although the variability of these suggests large 
vanations in biological availability. Mefenamic acid, however, gives lower 
plasma levels (although a higher dose is administered), which seems to be 
caused pnmanly by a low biovailabihty. Taking into account that in 
several systems that are regarded as indicative for antunflammatory 
potency mefenamic acid is less active than flufenamic acid (see e.g. 
Winder, 1967, Terada et al., 1972), we tend to conclude that for anti-
inflammatory therapy mefenamic acid must be clearly inferior to flufen-
amic acid. We do not know of course what the concentrations of the drugs 
at their site of action is, but the supenonty of flufenamic acid over mefen-
amic acid seems to be confirmed by clinical experience (see introduction). 
On the other hand, as indicated already, both drugs suffer from a variety 
of side-effects and for the moment it is questionable if either of the two is 
a useful addition to the therapeutic possibilities. 
Finally, it seems worthwhile to study the pharmacokinetic profile of 
mefenamic acid after administration of the drug m the form of a salt, for 
instance the sodium salt, which is freely soluble in water (Winder, 1967). 
Since the absorption of mefenamic acid probably is limited by its dissolu-
tion in the gastro-mtestinal fluid, the absorption might be improved by 
administering the salt form Such an improvement has been described for 
instance by Breimer (1974) for some barbituric acid derivatives. 
145 
NOTE added in proof: 
After completion of this chapter Angelucci et al. (J. Pharm. Sci. 65, 435, 1976) 
reported measurements of the plasma concentration-time curves of flufenamic acid in 
dogs and humans after administration of soft and hard gelatin capsules. Although the 
plasma concentration is measured at only 3 different times after administration their 
data suggest a higher biological availability of the drug from the soft gelatin capsules. 
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CHAPTER 10 PHARMACOKINETICS OF PYRAZOLONE 
DERIVATIVES IN MAN 
A. GENERAL INTRODUCTION* 
In search of effective synthetic substitutes for quinine Knorr in 1883 
obtained more or less by accident a compound for which later the generic 
name phenazone was proposed. Soon this compound appeared to exhibit 
interesting antipyretic properties. Since this was the primary effect aimed 
at, phenazone was put on the market as soon as it was established that the 
compound had a reasonably low toxicity. Under the suggestive name 
Antipyrine (at that time a trade name) it became available on the German 
pharmaceutical market in 1888. In later years it became clear that phena-
zone also had useful analgesic and antiphlogistic activities. The drug is used 
up to now, but almost exclusively in combination preparations. More 
important, however, is the fact that in the hands of the eany pharma-
ceutical chemists phenazone appeared to be an excellent starting material 
for the synthesis of a whole series of useful and effective antipyretic, 
analgesic and antiphlogistic compounds. These substances usually are 
designated as pyrazolone-derivatives, according to the name given by 
Knorr to the substance from which phenazone is derived by N-methylation 
('pyrazolone' is l-phenyl-3-methyl-2-pyrazoline-5-one). Especially the 
carbon atom at the 4-position in phenazone has been subject to sub-
stitution during the development of pyrazolone derivatives. Before going 
into this in some detail we have to define the nomenclature we use, since 
unfortunately some of the common, generic names are quite ambiguous 
and not systematically derived. In this chapter all names are derived from 
phenazone as the basic structure and for the substituents both position 
and chemical identity are indicated. Table 10.1 contains the nomenclature 
used in this chapter together with frequently used synonyms (including 
some trade names) and a more systematic chemical designation according 
to IUP AC rules (see also figure 10.1). The substitution reactions that were 
carried out at the 4-position of phenazone were quite diverse, but can be 
divided in two major groups. The first relatively small series is that of the 
4-alkyl substituted phenazones. If we restrict this introduction to the 
drugs that are relevant for our study, we should mention here one deriv-
* The history of the development of pyrazolone derivatives was shortly reviewed by 
Issekutz (1971). A general survey of chemical, physical and pharmacological 
properties of all pyrazolone derivatives was given by Krohs (1965). 
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£ TABLE 10.1 
Nomenclature of pyrazolone derivatives 
This chapter 
Phenazone 
4-isopropylphenazone 
4-ammophenazone 
4-methylaminophenazone 
4-dimethylanunophenazone 
4-isopiopylammophenazone 
4-methylammophenazone-4-methanesulfonate 
Frequently used synonyms 
antipyim 
propyphenazone 
isopiopylantipynn 
4-ammoantipyrm 
Ampyrone® 
monomethylammophenazone 
monôme thylaminoantipyrm 
ammophenazone 
ammopyrm 
amidopyim 
Pyiamidon® 
isopropylaminoantipynn 
Isopynn® 
noramidopyrinemethanesulfonate 
me tamizóle 
dipyrone 
Novalgin® 
IUP AC nomenclature 
l-phenyl-2, 3-dimethyl-3-pyrazolin-5-one 
l-phenyl-2, 3-dimethyl-4-isopropyl-3-pyra-
zolm-5-one 
l-phenyl-2, 3-dimethyl-4-ammo-3-pyrazolm-
5-one 
l-phenyl-2, 3-dimethyl-4-methylammo-3-
pyrazoün-5-one 
l-phenyl-2, 3-dimethyl-4-dmiethylammo-3-
pyrazolin-5-one 
l-phenyl-2, 3-dimethyl-4-isopropylamino-3-
pyrazohn-5-one 
l-phenyl-2, 3-dimethyl-?-pyrazolin-5-one-
4-methylaminomethanesulfonate 
ative: 4-isopropylphenazone, synthesized in 1931. The second, much more 
important, series of phenazone derivatives is based upon 4-amino-
phenazone. Soon after the discovery of phenazone it was established that 
the introduction of an amino-function at the 4-position led to a substantial 
increase in activity. As early as 1897 the drag 4-dimethylaminophenazone 
was placed on the market under the trade name Pyramidon®. In order to 
obtain a 4-dimethylammophenazone modification that was suitable for 
parenteral administration, 4-methylaminophenazone-4-methanesulfonate 
(Novalgin®) was developed in 1922. 20 Years later 4-isopropylamino-
phenazone was synthesized. It should be stressed that the drugs mentioned 
here are only a few out of a large number of drugs that have been 
developed and even clinically tested and applicated (for a more complete 
survey see Frohs, 1965). 
Numerous studies have been published concerning the pharmacology of 
the phenazone derivatives. All compounds have antipyretic, analgesic 
and antiinflammatory activities, but to a variable extent. Taking phenazone 
as a standard one should regard the fact that, although it exerts all three 
effects to such a degree that is was considered a very promising com­
pound at the time of its development, today the standard is so high that 
phenazone should be classified as a drug with only very moderate activity. 
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Figure 10.1 
Structural formulas of the phenazone derivatives discussed in this chapter. 
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The 4-aniinophenazone series, however, is more active. Especially 4-dime-
thylaminophenazone (Pyramidon®) has been the drug of choice for treat-
ment of fever and inflammatory conditions for a long time. Its antipyretic 
activity justifies its application even today under certain circumstances, 
but without careful control use should be minimized in view of the risk of 
serious side-effects. The same holds true for 4-methylaminophenazone-
4-methanesulfonate, which has, however, only about one tenth of the 
activity and acute toxicity of 4-dimethylaminophenazone (in animal 
experiments) but which can therefore be administered in higher doses. In 
this case the effects will not be brought about by the parent compound, 
which is not detectable in plasma, but by its metabolites 4-methylamino-
phenazone and (to a much smaller extent) 4-aminophenazone (Weiss et al., 
1974). Therefore one might conclude that also the pharmacological 
activity of 4-methylammophenazone is approximately one tenth ofthat of 
4-dimethylaminophenazone, although no direct evidence is available. 
4-Aminophenazone has not come into clinical use as an analgesic; 
occasionally it has been used for determination of the volume of total body 
water (Huckabee, 1956). Its antipyretic and analgesic action seems com-
parable with 4-dimethylaminophenazone (personal communications cited 
by Brodie and Axelrod, 1950).4-Isopropylaminophenazone is in use up to 
now, but only together with phenylbutazone in combination preparations 
(Tomanol®). According to Schoetensack et al. (1960) the drug has reason-
able antipyretic, analgesic and antiphlogistic activity. 
Finally, the only alkylsubstituted derivative of phenazone mentioned in 
this introduction, 4-isopropylphenazone, appeared to have effects compar-
able with 4-dimethylaminophenazone (Fromherz, 1937; Orestano, 1935; 
Bauer, 1959). Today it is a component of several popular combination 
preparations (eg. Saridon®), but it is doubtful whether the drug in the low 
doses employed contributes significantly to the effect of the combination. 
A large number of investigations has >een devoted to establishing side-
effects and toxicity of the phenazone derivatives. An excellent review 
concerning this matter with special reference to the human situation is 
available in the literature (Prescott, 1972). Phenazone and 4-isopropyl-
phenazone are relatively safe drugs, although occasionally hypersensitivity 
reactions, usually in the form of skin rashes, may occur. This type of 
toxicity has been described for the aminoderivatives as well, but much 
more dangerous complications are to be feared when using this class of 
compounds. The complications in question are the result of bone marrow 
depression. Especially agranulocytosis, with a high mortality, is a notor-
ious hazard of therapy with 4-dimethylaminophenazone (Pyramiden®) 
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and its sulfonic acid derivative (Novalgin®) (Hartl, 1965; Huguley, 1964; 
Sadusk, 1965). Most probably the pathogenesis of this type of agranulocy-
tosis depends upon immunological mechanisms and there is evidence that 
the phenazone nucleus is a primary determinant in this respect (Thier-
felder et al., 1964; Magis et al., 1968). However, direct evidence of agranu-
locytosis occurring in association with the use of phenazone or 4-iso-
propylphenazone has never been reported. Since on the other hand the 
causal relationship between the use of 4-dimethylaminophenazone (and 
4-methylammophenazone-4-methanesulfonate) and agranulocytosis is a 
well-established fact, one tends to regard the 4-amino group as an 
important secondary characteristic. The incidence of agranulocytosis by 
these drugs is not exactly known, but estimations range from 0.007 to 1%, 
with a mortality rate of about 75% (cf. for instance Huguley, 1964; Hartl, 
1965). The agranulocytosis may develop suddenly in patients who have 
taken the drug for some time without any problems and in a sensitive 
individual disappearance of granulocytes from the blood may be complete 
within 6 to 24 hours after drug intake. The risk of agranulocytosis makes 
4-dimethylaminophenazone and 4-methyIaminophenazone-4-methanesul-
fonate hazardous drugs that should be available only on prescription and 
only under strict medical control. This applies also to their use in combina-
tion preparations. For instance the presence of 4-methylaminophenazone-
4-methanesulfonate in combination with a spasmolytic in popular prepara-
tions like Buscopan® compositum and Baralgin® may carry the risk that 
this potentially dangerous drug is prescribed by physicians who are un-
aware of the exact composition of the preparations. In general one should 
prefer the administration of the spasmolytic alone, or together with a safe 
analgesic in a separate form. 
Although our study is confined to the phenazone derivatives in a strict 
sense, we mention here two other drugs that can be regarded as pyrazolone 
derivatives as well, viz. phenylbutazone and oxyphenbutazone. In these 
compounds a second carbonyl group is introduced in the pyrazole nucleus 
(see figure 10.1), which gives the drugs a clear acidic character, contrary to 
the phenazone derivatives that are all more or less basic. It is interesting to 
note here the analogy with the newer non-steroidal antiinflammatories, 
which as a rule have a free carboxylic acid group. Since the introduction of 
phenylbutazone (Butazolidin®) towards the end of the forties its excellent 
antiinflammatory (and antipyretic) properties have been established in 
many studies (Von Rechenberg, 1961). The same holds true for oxyphen-
butazone (Tanderil®) which is a metabolite of phenylbutazone. Unfortun-
ately these drugs show quite a large incidence of serious side-effects and 
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the same type of blood disorders as with 4-aminophenazone derivatives 
can be encountered, but several other dangerous complications as well 
(Prescott, 1972). 
The present pharmacokinetic study in man was undertaken in order to 
obtain insight in the influence of substitution in the 4-position of the 
Phenazone nucleus on the nature and the rate of the elimination of the 
Phenazone derivatives in man and on the other kinetic parameters. The 
results of these investigations are meaningful from two different points of 
view. Firstly, there is a good chance of getting some general ideas on 
structure-pharmacokinetics relationships and secondly, the pharmaco-
kinetic data will be helpful for interpreting the time course of the effects 
and for establishing optimal dosage schedules especially for those com-
pounds that are therapeutically employed. This may be the more 
important as the disposition of several of the commonly used drugs 
mentioned in this introduction was practically totally unknown (e.g. 4-iso-
propylphenazone and 4-isopropylaminophenazone). This chapter is 
divided into two parts: the first deals with the comparative pharmaco-
kinetics of phenazone and 4-isopropylphenazone, the second with a 
comparison of 4-dimethylaminophenazone, 4-methylaminophenazone, 
4-aniinophenazone and 4-isopropylaminophenazone. Concerning 
phenazone and 4-dimethylaminophenazone a lot of kinetic studies have 
appeared in literature already, some of which will be referred to in the 
following parts of this chapter, and in our investigations these two drugs 
were included mainly for reference purposes. 
B. PHENAZONE AND 4-ISOPROPYLPHENAZONE 
INTRODUCTION 
The fate of phenazone in the human organism has been extensively 
studied. Already in 1950 Brodie and Axelrod reported that phenazone 
after oral administration is completely absorbed and then evenly distributed 
throughout the body water. Therefore phenazone might be used for 
determining the volume of total body water (Soberman et al., 1949). They 
also noted a remarkably slow elimination of the drug in man (halflife in 
the order of 15 hrs). The fact that only about 5% of the dose was excreted 
unchanged in urine indicated that most of it is eliminated by metabolic 
transformation. Already in this first paper on human kinetics of phena-
zone Brodie and Axelrod identified the major metabolite: 30 to 40% of 
the dose is oxidized to 4-hydroxyphenazone, which is quickly and com-
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pletely conjugated with glucuronic acid and possibly with sulfuric acid. 
Three other metabolites have been found in urine, largely in a conjugated 
form: N-demethylphenazone (Schiippel, 1966) and further a hydroxy-
methylphenazone and a dihydrodiol of phenazone (Stafford et al., 1974). 
These last two metabolites suggest that the biotransformation of phena-
zone proceeds via the epoxide-dihydrodiol pathway. Phenazone is only 
slightly bound to plasma proteins (about 5%) and together with the fact 
that it is almost completely metabolized, this has led to speculations on 
the utility of the drug's elimination as a measure of drug metabolism by 
oxidative pathways in man. Vesell and Page (1968) indicated that the 
halflife of phenazone (5.1 to 16.7 hrs with an average value of 10.9 hrs in 
their study) was genetically controlled. Another interesting argument for 
the suitability of phenazone for evaluation of metabolic capacity lies in 
the clear correlation that is found between the rate of plasma elimination 
of phenazone and the rate of appearance in urine of the metabolite 
4-hydroxyphenazone (Huffman et al., 1974; Vesell et al., 1975). What is 
aimed at, however, is the possibility to predict the rate of elimination of 
other drugs on basis of the measured elimination of a standard compound. 
Now it is clear that phenazone is eliminated by oxidative processes and its 
predictive value should be restricted to other drugs that also are largely 
oxidated. The fact that the elimination rate of phenazone shows such a 
tremendous interindividual variation, but remains remarkably constant in 
the same individual examined over a period of more than 1 year, seems to 
suggest that it provides a reasonable reflection of the oxidative metabolic 
capacity of each individual (Davies et al., 1973; Davies and Thorgeirsson, 
1971a). Studies to confirm this, however, have seldom been unambiguous. 
Whereas Vesell and Page (1968) were unable to find any correlation 
between the halflives of phenazone and phenylbutazone in 28 twins, 
Davies et al. (1973) found a significant correlation between these halflives 
in 8 subjects. An equally significant correlation was found with the halflife 
of oxyphenbutazone (Davies and Thorgeirsson, 1971b). Smith and 
Rawlins (1974) reached again the conclusion that the halflife of phena-
zone could not be used to predict the elimination rate of phenyl-
butazone. In a comparative study on the elimination of phenazone, 
glutethimide, amobarbital and sulfinpyrazone, the halflife of phenazone 
appeared to be not correlated with that of any of the other 3 drugs (Kadar 
et al., 1973). The same negative result was found by Vesell et al. (1975) in 
a comparison of phenazone, 4-dimethylaminophenazone and phenacetin. In 
view of these results the predictive value of the halflife of phenazone 
seems to be very limited and not practically useful. Nevertheless one must 
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assume that it gives some indication of the metabolic status, especially 
since phenazone clearance, as expected, is not influenced by renal failure 
(Lichter et al., 1973). Evidence in favour of this assumption can be found 
indeed. Welch et al. (1975) showed a largely decreased halflife of phena-
zone in patients treated with anticonvulsants for more than 2 months. The 
same authors demonstrated that the elimination of phenazone can very 
well be evaluated from measurement of the decay of the concentration of 
phenazone in saliva (see also Vesell et al., 1975). There are several factors, 
known to alter hepatic function, that influence phenazone clearance in 
man. For instance phénobarbital treatment increases the rate of elimina-
tion of phenazone significantly (Vesell and Page, 1969; Kampffmeyer, 
1971). The degree of this increase seems to be under genetic control 
(Vesell and Page, 1969). Thyroid status is another factor: the halflife of 
phenazone is much shorter in hyperthyroid than in hypothyroid patients 
(Eichelbaum et al., 1974). Phenazone metabolism is also affected by age, 
alcohol consumption, caffeine and smoking (Vestal et al., 1975; Vesell and 
Passananti, 1973), by physical stress (Swartz et al., 1974) and by fever 
(Elin et al., 1975). The halflife of phenazone is decreased immediately by 
administration of hydrocortisone (Breckenridge et al., 1972) but 
prolonged under the influence of several other drugs (disulfiram, 
prazepam, allopurinol, nortriptyline, tetrahydrocannabinol and levodopa; 
Vesell and Passananti, 1973). On the other hand phenazone itself has 
enzyme-inducing properties (Breckenridge et al., 1970), leading to in-
creased glucuronidation of bilirubin (Orme et al., 1974) and to shortening 
of its own halflife and fall in its own steady state levels (Davies et al., 
1974). 
This short and incomplete anthology gives an indication of how much 
activity has been devoted to describing and interpreting the pharmaco-
kinetics of phenazone. Curiously enough no pharmacokinetic data at all 
are available in literature up to now with respect to 4-isopropylphenazone. 
The only more or less 'kinetic' observation was reported by Bauer (1959) 
who found the analgesic effect of this drug in mice to be of shorter 
duration than that of 4-dimethylaminophenazone. 
Since 4-isopropylphenazone is an extensively used drug in combination 
preparations we judged it worthwhile to study its pharmacokinetic behav-
iour in man, for instance to see if this drug might be expected to accumul-
ate when the combinations are used. Apart from this practical interest we 
wondered what would be the influence of isopropyl-substitution in phena-
zone and what (if any) would be the correlation between the pharmaco-
kinetic properties of phenazone and 4-isopropylphenazone. 
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MATERIALS AND METHODS 
Phenazone and 4-isopropylphenazone were obtained from OPG, Utrecht, 
The Netherlands. 
Preparation of samples and analytical procedure were as described in 
chapter 2. 
Drug administration 
Eleven young, healthy volunteers participated in this study. Seven of them 
took both phenazone and 4-isopropylphenazone. The other 4 volunteers 
were only disposable for one of the experiments. Prior to ingestion of the 
drug at nine o'clock at the day of experimentation, they were fasting 
overnight. After drug intake they remained without food for an additional 
3 hrs. No other drugs were taken during and for a period of at least two 
weeks before the experiments. The period between the two experiments 
was at least two weeks, but in some cases much longer. Longer intervals, 
however, did not influence the validity of the comparison unfavourably, 
since the pharmacokinetic behaviour of the two drugs under study was 
checked to be remarkably constant within the same individual over long 
periods of time (about 1.5 year). Blood samples were taken from the fore 
arm vein at regular intervals after drug administration. Samples of every 
aliquot of urine voided were collected after registering time and total 
volume of the urine production, for a period of at least 30 hrs (in case of 
4-isopropylphenazone) or 60 hrs (in case of phenazone). Phenazone was 
administered in a dose of 1000 or 500 mg in the form of a solution in 
about 100 ml of water. 4-isopropylphenazone was administered in the 
form of gelatin capsules containing 500 mg of the pure drug, together 
with about 150 ml water. Preliminary trials in which we administered 
4-isopropylphenazone as powder with a glass of water were unsatisfactory 
since the powder was irritating to pharynx and oral cavity. The drug's 
watersolubility is far too low to obtain solutions suitable for administra-
tion. 
RESULTS AND DISCUSSION 
As exemplified in figures 10.2 and 10.3 the pharmacokinetic behaviour of 
both phenazone and isopropylphenazone after oral administration can 
adequately be described on basis of the open one-compartment model. 
Looking at the curves (which are based on computer fit), especially the 
large difference in the rate of elimination is striking. This difference 
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о 4 isopropylphenazone 5 0 0 r r g oral 
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time (hr) 
Figure 10.2 
Comparison of the plasma curves obtained after oral 
administration of Phenazone (1000mg)and4-isopropyl-
phenazone (500 mg) to the same volunteer. Note the 
large difference between the halflives. 
plasma cone (mg/l,log scale)-
• Phenazone 500mg oral 
о 4 isopropylphenazone 500mg oral 
subject Μ В 
10 15 23 25 30 
time (hr) 
Figure 10.3 
Comparison of the plasma curves after oral adminis­
tration of phenazone (500 mg) and 4-isopropyl· 
Phenazone (500 mg). Note the large differences in 
halflife and apparent volume of distribution. 
TABLE 10.2 
Pharmacokinetic parameters for Phenazone and 4-isopropylphenazone. 
Subject' 
HA (23,60,172) 
HB (22,68,175) 
MB (24,80,186) 
WB (22,81,188) 
JE (24,90,186) 
KF (25,70,178) 
LH (24,66,176) 
ML (22,51,165) 
MR (22,54,167) 
JV (26,75,180) 
DZ (23,60,175) 
V/F 
(1) 
34 
49 
45 
41 
46 
31 
31 
-
-
32 
39 
W F 
ml/min 
32 
52 
43 
49 
45 
28 
30 
-
-
36 
50 
rel 
(hr) 
ri* 
(hr) 
PHENAZONE3 
18.1 
15.7 
17.2 
14.1 
17.0 
18.8 
17.0 
-
-
14.5 
13.0 
12.5 
10.9 
11.9 
9.8 
11.8 
13.0 
11.8 
-
-
10.1 
9.0 
Ta 
(min) 
12 
9 
6 
11 
6 
26 
7 
-
-
15 
42 
V/F 
(1) 
84 
73 
75 
122 
_ 
85 
-
76 
72 
89 
42 
W F 
ml/min 
'"el 
(min) 
t'/i 
(min) 
Ta 
(mil 
4-ISOPROPYLPHENAZONEs 
370 
235 
780 
850 
— 
750 
-
700 
350 
670 
370 
224 
310 
95 
144 
— 
113 
-
109 
207 
133 
114 
155 
215 
66 
100 
— 
78 
-
75 
143 
92 
79 
105 
141 
61 
75 
-
4 
-
92 
85 
25 
29 
1. Numbers in parentheses represent age (yr), bodyweight (kg) and height (cm); all subjects are male, except ML and MR 
2. Oral dose 1000 mg, except MB and HB (500 mg). 
3. Oral dose 500 mg. 
indicates that the introduction of the isopropyl group at the 4-position of 
Phenazone influences the pharmacokinetic behaviour to a large extent. 
Table 10.2 shows a compilation of all relevant pharmacokinetic para-
meters, and it is obvious at first sight that the impression the figures give is 
substantiated. We will now discuss the data in terms of the single processes 
and at any stage compare the results for phenazone with those for 4-iso-
propylphenazone. 
Absorption 
As a rule in our study the absorption of phenazone was more rapid than 
that of 4-isopropylphenazone. However, it is unallowed to draw far reach-
ing conclusions from this observation, since the drugs were not administer-
ed in the same formulation. The fact that phenazone is rapidly absorbed 
from a watery solution is just a confirmation of what should be expected 
for a drug with good water- and lipid-solubility. In case of 4-isopropyl-
phenazone the dissolution of the drug in the gastrointestinal juice might be 
a rate limiting step, since it has only a very low watersolubility. Disintegra-
tion of the capsules cannot be expected to take much time, since for other 
drugs we found extremely high absorption rates when administered in the 
same capsule. Optimal fit of the experimental plasma concentration data 
to the one compartment model required a certain lag period in case of 
4-isopropylphenazone. This also is a strong indication that before the 
actual absorption process becomes first order, some other step is rate 
limiting. The fact that by introducing this lag-time, a very good fit is 
obtained indeed, guarantees the validity of the estimated parameters, since 
obviously the lag-time is only a short induction period during which a 
steady concentration-gradient is established, whereafter the absorption 
process is merely first order. For phenazone it was unnecessary to consider 
the possibility of a lag-time, since this never led to an improvement of the 
fit. The analysis of an absorption process in terms of two parameters, the 
time constant for absorption and the lag-time, usually offers special 
difficulties with regard to the certainty of the estimated parameters. Un-
less many data points are available in the absorption phase one can easily 
imagine that a strong negative correlation exists between the lag-time and 
the time constant for absorption. In other words: prolonging of the lag-
time can adequately be compensated by shortening of the time constant 
for absorption and vice versa. This applies to some extent to the estimates 
presented in table 10.2 for 4-isopropylphenazone. Therefore, when judging 
the rapidity of the absorption process one should combine the influence of 
both lag-time and time constant. In case of 4-isopropylphenazone our data 
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suggest that the actual absorption can be very fast (see for instance subject 
KF) but that the overall absorption process takes much more time since a 
preceeding step (probably dissolution of the drug) is rate limiting. 
Volume of distribution 
As stated in the introduction phenazone is known to be distributed quite 
homogeneously over the total body water, although some binding to 
plasma proteins cannot be excluded. The volume of distribution for phena-
zone therefore can be expected to equal approximately the volume of 
body fluid, which is about 0.5 1 per kg body weight for persons of normal 
build. The values of V/F in table 10.2 are certainly in this order of 
magnitude, which implies that the biological availability of the phenazone 
solution probably is near to unity. Much larger estimates for V/F are 
found for 4-isopropylphenazone. Several factors may be responsible for 
this apparent increase in distribution volume. First of all 4-isopropylphena-
zone is much more lipophilic than phenazone itself. Employing the chloro-
form-water system we found for 4-isopropylphenazone and phenazone 
distribution coefficients of about 150 and 30 respectively (see chapter 3). 
Also since its watersolubility as such is very low, 4-isopropylphenazone 
might be expected to have special affinity for fatty tissue components. On 
the other hand this might be compensated to some extent by binding to 
plasma proteins, the degree of which is not known but which certainly 
may be expected to be higher than for phenazone. Secondly the bio-
availability of 4-isopropylphenazone in the form applied may be in-
complete. Obviously this would cause overestimated values for V. When 
for instance the bioavailability F would be about 0.5 the actual volumes 
would have half the values listed in table 10.2, which would bring them in 
the same order of magnitude as found for phenazone. In view of the 
regular absorption process which is seen (at least after the induction 
period) it seems unlikely, however, that the bioavailability would be so 
low, especially since the drug was administered on an empty stomach. A 
third phenomenon therefore seems to be more plausible, viz. a substantial 
first-pass effect. After absorption the drug goes via the vena porta directly 
to the liver where already at its first passage part of the drug may be 
extracted from the bloodstream. This is certainly not unlikely in view of 
the high clearance constants and taking into account that only negligible 
amounts of 4-isopropylphenazone are excreted unchanged in urine (see 
below). This first pass effect would diminish the amount of drug that 
reaches the general circulation intact, thereby decreasing the effective 
dose. Formally this effect can be regarded as a reduction of the biological 
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availability. Possible implications of the first-pass effect for 4-isopropyl-
phenazone are discussed below under 'clearance'. 
Elimination 
The halflives for elimination found in this study, show a large inter-
individual variability for both drugs. This variability is well-known for 
Phenazone (see e.g. introduction) but for 4-isopropylphenazone not, since 
for this drug no data at all were available up to now. In all of the seven 
subjects who received both drugs, 4-isopropylphenazone was eliminated at 
a much higher rate than phenazone, the ratio between the halflives varying 
from 3.0 to 10.9 with an average of 6.85. No correlation, however, existed 
between the halflives found for the two drugs in the same individuals. This 
suggests that different metabolic routes are primarily involved in the 
elimination of phenazone and its 4-isopropyl derivative. The tact that the 
elimination of the 4-isopropyl compound is much more rapid than that of 
the unsubstituted substance seems to indicate that the isopropyi group is 
indirectly or directly involved in the biotransformation process, since the 
drugs have all other molecular characteristics in common. Indirectly the 
isopropyi group could enhance the metaboUc transformation by increasing 
the lipid solubility and thereby facilitating penetration into the liver cells. 
On the other hand it is very unlikely that the penetration of the liver cells 
would be rate limiting for phenazone, since its distribution over the body 
water is definitely much faster than its elimination. Therefore this indirect 
influence may safely be neglected, and only a direct involvement of the 
isopropyi group in the metabolic process has to be considered. It is well-
known that the most important metabolite of phenazone is 4-hydroxy-
phenazone (cf. introduction). Obviously this metabolite cannot be formed 
in case of 4-isopropylphenazone. Most probably metabolic attack here is 
directed primarily towards the isopropyi group. So it is likely that, where-
as the 4-hydroxy metabolite of phenazone may be the result of cpoxida-
tion (Stafford et al., 1976), the most important metabolites of 4-iso-
propylphenazone will be produced by aliphatic (side chain) oxidation. The 
differences in rate of elimination might be (partly) explained on this basis. 
With regard to the remarkably large variability in the rate of elimination 
for the two drugs under study, it is important to note that this variability 
for phenazone most probably is under genetic control (Vessel and Page, 
1968). This may also be the case for 4-isopropylphenazone, but with 
regard to this drug also the influence of variations in hepatic bloodflow has 
to be taken into account. Contrary to phenazone, 4-isopropylphenazone 
exhibits such a large metabolic clearance that variations in the bloodflow 
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through the liver undoubtedly will be reflected in the metabolic clearance 
constant and consequently also in the halflife for elimination. This may be 
an additional factor contributing to the interindividual variability of the 
observed halflives. 
As far as practical implications of our data are concerned it seems 
justified at this stage of the discussion to throw doubt upon the rational 
basis of the addition of relatively small amounts of 4-isopropylphenazone 
to a lot of combination preparations. Our study reveals that small doses 
(for instance 150 mg as in Saridon®) cannot be expected to give rise to 
effective blood levels for a relatively weak compound, as 4-isopropyl­
phenazone is. Furthermore in many persons the elimination of the drug 
will be so rapid, that even if the peak concentration would be above the 
minimally effective concentration, such an effective level would only last 
for a short period of time. Unless a substantial synergism between the 
components of these combination preparations would be proven, the dis­
advantages of dealing with sometimes very diverse drugs simultaneously 
can only seldom be counterbalanced by possible advantages of lower 
toxicity. This is the more so, since it is very questionable whether these 
combinations offer any decrease of potential toxicity at all. Furthermore 
it has to be noticed that most drugs will not potentiate other drugs unless 
they reach reasonable plasma levels themselves. 
Renal clearance 
TABLE 10.3 
Cumulative renal excretion (% of dose) of Phenazone and 
Subject 
HA 
HB 
MB 
WB 
JE 
KF 
LH 
JV 
DZ 
Phenazone 
Q
r
% 
(unch.) 
6.0 
2.9 
1.7 
1.9 
2.4 
3.2 
3.9 
1.7 
5.1 
4-isoprop] /Iphenazor 
4-isopropylphenazone 
Q
r
% 
unch. met. 1 met. 2 
0.05 
0.11 
0.09 
0.07 
-
0.01 
-
0.02 
0.17 
1.64 
0.83 
1.24 
1.09 
-
0.77 
-
1.25 
1.50 
1.41 
1.73 
0.89 
1.26 
-
X 
-
1.40 
1.78 
χ not detectable. 
"met. 1" and "met. 2" refer to metabolites discussed in the text. 
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As shown in table 10.3 phenazone is excreted unchanged in urine for 1.7 
to 6% of the dose administered. From the detailed renal excretion graphs, 
an example of which is given in figure 10.4, we got the impression that the 
renal excretion rate fluctuated more or less proportionally to the urine-
flow. This was not surprising on the basis of the physicochemical proper­
ties of phenazone. Like alcofenac (chapter 8) phenazone exhibits an inter­
mediate lipid solubility, but further phenazone has a high watersolubility. 
гелаі excretion ratet uo/min.log scole)-
phenazone 
subtectJ V 
"1 lOOOmg oral 
cunuJatitv renal ежсгеікп 
(mg ) 
cumulative renal excretan 
( ·/. of dose ) 
2 
IO 20 30 40 5 0 60 timelhr) 
Figure 10.4 
Renal excretion rate and cumulative renal excretion of phenazone after an oral dose 
of 1000 mg. 
With regard to renal excretion this suggests a reabsorption which is far 
from complete and strongly dependent on the ultimate volume of urine 
produced. A positive correlation between the percentage of drug excreted 
unchanged and the average urineflow prevails indeed. Figure 10.5 indicates 
that the same type of correlation is found between the renal clearance 
constant and the urineflow. It should be noted that unlike the percentage 
excreted unchanged, the renal clearance constant determined has an 
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renal clearance constant ( ml/mm ) 
26 
24 
22-
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18-
16-
14-
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10-
Q8-
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0 8 10 12 14 16 ΐ 'β 
average urine flow (ml/mm) 
Figure 10.5 
The renal clearance constant of phenazone plotted against the average urine flow. 
Note the positive correlation; the line is the result of the regession analysis. 
absolute meaning, since its value is independent of the biological avail­
ability (cf. the discussion of the renal excretion of alclofenac in chapter 8). 
4-isopropylphenazone is practically not excreted unchanged. Table 10.3 
contains the relevant data concerning the renal excretion of this drug and 
shows that not more than about 0.1% of the dose appears in urine un­
changed. Of course this is a negligible fraction of the total dose administer­
ed. No correlation at all could be found with the rate of urine production. 
It is interesting to note that gaschromatograms of the urine extracts 
obtained after 4-isopropylphenazone administration show two peaks that 
seem to belong to metabolites as suggested by their course as a function of 
time. A representative example of the estimated renal excretion rates and 
cumulative renal excretion of these products together with the data for the 
unchanged drug is given in figure 10.6. Clearly the total amount of the 
'metabolites' is rather small. Table 10.3 shows that not more than about 
3 percent of the dose can be accounted for by renal excretion of the drug 
itself and presumable metabolites. The identity of the metabolites could 
not be established. 
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Figure 10.6 
Renal excretion rate and cumulative renal excretion of 4-isopropylphenazone and 
two presumable metabolites. See text for further explanation. 
It can be concluded that detailed analysis of the renal excretion of 
Phenazone and 4-isopropylphenazone proves that for all practical purposes 
the elimination of these drugs may be regarded as determined by meta-
bolic clearance alone. 
Clearance 
Phenazone has a low overall clearance constant; the values we found for 
код/Г range from 25—50 ml/min. Since presumably the biological avail­
ability is practically complete, we may assume that this range also applies 
to the absolute values for the clearance constant. Interestingly phenazone 
is cleared essentially at the same rate as Ibuprofen and alclofenac (see 
chapters 5 and 8), but because of its much larger volume of distribution a 
much longer halflife results. In case of 4-isopropylphenazone matters are 
much more complicated. From table 10.2 it is clear that the estimates for 
kçei/F can amount up to 850 ml/min. This implies in fact that here a 
substantial first-pass effect should be expected. Ideally under such circum-
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stances the total-body clearance constant should be determined in an 
absolute sense after intravenous administration of the drug. From the ratio 
between this clearance constant and the hepatic blood flow the fraction of 
the dose extracted at its first pass through the liver can be estimated and 
once this is known the fraction of the dose that was absorbed can be 
derived. Unfortunately no pharmacokinetic parameters for 4-isopropyl-
phenazone after intravenous administration are available. In order to get 
still some insight into the possible implications of the first-pass effect we 
wiH discuss this matter under the basic assumption that the whole dose 
administered has come to absorption. The fact that for pyrazolone deriv­
atives absorption as a rule seems to be practically complete may be 
regarded as an argument in favour of this assumption. When after oral 
administration a drug is absorbed, it is collected in the vena porta and goes 
directly to the liver. The drug can leave into two directions: one is with 
the bloodstream unchanged out of the liver, the other is into the liver cells 
to be metabolized. The relative contributions of these two ways of course 
depend upon the ratio of their capacities, which can best be expressed as 
the volume of blood that flows in either direction per unit of time. As far 
as the metabolic route is concerned, this flow should be interpreted of course 
in an abstract sense, viz. as the metabolic clearance. Now the clearance 
constants we use are always based on measurement of plasma concentra­
tions and should be termed plasma-clearance constants. What we need for 
our comparison is of course the blood clearance, since pyrazolone deriv­
atives can exchange rapidly between plasmawater and bloodcell-water. In 
vitro experiments that we performed showed that 4-isopropylphenazone 
rapidly penetrated erythrocytes, the concentration in the cells being equal 
to the surrounding plasma concentration. Thus we demonstrated that the 
plasma concentration is equal to the total blood concentration, which 
imphes that in this case the blood clearance is equal to the plasma clear­
ance код. Using the symbol fi for the bloodflow through the liver, the 
fraction (E) of the amount of drug arriving through the vena porta, that is 
extracted at first pass obviously can be defined as: 
„
 kCel 
fi 
The rest of the total amount passes through the liver unaffected, so: 
(10.1) 
kCel 
1 = 1 — ^ (10.2) 
l i 
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where I is the fraction of the absorbed dose of drug that comes in the 
general circulation intact (see also Rowland, 1972). Under the assumption 
of complete absorption, the clearance constants given in table 10.2 for 
4-isopropylphenazone can be seen as the ratio код/І. By rearrangement of 
equation 10.2 we obtain: 
1
 L'^ TTJ (юз) 
When in addition the hepatic bloodflow is known this equation allows 
calculation of I and then KQ
e
\ (and V). Table 10.4 gives the corrected 
values obtained this way for the subjects that participated in our study. 
Also the estimated fractions E and I are summarized. 
For the hepatic bloodflow we used a fixed value of 1500 ml/min, since 
no better individual estimates were available. Nevertheless it is obvious 
that the corrected distribution volumes are much closer to the correspond­
ing volumes for phenazone although definitely larger in most cases. Incom­
plete absorption and individually variable hepatic bloodflow are complicat­
ing factors that cannot be excluded and that may influence the data of 
table 10.4 to some (unknown) extent. 
TABLE 10.4 
4-isopropylphenazone: V and к о д corrected for fust-pass effect (see text for further 
explanation). 
Subject E 
HA 0.20 0 
HB 0.14 0 
MB 0.34 0 
WB 0.36 0 
KF 0.33 0 
JV 0.31 0 
DZ 0.20 0 
I V 
1
 "con. 
(1) 
.80 67 
.86 63 
.66 49 
.64 78 
.67 56 
.69 62 
.80 34 
*Cel, corr. 
(ml/min) 
295 
200 
515 
545 
505 
460 
295 
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С. 4-AMINOPHENAZONE AND ITS DERIVATIVES 
INTRODUCTION 
The elimination of 4-anunophenazone derivatives from the body appears 
to proceed by a common pathway with several consecutive metabolic 
steps. Alkylated 4-ammophenazone derivatives are first fully dealkylated 
and then for a small part excreted as such and for a major part acetylated 
and excreted in unne as 4-acetylaniinophenazone This pathway, however, 
does not account for the whole dose administered and it has to be assumed 
that another way, perhaps mvolvmg cleavage of the pyrazolone ring, can 
take care of a substantial amount of drug. Oxidative dealkylation of 
4-ammophenazone derivatives has been extensively studied. As a matter of 
fact 4-dimethylanunophenazone is used as a test substance in many inves­
tigations on drug metabolism in vitro (see e.g Mazel, 1971). In 1950 two 
papers appeared on the fate of 4-dimethylaimnophenazone (Pyramiden®) 
in man (Halberkann and Fretwurst, 1950, Brodie and Axelrod, 1950b). A 
small amount of the drug is excreted in urme unchanged (0—4%) and 
about half the dose is dealkylated to 4-ammophenazone. 4-Amino-
phenazone is excreted in unne as such for 10-35% and as acetylated 
compound 25—70%. 4-Acetylammophenazone is almost completely ex­
creted m unne. The excretion products of 4-methylaminophenazone— 
4-methanesulfonate are qualitatively and quantitatively the same as those 
of 4-dimethylaminophenazone. Obviously large mtermdividual variation m 
the amounts of excretion products occurs Apart from the metabolites 
mentioned Pechtold (1964) found also appreciable quantities of 4-methyl-
aminophenazone in unne of man after mgestion of the dimethyl product. 
He also showed the presence of traces of rubazomc acid ('Rubazonsaure') 
and a more substantial amount of methylrubazonic acid (see also Preuss 
and Voigt, 1965). These two metabolites, formed by azo coupling of two 
pyrazolone rings, are responsible for the red coloured urme which is 
observed after intake of 4-ammophenazone derivatives. Most authors 
mention also the occurrence of a small amount (less than 5% of the dose) 
of conjugated 4-hydroxyphenazone, indicating that deammation may take 
place. A complete survey of all these metabohtes excreted in urine after 
oral and rectal administration is given by Gradmk and Fleischmann (1973) 
and by Fleischmann (1973). The fact that the excretion patterns are very 
similar (also quantitatively) strongly suggests that oral and rectal adminis­
tration of 4-dimethylaminophenazone are practically equivalent. Two 
more metabohtes of 4-dimethylaminophenazone have been found m rabbit 
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and rat, viz. the 3-hydroxymethyl derivative and the corresponding 
carboxylic acid (Yoshimura et al., 1970). An intermediate in the forma-
tion of these metabolites is probably the aldehyde, which may be im-
plicated in allergic reactions (Shimeno and Yoshimura, 1972). 
After this brief survey of known metabolic routes we will shortly 
mention some relevant pharmacokinetic data from literature for each drug 
separately. 
4-dimethylaminophenazone 
Brodie and Axelrod found an elimination rate of 10-30% an hour for this 
drug. This corresponds with halflives in the range 2,3-7 hrs. They also 
showed absorption after oral administration to be near to complete. The 
drug is fairly evenly distributed throughout the body water, although some 
binding to plasma proteins occurs (about 15%). The concentration in the 
bloodcells is somewhat below the plasma concentration (see also 
Windorfer et al., 1973). The halflife of 4-dimethylaminophenazone can 
also be determined by measuring saliva concentrations as a function of 
time (Vesell et al., 1975). Saliva concentrations are definitely lower than 
plasma concentrations because of the binding of the drug to proteins in 
plasma. This binding, however, is rapidly reversible and relatively constant 
over the concentration range studied, so that the profile of the saliva 
concentration curve is parallel to that of the plasma curve. Vesell reported 
halflives for 4-dimethylaminophenazone ranging from 1.1 to 4.5 hrs, with 
a mean value of 2.7 ±0.3 hrs. The values that may be derived from data by 
Kaneo et al. (1973) fall within the same range. A very interesting approach 
to the assessment of 4-dimethylaminophenazone metabolism in man is 
given by Hepner and Vessel (1974). By using C14 labels in the dimethyl-
amino-group they suggest that breath analysis to measure output of radio-
active carbon dioxide provides useful information about hepatic meta-
bolism. Phénobarbital or disulfiram pretreatment led to a significant in-
crease and decrease respectively of the carbon dioxide output, which was 
also strongly diminished in case of portal cirrhosis. In this context it is 
interesting to note the results on demethylase activity established in 
human liver biopsies by Gold and Ziegler (1973). The demethylase activity 
appeared not to be influenced by several disease states, but decreased only 
upon severe tissue damage. This suggests that a prolonged halflife of 
4-dimethylaminophenazone in many cases will be caused by decreased 
accessibility of the enzyme compartment, rather than that it would reflect 
alterations in 'intrinsic' hepatic clearance. Gold and Ziegler did find 
highest demethylase activity in patients exposed to barbiturates, so here 
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metabolic capacity is enhanced indeed (which of course was to be 
expected). Since 4-dimethylaminophenazone is eliminated almost exclus-
ively by metabolic routes disturbances in renal function will not influence 
the elimination rate significantly (Leber et al., 1972). 
4-methylaniinophenazone 
No direct data on the pharmacokinetics of this substance are available. 
Some information, however, may be gathered from investigations on 
4-methylaminophenazone—4-methanesulfonate (Novalgin®), since Weiss et 
al. (1974) provided evidence that this drug already in the gastrointestinal 
tract decomposes to 4-methylaminophenazone, which then is absorbed. As 
a matter of fact it is quite unbelievable a priori that a relatively strong and 
very little lipophilic acid like 4-methylaminophenazone—4-methanesul-
fonate would be absorbed as such. The 4-methylaminophenazone appears 
to be readily absorbed and also eliminated at a high rate. From the data of 
Weiss we calculated a halflife of about 2.5 hrs for 4-methylamino-
phenazone. Brunk et al. (1974) studied the effect of thyroid status on the 
metabolism of 4-methylammophenazone—4-methanesulfonate in man. 
Since also after i.m. or i.v. administration of 4-methylaminophenazone— 
4-methanesulfonate the drug itself cannot be found in plasma, but only 
4-methylaminophenazone, we may assume that the kinetic data published 
by these authors should be interpreted as reflections of 4-methylamino-
phenazone elimination. In normal subjects they found halflives of about 
3 hrs, but significantly higher values were measured in hypothyroid 
patients. Large interindividual variations were observed. 
4-isopropylaminophenflzone 
This drug (trade name Isopyrin®) is used in combination with phenyl-
butazone in the preparation Tomanol®, which also has been the dosage 
form administered in the few studies that have been published. 4-iso-
propylaminophenazone appears to be rapidly taken up in the bloodstream 
after oral or intramuscular administration. It is distributed over the total 
watery phase of the body, and only negligibly bound to plasma proteins 
(Richarz et al., 1959). The drug crosses the placentabarrier readily and is 
excreted into milk in man (Gensichen et al. 1964). On basis of plasma 
concentration data in literature (Gensichen et al., 1964; Schmid, 1959) we 
made rough estimates of the halflife (7-9 hrs) and the volume of distribu-
tion (about 501) of 4-isopropylaniinophenazone. We have, however, 
serious doubts on the specificity of the analytical procedure applied in 
these studies, so the estimates should be regarded with due reserve. A last 
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observation worth mentioning with respect to 4-isopropylaminophenazone 
is that in rats and guinea-pigs the drug was found to be absorbed also 
percutaneously (Vogel et al., 1967). 
4-aminophenazone 
According to Huckabee (1956) 4-aminophenazone is a useful test-
substance for determining the volume of total body water, over which it is 
uniformly distributed. The compound is slightly protein bound. After i.v. 
infusion Huckabee obtained halflives averaging about 10 hrs and distribu-
tion volumes of 0.5 1 per kg body-weight. In his study the subjects 
remained supine but change of posture was noticed to increase the rate of 
disappearance of 4-aminophenazone. Vesell et al. (1975) determined the 
halflife of 4-aminophenazone on basis of the urinary excretion of this 
metabolite after administration of 4-dimethylaminophenazone. The 
indirect estimates obtained this way varied from 5-20 hrs with an average 
of 12.6 hrs. All these data, however, are highly disputable, since there is 
strong evidence, both from the present study and from animal experiments 
by Sawchuk (1972), that the disposition of 4-ammophenazone is governed 
by non-linear processes. In the discussion of the results of our study we 
will analyse these processes in more detail. 
The present investigations were planned primarily to establish possible 
general principles in the elimination of the 4-aminophenazone derivatives. 
Especially since literature data provide only scarce and indirect informa-
tion, mostly based on non-specific analytical procedures, it might be 
expected that a systematic approach as we used, would yield results that 
are useful and important also from a practical point of view. The drug 
4-dimethylaminophenazone which is the only one in the series that has 
been studied in detail earlier, was mainly included in this study for 
reference purposes, since in normal subjects it gives an impression of the 
oxidative dealkylation activity of the liver. 
MATERIALS AND METHODS 
4-Dimethylaminophenazone was obtained from OPG, Utrecht, The 
Netherlands; 4-methylaminophenazone from Hoechst, Frankfurt, 
Germany; 4-aminophenazone from Merck, Darmstadt, Germany and 
4-acetylaminophenazone from Aldrich, Milwaukee, Wisconsin, USA. 4-Iso-
propylaminophenazone (Isopyrin®) was supplied by Byk Nederland, 
Zwanenburg, The Netherlands, which is gratefully acknowledged. The sub-
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stance was the HCl salt and contained 2.5% amylum solani' (potato starch), 
but was used as such. Since all analytical procedures, including calibration 
graphs for gaschromatography, were performed with the same lot of the 
compound, no corrections for this 'contaminant' nor for the chloride had 
to be made at all. The same holds true with regard to 4-methylamino-
phenazone, which also was used as the HCl salt. The other drugs were used 
as the free base. 
Preparation of the samples and gaschromatographic analysis were per-
formed as described in chapter 2. Chloroform—water distribution coeffi-
cients were determined as described in chapter 3. 
Drug administration 
Six male healthy volunteers participated in this study. Every subject 
received an oral dose of any of the four drugs under investigation, in a 
random order at biweekly intervals. Some single experiments were 
repeated 1 year later. The results of these will be discussed separately in 
comparison with the findings of the main part of the investigations. 
The usual precautions with respect to reproducibility of drug absorption 
were taken: an overnight fast prior to and an additional three hours fast 
after drug ingestion. At regular intervals after drug intake bloodsamples 
were taken from a fore-arm vein, to a total of 10-12. Time and total 
volume of every urine production were registered and samples of every 
aliquot were collected for analysis. This was done for a period of at least 
30 hrs, depending upon the pharmacokinetic characteristics of the specific 
drugs. 
All drugs were administered in a dose of 600 mg as a solution in 100 ml 
water. The solutions were freshly prepared, just before ingestion. 
RESULTS AND DISCUSSION 
TTie complete cross-over design of this study allows a comparison of the 
pharmacokinetics of each drug within the same individuals. In view of the 
huge interindividual variations we observed, such a design is an essential 
prerequisite for comparative purposes. Some examples of the curves 
obtained are given in figure 10.7. The drawn lines represent the best fit 
according to the open one compartiment model which appears to describe 
the data very satisfactorily. Only as far as 4-aminophenazone is concerned 
an exception has to be made to this general statement, as will be shown in 
part D of this chapter. The pharmacokinetic parameters that were 
obtained by computer fit are summarized in table 10.5. Similar to the 
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findings concerning phenazone and 4-isopropylphenazone, also here large 
interindividual fluctuations are striking. 
TABLE 10.5 
Pharmacokinetic parameters for 4-aminophenazone derivatives after oral administra-
tion (I>=600 mg). 
Subject1 
JB 
AD 
HK 
PM 
RS 
RSi 
JB 
AD 
HK 
PM 
RS 
RSi 
JB 
AD 
HK 
PM 
RS 
RSi 
JB 
AD 
HK* 
PM* 
RS 
RSi* 
(23,63,178) 
(23,64,177) 
(23,73,181) 
(22,90,195) 
(22,70,190) 
(20,72,183) 
V/F 
(1) 
129 
44 
112 
55 
124 
127 
39 
31 
29 
35 
31 
53 
36 
30 
78 
57 
44 
29 
41 
46 
115 
56 
95 
59 
W F 
(ml/min) 
Tel 
(min) 
tìi 
(min) 
4-METHYLAMINOPHENAZONE 
450 
150 
440 
120 
870 
340 
284 
290 
255 
461 
143 
376 
197 
201 
177 
320 
99 
261 
4-ISOPROPYLAMINOPHENAZONE 
390 
290 
310 
260 
410 
360 
101 
106 
93 
134 
75 
148 
70 
73 
64 
93 
52 
102 
4-DIMETHYLAM1NOPHENAZONE 
250 
250 
430 
260 
470 
170 
144 
119 
181 
215 
92 
177 
100 
83 
125 
149 
64 
123 
4-AMINOPHENAZONE 
350 
170 
1120 
210 
530 
1140 
118 
277 
103 
267 
178 
52 
82 
192 
72 
185 
124 
36 
т
а 
(min) 
10 
6 
13 
10 
3 
26 
4 
8 
6 
0.7 
0.5 
11 
7 
6 
6 
0.5 
0.5 
4 
4 
17 
Π 
D 
9 
D 
1. Numbers in parentheses represent age (yr), bodyweight (kg) and height (cm); all 
subjects are male. 
* Plasma curve non-linear, see part D of this chapter. 
• Could not be determined because of non-linear plasma curve (cf. chapter 13). 
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Plasma curves obtained after oral administration of 4-aminophenazone and 3 
¡ves (D - 600 mg) in the same individual. 
Absorption 
The four drugs are very rapidly absorbed from the aqueous solution 
administered This is not unexpected since the drugs combine a reasonable 
water solubility with a rather high lipid solubility The absorption appears 
to start immediately after drug intake as evidenced by the absence of any 
lag-time in the fitting procedure and by the fact that often the peak 
concentration in plasma had already been reached before the first blood-
sample was taken (10—15 min after administration). In such cases the 
estimated value of the time constant for absorption cannot be very 
accurate since no data points are available m the actual absorption phase. 
This may explain the extremely low time constants for absorption (less 
than 1 minute) that are obtained in some instances. The error in these 
estimates is quite high, although it can easily be seen that their upper limit 
will not exceed some 3 mm On the other hand in this context, the 
question anses how fast the absorption process maximally can be. The 
most easy and understandable way of approaching this problem is by 
regarding absorption as a clearance process in which the gastrointestinal 
tract is cleared from drug Obviously this clearance then is limited by the 
bloodflow around the intestinal system (the bases under consideration will 
practically not be absorbed from the stomach) The other determinant 
with respect to the absorption rate is the volume that has to be cleared It 
can easily be seen that the shortest time constant for absorption, that may 
be expected, is given by 
V V 
'•-k?— = r- (104) 
^Ca, max Ί 
where т
а
 = time constant for absorption 
V0 = volume from which absorption occurs 
k c
a
 = 'clearance constant' for absorption 
fi = intestinal bloodflow 
Now the problem is to insert reasonable estimates for VQ and fj in this 
equation Taking into account that the drug solution is ingested after an 
overnight fast and that the drugs will not precipitate in the stomach, it is 
likely that the solution passes directly through the stomach to the small 
intestine Since also the small intestine, certainly the first part, will be 
empty, absorption there will start immediately and the effective volume 
from which absorption takes place will not be much larger than the 
volume administered Furthermore, the small intestine is known to be able 
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to absorb water at a very high rate, which might lead to an even smaller 
value for VQ- On the other hand it is very difficult to estimate the blood-
flow in the absorbing region. The small intestine is highly perfused, the 
bloodflow may be in the order of 1000 ml/min (somewhat below the 
bloodflow in the portal vein, which is approximately 1200 ml/min). 
Clearly, however, only a fraction of this total intestinal bloodflow 
represents the flow in the region where actual drug absorption takes place, 
since the absorption process will be completed already in the first part of 
the small intestine. Nevertheless these data indicate that under the 
experimental conditions of our study the drugs can be absorbed extremely 
fast. When for instance in equation 10.4 values for VQ and kca.max a r e 
inserted of 100 ml and 100 ml/min respectively the time constant т
а 
would be 1 min, but it would not be surprising that even smaller values 
were encountered since the effective V0 might be smaller and the effective 
kca might be higher than the values in this rough estimate. 
Volume of distribution 
The idea that the volume of distribution of pyrazolone derivatives usually 
is in the order of the volume of total body water seems to be confirmed 
also by the data in table 10.5. Of course it should be stressed again that 
since the drugs were administered orally, the volume terms are only deter­
mined relatively to the biological availability, which is essentially un­
known. Now the high rate and instantaneous start of absorption might 
suggest that the availability of the drugs from the solution is practically 
complete. In many cases this suggestion is supported indeed by the fact 
that the V/F estimates correspond to half a liter per kg body-weight or 
less. There are, however, some clear exceptions, especially in case of 
4-methylaminophenazone where much larger volumes are found. Neverthe­
less also this compound appears to be distributed similarly to the other 
pyrazolones studied as shown by the quite normal distribution volume 
exhibited by the subjects PM and AD. Therefore we tend to ascribe the 
large volume estimates to incomplete biological availability. Also the 
values found for the clearance constant provide evidence in favour of this 
assumption, because they are large when the volume is large and because 
they also have only relative meaning (with respect to F). Another possible 
explanation could be sought in the occurrence of a first-pass effect. Taking 
subject RS as an example it can easily be derived that when he would have 
absorbed the whole dose of 4-methylaminophenazone his pharmacokinetic 
characteristic would give rise to a substantial first-pass effect. The fraction 
reaching the circulation intact can be formulated as: 
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, , ''Cel" 
1 + 7~r— I f l 
- 1 
^ 
, , 870 
1 +77ГТ 
1500 
which would yield corrected values for V and код of 78 1 and 550 ml/min 
respectively. Despite this first-pass correction, still an incomplete bioavail­
ability would have to be assumed. Furthermore, it should be noticed that 
the first-pass assumption for the other subjects has much less significant 
influence. Therefore it is an unlikely explanation, especially since all 
estimates can easily be brought to very acceptable values by assuming that 
the subjects RS, JB, R Si and HK have absorbed 4-methylaminophenazone 
only for about 40%. It should be noticed, however, that in our experi­
mental set up a strongly impaired absorption can hardly be reconciled with 
the very high absorption rates observed. This discrepancy seems to point at 
intestinal metabolism as a possible process contributing to the apparently 
incomplete absorption. It is well-known that the intestinal flora exhibits a 
variety of drug metabolizing properties (Scheline, 1968; Goldman, 1973). 
In view of the work of Weiss et al. (1974) it is plausible that also alkylated 
4-aminophenazone dérivâtes are subject to such metabolism. Furthermore, 
the epithelial cells of the intestinal mucosa are equipped with several drug 
metabolizing enzyme systems so that biotransformation may take place 
during absorption (see for a review of these complications before and 
during drug absorption: Riegelman and Rowland, 1973). The same discus-
sion can be applied to some of the 4-dimethylaminophenazone data 
(especially subject HK) and to some of the 4-aminophenazone experiments 
(especially RS and HK). This last drug, however, exhibits a very peculiar 
pharmacokinetic pattern as will be discussed in detail below. 
In general the distribution of a drug is governed by its physicochemical 
properties: pKa, water solubility, lipid solubility, protein binding etc. 
Apart from these factors a specific interaction with certain tissue com-
ponents may become quantitatively so important that it influence» overall 
distribution appreciably. For the phenazone derivatives, however, there are 
no indications at all for such a specific tissue binding. Only the general 
physicochemical factors remain. The pKa is important in so far as it can 
cause differences in the fraction of drug that is unionized and therefore 
freely diffusable through biomembranes. 4-Dimethylaminophenazone has 
а рКд of 5, 4-aminophenazone of 4.1, the other two derivatives presum­
ably will have а рКз between these two extremes, although the values are 
not exactly known. For the degree of ionization this means that at physio­
logical pH (7.4) all 4 drugs are practically fully unionized (more than 
99.7%). Also with regard to solubility in aqueous and organic phases the 
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four drugs differ only to a minor extent. Measurements of the partitioning 
behaviour indicate that the chloroform—water partitioncoefficients at 
pH 7.4 decrease in the following order: dimethylamino > amino > iso-
propylamino > methylamino. At first sight this is a somewhat unexpected 
sequence since one would think that lipid solubility increases and water-
solubility decreases with increasing bulk of the subsituent. Probably more 
subtle changes in electron distribution upon substitution at the nitrogen 
atom predominate. However, without looking for sophisticated arguments, 
it is justified to note that solubility factors hardly can influence the 
distribution pattern, since the difference in partitioncoefficients is at most 
a factor 2 (cf. chapter 3). Also the partition ratio between saline and ery-
throcytes in vitro seems to rule out significant influence on drug distribu-
tion. For every one of the 4 compounds this ratio was near to one, inter-
individual differences being hardly significant. A factor that can have 
important consequences for the apparent volume of distribution as 
estimated on basis of total plasma concentrations is the possible binding to 
plasma proteins. However, phenazone derivatives of the type we are deal-
ing with are only slightly protein bound (Brodie et al., 1950a and 1950b). 
From preliminary data we assume the upper limit of the percentage 
protein binding to be 15, at plasmaconcentrations of about 10 mg/1. 
Assuming for the rest a homogeneous distribution over plasmawater and 
cellwater, it can be derived that the distribution volume on basis of the 
plasma concentration may be some 10% lower than the total body fluid. 
Some of the estimates for V/F in table 10.5 indeed seem to be slightly 
below the volume of the total body fluid, so it appears worthwhile to 
consider the possible influence of protein binding in more detail. More 
direct measurements will be needed to clarify this matter. 
Elimination 
The individual values for the time constant for elimination rej that are 
given in table 10.5 show a large interindividual variation. The most striking 
variation occurs with 4-ammophenazone and 4-methylaminophenazone. 
This is also reflected in table 10.6 where the mean time constants together 
with their standard deviation are summarized for each of the four drugs. It 
is interesting to note that due to the large standard deviation the average 
elimination time constant for 4-aminophenazone is not significantly differ-
ent from any of the other ones, whereas these three values are all signifi-
cantly different from each other. Furthermore, the mean time constants 
for elimination of 4-dimethylamino-, 4-methylamino- and 4-isopro-
pylaminophenazone in each individual appear to be correlated, the level of 
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TABLE 10.6 
Average values of T
e
j for 4-aminophenazone derivatives 
4-aminophenazone 
4-methylaniinophenazone 
4-isopiopylaininophenazone 
4-dimethylammophenazone 
Average т
е
| ± SD 
(min) 
166 ± 92D 
302 ± 108* 
110± 27* 
155+ 49* 
* significantly different from each other, Ρ < 0.02 
D not significantly different from any of the other averages, Ρ > 0.20 
Xel methyl (mm) 
500-
400 
-Tel isopropyl (mm)-
300 
200 
100 
r = 0 8 4 4 
P<0025 
100 200 
Xel dimethyl (mm) Xel isopropyl (mm) Tel dimethyl (mm) 
Figure 10.8 
Correlation between the time constants for elimination of 4-methylaminophewzone, 
4-dimethylaminophenazone and 4-isopropylaminophenazone. The drawn line is 
obtained by the regression analysis. Since the intercepts are not significantly different 
from zero also a regression line through the origin is calculated (dotted). 
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significance of this correlation being at least Ρ < O.US (figure 10.8). Again 
4-aminophenazone takes a separate position in that its elimination time 
constants are not correlated at all with any of the other three (P > 0.30). 
Although it is no indisputable proof, these correlations suggest a common 
elimination mechanism for the three alkylated 4-aminophenazone 
derivatives, while 4-aminophenazone itself is eliminated via another route. 
Interestingly this is totally in line with that part of the metabolism that is 
known: the N-alkyl derivatives are subject to oxidative dealkylation, but 
4-aminophenazone is for a major part acetylated and for a minor part 
excreted in urine unchanged. Taking all considerations together there 
seems to be no reason at all for discussing 4-aminophenazone kinetics in 
the context of the pharmacokinetic behaviour of its N-alkylated derivat­
ives. There are even more arguments to discuss 4-ammophenazone 
separately, especially the fact that its pharmacokinetic behaviour is clearly 
non-linear. As far as possible the time constants for elimination of 
4-aminophenazone given in table 10.5 are the real ones, based on the 
ultimate steepest and linear part of the plasma concentration-time curve. 
Unfortunately it cannot be excluded that some of the estimates are still 
too high, because possibly the plasma concentration was not always 
followed long enough. Also for this reason we prefer to restrict the 
pharmacokinetic comparison to the alkylated derivatives and to pay 
special attention to 4-aminophenazone at the end of this chapter. 
The rate of elimination of the 4-alkylaminophenazone compounds 
decreases in the following order: 4-isopropylamino > 4-dimethylamino > 
4-methylamino. Referring to the presumed common metabolic pathway, 
this sequence might be explained on basis of the ability of the alkyl groups 
to resist oxidative metabolic attack. Then the isopropyl group seems to be 
very labile and more easily removed than a methyl group, whereas the 
presence of a second methyl group on the same nitrogen atom leads to 
increased rate of demethylation. One might even think of the number of 
carbon atoms attached to the nitrogen, as determinant for the rate of 
oxidative dealkylation, the rate being highest in case of 3 and lowest in 
case of one carbon atom. It should be remembered, however, that one 
cannot be sure that the major part of the metabolism of 4-aminophena­
zone derivatives proceeds via dealkylation since usually not more than 
about 50% for the corresponding metabolites could be traced in urine. 
Nevertheless it is interesting that the sequence found is the same as that of 
renal excretion halflives of the dextro-isomers of the corresponding 
N-alkyl-amphetamines in man, which were reported by Vree (1973). 
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JB 
AD 
HK 
PM 
RS 
RSi 
2.2 
4.9 
-
6.1 
-
— 
(3.5)1 
(7-4)' 
(8.2)' 
0.08 
0.65 
0.94 
0.16 
0.28 
0.17 
Renal excretion 
Alkylated aminophenazone derivatives are excreted in urine unchanged 
only to a very low extent. Table 10.7 shows the cumulative amounts of 
intact drug that appeared in urine and fig. 10.9 gives a representative 
example of the renal excretion rates and cumulative renal excretion as a 
function of the time after administration. For the sake of completeness 
abo 4-aminophenazone is included, but as stated before these data will be 
discussed separately at the end of this chapter. 
TABLE 10.7 
Cumulative renal excretion (%of dose) of 4-aminophenazone derivatives 
Subject MAP 1AP DAP AP 
0.32 16.5 
* 24.6 
0.01 11.3 
* 41.5 
* 29.6 
0.35 3.8 
1. Percentage excreted as metabolite (4-ammophenazone) 
* not detectable 
- not determined 
MAP = 4-methylaminophenazone 
IAP = 4-isopropylaminophenazone 
DAP = 4-dimethylammophenazone 
AP = 4-aminophenazone 
The renal clearance constant cf 4-dimethylaminophenazone and 4-iso-
propylaminophenazone is equal to or somewhat smaller than the urine-
flow, about 1 ml/min. It can safely be assumed that the glomerular filtra-
tion rate of these drugs is much higher. Even when protein binding is taken 
into account the filtration rate will be at least some 75 ml/min. Therefore 
substantial reabsorption must occur, at a rate higher than or equal to the 
rate of water reabsorption. This is quite conceivable in the light of the 
intermediate lipid- and watersolubility of the drugs. For 4-methylammo-
phenazone the renal clearance constant is somewhat higher than the rate 
of urine production. Interestingly this drug has the lowest partition 
coefficient of all phenazone derivatives we studied, which might cause the 
lowest reabsorption. For some of the volunteers also the amount of 
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4-aimnophenazone after administration of 4-methylammophenazone was 
quantified. This amounted up to 8% and although not quantitatively 
determined, appreciable amounts of 4-ammophenazone appeared in urine 
after administration of the other derivatives as well. Furthermore, in any 
case large quantities of 4-acetylammophenazone were excreted in urine. 
Unfortunately our gaschromatographic analysis did not allow accurate 
measurements of the amounts, but rough estimates suggest that especially 
for 4-methylaminophenazone a major part of the dose administered may 
be accounted for by renal excretion of acetylated aminophenazone. 
Figure 10.9 
Renal excretion rate and cumulative renal excretion after oral administration of 
4-anúnophenazone and derivatives to the same volunteer (D = 600 mg). After admin-
istration of 4-methylaminophenazone also 4-aminophenazone is found in urine. 
nenal excretion rate — 
(mg/mm. log scale) 
cumul renal excretion 
a. Renal excretion of unchanged and demethylated 4-methylammophenazone. 
b. Renal excretion of unchanged 4-isopropylaminophenazone (left) and 4dimethyl-
aminophenazone (right). 
с Renal excretion of unchanged 4-aminophenazone. 
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Gearance 
Considering the factors discussed above in connection with the volume of 
distribution (and the biological availability) and regarding the data in 
table 10.S it seems reasonable to value the clearance constants for 4-iso-
propylamino-, 4-dimethylamino- and 4-methylaminophenazone at 
approximately 350, 250 and ISOml/min respectively. For all practical 
purposes the clearance is determined by metabolic processes. Speculating 
once again on a common mechanism, it may be interesting to define the 
metabolic clearance constant in more detail. As will be shown in 
chapter 13 a metabolic clearance constant k ç m represents the ratio 
Ощ/Код, where 0m is the capacity of the system involved (e.g. in μg/min) 
and Код is the Michaelis-Menten constant for the enzyme-substrate 
complex (e.g. in mg/1). When more than one enzymatic pathway occurs 
simultaneously, the metabolic clearance constant obviously can be given 
by: 
kCm = Σ ЕІН- ( 1 0 · 5 ) 
і = 1 κ Μ , ι 
This relationship indicates that differences in overall clearance constant 
can be attributed to differences in metabolic capacity or in the Michaelis-
Menten constant. In vitro investigations may shed light upon the question 
which enzymatic parameter primarily changes upon variation in the 
substrate exposed. In case of the metabolism of N-alkyl amphetamines by 
rat liver microsomal preparations there are strong indications that the 
^max
 v a l u e varies significantly with varying alkyl-group (Henderson et al., 
1974), whereas the Код values change much less (Henderson, 1976). On 
the other hand there is little doubt that the enzyme system involved 
exhibits a remarkable multiplicity in the sense that it contains several more 
or less different enzymes specifically directed towards the individual sub­
strates of an apparently homogeneous group. The correlation we found 
between the time constants for elimination should be based on a similar 
correlation in the respective clearance constants and seems to suggest a 
common denominator for the possibly different enzymes involved. Such a 
'unity in multiplicity' could be expected when all enzymatic activities we 
are dealing with would be reflections of one genetically determined 
metabolic system. Although this may be an attractive and likely assump­
tion much more work will be needed to confirm it. 
One more remark should be made concerning the metabolic clearance of 
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these drugs. As has been discussed before one may expect a measurable 
first-pass effect to occur for drugs with a metabolic clearance constant that 
is not small with respect to the hepatic bloodflow. Since the alkylated 
aminophenazones have equal and rapidly exchangable concentrations in 
plasma and bloodcells the total blood clearance has the same magnitude as 
the plasma clearance and these are the values that have to be compared 
with hepatic bloodflow, which normally lies in the range of 
1500-2000 ml/min. Clearly, the largest first-pass effect (if any) should be 
expected to occur in case of 4-isopropylaminophenazone with a metabolic 
clearance constant of about 350 ml/min. It can easily be calculated that 
the fraction of the dose metabolized at its first pass through the liver will 
not exceed some 20%. This implies that the volume of distribution and the 
clearance constant may be overestimated to the amount of 20% 
maximally. Mostly, however, the influence of first-pass metabolism will be 
significantly smaller and will remain within the limits of accuracy of the 
estimated and computer fitted parameter values. Therefore it seems 
justified to neglect corrections for first-pass effects with regard to the 
results of this study. 
D. 4-AMINOPHENAZONE ELIMINATION 
The drug 4-aminophenazone is eliminated in a way totally different from 
its N-alkylated derivatives. As pointed out already in the introduction the 
major metabolic pathway here is N-acetylation. Further substantial quanti-
ties are excreted in urine unchanged. In this study large interindividual 
variations in the rate of renal excretion were observed. Interestingly in all 
volunteers some evidence was obtained in favour of non-linear renal 
excretion processes. Fig. 10.10 gives an example of this, from which it is 
obvious that the rate of excretion in urine is not simply proportional to 
the average plasma concentration. Unfortunately excretion of drug seemed 
to be strongly dependent on the rate of urine production. Although it was 
impossible to find a correlation between the amount excreted unchanged 
and the average urine flow in the group of subjects, the individual 
fluctuations in the renal excretion rate over a certain period were parallel 
to fluctuations in the amount of urine produced in that period. The lack 
of correlation between the two variables in an overall picture most 
probably is due to non-hnearities in the excretion mechanism as such. 
Assuming that the renal excretion rate can be represented by a combina-
tion of glomerular filtration and tubular secretion, we were able to derive 
the relevant parameters in 4 of the subjects. These are summarized in 
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renal едсгеііоп rate (¿jg/min) 
400-
300 
200-
average plasma cone ( —-r ) 
Figure 1010 ml 
Renal excretion rate of 4-aminophenazone as a function of the corresponding average 
plasma concentration m two volunteers. Note the non linear curves, indicating a 
possible occurrence of tubular secretion 
TABLE 10.8 
Parameters describing tubular secretion of 4-ammophenazone 
Subject 
AD 
PM 
RS 
RSi 
TM 
g/min) 
60 
120 
140 
15 
KT 
(mg/l) 
1 4 
1.4 
0.4 
0.5 
Filtration 
(ml/mm) 
35 
35 
90 
15 
table 10.8, but they should be regarded with due reserve since the relative 
error in these estimates may be as high as 100% Nevertheless it appears 
that the secretory pathway can easily be saturated, that its transport 
maximum is in the order of 100μg/mm (6 mg/hr) but highly variable 
intermdividually and that glomerular filtration (including back diffusion) 
causes a clearance which is usually below the maximal value attainable but 
definitely higher than the rate of unne production The excretion of un­
changed 4-aminophenazone is completed within 25 hrs after drug intake 
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and the amount is highly variable (4-40% of dose, see table). Large 
amounts of 4-acetylaminophenazone appear in urine as well. This 
metabolite is excreted over a much longer period. Unfortunately our 
analytical procedure did not allow an accurate measurement of the acetyl-
derivative, but according to rough estimates in some subjects it seems to 
account for the missing part of the total dose administered. In chapter 13 
it will be demonstrated that a mechanism of elimination which is saturable 
at the prevailing plasma concentrations can lead to deformations in the 
plasma concentration curve, provided that its clearance constant under 
unsaturated conditions (i.e. its maximum value) represents more than 20% 
of the total body clearance. The deformations will only be clearly visible 
when this percentage becomes about 50. The maximal clearance constant 
that can be obtained by the secretory mechanism can be defined as the 
ratio Tj^/Kf and then it can easily be derived that in some of the subjects 
certainly a non-linear plasma curve may result from the tubular secretion 
process. This is found indeed in several experiments. Intriguingly, however, 
the plasma curve of for instance subject RS did not show any indication at 
all for non-linear processes (see fig. 10.12), whereas his secretion character­
istics might be expected to lead inevitably to a non-linear plasma curve. On 
the other hand the plasma curve of subject RSi obviously can only be 
described by non-linear processes (figure 10.11), although in this person 
renal clearance gives no reason at all to assume visible deviations from 
first-order behaviour. Now the first example (RS) could be explained by 
assuming that the plasma curve was not followed long enough to observe 
the predicted bending of the curve. This is a likely possibility since the 
estimated K-p is rather low (Kj = 0.4 mg/1) and since the bending occurs at 
plasma concentrations in the order of magnitude of Kj and the ultimate 
straight line corresponding to maximally attainable clearance is only 
reached when the plasma concentration is still much lower, e.g. < 0.1 Κχ 
(chapter 13). As a matter of fact this implies that the slope of the curve 
for RS will be concentration-dependent, since it represents the elimination 
at more or less saturating levels. It will be shown below that the concentra­
tion-dependence of the halflife was observed indeed. So far the argument­
ation is satisfactory, but difficulties remain with regard to the second 
example (subject RSi) where a clearly non-linear plasma curve is found 
contrary to what might be expected on basis of the low renal clearance 
involved. These observations seem to point out that 4-aminophenazone 
elimination is more complicated than a combination of just one saturable 
mechanism (tubular secretion) with a linear elimination system consisting 
of an excretory and a metabolic pathway. This is substantiated by the 
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Plasma curve after oral administration of 4-aminophenazone (600 mg) to a volunteer 
with typical capacity-limited elimination. 
discrepancy prevailing between the characteristic parameters ot the non-
linear process derived from analysis of renal excretion, and those derived 
from appropriate analysis of the non-linear plasma curves. This last type 
ot analysis will be discussed in detail in chapter 13. The kinetic and 
metabolic parameters that could be calculated by thorough analysis of the 
plasma curves after 4-aminophenazone are given in table 10.9. Three of the 
volunteers exhibited no signs of non-linear pharmacokinetics, the other 
three did. Two of the volunteers received the same drug in the same dose 
one year later. Also the parameters derived from this repeated experiment 
are inserted in table 10.9. Of course it is quite an unusual phenomenon 
that the same drug is eliminated according to two different models in 
different subjects, who all are in a good physical shape. The fact that the 
drug under consideration is metabolized by acetylation may be specifically 
meaningful in this respect. It is well-known that the rate at which people 
are able to acetylate some drugs is not normally distributed, but that a 
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TABLE 10.9 
Parameters for linear and non-linear eliminatioivof 4-ammophenazone. 
(see text for further explanation). 
Subject 
JB 
AD 
H K 5.74 
4.75 
PM 
RS 5.74 
4.75 
V/F 
(1) 
41 
46 
115 
51 
56 
95 
44 
(ml/min) 
350 
170 
1120 
520 
210 
530 
160 
Tel 
(min) 
118 
277 
103 
98 
267 
178 
277 
(nWD 
3.5 
4.1 
4.3 
f 
0.59 
0.77 
0.64 
Qm 
(mg/min) 
2.31 
1.66 
0.57 
RSi 59 1140 52 2.2 0.93 2.33 
genetically determined bimodal distribution occurs. The two groups are 
referred to as slow and fast acetylators. The best-known example is 
the antituberculous drug isoniazid (Bönicke and Reif, 1953; Bönicke and 
Lisboa, 1957; Evans et al., 1960). According to Peteis et al. (1965) the 
slow-acetylation phenomenon is caused by a genetically determined 
reduced liver acetyltransferase activity. Several other drugs exhibit the 
acetylation polymorphism as well, but there are also some drugs that 
appear in urine in acetylated form but that do not show polymorphism 
(Evans and White, 1964). Presumably there are several acetylation 
enzymes present, not only in the liver but also elsewhere in the body 
(Hearse and Weber, 1973). Substantial acetylation activity is found for 
instance in bloodcells. Interestingly the acetyltransferase present in these 
cells is apparently not of the polymorphic type (Drayer et al., 1974). The 
blood contains also deacetylation activity but the rate of deacetylation is 
much smaller than that of acetylation. 
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Returning to the elimination of 4-aminophenazone one is forced to 
assume that the mechanism of this elimination will be very complex. On 
the one side there is the renal excretion, partly linear, partly definitely 
non-linear, with probably large interindividual variation in determining 
parameters. On the other side we are dealing with metabolic trans­
formation, for the major part acetylation in which a lot of different 
enzymes may be involved. The discrepancy between the renal excretion 
parameters and the parameters describing the plasma decay curve suggest 
that also the acetylation may be a non-linear process, where at 'thera­
peutic' dose levels saturation phenomena can become predominant. 
Unfortunately it is very difficult to establish on the basis of plasma curves 
whether one or more non-linear mechanisms of drug elimination are 
prevailing. As will be shown in chapter 14 it is virtually impossible to 
discriminate between one or more partly saturated meclianisms since the 
pooling of several non-linear pathways usually leads to plasma curves that 
can easily be described by just one non-linear clearance function. Of 
course the parameters estimated on basis of such a single non-linear 
clearance function are basically dose-dependent, so that they can hardly be 
used for pharmacokinetic modelling. They have only significance as 
operational parameters within a relatively small dose range. Now accepting 
the fact that we have some evidence that two non-linear mechanisms are 
involved in 4-aminophenazone elimination together with at least one 
linear, we have to content ourselves with the following definition of the 
clearance function. 
" [ Vcel= l - f + KM+C keel (10.6) 
where Vc
e
i = the plasma-clearance function 
Код = the apparent Michaelis-Menten constant between drug 
and elimination mechanism; in case of more than one 
non-linear pathway, it is some kind of weighted average 
of the individual values 
kçe] = the maximally attainable clearance constant. This clear-
ance is obtained when no saturation at all occurs 
( C « K M ) 
С = plasma concentration of drug 
f = that part of the maximal clearance kçei that proceeds 
via potentially saturated pathways 
(details concerning this equation and its derivation and implications can be 
found in chapter 13). 
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Equation 10.6 indicates that the clearance will always be smaller than 
kçei, unless C « K j ^ . Asa matter of fact, with decreasing plasma concen-
tration the clearance is increasing and the elimination time constant (so 
the halflife as well) is shortening. This effect results in plasma curves as 
exemplified in figure 10.11. Although theoretically bending of the semi-
logarithmic plasma curve must occur, provided that f is large enough, one 
can imagine that it will not always be detected in an experimental 
situation. It can easily be overlooked when the plasma concentration is not 
followed to levels smaller than Код. This might be the case of the three 
subjects in this study, who did not show any signs of non-linear elimina­
tion. From equation 10.6 it can be derived that in such a case an apparent 
halflife (І&цт.) should be expected, that is defined by: 
V Км + С 
t *
a p p . = 0 п 2 ) г е и р р . = 0 . 6 9 3 ^ К м + ( 1 _ 0 С (ЮЛ) 
where V = the volume of distribution of the drug (and the other symbols 
as defined above) 
This equation implies that the apparent halflife can have values all over the 
,. 0.693V , 0.693V ,
 t . , i U , , . , , 
range trom-; ¿-,—^. to -¡ and that the value can be expected to be 
kceiO-f) kce! 
higher, the higher the plasma concentration range is in which the measured 
data points are lying. One of the volunteers with a seemingly first-order 
elimination received an oral dose of 600 mg 4-aminophenazone twice with 
an interval of approximately 1 year. At these two occasions very different 
plasma levels were measured and the apparent halflife was 1.5 times higher 
at the time that the highest plasma levels were measured (192 versus 
124 minutes; see figure 10.12). This difference is in line with the predic-
tions from equation 10.7. Furthermore it was interesting to observe that 
on both occasions the same amount of drug was excreted unchanged, 
although in the experiment with the low plasma levels most probably only 
about half as much of the dose had reached the general circulation as 
compared with the other experiment. This observation again is compatible 
with a clearance function as given in equation 10.6 since a saturable 
excretion mechanism yields a relatively higher contribution to overall 
elimination when the plasma levels of the substance to be eliminated are 
lower. One has to be careful, however, in his conclusions since the two 
experiments are separated by a long time-interval, in which the elimination 
characteristics might have changed. On the other hand individual acetyl-
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Figure 10.12 
Plasma curves after oral administration of 4-aminophenazone (600 mg) to the same 
volunteer on two different occasions (interval about one year). Note the large differ­
ences in halflife and apparent volume of distribution. See text for further explana­
tion. 
ation rates have been reported to remain strikingly constant over penods 
of at least a year (Das and Eastwood, 1975; White and Evans, 1968). 
At this stage discussion of the results of the other repeated experiment is 
pertinent. Subject HK received his doses at exactly the same time as RS. 
Contrary to RS, however, his plasma curves showed clear signs of non­
linear kinetics (see figure 10.13). It is interesting that he also had much 
lower plasma levels in the first than in the second experiment. But, what is 
more, the ultimate halflife was practically identical at both occasions (103 
and 98 minutes). Also the estimates of Код and f were not significantly 
different in the two experiments. The relative constantness of the para­
meters estimated for HK together with the literature data mentioned 
suggest that our explanation of the plasma curves of subject RS will be 
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Figure 10.13 
Plasma curves after oral administration of 4-aminophenazone (600 mg) to the same 
volunteer on f wo different occasions. The elimination is clearly non-linear and there 
is a striking difference in the apparent volume of distribution. Nevertheless, the other 
pharmacokinetic parameters as obtained by computer fit are about the same for both 
curves. See text for further explanation. 
correct. It remains a problem how the large differences in the amount of 
drug that reaches the circulation intact arise. Analogously to the alkylated 
4-aniinophenazone derivatives, impaired absorption is not a likely cause. 
Metabolism in the intestinal contents or in the gut wall is much more 
probable, but it is not clear how this could be so variable (even intra-
individually). A further possibility might be the occurence of a hepatic 
first-pass effect. Some of the estimates for k^gj/F are in the order of one 
third or more of the hepatic blood flow, which might give rise to substant­
ial metabolism at first pass through the liver, provided that a major part of 
this clearance is a consequence of biotransformation in the liver. However, 
since the contribution of renal excretion certainly is not negligible and 
since it is possible that more than one acetylating system (also extra-
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hepatic) takes care of biotransformation, the significance of a first-pass 
effect is doubtful. This is the more so, when a capacity-limited hepatic 
metabolism occurs. In that case the metabolic system may become saturat­
ed during the passage of large amounts of drug from the portal vein 
through the liver to the general circulation. Figure 10.14 shows a theoreti­
cal example of such a saturable first-pass effect and it is obvious that only 
very minor amounts of drug are extracted at first-pass, although the 
ultimate clearance constant is high. Especially since in case of 4-amino-
phenazone Код presumably is very small, the initial concentrations in the 
portal vein can easily saturate the hepatic metabolic system. It should be 
mentioned that Das and Eastwoord (1975) found the acetylation of 
sulfapyridine to be independent of the dose (2 to 8 g per day), which 
result, however, cannot be extrapolated to other drugs that are largely 
acetylated. Whether or not a so-called capacity-limited elimination 
becomes detectable is not dependent on the metabolic capacity but only 
on the MichaeUs-Menten constant. This Код may differ to a huge extent 
among various drugs. 
plasma cone ( m g / I;log scale) 
2 0 
im 
1ÓO 200 300 400 500 
Figure 10.14 time (mm) 
Theoretical curves for drugs wif/i capacity-limited elimination, that have a high 
maximal clearance constant. Despite a very high metabolic clearance usually no sub-
stantial first-pass effect is observed, since the metabolism is easily saturated. The 
parameters used for the simulation are: 
VG=VL = 51'VC= H l.kca = 2 l/min, kLC= kCL =1.5 //m/„, kCr=0.1 l/min and 
further the combinations of Км = 5 mg/l with ¿>m - 5; 3.75 and 2.5 mg/min (curves 
1, 2 and 3) and of АГд/ = 2 mg/l with Q
m
 = 2 and 1 mg/'min (curves 4 and 5). 
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TABLE 10.10 
Percentage of 4-ammophenazone excreted unchanged with т
е
] and f. 
(see text for further explanation) 
auDje 
JB 
AD 
HK 
PM 
RS 
¡et 
5.74 
4.75 
5.74 
4.75 
У
г
7о 
16.5 
24.6 
11.3 
10.7 
41.5 
29.6 
28.5 
T
el 
(min) 
118 
277 
103 
98 
267 
178 
277 
f 
-
-
0.59 
0.77 
0.64 
_ 
— 
RSi 3.8 52 0.93 
When comparing the amount of 4-aminophenazone excreted unchanged 
with the time constants for elimination, one observes some kind of 
relationship (table 10.10). It seems that the subjects who have the longest 
time constant for elimination excrete the largest amounts unchanged in 
urine. Most probably, this means that in these cases the acetylation is 
slower, indicating that the rate of elimination is a good reflection of the 
rate of metabolic transformation. As an example especially comparison of 
the data of the subjects PM and RSi is very illustrative. It is also interesting 
that the fraction f in these subjects shows an inverse relationship with the 
percentage excreted unchanged. This suggests even that the major part of 
the fraction that is eliminated by potentially saturated systems is based on 
metabolic routes. So, despite of the sometimes substantial renal excretion, 
the profile of the plasma curve appears to be determined primarily by 
biotransformation (acetylation) of the drug. When we examine the time 
constants for elimination in this respect we tend to conclude that also in 
4-aminophenazone elimination a distinction between slow and fast 
acetylators may be made. In this sense the subjects RSi, JB and HK might 
be classified as fast, the other three as slow acetylators. However, this 
division is quite arbitrary, since another division may be necessary when 
other doses of the drug are applied. The metabolic clearance and therefore 
the elimination rate of the drug is determined by both the capacity of the 
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metabolic system and the apparent Michaelis-Menten constant. Differences 
in capacity can be the result of differences in the amounts of enzyme and 
differences in the nature of the enzyme. The Michaelis-Menten constant 
probably will be solely determined by the nature of the enzymes involved. 
When we compare again the subjects PM and RSi it is obvious that Код is 
different but the capacity as well (the capacity is equal to f.Ki^.kc
e
[, so 
0.57 mg/min and 2.33 mg/min for PM and RSi respectively). Taking into 
account the relative errors of the estimates one may conclude that the 
difference in capacity is much more significant than the difference in Код. 
At the moment further investigations into this matter are planned in order 
to obtain more straightforward data. It is remarkable, however, that the 
present results point to differences in metabolic capacity as the pre­
dominant cause of variations in the rate of acetylation of 4-amino-
phenazone and that this co-incides with the results of Peters et al. (1965) 
on isoniazid acetylation. 
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CHAPTER 11 PARACETAMOL AND PHENACETIN 
INTRODUCTION 
At the end of the 19th century acetanilide was introduced as an anti-
pyretic agent. Acetanilide is a rather toxic compound, but it was soon 
established that the pharmacological effect probably resides in a meta-
bolite: 4 acetylaminophenol (paracetamol). Already at the turn of the 
century paracetamol and its ethoxy-derivative phenacetin became available 
for antipyretic-analgesic purposes. The use of phenacetin, especially in 
combination preparations became widespread. Probably the fact that 
phenacetin has some psychotropic effect, causing a light euphoria, and 
leading to habituation, has contributed to its popularity. Abuse of phena-
cetin-containing analgesic preparations is not seldom encountered and is 
very dangerous in view of the severe nephrotoxicity of such preparations 
on long-term use (Raaflaub and Dubach, 1972; Höffler et al., 1973; 
Rüegger et al., 1973; Bock et al., 1973; Dubach et al., 1974; Dubach et al., 
1975). 
Although it is still a point of controversy whether phenacetin or acetyl-
salicylic acid (with which it is usually combined) is the most nephrotoxic 
drug (e.g. Presscott, 1972), it seems that withdrawal of phenacetin from 
some proprietary analgesics has a beneficial effect on the incidence and 
seriousness of analgesic nephropathy (Murray, 1972). From the recogni-
tion of the risks of phenacetin, a tendency originated to recplace it by 
paracetamol which never had been as popular as phenacetin and which in 
most countries was not marketed until the fifties. Accordingly the ex-
perience with this drug is limited as compared with phenacetin, but up to 
now no serious side-effects of chronic administration of normal doses have 
been reported. Paracetamol overdose may cause a lifethreatening hepatic 
damage (Prescott et al., 1971; Prescott and Wright, 1973; Clark et al., 
1973; James et al., 1975; Mitchell et al., 1973a, b; Jollow et al., 1973; 
Potter et al., 1973). 
Glutathione has a protective effect against the hepatic necrosis and on 
rational grounds glutathione-like nucleophiles, such as cysteamine, have 
been proposed and successfully applied to the treatment of severe para-
cetamol overdosage (Mitchell et al., 1974; Prescott et al., 1974). Possibly 
methionine and vitamin E (α-tocopherol) provide a similar protection 
(McLean and Day, 1975; Kelleher et al., 1974). The doses at which this 
serious toxicity appears can hardly be estimated, but it seems that 
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10 grams can be fatal, although much higher doses have been tolerated 
without irreversible damage. 
In normal doses however paracetamol is one of the safest minor anal-
gesics, which certainly deserves a place in analgesic therapy. As far as 
phenacetin is concerned the situation is different: it will be difficult to 
find any argument at all for retaining this drug on the market. 
PHARMACOKINETICS 
a. Phenacetin 
Plasma levels of phenacetin after oral administration have often been 
reported (Brodie and Axelrod, 1949; Prescott et al., 1968;Prescott, 1969; 
Prescott et al., 1970; Harris and Riegelman, 1969; Kampffmeyer, 1971; 
Pantuck et al., 1972). The dosages applied usually were high (1.5 g) in 
order to obtain easily measurable plasmalevels. Halflives of 0.5—l.Shrs 
have been measured. On basis of the literature data we estimated the 
volume of distribution to be at least 601. 
Methods 
Since phenacetin as a rule is used in low dosage (mainly in combination 
preparations where the phenacetin content seldom exceeds 250 mg) we 
administered 500 mg of phenacetin to 8 fasting, healthy volunteers, 
6 male, 2 female, age of 19-23 years, body weight 55—74 kg. Phenacetin 
was emulsified with the use of Tween 80. Bloodsamples were taken from a 
forearm vein at regular intervals after drug intake for a total period of 
8 hrs. Urine samples were collected up to 24 hrs after drug administration. 
Gas chromatographic analysis was performed as described chapter 2. 
Results and discussion 
In 6 volunteers the phenacetin level in plasma did not exceed 1 mg/1, the 
2 remaining subjects showed maximum levels of 3—4 mg/1. The profile of 
the 'plasmacurve' was very irregular and not useful for pharmacokinetic 
analysis. Urinary excretion of unchanged phenacetin accounted for less 
than 0.5% of the dose administered in 7 subjects and for 0.90% in the 
other subject. Paracetamol, the main metabolite of phenacetin, was 
present in all samples, but its concentration was not determined. 
The explanation for the very low phenacetin levels was provided by the 
work of Raaflaub and Dubach (1975), who determined plasma levels of 
phenacetin after oral as well as after intravenous administration. On basis 
of the i.V. experiments they could calculate the real total body clearance 
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of phenacetin. A clearance constant of 1-2 1/min was obtained, which is 
near to the hepatic bloodflow. Since the elimination proceeds almost 
exclusively by hepatic metabolism, a substantial firs-pass effect may be 
expected. Raaflaub and Dubach presented evidence that the first-pass 
effect was diminished with increasing dose. A similar phenomenon was 
observed in case of salicylamide (Barr, 1969). As the authors indicated 
such a phenomenon is caused by capacity-limited metabolism at the first 
passage of the drug through the liver or even before or during absorption. 
In such a situation a quantitative approach yields a model and plasma 
curves as depicted in figure 11.1. The area under the plasmacurve increases 
plasma cone (mg/l ; log scale) 
100-1 
002-
001-1 1 1 1 1 ' 1 • 1 ' 1 1 . 1 
2 4 6 β 10 12 14 
time ( Mr ) 
Figure 11.1 
Theoretical plasma curves demonstrating the occurrence of a saturable first-pass 
effect. The parameters used are based upon phenacetin data from the literature (VQ 
•VL= 51, Vc = 301, kca · ¡Sl/hr, kLc = *C£ = Ml/hr, Qm = 500mg/hr, Км = 
10mg/l). The dose is varied and it may be noted that at the low doses the first-pass 
effect is very pronounced, leading to very low plasma levels. See text for further 
explanation. 
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disproportionately with increasing dose. Low doses give no appreciable 
plasma levels at all, so that the admihistration of a dose of for instance 
250 mg phenacetin can only be effective as far as paracetamol is formed. 
From this point of view it is not sensible to use phenacetin in the form of 
the common combination preparations. Furthermore contrary to para-
cetamol (see below) the biological availability of phenacetin has been 
shown to be strongly dependent on the pharmaceutical formulation 
(Prescott et al., 1970). 
b. Paracetamol 
The pharmacokinetic behaviour of paracetamol has been extensively 
studied (Nelson and Morioka, 1963; Gwilt et al., 1963; Cummings et al., 
1967; Prescott et al., 1968; Grove, 1971; Albert et al., 1974a). For the 
halflife average values in the range of 1.5—2.5 hrs have been reported and 
the volume of distribution according to one compartment kinetics may be 
estimated at some 501. Consequently the clearance constant will be in the 
order of 200—400 ml/min. Normally less than 5% of this total clearance 
consists of renal excretion. 
Neither the presence of food (Jaffe et al., 1971 ; McGilveray and Mattok, 
1972) nor the pharmaceutical formulation (Prescott, 1969; McGilveray et 
al., 1971 ; Glynn and Bastain, 1973; Richter and Smith, 1974; Albert et al., 
1974b) seem to influence the biological availability negatively, although 
these factors may cause variations in the rate of absorption. 
Methods 
15 volunteers received a single oral dose of paracetamol (500 mg) in 
different formulations (tablet, capsule, elixir). The subjects, 13 male, 
2 female were pharmacists, participating in a course on pharmacokinetics. 
The drug was ingested at 11.00 hr in the morning and bloodsamples (6) 
were taken at regular intervals for 5 hrs thereafter. 
Paracetamol was determined as described in chapter 2. The concentra-
tion data were given a weight factor on basis of the accuracy of each 
individual value, as determined from 3-6 analyses. Taking into account 
the relative weights, the data were analysed by computerfit according to 
the program Farmfit. 
Of course under the relatively uncontrolled conditions of this investiga-
tion, no real biopharmaceutical pattern can be evaluated, but if systematic 
variations would occur, this still might be related to the dosageform. 
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Results and discussion 
Several examples of the plasmacurves obtained are represented in 
figure 11.2. The data do not allow any statement on differences in absorp-
tion rate or bioavailability. Therefore we summarize the average pharmaco-
kinetic parameters together with their standard deviation in table 11.1. It 
may be noted that the absorption of paracetamol is rapid in any case and 
that optimal fit requires only small lagtimes, although the variation in 
these parameters is high. The total body clearance constant and the 
volume of distribution (at least their value relative to F) show remarkably 
little variation. This indicates that differences in biological availability will 
be negligible for practical purposes. 
œ 35 эоо 60 35 MO 60 ιβο эоо 
timet min) 
Figure 11.2 
Typical fitted plasma curves obtained after oral administration of 500 mg para­
cetamol to 9 volunteers. The dosage forms are: elixir (1, 2), capsule (3, 4, 5) and 
tablet (6, 7, 8, 9). See text for further discussion. 
These data suggest that biopharmaceutical factors are not very critical 
with respect to paracetamol. Furthermore the relatively rapid absorption 
indicates that the analgesic effect of paracetamol may be expected to 
become prominent already soon after drug intake. 
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TABLE 11.1 
Average pharmacokinetic parameters for paracetamol (n=15) 
Mean 
SD 
V/F 
(1) 
48 
8 
(ml/min) 
370 
80 
T
el 
(mm) 
141 
32 
'"a 
(mm) 
18 
16 
lag 
(mm) 
12 
8 
Together with the fact that paracetamol is a very safe drug (in normal 
doses), these observations confirm the suitability of paracetamol as a 
general minor analgesic. As a matter of fact one might wonder if not 
paracetamol should be preferred over for instance acetylsalicylic acid and 
its derivatives in those cases where no anti-inflammatory effect is needed. 
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CHAPTER 12 SUMMARY OF SECTION II 
The rate of elimination of drugs from the body is mainly determined by 
two pharmacokinetic parameters: the clearance, which is a measure for the 
efficiency of the eliminating organs with respect to a particular drug, and 
the volume of distribution, which determines how large the (apparent) 
volume is, from which the drug has to be cleared. Obviously both para-
meters will be closely related to the physicochemical properties of the 
drug. 
Section II deals with the disposition of several antiinflammatory and anti-
pyretic analgesics in man, in so far as their pharmacokinetic behaviour can 
be adequately described by linear processes. For structural reasons also one 
drug with a clearly non-linear elimination is included in this section, viz. 
4-aminophenazone. 
The pharmacokinetic data were obtained by administering normal, usual 
doses of the various drugs orally to young, healthy volunteers (mostly 
students), taking blood samples at regular intervals after ingestion, measur-
ing plasma concentrations and renal excretion rates and analysing the 
measurements according to pharmacokinetic models, usually the one-com-
partment model. 
Of course the general applicability of the figures is limited, in so far as only 
a selected, rather homogeneous group out of the whole population has 
been studied. Nevertheless our studies provide a general insight into the 
pharmacokinetic features of the drugs under consideration and they give 
information on the mechanisms of elimination involved. Furthermore the 
cross-over design of the investigations is highly useful for relating 
molecular structure with pharmacokinetic properties as well as for 
establishing biopharmaceutical differences between various dosage forms. 
In chapter 4 the fundamentals of linear pharmacokinetics are outlined. 
All rate processes are assumed to be governed by linear, first-order dif-
ferential equations. A general approach to the formal description of 
pharmacokinetic models is proposed and the relevant concepts and notions 
are discussed in detail. Attention is paid also to the possible accumulation 
of drugs on chronic dosage. 
The remaining chapters of section II are devoted tot the specific drugs. 
Ibuprofen (Brufen®) and alclofenac (Mirvan®) are the subject of 
chapters 5 and 8 respectively. These two drugs show a small volume of 
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distribution (ΌΟΙ), even smaller than the volume of extracellular fluid, 
which is probably caused by binding \o plasma proteins. Also their clear­
ance constant is rather small (30-50 ml/min), but due to the small volume 
of distribution the halflife of these drugs is short (1.5-3 hr). Although the 
total clearance of Ibuprofen and alclofenac is about the same, large dif­
ferences exist in the relative contributions of renal and metabolic 
clearance. Ibuprofen is hardly excreted unchanged in urine, whereas alclo­
fenac may be excreted in urine for amounts up to 50% of the total dose 
administered. These differences are assumed to be related to differences in 
physicochemical properties. The lower the water solubility, the smaller the 
fraction of the dose excreted in urine. Further, a high lipophilicity 
enhances tubular reabsorption, thereby diminishing net renal excretion. 
Also binding to plasma proteins may be an important factor, since it 
lowers the plasma concentration of free drug, which is available for 
glomerular filtration. Especially Ibuprofen is almost completely protein 
bound in the therapeutic concentration ranges. Contrary to alclofenac, 
Ibuprofen exhibits clear signs of a tubular secretion process, but this is 
easily saturated and has only a low capacity. The renal excretion of un­
changed alclofenac correlates with the urine flow: the higher the average 
urine flow, the larger the amount of alclofenac appearing in urine. 
Both drugs are rapidly absorbed. For Ibuprofen we found the time con­
stant of absorption to be dependent on the formulation of the drug: when 
comparing a solution with capsules and commercial tablets the solution 
appears to be extremely rapidly absorbed, the absorption of Ibuprofen 
capsules is somewhat slower and that from the commercial tablets still 
slower, but even for the tablets peak concentrations in plasma are usually 
reached within 1.5 hr. In case of alclofenac we compared tablets and 
suppositories, both commercial dosage forms. These appear to be equivalent 
for all practical purposes. 
As was to be expected on basis of the single dose experiments, we con­
firmed that neither Ibuprofen nor alclofenac tend to accumulate during 
chronic administration in the usual dosage regimens. 
In chapter 6 the pharmacokinetics of the separate optical isomers of Ibu­
profen is discussed. Evidence is found to support the view, that in the 
human body inversion from levo- to dextro-ibuprofen occurs. 
Chapter 7 describes a comparision of the human pharmacokinetics of 
Ibuprofen and ibufenac. The volume of distribution of ibufenac seems to 
be somewhat larger than that of Ibuprofen. It is absorbed much more 
slowly and usually eliminated less rapidly than ibuprofen. The elimination 
clearance, however, tends to be higher for ibufenac than for ibuprofen. 
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Indications were found for an enterohepatic circulation of ibufenac. 
The topic of chapter 9 is the pharmacokinetic behaviour of flufenamic 
acid (Arlef^) and mefenamic acid (Ponstan®) in man. These two 
fenamates show rather irregular plasma curves, and it was impossible to fit 
the data according to simple models. Relative values for the clearance 
constant were obtained by measuring the area under the plasma curve. The 
two fenamates have a remarkably low watersolubility. Especially in case of 
mefenamic acid this seems to cause difficulties in the absorption process. 
The absorption of this drug is enhanced by food intake. We assume that 
this is related to the production of bile, by which the drug may be emul-
sified to a better absorbed form. 
Chapter 10 deals with some phenazone derivatives. A typical aspect of 
the pharmacokinetic behaviour of phenazone and its derivatives is the large 
interindividual variation. This is well-known for phenazone itself but we 
found also for the other derivatives much more pharmacokinetic variab-
ility than for the aromatic acids, even within the rather homogeneous 
group of volunteers we studied. 
Phenazone derivatives have a volume of distribution which is approx-
imately equal to the volume of total body water (3040 1) or somewhat 
higher for some lipophilic and less hydrophilic derivatives like 4-isopropyl-
phenazone. In this series of compounds large differences in clearance 
exist, ranging from 30-50 ml/min for phenazone to 500 ml/min or more 
for 4-isopropylphenazone and 4-aminophenazone. Renal clearance plays 
only a minor role for phenazone derivatives (0-6% excreted unchanged). 
Introduction of an isopropyl group in phenazone leads to a much more 
rapid metabolism (probably oxidation of the isopropyl group). The same 
holds true for substitution of a dimethylamino group in phenazone, lead-
ing to 4-dimethylaminophenazone. Also here the higher clearance is caused 
by metabolic instability of the substituent, since metabolism pre-
dominantly occurs via N-demethylation. The first demethylated meta-
bolite 4-methylaminophenazone tends to have a somewhat longer halflife 
than 4-dimethylaminophenazone. It appears that the N-methyl group is a 
better leaving group when it is accompanied by a second methyl group 
than when the amino function is monosubstituted. 4-Isopropylamino-
phenazone is more rapidly eliminated than 4-dimethyl- or 4-methylaniino-
phenazone, indicating that the isopropyl group is more rapidly removed 
than the methyl group. 
The consequences of the pharmacokinetic parameters for the rationality of 
some combination preparations is discussed. 
The clearance of 4-aminophenazone appears to be essentially non-linear. 
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This substance is eliminated partly by renal excretion (in some cases up to 
40%, unusually high for a phenazone derivative) and for the rest by 
N-acetylation. The relative contributions of renal and metabolic pathways 
to the overall non-linear elimination is discussed in detail with special 
reference to the possible occurrence of genetically determined fast and 
slow acetylation behaviour. Although non-linear pharmocokinetics is the 
subject of section III we preferred to discuss 4-aminophenazone in the 
context of the other phenazone derivatives. 
In chapter 11 briefly some pharmacokinetic information concerning 
phenacetin and paracetamol is presented. In normal doses phenacetin 
usually gives only negligible plasma levels. The explanation for this pheno-
menon can be found in the occunence of a substantial first-pass effect. 
This is not the case with paracetamol and since furthermore the absorption 
of phenacetin is strongly dependent on the pharmaceutical formulation, 
whereas that of paracetamol is almost independent of such factors it seems 
that the pharmacokinetic profile is strongly in favour of the use of para-
cetamol instead of phenacetin. 
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SECTION III 
NON-LINEAR PHARMACOKINETICS 

CHAPTER 13 LINEAR AND NON-LINEAR KINETICS OF 
DRUG ELIMINATION 
INTRODUCTION 
Pharmacokinetics approaches the behaviour of drug in man or animals as 
diffusion in and out various compartments and elimination from a central 
compartment. In general, all kinetic processes are assumed to be first-
order, so that the rate of drag transfer is supposed to be directly propor­
tional to the drug concentration in the compartments. The kinetic proces­
ses may then adequately be described by a set of linear differential equa­
tions. (linear pharmacokinetics). Elimination of drug proceeds mainly by 
the liver and the kidney. In these clearance organs elimination depends on 
the plasmaflow through the organs and the extraction or filtration effi­
cacy. In general the rate of elimination is proportional to the concentra­
tion of drug in the plasma entering the clearance organs: 
dQel 
rt^Vcei-C 03.1) 
Here is dQei/dt the quantity of drug (e.g. mg) eliminated per unit of time 
(e.g. hrs), while С is the concentration of drug in the plasma and Vçej the 
total body clearance (e.g. l/hr). The clearance Vçei may depend on the 
flow, the concentration, the condition of the organs, protein binding etc. 
The clearance therefore in general will not be a constant. Obviously linear 
kinetics is achieved only when the clearance is constant. In that case the 
clearance Vcel т а У be replaced by a clearance constant k-Cel- ^ ^ е 
clearance is constant the rate of elimination is directly proportional to the 
concentration entering the clearance organs, so that linear kinetic elimina­
tion may also be termed SMpp/y-limited elimination. 
On the other hand a substance such as ethanol, in the concentration 
present in man following 'normal' doses, is eliminated at a constant rate 
(zero-order elimination) which indicates that the elimination is merely 
capaci'rv-limited. Since most if not all drugs are for a major part eliminated 
by enzymatic conversion into metabolites it could be expected that several 
other drugs might show capacity-limited elimination in man (or animals). 
In such cases the total body clearance is not constant and proceeds via 
non-linear kinetics. This indeed has been confirmed, the best known 
example being the kinetics of salicylic acid, as analyzed in detail by Levy 
et al. (1972). It should be noted that also the renal excretion or part of 
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this may exMbit capacity-limited behaviour viz. when tubular secretion 
occurs. 
In case of capacity-limited elimination the profile of the semi-loga­
rithmic plasma concentration versus time curve will be dose dependent. 
Only under circumstances that the body may be regarded as a single com­
partment analytical solution of the appropriate differential equation can 
be obtained. 
Such a solution has been given by Lundquist and Wolthers (1958), when 
the capacity-limited pathway is the only channel of elimination. Similar 
solutions have been given by Levy (1972) and Wagner (1971, 1973). 
In this chapter drug kinetics will be discussed for the case that drug 
elimination occurs via a single metabolic pathway that is capacity-limited 
while simultaneously supply-limited elimination occurs. In addition a 
procedure will be proposed by which initial estimates of the essential 
kinetic parameters can be obtained from the plasma concentration curves. 
The theory and consequences of capacity-limited elimination via two or 
more metabolic pathways will be discussed in chapter 14. 
THEORY 
Ш 
kCel Q r ' ' Qm 
(1-0 кед 
, + c 
Figure 13.1 
Block diagrams representing linear and non-linear kinetics of elimination from a 
single compartment. 
I Merely supply-limited elimination characterized by the clearance constant. 
II Merely capacity-limited elimination Characterized by the enzyme constants KM 
and Or» It fact the clearance is not constant but is maximally equal to Ùml^M· 
III Supply-limited and capacity-limited elimination. A fraction is eliminated by a 
linear clearance process at all concentrations while the rest is eliminated by a 
capacity-limited process. The maximum contribution to the total body clearance 
of this pathway is f. kce¡. 
1. Supply-limited elimination of drag from a single compartment 
If a drug is eliminated merely be linear elimination kinetics i.e. a supply-
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limited clearance process, the total body clearance is constant, so that ^Qel 
= kçei. Then the following holds true for the rate of change of drug in the 
body in the absence of absorption processes. (See blockscheme tig. 13.1) 
f ^ - k C e l - C (13.2) 
Here dQ/dt is the rate of disappearance of drug (e.g. mg/h), k(;e¡ the 
clearance constant (e.g. in 1/h), С the plasma concentration at any time t 
(e.g. mg/1). 
Under the supposition that the volume of distribution remains constant 
there is direct relationship between change in quantity (dQ) and the 
change in the concentration (dC). 
The equation then may be written as follows: 
dC_ kCel _ dC - 1 _ „ , » 
- - - — - C o r - — 'C (13.3) 
The time constant (turnover time) directly relates to the clearance con­
stant код, provided that the clearance constant and the volume of dis­
tribution are constant. 
lerV/kCd O 3 · 4 ) 
The solution of equation 13.3 is well-known: 
In С = In A - t/rel (13.5) 
or 
C = A-e- t / r e 1 = A-2-t/t1'* (13-6) 
Here A is the apparent initial concentration. This implies that A depends 
on the boundary conditions. In case of i.v. administration A equals D/V 
and in case of enteral administration and rapid absorption as compared to 
elimination: A = D.F/V. Here D is the dose and F the bioavailability. For 
reasons of simplicity F will be considered to be equal to unity. 
The total body clearance is the sum of the clearance constants represent­
ing the various metabolic pathways, renal excretion and possibly other 
elimination mechanisms (saliva, sweat, bile, lungs, faeces). In formula: 
kCel = kCr + kCm, + kCm2 (13.7) 
Here kcr is the renal and kcm the metabolic clearance constant. The latter 
represents various metabolic pathways, while the former represents 
glomerular filtration, tubular secretion and tubular reabsorption. 
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2. Capacity-limited elimination from a single compartment via a single 
metabolic pathway. 
The rate of elimination then merely depends on the rate of bio-transforma­
tion via a single pathway and in the absence of absorption, may be describ­
ed by use of a Michaelis-Menten equation. The clearance is not constant 
but concentration dependent, so: 
VCel = Qm/CKM+C) = ^Cel [ Κ Μ / ^ Μ + Ο ] ( 1 ^ 8 ) 
Here Qm is the metabolic capacity of the liver enzymes involved (in mg/h) 
and equal to the V
n i a x when only one enzyme is involved while Код is the 
(apparent) Michaelis-Menten constant (mg/1), and k^gi is the clearance 
constant at low plasma concentration (С < Код). 
It is obvious that for low plasma concentrations, such that С < Код, the 
disappearance rate will be again directly proportional to the plasma con­
centration. Then the clearance is again concentration independent (Vçej = 
kçei). So the total body clearance under the condition that elimination 
proceeds merely via a single metabolic pathway depends only on the meta-
bolic capacity and the dissociation constant, provided that С is small as 
compared to Код. Then we obtain: 
kCel = Qm/KM whUe rei=V.KM/Qm (13.9) 
On the other hand as long as О Код it is clear that the clearance is 
inversely proportional to the plasma concentration. 
Vcel = keel -Км/С and f = - Q
m
 (13.10) 
which means that elimination under those circumstances proceeds as a 
zero-order process. The well-known equation then becomes: 
C = A - t . Q
m
/ V (13.11) 
This obviously holds true for the disappearance of ethanol from plasma in 
man, following the intake of two glasses of whiskey (Lundquist and 
Wolthers, 1958; Haggard et al., 1941; Wagner and Patel, 1972). 
Under the given conditions of equation 13.8 the differential equation 
governing the change of drug concentration in the body becomes: 
f = - ^ - [ K M / ( K M + C ) ] . C (13.12) 
Here the time constant т
е
\ is related to the clearance constant at low 
plasma concentration according to equation 13.4. 
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The equation can be integrated, but the solution is implicit with respect 
to the plasma concentration. 
In С = In A + (A-C)/KM -t/7 e i (13.13) 
Plasma concentrat ion ( r n g / l , log scale) 
100l D. variable ,KM=, 10 mg/l 
Plasma concentration (mg/l, los scale) 
D-TOOny;, KM=variable 
ttOjmg/l) 
Figure 13.2 
Plasma concentration curves based on equation 13.13 showing non-linear kinetics of 
elimination. The volume of distribution and the metabolic capacity are kept con­
stant V=50l and é m = 5() mglhr. 
a. The dose is varied as indicated in the figure from 10 to 5000 mg. K\fis constant 
(10 mg/l). The plasma curves become flat at higher dose, but they are straight 
lines with a slope determined by т
е
і when С < 0,1 Км. (т
е
і = 10 hrj. 
b. Км is varied from 0,3 to 100 mg/l, while the dose is constant (Ü - 100 mg). The 
whole curve becomes flatter when Кщ becomes higher. For K\f > 10 mg/l prac­
tically no capacity limitation can be seen. 
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In fig. 13.2 theoretical plasma concentration curves have been given, based 
on equation 13.13. The profile of the curve is dose dependent. However 
for low plasma concentrations always a straight line is obtained for which 
the slope is determined merely by r
e
] . Linear pharmacokinetic behaviour 
of course is only obtained when the plasma concentration becomes 
negligible with respect to Код. As a rule this will require the plasma 
concentration to be smaller than about 0,1 Код. At such low concentra­
tions equation 13.13 reduces to the following one: 
In С = In A* - t/Tel O 3 · 1 4 ) 
Here In A* refers to the apparent initial concentration obtained by extra­
polating the straight line to the ordinate. See fig. 13.3. LnA* may be 
derived from equation 13.13, when С may be neglected with respect to A, 
so: 
In A* = In A + A/KM (13.15) 
The apparent dissociation constant Код can be calculated from the differ­
ence between the intercept, In A*, of the extrapolated straight line for 
which the slope is determined by т
е
і and the real intercept of initial 
plasma concentration In A. See fig. 13.3. After transformation to decimal 
logarithm the following relation may be obtained: 
K M = A.log e/ (log A*/A) = 0.434Α/ΔΙ (13.16) 
where ΔΙ = log A* — log A is the difference between the extrapolated and 
real intercept when the data are plotted on a decimal, semi-logarithmic 
scale. Experimentally τ61 and therefore also VÁ may be calculated from the 
straight part of the semilogarithmic plasma curve at sufficiently low 
plasma concentrations. It is therefore essential that sensitive assay proce-
dures are available which allow us to get unambiguous data in the region 
where dose-independent kinetics apply. Subsequently the metabolic 
capacity, Qm, may be calculated from Код and kçei or т
е
\ and V: 
Qm = 1 4:el^M ° r Q M = V.KM/Tel (13.17) 
Код and Q
m
 may also be calculated from the time difference Δί between 
the straight line of the semi-logarithmic plasma curve and a line parallel to 
that starting from A. 
It can easily be derived that: 
Агр] . AV 
K M = A ^ a n d Q m = t ï О3·18) 
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ι concentration (mg/l, iog scale) 
4 8 12 16 20 (h) 
iïgure 13.3 
Outline of the procedure for the initial estimation of the values of Км and Q
m
. The 
parameters for the given curve are: D = 2000 mg, V =501, K\f = 10mg/t, Q
m 
= 200 mg/hr and т
е
/ = 2,5 hr. Aland ΔΓare explained in the text (see equations 13.16 
and 13.18). 
Obviously the constants Код and Q
m
 calculated in this way bear only a 
relation to the real values if the requirements set before have been ful­
filled. For ethanol and to some extent also for phenytoin the equation 
holds reasonably true so that the kinetic and enzyme parameters of these 
drugs have been calculated with the procedure outlined before. See 
table 13.1 and discussion. 
It is in general unlikely that a single capacity-limited pathway is the only 
way of drug elimination. For most drugs supply-limited elimination will 
occur simultaneously with capacity-limited elimination via one or more 
pathways. 
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3. Simultaneous supply- and capacity-limited elimination from a single 
compartment. 
If one metabolic pathway becomes capacity-limited by increasing the dose, 
then at the low concentration range (C ^  Код) a fraction, f, of the total 
body clearance occurs via that pathway. 
The clearance or clearance function then becomes: 
VCel = (1-Okcel + Q n A l + O 1 3 · 1 9 ) 
Here (l-O^Cel represents that part of the total body clearance that 
remains concentration independent while the other part f.kc
e
| equals 
Q
m
/K]^ only at low plasma concentration (С < Код) and decreases at 
higher concentrations (saturation effect). 
The change in the plasma concentration now can be described by the 
following differential equation: 
(i-0+f.KM/(KM-K:) (13.20) dÇ = _ l 
dt ТА 
Integration with boundary condition (t=o, C=A) leads to an implicit solu­
tion for C: 
1+(1-0A/KM 
1пС = 1пА+ тгз» In' 1-K1-0C/KM 
7 7 (13.21) 
T
el 
A similar differential equation and solution have been given by Wagner 
(1971). 
Theoretical plasma concentration curves for a drug with Код = 3 mg/1 are 
shown in figure 13.4. Clearly at low plasma concentration (С < Код) al­
ways parallel straight lines are obtained of which the slope is solely deter­
mined by Tel- However, at very high plasma concentrations also straight 
lines are obtained which are flatter. 
The concentration-dependent component ОпДКод+С) in the apparent 
clearance progressively becomes less important with respect to the concen­
tration-independent component (l-f^Cel У^ increasing the plasma con­
centration. Obviously this will occur earlier as f is smaller. It is worthwhile 
to consider first the situation that the plasma concentration is large with 
respect to Код but that Q
m
IC is not yet negligible to (1-Г)кс
е
\. In that 
case equation 13.19 reduces to: 
се1 = (1-0ксе1 + -сГ ( 1 3 · 2 2 ) 
and equation 13.20 becomes 
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Plasmaconcentrationfmg/l, Iqg scale)-
D χ variable, Qm =. SOir^/h 
f.0 67, KM.3mg/l 
Plasmaconcentration (mg/l, Iqg scale) -
D.IOOOrns, Qn^SOnTg/h 
fand K M = variable 
5000(m5) 
006-
004 
24 
с , , .
 ( h )
 " " "
 ( h ) 
Hgure 13.4 
Plasma concentration curves in case of combined linear and non-linear kinetics of 
elimination. The volume of distribution and the metabolic capacity of the saturable 
system are kept constant: V=50l and Q
m
 = 50 mg/hr. 
a. Dose variation from 100 to 5000 mg for a theoretical drug that for 2/3 is elimi­
nated by a potentially capacity-limited pathway (f = 0.67;. KM - 3 mg/l and 
τ
e
¡ = 2 Ar. At concentrations below 0,1 Км the curves are parallel. 
b. Variations of the fraction of the total body clearance that proceeds via a capa­
city-limited pathway, from f= 0,2 to ƒ = 1. Pie clearance constant keel и kept at 
25 l/hr, which means that т
е
; = 2 hr. So Кщ is varied along with f according to: 
Qm 2 
fkCel 
It is clear that capacity-limitation will not be detected when f < 0.2. 
dÇ 
dt 
1 
Tel ( • ^ 1 - м c = l b û Ç _ ^м ^el Tel 
Integration with boundary condition (t=o, C=A) leads to: 
•t/T*, f C = Ae w «I 
r
el 1-f 
K M ( 1 - -^Й) 
(13.23) 
(13.24) 
Where т
е
і = "TT is the time constant corresponding with the dose-indepen­
dent part of the clearance ( l-f)k C e l . This equation describes the plasma 
concentration curve for concentrations about 10 times Км. The influence 
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of the second term in the equation becomes progressively less the more С 
is larger with respect to Kj^.f/O-f). In practice the equation at sufficient­
ly high concentration values will appear as a nearly linear line on semilog 
plot.the slope of which will be close to Ι/τ^. This may easier be seen from 
equation 13.22, where ultimately Q
m
/C may be neglected with respect to 
(1— O^Cel· s o ^at a concentration independent clearance results. There­
fore at very high plasma concentrations elimination is also merely supply-
limited. In this extreme case the clearance process can be simply described 
as: 
so 
YCel=O-0kCel (13.25) 
f ^ - í = - 0 - 0 - (13.26) 
dt r j , т
е
| 
which upon integration leads to: 
1пС = 1пА—*— (13.27) 
7
 el 
So in general the contribution of the capacity-limited pathways can be 
calculated from the ratio of the slopes of the two straight line segments in 
a semilogarithmic plasma concentration-time plot. It should, however, be 
realized that the correct slope for τ£ι is only found at very high plasma 
concentrations. Consequently f will be underestimated from most experi­
mental data. See discussion. When f = 0.5, so that 50% of the total body 
clearance (at С < Код) occurs via a potentially capacity-limited pathway, 
the limiting slope at high plasmaconcentrations is a factor 2 less than the 
slope in the low concentration range where linear kinetics prevail, but the 
correctness of the estimation will be strongly dependent on the number of 
plasma data available and the height of the dose given. If however, the 
potentially capacity-limited pathway contributes to less than 20% to the 
overall clearance the difference in slope is hardly accessible. See 
fig. 13.4. 
This implies that capacity-limited elimination pathways may easily be 
overlooked. However, a capacity-limited pathway which contributes little 
to the overall body clearance may be of importance with regard to inter­
ference with the elimination of other drugs which are metabolized via the 
same enzymatic processes. 
The straight line at low plasma concentrations (С < Код) is given by the 
following equation which is derived from equation 13.21 by neglecting С 
with regard to Код: 
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In С = In A + 1-f 
In 
K M 
t (13.28) 
The intercept of this straight line, In A*, is larger than the real intercept 
and can be represented by the following equation, analogous to equa­
tion 13.15 
In A* = In A + -^-{ In 1+(1-
'K M 
(13.29) 
Since f can be calculated from the ratio in the slopes of the straight line 
segments at very high (С > Код) and at very low (С < Код) plasma concen­
trations, Код may be calculated from the difference between the real and 
the extrapolated intercepts in a semilog plot according to the following 
relation, obtained from equation 13.29, by rearrangement and transtor-
mation to decimal logarithms: 
f 
ΔΙ=- (1-0 log l+(l-f)A/KM (13.30) 
The apparent Michaelis-Menten constant, Код, can also be calculated from 
the time shift Δί between the straight line according equation 13.28 and a 
parallel straight line starting at A. It can be derived that 
f , rel 
' 1+(1-0A/KM Δί=- (1-0 log e log (13.31) 
Once Код has been determined, also the metabolic capacity of the enzyme 
system concerned, becomes quantitatively accessible on the basis of: 
Qm = f - k C e l - K M = f — K M 
r
el 
(13.32) 
Some examples of combined capacity- and supply-limited elimination are 
shown in fig. 13.5. Salicylic acid has been administered orally as a solution 
but absorption is very fast with respect to elimination so that equa­
tion 13.21 in good approximation holds true. Parameters calculated 
according to the procedure outlined before are summarized in table 13.1. 
Since experimentally f is underestimated the initial values of Код and 
Q
m
 obtained will not be optimal. Therefore the initial values obtained for 
KM and Q
m
 have been used in a non-linear curve-fitting computer program 
in order to obtain more reliable values of the in vivo enzyme parameters. 
From table 13.1 it may be seen that the initial values that follow from the 
procedure outlined above, give a reasonable estimation of the values 
obtained by curve-fitting. 
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Figure 13 5 
Plasma curves of different doses of salicylic acid in the same human sub/ect The 
experiment with the larger dose has been done twice (the open triangles 3 months 
after the closed ones) At low plasma concentration parallel lines are obtained from 
which т
е
[ can be estimated At high concentrations also straight lines are obtained. 
See table 13.1 and text for further explanation. 
DISCUSSION 
In general the main importance of graphical methods for estimation of 
pharmacokinetic parameters lies in the possibility of obtaining initial 
estimates which can be used for subsequent digital computer fitting proce­
dures Of course the precision of these initial approximations is dependent 
on the number of experimental data available and the accuracy and the 
sensitivity of the method used for the assay of the plasma concentration. 
For instance in the well-known method of residuals for compartmental 
analysis it is essential to have enough data for correctly estimating the 
slope of the extrapolated straight lines. Furthermore deeper compartments 
can easily be overlooked when plasma concentration has not been follow­
ed long enough At least the same degree of accuracy, sensitivity and 
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specificity of the assay method is required for optimal application of the 
procedure outlined above. For the most simple model of capacity-limited 
elimination (equations 13.12 — 18) where the saturable metabolic path­
way is the only mechanism of elimination the graphically estimated values 
for Код and Q
m
 may be a good approximation of the real value, provided 
that the slope of the straight line at low plasmaconcentrations (so r
 e
i) and 
by that the extrapolated intercept A* is accurately determined. As a 
matter of fact this straight line can only be estimated from concentration 
data in the region where the plasmalevels are negligible with respect to 
Код. When enough data are available below 0.1 Код it will be possible to 
obtain Код and Q
m
 values with an error of only a tew per cent. Of course the 
magnitude of the deviation of the estimated parameters from the real ones 
will become larger when the plasmaconcentration has not been followed 
long enough. Nevertheless the method will always indicate the order of 
magnitude of the parameters and provide an initial estimate for a sub­
sequent computer fitting. As far as the second model, with simultaneous 
supply- and capacity-limited elimination is concerned another complicat­
ing factor may arise. The estimated value of Код is dependent, not only on 
ΔΙ, the accuracy of which is determined by the factors discussed above, 
but also on f. This fraction f is estimated from the ratio of the slopes of 
the two straight lines which arise at very high and at very low plasma 
concentration. Now Тс\ can only be determined accurately at such high 
plasma concentrations that contribution of the saturated mechanism to 
the overall elimination is negligible with respect to the contribution of the 
mechanism(s) that remain(s) linear over the whole experimental concentra­
tion range. It is doubtful whether this situation will ever be reached at all. 
For instance the maximum dose that can safely be administered may be a 
serious restriction in this respect. Therefore the estimated values for the 
parameters according to the model with combined capacity- and supply-
limited mechanism as a rule will deviate more from the real values than in 
the case of the simplest model. Once again it should be stressed that 
computer fitting starting with the initial graphical estimates of the para­
meters will greatly improve the accuracy of the approximations. 
In the kinetic parameters calculated from the experimental data from our 
laboratory and the literature certain errors may have been introduced. 
In the case of ethanol from data by Wagner and Patel (1972) it is 
assumed that absorption is both complete and rapid with respect to 
elimination. These suppositions seem to be reasonable. Ethanol is known 
to be oxidized in man for 90 to 98% so that f is practically unity. 
However, two distinct mechanisms are available: the liver alcoholdehy-
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TABLE 13.1 
Estimated and computer fitted parameters for some drugs that show capacity-limited elimination 
Ethanol Salicylic acid Phenytoin 4-hydroxybutyric acid 
D(mg) 48000a 64000b 770c 1155c 250° 2900е 4000е 4500е 
A %
s
t 
Aest 
Aflt 
»V'fit 
e·. es* 
k'eit 
T
el' est 
k
est 
'
r
ei, fit 
''cal 
ffitfe 
K M, est 
K M, fit 
V
es t 
cel, cal 
"Veal 
(mg/1) 
(mg/1) 
(mg/l) f 
(1)8 
(hr) 
(hr') 
(hr) 
(hr1) 
(hr) 
(hr"1) 
(mg/1) 
(mg/DS 
(1) 
(l/hr) 
(mg/hr) 
6,6.10' 
1330 
1310 
36,7 
(1,7) 
_ 
-
0,43 
2,33 
0,42 
(0,06) 
2,38 
-
-
210 
200 
(45) 
27,1 
64,5 
12900 
7,2.10« 
1220 
1320 
48,5 
(1,4) 
— 
-
0,68 
1,47 
0,60 
(0,08) 
1,67 
-
-
190 
140 
(30) 
43,4 
72,3 
10100 
600 
125 
129 
5,98 
(0,16) 
7,2 
0,14 
3,3 
0,30 
2,8 
(0,3) 
0,36 
0,54 
0,79 
(0,09) 
21 
26 
(17) 
6,0 
2,1 
44 
2500 
200 
191 
6,0 
(0,8) 
9,7 
0,10 
3,3 
0,30 
2,5 
(0,6) 
0,4 
0,66 
0,91 
(0,16) 
25 
27 
(30) 
6,0 
2,4 
59 
5,90 
4,55 
4,66 
53,7 
(1,4) 
— 
-
21 
0,048 
20,0 
(0,8) 
0,05 
1,00 
1,00 
16 
10 
(4) 
54 
2,7 
27 
1170 
220 
201 
14,4 
(0,9) 
1,3 
0,77 
0,62 
1,61 
0,44 
(0,18) 
2,27 
0,48 
0,85 
(0,11) 
25 
31 
(43) 
14 
31,8 
840 
9900 
250 
244 
16,4 
(0,8) 
2,7 
0,37 
0,83 
1,20 
0,46 
(0,20) 
2,17 
0,70 
0,88 
(0,03) 
14 
10 
(9) 
16 
34,8 
310 
900 
230 
238 
18,9 
(1,2) 
2,1 
0,48 
0,61 
1,64 
0,56 
(0,49) 
1,97 
0,71 
0,85 
(0,07) 
36 
15 
(28) 
19 
33,9 
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Explanation of the symbols used m table 13.1. 
The symbols A*. A, V, т, к, f, Кщ, kçei and Qm are explained in the text. The 
suffixes est, fit and cal mean 'estimated', 'fitted' and 'calculated' respectively. 
'Estimated' refers to the graphical parameter determination, 'fitted' are the values 
directly obtained from the computer fitting program and 'calculated' values are 
derived from estimated and fitted parameters according to the equations described in 
the text. 
Vgst,s ΜΒ best possible estimation of the actual volume of distribution and is used 
for calculations of kce¡iCai and Qm.cah while 'V'flt is justan operational magnitude, 
leaving out of consideration distribution or absorption processes, and used for 
descriptions according to eq. 13.13 or 13.21. 
Legend to table 13.1 
a. Data from Wagner and Patel (1972) For estimation of the parameters as well as 
for the curve fitting the zero-time has been taken after absorption can be 
expected to be completed. Therefore the intercept A and the volume 'V'fit do not 
correspond to the actual volume of distribution
 е
ц, which has been estimated 
for the whole plasma concentration curve. 
b. Data from Haggard et al (1941). Same remarks as under a. 
с Two oral doses (potto) were given to the same subject. Absorption is very rapid 
(see fig. 13.5). Therefore a close agreement exists between V
es
t and 'V'fit and the 
curves can be handled as if i.V. administration was applied 
d. Data from Glazko et al. (1969). Based on mean plasma concentration values in 6 
persons who received 250 mg of Phenytoin by i.V. infusion. Concentration points 
in the distribution phase have been left out when estimating the parameters or 
fitting the curve. 
e. Data from v.d Pol et al (1975) m three patients following Lv infusion. The 
distribution phase has been left out for estimation of the parameters and curve 
fitting.
 D j 
f. The magnitude of A fit has been calculated from 'V'fit and the dose D (A =,7-7^ 
since by the computer program used 'he experimental points are fitted to an 
equationm which A is written explicitly as - ^ « , that "V" is fitted directly. 
g. The number m parentheses represents the error in the fitted parameter value. See 
text for further explanation. Errors are only given for parameters that were 
directly fitted and not for those that were calculated from fitted values, since such 
errors would hardly be meaningful. 
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drogenase and the liver microsomal oxidizing system. The relative con­
tribution of these systems to the overall metabolism of ethanol are depen­
dent on the plasma concentration that exists. 
Some problems arise with regard to the calculation of the kinetic para­
meters in this case. As will be discussed in chapter 14 an apparant Код is 
expected to come out, which is a function of the two Код values for both 
systems and their relative importance or weight. For the moment it is 
sufficient to note that the Код value given in table 13.1 is in the expected 
order of magnitude. The two metabolic systems have different Код values 
as follows from in vitro studies. For alcohol-dehydrogenase Код is about 
80 mg/1 and for the microsomal oxidizing system Код is about 400 mg/1 
(Lieber, 1973). Important parameters obviously are the metabolic capacities 
of the two systems concerned, for which unfortunately no information is 
available. In our analysis with regard to ethanol we now used the simplest 
model. It should be noted that the calculated metabolic capacity Q,,, seems 
to be a very reasonable overall estimate. As far as Код is concerned however 
one must bear in mind that the calculated values actually may be the result 
of some combination of two constants. Further analysis can only be done 
when more accurate data become available. 
Phenytoin seems to be hydroxylated for about 80% (Glazko et al., 
1969). Assuming this to be due to a saturable metabolic system, one 
would expect the fraction f to be about 0.8. However a good computer 
fitting of the data requires f=1.0, as shown in table 13.1 so we are forced 
to conclude that the data are not totally sufficient for discriminating 
between the several possibilities. 
In case of salicylic acid, absorption form the oral route is fast with 
respect to elimination, but at least two capacity-limited pathways are in­
volved. This implies that the procedure according to equation 13.21 may 
not be applied unless additional requirements have been fulfilled. When 
two different capacity-limited pathways occur simultaneously with a con­
centration independent fraction, the mathematical relationship between 
plasma concentration and time becomes more complicated. The calcula­
tion of the kinetic parameters is not straight forward anymore. 
However, in the case of salicylic acid elimination in man the Код values 
of the two metabolic systems that are easily saturated, are in the same 
order of magnitude as may be seen from renal excretion data by Levy et 
al. (1972). 
It may be calculated that if two saturable pathways are involved with the 
same Код value the differential equation may be written as a single path­
way while the overall capacity is the sum of the two capacities. Our data 
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do not allow a more detailed analysis. The overall values obtained for 
salicylic acid from plasma data agree reasonably with the data obtained 
from renal excretion of metabolites by Levy et al. (1972) 
The errors in the kinetic and enzyme parameters as given in table 13.1 
reflect the goodness of fit of the aata ю the model. When many data are 
used this error can be regarded as the standard error. In the cases that are 
described here however the number of experimental data is certainly not 
enough with respect to the number of parameters to be fitted, so that the 
exact meaning of the value of the error is somewhat obscure. Of course the 
error is strongly dependent upon the number of data available and this 
may contribute to the fact that some parameters show a rather large error 
although on inspection the fitted curves excellently adapt the experimen­
tal points. As a matter of fact the magnitude of the error in a parameter 
reflects the degree of sensitivity of the fitted curve to changes in that 
parameter. The error in Код and r
e
] might still be enlarged by the strong 
positive correlation which appears to exist between these two parameters. 
In general non-linear pharmacokinetics deals with all processes that 
deviate from first-order kinetics. There are, however, only a few processes 
for which a better description than first-order approximation is possible. 
These are drug metabolism (as discussed in the foregoing paragraphs), 
some types of renal excretion and drug-protein binding. 
Renal excretion 
In the kidney two basic processes mostly play an important role in drug 
excretion: glomerular filtration and passive reabsorption. These two pro­
cesses may be summed up to yield one linear renal clearance constant. 
Two other saturable, so non-linear, mechanisms may be relevant for the 
elimination of a number of special drugs: tubular secretion (e.g. for many 
aromatic acids) and sometimes active tubular reabsorption (e.g. glucose, 
uric acid). The tubular secretion again can be related to the plasma concen­
tration by an equation totally analogous to equation 13.8. The quantity of 
drug eliminated per unit of time by a tubular secretion process can be 
written as: 
dQ T T M 
where 
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Τ\ι = tubular transport maximum (e.g. mg/h) 
Kj = apparent dissociation constant between drug and transport 
mechanism (e.g. mg/1) 
С = plasma concentration 
Some characteristics of tubular secretion have been discussed in 
chapters 5, 8 and 10. 
Drug-protein binding 
Of course drug-protein binding will not influence the intrinsic clearance of 
a drug (calculated on basis of free drug concentration) but only the 
apparent clearance (on basis of total plasma concentration). When a 
certain drug, which is strongly bound to plasma proteins, can achieve such 
high concentrations that it exceeds the protein-binding capacity there will 
be a disproportional increase in free drug concentration, available for 
diffusion. The excess is causing an increase in the apparent volume of distri­
bution, which automatically will lead to a directly proportional increase in 
apparent total body clearance. 
Figure 13.6 shows the relationship between clearance and drug concen­
tration for some theoretical drugs with different degree of protein binding. 
It is important to notice that in any case the clearance is constant over 
substantial concentration ranges, so that the effect of the protein binding 
may be detected clearly only in a few instances. Furthermore, it is interest­
ing to see that the effect of protein binding is just opposite to that of 
saturable elimination (see fig. 13.7). 
As a matter of fact one might wonder if not in many cases capacity-
limited elimination cannot be detected since it is balanced by the conse­
quence of drug-protein binding. A very nice experimental example of the 
influence of protein binding on pharmacokinetic behaviour can be found 
in the work of Burns et al. (19S3) who found that increasing the daily 
dose of phenylbutazone in man (200,400, 800 to 1600 mg) led to a much 
less than proportional increase in plasma plateau concentration. This is 
exactly as would be expected for a strongly protein-bound drug in high 
concentrations: increase in dosage effectively counterbalanced by a con­
comitant increase in apparent total body clearance. The influence of drug-
protein binding on drug distribution and elimination has been discussed 
for instance by Kriiger-Thiemer et al. (1966), Dayton et al. (1973) and 
Schoenemann et al. (1973). 
Finally it should be noticed that description of plasma concentration 
curves in terms of Michaelis-Menten formulas implies the presupposition of 
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an equilibrium between the drug concentration in plasma and in the com­
partment where metabolic conversion or tubular secretion takes place. We 
cannot be sure that this assumption is justified for all drugs. 
N ^ l : Apparent t o t a l body clearance ( l / h ) 
20 40 60 80 100 200 400 600 BOO 
С : plasma concentration (mg/l ; leg scale) 
Figure 13.6 
Apparent total body clearance as a function of plasma concentration with different 
degrees of drug-protein binding for a hypothetical drug (MW 320). Equation accor­
ding to Kruger-Thiemer et al. (1966). 
^C»\ 'Apparent total body clearance ( l / h ) - (ml/min) 
1-175 
150 
125 
100 
75 
I ' I ' I 
20 40 60 Θ0 100 ZOO 400 600 800 
C: plasma concentration ( m g / l ; \og scale) 
Figurel3.7 
Apparent total body clearance as a function of plasma concentration and Км for a 
hypothetical drug (MW 320). Elimination is assumed to occur via parallel supply- and 
capacity-limited pathways. 
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APPENDIX I 
DERIVATION OF EQUATIONS 13.18 AND 13.31 
With respect to figure 13.3 one can conceive of two points with the same 
concentration, one on the straight line starting from log A* and one on the 
parallel line from log A, which are a time distance At apart. One can write 
for these points: 
lnC = l n A * - — = I n A + r A - — 
Tel К
м
 т
е 1 
(13.14/15) 
and 
i ^ i * t - A t , , ,
 A t At 
In С = In A In A - + 
Tei Tel Tgi 
(13.5a) 
From comparison we see that 
A At
 v
 А т
е 1 (13.18) 
Essentially the same procedure can be applied for deriving equation 
13.31. Then the two points are given by: 
lnC = l n A * - — = l n A + Y^j In 
'"el 
l_übuA 
KM 
and 
In С = In A - — Ч - — 
'"el '"el 
From comparison it follows that 
At f 
- — (13.28/29) 
T
el 
(13.5a) 
'"el 1-f 
In ! | 0 - 0 A 
KM or 
At = f.Tel ( 1 - 0 log e 
Ч ^ (13.31) 
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APPENDIX II 
INTEGRATION OF EQUATION 13.20 
£ = _ - L ( 1_ f +J^Ljc (mo) 
dt т
е
і K M + C 
Rearrangement leads to 
_ K M + C 
[Км 
Now integration is straightforward and, with the boundary conditions 
(t=0, C=A) the solution is equation 13.21. 
-    Π f Τ dt „ „ „ , , 
— dC= - + dC = (13.34) 
+ 0-0с]с ^ [c KM + ( i - o c J a L rel 
APPENDIX III 
Equation 13,13 is just a special form of equation 13.21, viz. for the case 
where f=l. Equation 13.21 reduces to equation 13.13 as f approaches 
unity. Starting with equation 13.21 we have to calculate 
•(l-f)C/KM t Г f 1 + 
lim (In C) = In A lim кЦ-І і і -ГТ" 
f->l Tel f ^ l ^ - f 1 + l 
(13.35) 
•(1-0A/KM J 
Simple rearrangement gives 
um p -
 l n ι + (i-f) с/км "I = lim LL l n Л +(i-f) (c-A) \1 f-i[ilf,  I+(I-OA/KMJ ™Li-flnl1  KM + (i-0A;J 
Since the following equation obviously holds true (13.36) 
(l-f)(C-A) 
1 < : K M + ( 1 - 0 A < 0 ( 1 3 · 3 7 ) 
the logarithm in equation 13.36 can be expanded into a Taylor series, so 
that equation 13.36 can be written as: 
Zlltf (1-0 (C-A) _ ( l - Q
2
 (C-A)2 
K M + ( 1 - 0 A 2[K M + ( 1 - 0 A ] 2 
( l - Q 3 (C-A)3 
3 [ K M + ( 1 - 0 A ] 3 ™і[км + 
A) 
( 1 - 0 A 
233 
f (1-0 (С-A)2
 + 1 = Ç^A 
2[KM+(l-f)A]2 J KM 
(13.38) 
By substituting tìiis result into equation 13.35 we obtain equation 
13.13. 
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CHAPTER 14 TWO CAPACITY-LIMITED PATHWAYS 
OCCURRING SIMULTANEOUSLY 
INTRODUCTION 
In chapter 13 equations have been given for the plasma concentration as a 
function of time for drugs that show capacity-limited elimination via a 
single pathway as well as supply-limited (linear) elimination. The equations 
appeared to be quite satisfactory for describing plasma curves for several 
drugs. However, as indicated already, evidence is available that at least for 
salicylic acid and ethanol two non-linear pathways are involved. In this 
chapter the appropriate equations will be derived for elimination via two 
capacity-limited pathways with or without simultaneous supply-limited 
elimination and the possibility of distinguishing the routes will be dis­
cussed. Analogously to the symbols used in chapter 13 we will refer to the 
capacities of the two non-linear mechanisms as Q
m i a n d Q m 2 to their 
Michaelis-Menten constants as Код! and KMI and to their relative contri­
bution to the maximal clearance as fj and fj. Again kçej represents the 
maximal clearance constant, so obviously Ö m i =fiK^j1kçe[ and 
Qtfto = ^Кмг^СеІ- The time constant for elimination when no saturation 
occurs at all is r e i ( = ¿ ^ j ) . 
TWO CAPACITY-LIMITED PATHWAYS ALONE 
If a drug is eliminated merely via two metabolic (or secretory) routes that 
can be saturated at the prevailing levels of the plasma concentration, the 
following differential equation describes the elimination process (in a one 
compartment model with i.v. administration): 
dÇ. 
dt ' KM.+C K M 2 + C 
ы
 (14Л) 
Since here the two non-linear mechanisms are the only channels of elimi­
nation, it is obvious that f! + f2 = 1. 
Equation 14.1 can be integrated, leading to a solution which is implicit 
in С With the boundary condition [t=0; C=A (= Q)], one obtains (see also 
appendix): 
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С = In А + + 
f i K M l + f a K M 2 т еі 
+ f i f 2 ( K M 1 - K M 2 ) 2 i n ^ Γ , Κ Μ , + Γ , Κ Μ ^ + Κ Μ , Κ Μ , 
(f, Κ
Μ ι
 + f, K M 2 У ОД K M l + fг К М 2 ) + K M l К М 2 
(14.2) 
When K^j would be equal to Kj^2 equation 14.2 clearly reduces to 
equation 13.13. Of course also on basis of equation 14.2 ultimately a 
straight line is obtained in a semilogarithmic plasma curve (viz. when С is 
very small with respect to the smallest Код). The slope of this straight line 
is determined solely by T
e
j. From equation 14.2 one can easily derive 
expressions for timeshift ΔΙ by procedures similar to those outlined in 
chapter 13. Unfortunately these expressions are not practically useful, 
since they do not allow separate estimation of fj, f2, Kj^ and Kf^2. It 
should be noticed that it is virtually impossible to obtain such estimates on 
basis of the plasma curve alone. 
TWO CAPACITY-LIMITED COMBINED WITH ONE OR MORE 
SUPPLY-LIMITED PATHWAYS 
In general it is unlikely that a drug would be eliminated exclusively via 
mechanisms that are saturated at normal plasma concentrations. Usually 
other mechanisms of elimination will contribute to the clearance process 
as well. These 'secondary' mechanisms may be less specific and have low 
affinity for the specific drug, but especially when high drug levels are 
sustained for longer periods, they can become quantitatively important. In 
the case that two capacity-limited mechanisms are accompanied by one or 
more supply-limited routes, the plasma concentration as a function of time 
in a one compartment model with i.v. administration is governed by the 
following differential equation: 
dÇ 
dt 
f'KM, fiKM2 
1 2
 к
М і
+ с к
М 2 +с 4 ( 1 4 - 3 ) 
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Integration yields the following equation implicit in С (see also appendix): 
In С = In A + *———t——— In 77-^ 
( l - f . - f î H p - q ) C-p 
KMt +Км2 + д + ( 1 - ^ - Г г ) р A-q t 
+
 ( l - ^ - f ^ i q - p ) ^ C - q " r
e l 
where ρ and q are the roots of the following quadratic equation: 
(14.4) 
1-fi-fî l - f i - f î 
It can easily be shown that the discriminant of equation 14.5 is always 
> 0, so that the equation has always two real, different roots. With regard 
to equation 14.4 the same remarks can be made as for equation 14.2. The 
ultimate straight line which is obtained in a semilogarithmic plot is deter-
mined exclusively by т
е
і and it is virtually impossible to obtain reliable 
estimates for the various enzymatic parameters on the basis of plasma 
concentrations alone. 
DISCUSSION 
It has been shown in the foregoing paragraph that relatively simple inte­
grated equations are obtained for the plasma concentration in case of 
elimination via two capacity-limited pathways with or without simul­
taneous supply-limited pathways. As a matter of fact even certain more 
complicated models can be analysed by the same mathematical methods as 
described in the appendix. In principle these integrated equations can be 
used for computer fit of experimental data to the models under discussion. 
It appears, however, that complicating the model by addition of extra 
parameters as in equations 14.2 and 14.3 does not lead to special charac­
teristics in the theoretical plasma curves obtained by which these could be 
distinguished from the simpler equations in the foregoing chapter. When 
for instance theoretical data are generated on basis of equation 14.2 one 
finds that this simulation can easily be adapted to the much simpler 
equation 13.13. The same holds true for equation 14.4 with respect to 
237 
equation 13.21. As an illustrative example we simulated the model of 
equation 14.2 on basis of Км values as estimated for ethanol by indepen­
dent procedures (90 ml/1 and 400 mg/1, L·eber, 1973). Since it is obvious 
that the relative contributions of the two mechanisms (alcoholdehydro-
genase and the microsomal oxidative system) are dependent upon the 
plasma concentration range studied we inserted variable values for f ι (and 
consequently fj, which is 1—fi). At first sight already it is clear that no 
charactenctic features at all are present in the plasma curves and that they 
are highly similar to those obtained from equation 13.13 (see figure 14.1). 
plasma cone (mg/l log scale) 
1 0 0 0
 "^SS^r-^ 
500- \ 4 X \ ~ ^ \ 
200 \ \ \ ^ ч ^ \ 
100; \ \ \ \ \ 
100 200 300 400 500 
time С mm) 
Figure 14 1 
Some examples of plasma curves simulated on basis of the simultaneous occurence of 
two capacity-limited pathways of élimination, according to equation 14 2 The para-
meters are K\fi = 90 Км2 = 400 mg/l and Te¡=30 min (based on estimates for etha-
nol) The fractions ƒ, and ƒ,, representing the relative contribution of the two 
pathways, are varied, from the left to the right ƒ, = 0, ƒ, = 0,2, ƒ, = 0,5, ƒ, = 0,8 and 
fi-1 (the sum of ƒ', +ƒ,=/ , / See text for further explanation 
When from the simulated curve a lot of concentration data (about 40), at 
regular intervals, so describing the whole curve, are taken and when these 
data are subjected to computer fit according to equation 13.13 an excel-
lent fit is obtained Table 14.1 shows some examples of this. It may be 
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TABLE 14.1 
Some typical results obtained when data, generated according to equation 14.2 (with 
D = 50 g, V = 50 1) are fitted on basis of equation 13.13 (which yields a pooled 
Код value). 
Fit according to eq. 13.13 
^M Tel 
Parameters used for 
simulation1 
f. K M I 
0.2 90 
0.6 90 
0.8 90 
KM, 
400 
400 
400 
T
el 
30 
30 
30 
f,K :. +«'iK i 
338 
214 
152 
320 ± 0.7% 30.6 ± 0.2% 
196 ± 1.4% 31.8 ± 0.6% 
142 ± 1.1% 31.7 ± 0.6% 
1. KM in mg/1; т е і in min. 
noted that the error in the fitted parameters is so small that experimental 
data will never allow a more thorough analysis. When the same data are 
fitted according to equation 14.2 also a good fit can be obtained, at least 
when the start guess for the fitting procedure is good. This implies that in 
practice at least two major difficulties would be encountered. Firstly, 
experimental data can never be as exact as the simulated data are and 
secondly, as stated above, there is no simple way for obtaining estimates 
that are useful as starting values for the computer fit. The apparent Код 
which is obtained by the pooling of two capacity-limited pathways has a 
value intermediate between the two separate K^'s and is closer to one of 
these as the contribution of the mechanism to which Код belongs, is 
increasing. From the table it becomes clear that the apparent Код is 
reasonably approximated by the weighted average fiKj^j +f2Kj^2. In 
our example we used Код values of 90 and 400 mg/1, the difference being a 
factor 4—5. This difference is much larger than the difference between the 
KM values for salicylc acid with respect to its two elimination pathways 
that are saturable at therapeutic plasma levels (formation of salicyluric 
acid and of phenolic glucuronide). According to the data of Levy et al. 
(1972) this difference can be expected to be less than a factor 2. 
Obviously this fact will make the approximation by one mixed non-linear 
pathway even better for salicylic acid than for ethanol. Furthermore, the 
relatively small difference between the constituting Kj '^s leads to practi­
cally constant pooled parameters. Therefore, it is justified to treat 
salicylate kinetics on basis of equation 13.21. This conclusion cannot be 
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extended to the case of ethanol, since a difference of a factor 5 in Код 
values may lead to concentration-dependent pooled parameters (cf. also 
Sedman and Wagner, 1974). On the other hand it seems possible to obtain 
reliable estimates for the separate pharmacokinetic and metabolic para­
meters occurring in the equations 14.1. to 14.4 on basis of the concen­
tration dependence of the fitted, pooled parameters. Requirements for this 
approach are firstly that the difference in individual Код values is a 
factor 5 or more and secondly that plasma curves after a wide range of 
doses can be measured. In this respect ethanol seems a promising drug, 
especially in animal experiments. These aspects are currently under inves­
tigation. 
APPENDIX I 
Integration of equation 14.1 
dÇ 
dt 
UK M, f 2 K M 2 
_к
М і
+с к
М 2 +с 
с 
'"el 
( f .K M l C + faKMaC + K M | K M a ) _ ç _ 
(K M i +C)(K M 2 + C) Tel (14.6) 
( K M i + C ) ( K M 2 + C ) 
( f . K ^ C +f2KM 2C + K M i K M 2 )C dC = 
f l f 2 ( К М ! - ^ ) 2 
с
 +
 { f ,K M l +f 2 K M 2 } { K M I K M 2 + ( f 1 K M i + f 2 K M 2 ) C } + 
+ f l K M i + f 2 K M 2 
dC = 
r
el 
dt (14.7) 
Now integration is straightforward and with the boundary condition [t=0, 
C=A] the solution is equation 14.2. 
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APPENDIX II 
Integration of equation 14.3 
dÇ 
dt 1-и-Ь+. 
Ъ^М! {гКМ2 
ΚΜ,+C К
М 2+С j Tei 
Км, ΚΜ,+Ο-ωκΜ, c-Ki-fi )KM2c+(i-fi -f2)c2 
(KMi+C)(KM2+C) Tel 
After rearrangement: 
(Км.+с) (ΚΜ,+C) 
( l-f . -f î ) с 
с
2
 + 
l- f |- f i l-fi-fa J 
(14.8) 
dC = 
'"el 
dt (14.9) 
The quotient in the left side of equation 14.9 again can be split, so that we 
obtain: 
(¿ + J - + - b C-q J Tel С C-p -q 
K M 1 + K M 2
+ P + ( i - f i - f2)q 
where a = —j-t—^—7-7-7 г ( l- f i- fa) (p-q) 
. K M . + K M ^ + q + O - f . - f Q p 
( i - f i - f i ) (q-p) 
(14.10) 
(14.11) 
(14.12) 
and ρ and q are the roots of the quadratic equation between the brackets 
in the denominator of the left side of equation 14.9. 
Integration of equation 14.10 leads simply to equation 14.4. 
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CHAPTER 15 ACCUMULATION KINETICS IN CASE OF 
CAPACITY-LIMITED ELIMINATION 
INTRODUCTION 
Many drugs are administered to patients repeatedly over a certain period in 
a fixed schedule. One of the main objectives of applied pharmacokinetics 
is to enable physicians to predict the behaviour of the plasma concen-
tration of drugs on chronic administration and to estabUsh optimal dosage 
regimens. In combination with pharmacodynamic data, pharmacokinetics 
can give insight into the risk of too low, so subtherapeutic, dose levels as 
well as too high, possibly toxic levels. Especially for drugs with a small 
thereapeutic index this information is extremely important. It is well-
known for instance that effective antirheumatic action of salicylates 
requires plasma concentrations that are only slightly below toxic levels. 
This implies that in practice a patient often will be 'titrated' until the first 
signs of intoxication will become noticeable. As we have seen already 
salicylic acid is one of the compounds that exhibit capacity-Umited elimi-
nation in a therapeutic dose range and study of its behaviour on chronic 
administration serves highly useful purposes, especially since the drug 
mostly is administered in repetitive regimens. The same holds true for 
Phenytoin and ethanol; the former is used extensively as anticonvulsant-
antiepileptic, the latter is an important source of abuse and since legal 
sanctions can be imposed, understanding of its behaviour in the body is 
highly important also for the proper authorities. 
In this chapter the theoretical basis of drug accumulation in case of 
capacity-Umited elimination will be discussed. Whenever possible, 
equations will be given that allow estimation of plateau levels, without 
extensive numerical calculation. 
THEORY 
When the elimination of a drug proceeds exclusively via linear, supply-
limited mechanisms a very simple relationship exists between the average 
plateau concentration Cp], the dose D (in case of oral administration FD), 
the dosage interval At and the overall clearance constant of the drug kçei. 
с>л55Г <4'69) 
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This equation has been derived in chapter 4 and is valid, irrespective of 
the number of compartments and the way of administration as long as 
linear kinetics prevail (see also Van Rossum, 1968; Van Rossum and 
Tomey, 1970). The average plateau concentration is directly proportional 
to the 'dose flow' ^ (e.g. in mg/hr) and inversely proportional to the 
clearance constant. From this equation it is obvious that when the 
clearance function is not a constant, but decreasing with increasing plasma 
concentration, one should expect a disproportionate rise in plateau levels 
with increasing dose flow. This imphes that drugs with capacity-limited 
elimination may easily be overdosed, when the dose is increased because of 
a too low effectiveness. On the other hand, once toxic levels have been 
reached a slight decrease in dose may cause subtherapeutic levels. Experi-
mental evidence for this will be discussed in chapter 16, with special refe-
rence to sodium salicylate. In the following paragraphs the mathematics of 
accumulation in case of capacity-limited elimination are discussed. The 
main problem here is that no explicit equations for the plasma concen-
tration as a function of time are available. Therefore repeated oral admini-
stration cannot be formulated analytically and the only way of calculating 
plasma levels after chronic oral administration is by numerical integration 
of the appropriate differential equations. There are, however, two other 
cases where at least the plateau levels can be expressed in a general for-
mula, viz. repeated intravenous injections and continuous infusion of 
drugs. In linear kinetics the average plateau concentration is independent of 
the way of administration, but this cannot be assumed to be generally true 
in capacity-limited kinetics. It is very well conceivable that the rate at 
which a drug enters the body is determining the degree of saturation and 
thereby the decrease of the clearance function and the increase of the 
steady state levels. It is difficult to predict the exact influence of the rate 
of entering, but it seems logical that repeated i.v. injections and continuous 
infusion form the two extreme cases and that repeated oral administration 
will lead to intermediate accumulation values. Therefore we give first the 
two possible mathematical approaches and discuss the pitfalls afterwards. 
I REPEATED I.V. INJECTIONS 
Once a steady state has been reached the plasma concentration at the end 
of any interval will be the same. Furthermore just after the injection the 
plasma concentration will be higher than that at the end of the foregoing 
interval to the amount of D/V. These obvious facts allow the following 
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analysis: 
a. Capacity-limited elimination only. 
From chapter 13 we have the equation for the plasma concentration: 
lnC = l n A + £ = £ - — (13.13) 
KM 7"el 
For plateau level calculations this equation can be rearranged to: 
lnCpl,min = ln(cpl,inin + ^ Г ) + Щ
л
 " — ί
1 5
·
1 ) 
in which Cp] jujjj = the minimal plateau concentration (at the end of the 
dosage interval). 
From equation 15.1 Cpj^jjj can be defined as: 
C p I
'
m i n =
v [ e ( A t / T e i - D / V K M ) _ 1 ] ( 1 5 ' 2 ) 
In linear pharmacokinetics the same type of equation can be defined, the 
only difference being that the exponent in the denominator contains only 
At/Tgj. Obviously equation 15.2 predicts much higher accumulation 
plateaus than in linear kinetics could be found. When D/VKj^  > At/r
e
|, 
which means nothing else than Ό/At > Ο,γ, (= the metabolic capacity), no 
plateau at all will be obtained, but accumulation would go to infinity. This 
result was to be expected of course, since under those circumstances the 
dose per unit of time is higher than the maximum amount that can be 
eliminated during that time. The ratio between the ultimately reached 
plateau level and the level after a single dose is now determined not only 
by the dosage interval and T
e
j but also strongly by the metabolic capacity. 
The maximal plateau concentration Срі ) П і а х can easily be derived from 
equation 15.2 by making use of the relationship Cpl ) m ax = 
Cpl.min + D/V. So: 
(15.3) 
-pl,max
 v
[ 1 _ e ( D / V K M - A t / 7 e l ) ] 
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b. Simultaneous supply- and capacity-limited elimination. 
In general it will be unlikely that an extreme situation as depicted above 
prevails. Most probably part of the elimination process will be based on 
first-order processes. Therefore the use of equation 13.21 will be a 
more realistic approach: 
f K M + ( l- f )A t 
" - • • • А + і Ь - ^ + О-ОС - 4 ( l 3 ' 2 1 ) 
By analogous procedures as used above one can easily find expressions for 
Cpl min a n ^ Cpl щах- An important difference is, however, that no 
explicit equations for the plateau concentration can be formulated and 
that the resulting equations are not very convenient (see also Tsuchiya and 
Levy, 1972). It is interesting to note that in this case accumulation is 
restricted to an upper limit so that always a plateau will be reached 
(provided of course that f < 1). Another interesting feature is that at high 
dose and plasma levels the accumulation plateau ultimately is again 
directly proportional to the dose. This can easily be seen by assuming Код 
in equation 13.21 to be negligibly small with respect to (1-0 A and 
(1-f) C. Then equation 13.21 reduces to: 
1пС = 1пА+ т-
е
 In £- - — (15.4) 
1-f С ì e l 
For plateau level calculations this leads to: 
D 
л η ι /r. _L D
 ч
 , f . 4>l,min + V 
l n Cpl,min- l n(cpl,min+ у ' + ~f с 
^pl, min 
_ Δί О 5 · 5 ) 
T
el 
So that 'Jie following equation for Cpj ^
п
 is obtained: 
D 
-ρΐ,πύη
 v
| -
e
( i _ 0 A t / T
e l _ 1 ] 
(15.6) 
This equation is in fact the same as would be obtained in case of linear 
kinetics with a time constant for elimination of т
е
і/1— f. Since in linear 
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pharmacokinetics the height of the average plateau concentration is 
directly proportional to the time constant for elimination we can expect a 
similar proportionality, but then with the ratio r
e
]/l-f in case of partly 
capacity-limited elimination. This clearly will give rise to much higher 
plateau levels: the larger f, the higher the steady state level. 
Π CONTINUOUS INFUSION 
The most convenient approach to pharmacokinetics of chronic admini­
stration is to regard it as a continuous infusion, since then simple differen­
tial equations can be defined, that can easily be integrated. In the plateau 
situation the rate of infusion is equal to the rate of elimination (e.g. in 
mg/hr) so that a simple equation results from which the plateau concen­
tration can be calculated. Applying this principle to a one compartment 
model in its general form we obtain the following equation: 
A t -
v C e l C p i (І5 7) 
where 
% = rate of infusion (e.g. mg/hr) 
Vçei = clearance function (e.g. 1/hr) 
Cpi = plateau concentration (mg/1) 
In case of linear pharmacokinetics the plateau concentration calculated 
this way is equal to the average plateau concentration that is reached after 
repeated oral, i.v. or other administration. This is not so for drugs that are 
(in part) eliminated by capacity-limited mechanisms. Then the concen-
tration Cp| from equation 15.7 provides the lower limit of the expected 
average plateau concentration after administration via another way. 
Equation 15.7 can be specified for the two models that we consider in this 
chapter: 
a. Capacity-limited elimination only. 
In this case the following relationship is obtained: 
D Qm
 Г і =
К
М
к
С е 1 *
М
 _ÇjA 
ΔΪ = KÜTC^ ρ 1 K M +C p l LPl K M +C p l те 1 (15*> 
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After rearrangement this leads to the following equation: 
KMD/At _ KMD/At K M r e l Ο/Δί 
CP1 = · 
Q
m
 - DMt 
K M k C e l - D/At
 K M V - тер!** (15.9) 
With the aid of this simple equation the average plateau concentration can 
be calculated very easily. As indicated already above no plateau will be 
reached when D/At > Q
m
. 
b. Simultaneous supply- and capacity-limited elimination. 
In this case equation 15.7 may be specified as follows: 
D^ 
At l - f + K M + C p l 
kCel c p l : 1 -
fC 2L 
K M + C p l 
kCel c pl 
Equation 15.10 can be rearranged to a quadratic equation in Cpj: 
Cpl2 + ( 
K M _ D 
1-f At(l-f)kcel ) C p l -
DKM 
At(l-0kcel 
(15.10) 
= 0 (15.11) 
This equation has two different roots, a positive one and a negative one. 
The relevant solution of course is the positive root. Equation 15.11 
appears to provide a good approximation of the actual average plateau 
concentration that is reached also after chronic oral administration. The 
equation is especially useful since it can easily be solved without the need 
of computer facilities. The validity of this approach has been confirmed by 
comparison of the data obtained with values calculated by numerical 
methods (see below). 
DISCUSSION 
When drugs are administered for a long period of time, this most 
frequently occurs via the oral route. Since it is impossible to obtain 
explicit expressions for the course of the plasma concentration in case of 
capacity-limited elimination, one cannot formulate a general integrated 
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equation for the plasma concentration after chronic oral administration 
under these circumstances. Therefore, the plasma concentration has to be 
calculated by numerical integration of the appropriate differential 
equation, which is generally valid for a one compartment model, over the 
jth interval: 
dC D , l - e ~ j A t / r a _ t / T . VCel ¿ Г ^ 7 ( 7 — ^ 6 t / r a--^C (15.12) 
where r
a
 = time constant for absorption of the oral dose 
D = dose that is given in each interval 
Δι = dosage interval 
V = (apparent) volume of distribution 
Vçei = the (concentration-dependent) clearance function 
t = time after last dose (0 < t < Δι) 
Figure 15.1 shows some examples of plasma curves simulated on basis of 
this equation. For comparative purposes the figure contains also the course 
of the plasma concentration after continuous infusion with the same dose 
flow as the oral curves. (It may be remarked that for the continuous 
infusion generally valid integrated equations for the plasma concentration 
as a function of time can be derived. The method of integration is similar 
to that given in the appendices to chapter 13 and 14.) The parameters used 
for the simulations in fig. 15.1 are in the range that we usually find for 
salicylate. From the figure it can be seen that irrespective of the dosage 
interval the plateau concentration ultimately reached is about the same 
when the total daily doses are equal. There is of course the normal diffe­
rence in the amplitude of the fluctuations in the curve; the shorter the 
dosage interval the smaller the amplitude. A more specific consequence of 
capacity-Umited elimination is the fact that in the steady state situation 
the amplitude of the oscillations is diminishing strongly with increasing 
plateau concentration, because the rate of elimination is then decreasing. 
Experimental examples of this phenomenon will be shown in the following 
chapter. For the curves of fig. 15.1 and for several others too, we calcu­
lated the average plasma concentration during the plateau situation. 
Table 15.1 gives a compilation of such values in comparison with the 
values calculated from equation 15.11. These data indicate that neither the 
dosage interval nor the absorption rate influence the average plateau con­
centration that ultimately is obtained, significantly. Furthermore the table 
illustrates convincingly the validity of the 'infusion approach': the values 
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Figure 15.1 
Simulated course of the plasma concentration in case of combined supply- and 
capacity-limited elimination when a drug (V =81, Te¡ = 3.5hr. f =0.8, 
Км= 25 mg/l) is orally administered (т
а
 = 1 hr) or infused (D/At= 125mg/hr). The 
dosage interval and consequently the degree of fluctuation is changed. See text for 
further explanation. 
TABLE 15.1 
Average plateau levels, C p | n u r n , numerically calculated on basis of equation 15.12 as 
compared with the values obtained by solving the quadratic equation 15.11 (V= 8 1, 
τ
 e
| = 3.5 hr, f = 0.8, Кщ = 25 mg/l; these parameters are in the order of magnitude 
as found for salicylate). It may be noticed that the simple infusion approach yields 
accurate estimates of C-j after chronic oral administration in these cases. 
D 
(mg) 
1000 
750 
500 
2000 
500 
250 
At 
(hr) 
8 
6 
4 
8 
8 
, num 
185.5 
185.4 
185.3 
452.0 
65.0 
C p, (eq. 15.11) 
185.3 
185.3 
185.3 
452.0 
64.6 
calculated from equation 15.11 are practically identical to those obtained 
by numerical integration of equation 15.12. This implies that for drugs 
with pharmacokinetic characteristics similar to salicylate we now have a 
simple and reliable method for calculation of plateau levels on chronic oral 
administration. Apart from the height of the plateau level, also the rate at 
which it is reached is important. Figure 15.2 gives an example of this from 
which it can be seen that the rise in the plasma concentration is somewhat 
average plasma cone (mg/l ) 
I 1 1 1 1 1 r1 
10 20 30 40 50 60 70 
t ime ( hrs) 
ñgwe 15.2 
Rate of accumulation in case of combined supply- and capacity-limited elimination. 
Parameters: V=8I,Te¡ = 3.5 hr, f= 0.8, KM = 25 mg/l, D/&t = 125 mg/hr. M is varied 
(from left to right: Δί = 8, 6 and 4 hr) and the right curve is based on continuous 
infusion. Note that the increase of the average plateau level is somewhat more rapid 
as the dosage interval increases, but that the ultimate plateau is the same. 
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faster for the longer dosage intervals. The reason for this is obvious: when 
a larger amount is administered at once the degree of saturation of the 
eliminating systems is higher. One might make use of this by administering 
a high first dose which can give rise to a practically instantaneous plateau 
level. This dosing procedure is especially effective for drugs with a largely 
capacity-limited elimination. On the other hand the saturation pheno-
menon leads to a retarded approach of the plateau level as compared to 
the case when only linear elimination occurs. In linear pharmacokinetics 
the plateau situation is reached when jAt>Tç\. When capacity-limited 
elimination prevails т
е
] is increasing with increasing plasma levels. As a 
consequence the rate at which the ultimate plateau concentration is 
reached is smaller, although the accumulation quantitatively is much more 
pronounced than in linear kinetics. 
In the figures 15.3 and 15.4 the average plateau level as a function of the 
dose and of f (the fraction of the maximal total clearance proceeding via 
average plateau cone (mg/l) 
150 
100 
•Jt ( m g / h r ) 
Figure 15.3 
Average plateau concentration as a function of the dose flow D/At, with varying 
contribution of the capacity-limited pathway (f). Note the much more than propor­
tional increase of the plateau level when going from low to high doses. Obviously the 
degree of accumulation is strongly dependent on f (see also fig. 15.4). Both the case 
with the highest degree of accumulation (repeated i.v. infections) and that with the 
lowest one (infusion) are plotted, but obviously these are hardly different for a drug 
with the parameters used for calculation (V= б l, т
е
/ = 3 hr, Км= 25 mg/l). 
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average plateau cone (mg/ l ) 
02 04 06 08 10 
Figure 15.4 f 
Average plateau concentration as a function of the contribution of the capacity-
limited pathway to the overall clearance. Note the enormous increase of the average 
level when f exceeds 0.5 (cf. legend to figure 15.3). 
capacity-limited pathways) is depicted. The shaded areas represent the 
region in which the average plateau level in case of various absorption rates 
is lying. The upper limit is based on repeated intravenous injections, the 
lower limit on continuous infusion. Numerical calculations indicate that 
usually the infusion gives the best approximation of the oral case, unless 
absorption is extremely rapid. Figure 15.3 clearly illustrates that the 
increase in the plateau level with increasing dose is much more than 
directly proportional. At high dose levels, however, there is a proportional 
increase, as discussed above in this chapter. It is obvious that the fraction f 
is a primary determinant for the degree of accumulation. This is confirmed 
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indeed by figure 15.4 which shows the enormous rise of the plateau level 
with increasing f at a constant dose. As a matter of fact the accumulation 
may proceed without an upper limit when f=l (see above). Nevertheless, as 
long as f < 1 always a plateau will be reached. It should be noticed that in 
those cases where the plateau level is extremely changing with the dose, 
also the biological availability of the drug on oral administration has 
profound influence on the plateau characteristics. 
In conclusion it appears that the simple 'infusion approach' outlined in 
this chapter provides very useful information concerning the accumulation 
of drugs that are eliminated (in part) by capacity-limited pathways. There 
are several examples of papers appearing in the literature, where the 
authors failed in describing adequately the steady state levels observed. A 
typical example can be found in the work of Lund et al. (1974) on the 
pharmacokinetics of phenytoin after multiple doses. When the procedures 
outlined in this chapter are applied to their data it appears to be easy to 
understand the observations and to predict plateau levels of phenytoin 
after chronic administration or infusion. The same holds true for studies 
on ethanol accumulation (Forney and Hughes, 1963; cf. also Levy, 1975). 
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CHAPTER 16 PHARMACOKINETICS OF SALICYLATES IN 
MAN 
A. INTRODUCTION 
In the beginning of the 19th century there was an industrious search for 
quinine substitutes. Many bark preparations with a bitter taste were tested. 
The white willow (salix alba) appeared to be a promising source of 
antipyretic preparations and in 1827 from the bark of this tree salicin 
(glycoside of salicylalcohol) was isolated by Leroux. Salicin was the star-
ting material for the synthesis of salicylic acid by Piria in 1838. Salicylic 
acid became available in large amounts when Kolbe developed his famous 
synthetic route (1860). The antipyretic effectiveness of salicylic acid was 
soon established, but its oral use had serious drawbacks because of its bad, 
bitter taste but especially because of gastro-intestinal complaints. The free 
add is very irritating to the mucosa of the gastro-intestinal tract and in 
high concentrations it even has a keratolytic effect. For the latter purpose 
it is applied externally up to today. An important improvement was the 
introduction of sodium salicylate by Buss in 1875. Sodium salicylate 
appeared to be a useful therapeutic for the treatment of rheumatic fever 
and it was successfully applied to other rheumatic diseases as well. Many 
other derivatives of salicylic acid have been prepared afterwards with the 
objective to find a more suitable and more convenient administration form 
of the pharmacologically active salicylate ion. Here we only mention one 
of these, viz. acetylsalicylic acid, introduced by Dreser in the nineties of 
the last century. Acetylsalicylic acid was found to have about equal 
antiinflammatory and antipyretic action as sodium salicylate but a much 
better general analgesic action. Ever since their development the salicy-
lates, especially sodium salicylate and acetylsalicylic acid, have been the 
drugs of choice for the treatment of inflammatory disordere. Furthermore 
acetylsalicylic acid (aspirin, which in some countries is still a trade name) 
is the active substance in numerous antipyretic and analgesic preparations, 
many of which are available without prescription. The salicylates have 
been the subject of an enormous number of studies. Many relevant aspects 
have been reviewed in comprehensive monographs (Gross and Greenberg, 
1948; Dixon et al., 1963; Smith and Smith, 1966). Since the appearance 
of these books the flow of information is still increasing. Side-effects and 
toxicity have been comprehensively reviewed by Prescott (1972). In this 
introduction shortly some important data on the metabolism and the 
pharmacokinetics of salicylic and acetylsalicylic acid will be reviewed that 
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are significant for interpreting the results of our own investigations. 
Acetylsahcyhc acid is rapidly deacetylated in man to salicylic acid, the 
half life is about 20 minutes (Rowland et al., 1967, Rowland and Riegel-
man, 1968, Rowland et al., 1972). Although acetylsahcyhc acid is unstable 
m aqueous solution it was established that on oral administration the drug 
itself is absorbed, leading to substantial plasma levels for the first hour 
after administration (see also Mandel et al., 1954, Leonards, 1962). The 
rapid deacetylation of acetylsahcyhc acid implies that only formulations 
that are very fast absorbed can be considered when the superiority as an 
analgesic of acetylsahcyhc acid over salicylic acid is aimed at. Both 
acetylsahcyhc acid and salicylic acid have a small volume of distribution 
(<10 1). Whereas the elimination of acetylsahcyhc acid appears to 
proceed exclusively by deacetylation, salicylic acid shows a more complex 
pattern. The elimination pathways are summanzed m figure 16 1, based on 
literature data (Levy et al. 1969, 1972, Tsuchiya and Levy, 1971, Bedford 
et al., 1965, Boreham and Martin, 1969, Schachter and Mams, 1958, 
0rCONHCH2COOH 
sa l icy lur ic acid 
СООС
б
НдО
б 
aCOOH с 
•он 
dicyl ¿ lucuron ide 
4OH 
salicylic a c i d ^ ^ * 
^ x X O O H 
^ - " O C f i H c O , 
phenolic ¿lucuromde 
H O ^ ^ X O O H xx 
"OH 
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- + 4 5 - 5 5 % 
-*• 7 - 1 2 % 
•+ 5 - 2 5 % 
-+ 1 5 - 2 5 % 
•* 4 3 % 
Capaci ty l i m i t e d in t h e r a p e u t i c dose range 
Figure 16 1 
Pathways of elimination of salicylic acid in man. 
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Williams, 1959). Many pharmacokinetic studies have been performed with 
salicylic acid in man and a large range of plasma halflives have been 
reported (e.g. 6 hrs: Brodie et al., 1959; 19hrs: Swintosky, 1956; 
3.5—4.5 hrs: Rowland and Riegelman, 1968). In several of the references 
mentioned the authors indicated that the kinetic behaviour of salicylate 
was apparently dose-dependent, in the sense that the rate of elimination 
was decreasing with increasing dose. As the crown on very nice thorough 
analyses of urinary excretion patterns of the metabolites of salicylic acid, 
especially by Levy and co-workers, in 1972 the effective characterization 
of salicylate elimination was accomplished (Levy et al., 1972). Two of 
the metabolic pathways appear to be capacity-limited in a therapeutic dose 
range, viz. the formation of salicyluric acid and of salicyl phenolic 
glucuronide. As demonstrated in chapter 13 (van Ginneken et al., 1974) 
also the profile of the plasma curve can be adequately described on basis 
of Michaelis-Menten kinetics. As far as the renal excretion of unchanged 
salicylate is concerned, we present evidence in this chapter that non-linear 
mechanisms are involved. In fact already in 1955 Gutman et al. indicated 
that tubular secretion must be assumed to contribute to the excretion of 
salicylate. Salicylic acid may be subject to other non-linear processes as 
well. Evidence has been given for instance for non-linear disposition of 
salicylic acid in rat brain (Gonzalez et al., 1975). Autoradiographic studies 
in mice, however, have shown that only very small amounts of salicylate 
penetrate into brain (van Ginneken and van Rossum, unpublished results). 
Salicylate crosses readily the placenta barrier, its concentration in neonatal 
plasma appeared to be even higher than in maternal plasma (see for a 
discussion of this phenomenon Garretson et al., 1975 and Levy et al., 
1975). Salicylates are mostly applied in case of joint disease and therefore 
it is interesting to note that they appear quite rapidly in the joint fluid in a 
maximum concentration about 2/3 of the plasma concentration, 
independently of the disease state, which on the other hand does influence 
the rate of appearance (Soren, 1975). 
Some authors suggested that the kidney might be responsible for an 
important part of salicylate metabolism, especially salicyluric acid forma-
tion (von Lehmann et al., 1973). However, the finding of Lowenthal et al. 
(1974), that anephric patients show a normal rate of formation of salicy-
luric acid and other metabolites seems to rule out the possibihty of renal 
metabolism. 
The present investigations were performed in order to test the several 
aspects of capacity-limited elimination as outlined in the chapters 13—15, 
both on single and multiple dosing. The main goal was to obtain quanti-
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tative insight in the accumulation characteristics of salicylate and the 
factors that are primary determinants for this. It needs not to be said that 
such information is extremely valuable tor establishing and interpreting 
dosage regimens in clinical practice. As will be discussed, plateau levels of 
salicylate are highly sensitive to changes in dose (or biological availability), 
but also to changes in the nature of the clearance function. In this respect 
the renal clearance of unchanged salicylate may be of utter importance. 
Therefore the excretion by the kidneys was studied in some detail. Also 
some biopharmaceutical aspects are included. These are specifically 
meaningful in two ways. First it has been mentioned already that for 
general analgesic aims acetylsalicylic add should be dispensed in a dosage 
form that is very rapidly absorbed. This is the more so since acetylsalicylic 
acid has much more side-effects than sodium •salicylate, so that only when 
appropriate use is made of its higher effectiveness, acetylsalicylic acid is to 
be preferred over sodium salicylate. Secondly, other biopharmaceutic 
characteristics may be desired for long term therapy of inflammatory 
conditions. In this case especially the height and the constantness of the 
plasma concentration are important features, rather than a shortlived 
peakconcen trat ion. It will be shown indeed that drug formulations, that 
are hardly useful for single dose administration, may be very suitable for 
sustaining constant plasma levels. 
B. MATERIALS AND METHODS 
Drugs 
The following dosage forms have been applied in this study: 
Sodium salicylate aqueous solution, containing sodium salicylate and 
sodium bicarbonate in a weight ratio 2:1; EnterosaUcyl® tablets (Sarein, 
France), containing 500 mg sodium salicylate (~431 mg salicylic acid) in 
an enteric coated form; Rhonal® tablets (Specia, Paris, France), containing 
500 mg acetylsalicylic acid (~385 mg salicylic acid) in the form of coated 
microcrystals; Ascal® powder (ACF Chemiefarma, Maarssen, The Nether-
lands), containing calcium acetylsalicylate corresponding with 500 mg 
acetylsalicylic acid; Salipyrin (phenazone salicylate), an equimolecular 
compound of phenazone and salicylic acid, administered as an aqueous 
suspension; Sodium benzoate solution containing sodium benzoate and 
sodium bicarbonate in a weight ratio 2:1; Be ne mid® tablets (MSD, 
Westpoint Pa, USA) containing 500 mg probenecid; D-glucuronolactone 
aqueous solution; Diuramon® tablets (ACF Chemiefarma, Maarssen, The 
Netherlands) containing 400 mg ammoniumchloride in enteric coated 
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form, Sodium bicarbonate m powder form 
Sodium salicylate, sodium benzoate and phenazone salicylate (Salipynn) 
were obtained from OPG, Utrecht, The Netherlands, D-glucuronolactone 
from Sigma, St. Louis, Mo, USA. 
Drug administration 
All participants in this study were young, male healthy volunteers (age 
20—25 years). Furthermore 4 of the subjects participating m the inves­
tigations on repeated admimstration were patients who where taking 
salicylates chronically because of rheumatic disease (patients K, Z, J and 
T V 
In the single dose expenments the subjects were fasting overnight pnor 
to and for an additional 2 hrs after drug intake. Four subjects received oral 
doses of sodium salicylate solution, Ascal®, Rhonal® and Enterosahcyl® 
m a crossover design, with intervals of one week. Four other volunteers 
took Salipynn (aqueous suspension) and equimolecular doses of sodium 
salicylate (solution) and phenazone (solution) at biweekly intervals In the 
experiments on chronic administration the subjects took a dose 3 times 
daily and in one case (subject T) 4 times daily for periods of at least one 
week. In the investigations of kinetic interactions the subjects took a single 
dose of sodium salicylate in solution (usually 750 mg) and several doses of 
the substance that was assumed to affect the kinetic behaviour of 
salicylate. The doses were planned to yield a constant plasma level of these 
substances. In case of benzoate and D glucuronolactone pilot expenments 
were performed in order to obtain insight into the pharmacokinetics of 
these substances. For probenecid sutticient data are avauable in literature 
(Dayton et al, 1963). 
In all experiments bloodsamples were taken from a fore arm vein, at 
regular times after drug administration. In most cases time and total 
volume of every aliquot of urine voided were registered and samples were 
collected for analysis. 
Preparation of samples and spectrophotofluorometric analysis 
As described in chapter 2. All concentrations were determined m terms of 
salicylic acid. 
* The kind co-operation of Prof Dr С L H Majoor (Head of the department of 
Internal Medicine, University of Nijmegen) and Dr F W J Gnbnau (departments of 
Internal Medicine and Pharmacology) is gratefully acknowledged in this connection 
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С. PLASMA CURVES AFTER SINGLE DOSE 
It has been discussed already in chapter 13 that the pharmacokinetic 
behaviour of salicylate can be described on basis of combined 
capacity-hmited and supply-limited elimination. This implies that the 
profile of the plasma curve for salicylate (assuming a one-compartment 
model) is fully defined by four fundamental kinetic parameters: the 
volume of distribution (V), the maximally obtainable total body clearance 
(kçei), the apparent Michaehs-Menten constant (Код) and the fraction that 
is eliminated by the saturable pathway (f). Figure 16.2 gives an example of 
a plasma curve together with the renal excretion of salicylate (see also 
fig. 13.5) and table 16.1 shows these parameters as they were obtained in 
several experiments. The values have been obtained by apphcation of the 
computerfit program Farmfit. All data have been handled according to a 
one-compartment model with intravenous administration. However, 
sodium salicylate was always given orally, but smce the absorption was very 
rapid as compared to the elimination the i.v. model gives a good approx­
imation. It should be remarked that the curves will deviate from what is 
found after i.v. administration since distribution is concealed under the 
absorption phase. 
TABLE 16.1 
Pharmacokinetic parameters for salicylic acid obtained after oral administration of a 
single dose of sodium salicylate in aqueous solution 
Subject1 
BA 
HA 
J Bo 
ВС 
AL 
JM 
WR 
HS 
HV 
JZ 
Dose2 
(mg) 
750 
750 
800 
750 
750 
750 
750 
770 
1150 
750 
750 
1200 
V/F 
(1) 
6 1 
86 
79 
7 7 
7 8 
8 3 
8 3 
6 0 
6 0 
7 4 
6 5 
6 6 
KM 
(mg/l) 
38 
33 
30 
37 
31 
23 
56 
26 
27 
56 
34 
31 
f 
0 77 
0 85 
0 89 
0 72 
0 84 
081 
0 78 
0 79 
0.91 
096 
0 80 
0 78 
Tel 
(hr) 
29 
31 
2 3 
4 5 
31 
27 
29 
28 
25 
29 
3 0 
31 
kCel 
(1/hr) 
21 
28 
3 4 
17 
25 
31 
29 
2.1 
24 
26 
22 
21 
Qm Or3 
(mg/hr) (%dose) 
61 
79 
91 
45 
65 
58 
127 
44 
59 
140 
59 
51 
9 4 
10 
122 
0 4 
56 
21 
53 
15.1 
15 1 
73 
133 
89 
1. all subjects male, age 21-26 yr, body weight 64-8/ Kg 
2. dose expressed as free salicybc acid 
3 Qj = amount of salicybc acid excreted in urine unchanged 
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Plasma curve and renal excretion of salicylic acid after oral administration of a dose of 
800 mg (in the form o/ a sodium salicylate solution). Note the non-linear decay of 
the plasma concentration. 
Volume of distribution 
The volume of distribution cannot be determined absolutely after oral 
administration, since the biological availability of the drug is not known. 
Comparison of our data with those of Rowland and Riegelman (1968) 
after i.v. administration suggests that the availability of the salicylate in 
aqueous solution must be nearly complete. Also comparison of the 
solution with other formulations (see below) indicates the highest biolo­
gical availability for the solution. The absorption rate of salicylate from 
the aqueous solution can be extremely high. Time constants for absorption 
have been estimated graphically and they appear to be in the range from 
0.5 to 10 minutes, in most cases not exceeding 3 minutes. The first blood 
sample usually was taken after 10 minutes and in practically all experi­
ments at that time already maximal plasma levels had been reached. Such 
high absorption rates have been discussed already in chapter IOC. Apart 
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from the factors indicated there it should be taken into account that the 
absorption of salicylate may start in the stomach already. Nevertheless the 
major part will be absorbed from the small intestine, especially when as in 
our study the drug is administered in solution and on an empty stomach. 
The volume of distribution of salicylic acid is small. The table shows values 
that all are smaller than 101, which is comparable to the values found for 
Ibuprofen (chapter 5) and alclofenac (chapter 8). This small volume of 
distribution is related to the physicochemical properties of the drug: 
salicylic acid is bound to plasma proteins for about 70% at total plasma 
levels of 50 mg/1 (Kucera and BullocK, 1969). This is substantially less 
than found for Ibuprofen, but on the other hand the lipid solubility of 
salicylic acid is lower than that of ibuprofen. These two factors seem to 
counterbalance each other so that the same distribution volumes are found 
for both drugs. As compared to alclofenac, salicylic acid is more lipophilic 
and probably more protein bound, so the situation is just the other way 
around. Salicylic acid takes an intermediate position among the three 
drugs that all have approximately the same volume of distribution. In a 
physiological sense the distribution volume will represent primarily the 
extracellular fluid. Indirect evidence for this may be found in the fact that 
after single dose experiments the concentration of salicylate in the red 
blood cells appeared to be only 1—2% of the corresponding plasma con­
centration. Interestingly in vitro much higher penetration into erythro­
cytes has been reported (Schanker et al., 1964). The reason for this 
discrepancy is not clear, especially not since in vivo the concentration in 
the erythrocytes varied proportionally with the plasma concentration, 
indicating a rapidly established distribution equilibrium. Nevertheless, the 
fact that such low erythrocyte levels are found suggests that also in other 
cells the concentration will be much lower than the plasma concentration. 
Whole body autoradiography in mice yielded results that are fully in line 
with this expectation (van Ginneken and van Rossum, unpublished data). 
The apparent Michaelis-Menten constant Код 
Код is the parameter that primarily determines whether or not the slope of 
the semilogarithmic plasma curve changes with the dose. As long as the 
plasma concentration is small as compared to Kj^ j no signs of capacity-
limitation will be visible and a slope will be obtained which corresponds 
to the case that no saturation at all occurs and the clearance is maximal. In 
view of the Код values reported in table 16.1 the ultimate time constant 
for elimination may only be determined with reasonable accuracy when 
sufficient concentration data are measured below a limit of about 20 mg/1 
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and even then computerfit will be necessary since by graphical procedures 
the endslope will always be underestimated. The Код used in the 
description of salicylate elimination is a purely operational parameter and 
not a true enzymatic constant. It has been discussed before that at least 
two saturable metabolic pathways are involved, but furthermore the renal 
excretion exhibits clearly non-linear features (see below). This implies that 
the Код in this context is a complex parameter made up by at least three 
elementary constants and their respective weights. Fortunately the three 
components have values that do not differ too much so that the combined 
parameter for all practical purposes may be regarded as a dose-independent 
constant (see also discussion in chapter 14). This is substantiated by the 
experiments in which different doses have been administered to the same 
volunteer: the Код values obtained are in no case significantly different. It 
is important to note that the Код values in table 16.1 are calculated on 
basis of salicylic acid concentrations. Of course other values would be 
obtained when the parameters were expressed on basis of another mole­
cular species (for instance sodium salicylate), the difference being a 
constant factor, correcting for differences in molecular weight. Since Код 
is derived from concentration data only, its estimation is independent of 
the volume of distribution (and the biological availability). The same holds 
true for the estimation of f, the fraction of the maximal total body 
clearance proceeding via saturable pathways. 
The fraction f 
Under normal circumstances f appears to be in the order of 0.80. Large 
variations may occur, however, in the estimation of this parameter. Since 
such variations have profound influences on the profile of the plasma 
curve but especially on the height of the plasma levels reached after 
chronic administration, it is of extreme importance to look after the fac­
tors that may alter f. From figure 16.1 it can been seen that two metabolic 
pathways are saturable at usual therapeutic dose levels, viz. formation of 
salicyluric acid and of salicyl phenolic glucuronide. It is conceivable that 
part of the variability of f is due to differences in the capacity of these two 
mechanisms. This may account for some interindividual variation but 
definitely not for the intraindividual variation. Furthermore in many cases 
f tends to be higher than the maximal contribution of these metabolic 
pathways. As indicated already it is very likely that f comprises also part 
of the renal excretion. Now the renal excretion of salicylate is a very 
complicated process (see below) but we can be sure that the fraction of 
the total amount appearing in urine that is excreted by a linear process is 
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highly dependent on urinary pH. Acidification of urine leads to a' clear 
decrease of the contribution of linear excretion and to an equally clear 
increase in f, whereas alkalinization has the opposite effect. Actually these 
changes may be drastic enough to explain most of the intrainindividual 
variations in f that are experimentally encountered. Unfortunately for the 
moment it is impossible to incorporate these factors into a generally 
applicable model for description of salicylate kinetics under variable 
urinary pH. One of the objectives of our current investigations is to find a 
relationship between f and urinary pH, that combines easy accessibility 
with sufficient predicting value. The enormous advantage of such a rela-
tionship will become clear in the discussion of plateau levels after chronic 
administration. 
fórameters describing the ultimate, linear elimination 
Table 16.1 contains also values for τ
 e
i and kçei/F. These parameters 
have the same meaning as in linear pharmacokinetics (section II). In case 
of salicylate they refer to the linear phase that is reached when the plasma 
concentration is sufficiently small with respect to the operational Код. 
Roughly speaking these parameters are the sole determinants of the plasma 
decay curve when doses of less than about 500 mg acetylsalicylic acid or 
sodium salicylate are given. It may be noted that τ
 t[ (and tío, which is 
0.69Tej) are rather small. The halflife as a rule is somewhere around 
2.S hrs, which is smaller than values that have been published in literature 
(see introduction). The explanation is obvious: when concentration data 
of salicylate are graphically analysed according to linear pharmacokinetics 
the halflife will always be overestimated, unless the concentration is 
followed for long times and to very low levels; only computerized analysis 
on basis of the appropriate non-linear model can yield adequate estimates 
of the 'true' halflife. The (maximally attainable) clearance constant kçei is 
in the same order of magnitude as found for ibuprofen and alclofenac 
(chapter S and 8). Only the phenomenon of saturable metabolism makes 
the clearance of salicylate totally different from that of these drugs. 
The capacity of the saturable pathways Qm 
When dealing with one capacity-limited pathway of elimination, the 
relevance of Q m is straightforward. Then it represents the maximal 
amount of drug that can be eliminated via that pathway. As a matter of 
fact the term 'capacity-limited' is derived from the phenomenon that in 
such a case at very high plasma concentrations a constant amount of drug 
is eliminated per unit of time, as determined by the capacity of the system 
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(Qff,). A simple, clearcut formula gives the relationship between Q
m
 and 
other parameters: 
Qm = f-KM-kCel O 6 · 1 ) 
As argued before (chapter 13) in our fitting procedure we use equations 
from which Q
m
 is eliminated by use of this equation, but of course it can 
easily be calculated from the fitted parameters. In case of salicylate Кщ is 
some kind of weighted average of individual Michaelis-Menten constants 
and f is constituted by at least three different processes. Therefore a value 
for Q
m
 calculated according to equation 16.1 (as given in table 16.1) 
cannot be interpreted in terms of single processes but is only meaningful in 
as far as it may give an impression of the total amount of drug that can be 
eliminated by all saturable processes together. 
D. RENAL EXCRETION 
The renal excretion of salicylate is strongly dependent on the pH of the 
urine (Smith et al., 1946; Williams and Leonards, 1948; Hoffman and 
Nobe, 1950; Smith and Smith, 1966; Levy and Leonards, 1971). The 
typical pictures that are obtained by plotting the apparent renal clearance 
constant versus the urinary pH are illustrated in figure 16.3. Over the pH 
traject from 5.5 to 7 the renal clearance constant shows an increase of as 
much as a factor 100. When compared with the total body clearance con­
stant of salicylate this implies that at pH5.5 about one percent of the 
clearance proceeds by renal excretion whereas at high urinary pH this 
percentage may rise up to 30. This, however, is a simplification of the 
actual behaviour since part of the elimination occurs by saturable ways. As 
a matter of fact figure 16.4 shows that the renal clearance itself is a com­
plicated concentration-dependent process. This figure gives the relation­
ship between the renal excretion rate of salicylate and the average plasma 
concentration over the interval during which the excretion rate is estimat­
ed, in one and the same individual. To avoid pH influences as far as 
possible only excretion rates at a urine pH between 5.5 and 6.0 are 
plotted, since in this range the pH dependence of the excretion is rather 
small. Obviously the graph exhibits three distinct phases, which may easily 
be explained by assuming three processes to correspond with these phases, 
viz. tubular secretion, active tubular reabsorption and glomerular filtration 
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Figure ¡6.3 
Renal clearance constant (k(y) of salicylic acid as a function of urinary pH. The renal 
clearance increases strongly with increasing pH. 
(combined with passive, pH-dependent backdiffusion). Further it has to be 
assumed that salicylate has a higher affinity (so a lower Kj) for the secre-
tion mechanism than for the reabsorption mechanism, and that the 
capacity of the active reabsorption exceeds that of the secretion substan-
tially. Under these assumptions the first rapid increase in excretion rate 
corresponds primarily with tubular secretion which is soon saturated. The 
drop in the curve represents the active reabsorption mechanism which 
becomes predominant especially after the secretion has become saturated. 
Ultimately, when both secretion and active reabsorption are saturated, 
further increase in plasma concentration leads to a proportionally increase 
in renal excretion rate. The slope of the resulting straight line then is 
determined exclusively by the linear part of the renal excretion process, so 
the sum of filtration and passive backdiffusion. From the data of 
figure 16.4 it can be derived that subject JB shows a linear renal clearance 
constant (filtration and backdiffusion) of about 0.6 ml/min at urine pH 
values of 5.5—6.0. This falls in the range that is normally encountered. The 
non-linear processes cannot be analysed quantitatively on basis of this type 
of plots. We can only estimate the difference in the capacity of the two 
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non-lmear mechanisms. It appears that the capaaty of the active reabsorp-
tion exceeds that of the secretion to the amount of 50 pig/mm (3 mg/hr). 
It is interesting to note that the possible explanation given here coincides 
with the well-known paradox effect of salicylates on une acid excretion. 
renal excretion rote ( i jg/mln) 1 
2 0 0 
150 
100-
5 0 
0 
- 5 0 -
Figure 16 4 
Renal excretion rate (at unne pH 5 5-6) of salicylic acid as a function of the corres 
ponding average plasma concentration As discussed in the text the curve indicates 
the occurrence of tubular secretion as well as active reabsorption. The curve can be 
analysed to get an impression of the relative contributions of filtration, combined 
with passive backdiffusion (Gl·) and of tubular secretion, combined with active 
reabsorption (TS + AR) Obviously the capacity of the active reabsorption 
mechanism exceeds that of the secretion mechanism. 
This paradox effect implies the phenomenon that salicylates in low doses 
inhibit uric acid excretion whereas high doses have the opposite effect. An 
attractive assumption to account for this paradox is that low doses of 
salicylate inhibit the tubular secretion of une acid, whereas only at high 
doses the active reabsorption of uric acid from the tubular unne may be 
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inhibited to such a degree that the net result is an increase in the amount 
of uric acid excreted. The type of plots as depicted in figure 16.4 seems to 
be very useful for interpreting renal clearance mechanisms and the expla-
nation we gave for the course of the graph is supported by a lot of 
previous research. Especially the elegant work of Gutman et al. (1955) on 
the mechanism of renal excretion of salicylate provides strong evidence in 
favour of the complicated excretion patterns discussed here. Gutman 
could not establish the occurrence of active reabsorption beside passive 
backdiffusion from the renal tubuli. In view of our data, however, it seems 
reasonable to assume the existence of such a mechanism. The picture of 
figure 16.4 is a very general one, at least when urinary pH is kept low 
(pH < 6.5). Similar patterns were obtained in all subjects in whom we 
renal excretion rate (¿ig/min) 1 
1000 
eoo 
600-
400-
200-
100 ' 200 ' 300 
plasma cone. ( i ig/ml ) 
Figure 16. S 
Renal excretion rate of salicylic acid as a function of plasma concentration in the 
same subject as in figure 16.4, but at higher urinary pH (6.5-7). It may be noticed 
that the relationship as seen in figure 16.4 is not seen here. See text for a discussion 
of this difference. 
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were able to measure salicylate levels and corresponding excretion rates 
over wide ranges of plasma concentration. Difficulties arise, however, 
when higher urinary pH values are involved. At increasing pH the passive 
backdiffusion of salicylate decreases strongly (figure 16.3), so that the 
linear part of the excretion process becomes increasingly important. On 
the other hand it is likely that the active mechanisms that contribute to 
the overall excretion are not or much less dependent on the pH of the 
urine. Then one might expect that the increase in the efficiency of the 
filtration process conceals the occurrence of more specific mechanisms. 
This is found indeed as exemplified in figure 16.5. The data in this figure 
are obtained in the same subject as the data in figure 16.4, but now the 
urine pH varies from 6.5 to 7.0. Clearly the data points are much more 
scattered, which is presumably caused by the fact that in this pH interval 
the pH dependence is so strong already that no uniform filtration 
efficiency is met anymore. The large variability of the renal clearance of 
salicylate under the influence of urinary pH suggests that this might be 
reflected in the plasma curve. Therefore we performed some investigations 
in which the volunteers ingested ammoniumchloride or sodiumbicarbonate 
in order to produce acid and alkaline urine respectively. The intake of the 
salts was started on the morning of the day prior to the day at which 
the experiments began and was continued throughout the course of the 
TABLE 16.2 
Effect of alkalinization or acidification of the urine (by repeated intake of sodium 
bicarbonate or ammonium chloride respectively) on the pharmacokinetics of salicylic 
acid (l.S g in the form of sodium salicylate solution) 
Treatment 
NaHCOa 
NH4CI 
ЫаНСОз 
NHÍCI 
NaHCOa 
NH4CI 
V/F 
0) 
9.0 
9.2 
7.8 
8.1 
6.8 
7.6 
KM 
(mg/l) 
48 
56 
45 
45 
28 
25 
f 
0.95 
1.00 
0.92 
1.00 
0.78 
0.92 
Tel' 
(hr) 
2.9 
3.3 
3.2 
3.4 
3.5 
4.0 
Qr2 рн;
г
, 
(% dose) 
11.1 
0.5 
21.2 
4.3 
24.0 
2.7 
6.81 
5.23 
7.18 
5.02 
7.09 
5.13 
1. т
е
і refers to the ultimate straight part of the plasma curve 
2. Qr = amount of salicylic acid that is excreted in urine unchanged 
3. pHyjav e weighted average of the pH of all urine samples produced during each 
experiment 
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experiment. The dose was 3 and 6j> daily for sodiumbicarbonate and 
ammoniumchloride respectively, divided in 6 fractions. Figure 16.6 shows 
an example of the plasma curves obtained and table 16.2 summarizes the 
relevant data and fitted parameters. Clearly the concurrent administration 
of ammoniumchloride leads to a slower elimination of salicylate from 
plasma than the bicarbonate treatment. This was to be expected on basis 
of the influence on renal excretion of unchanged salicylate. Table 16.2 
indicates that the fraction of the dose that is excreted in urine is much 
higher after sodiumbicarbonate than after ammoniumchloride. Further it 
should be noted that the apparent Код values are not different in the two 
sets of experiments, whereas f tends to increase on ammoniumchloride 
treatment. Also this is not unexpected: Код should be independent of 
passive backdiffusion mechanisms, and the fraction that is eliminated by 
capacity-limited pathways should incerease when the linear renal clearance 
decreases. The differences in f are not statistically significant because of 
piasi 
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Figure 16.6 
influence of alkalinization or acidification of the urine on the profile of the plasma 
curve of salicylic acid. Note the lower rate of élimination, when У Я4 Cl is ingested. 
See text for further details. See also table 16.2. 
270 
πα cone ( mg/l.log scale)-
sodium salicylate 
1.5 gr oral 
subj L s 
» » N a H C 0 3 
• •NhUCL 
the relatively large error in this parameter, but they are consistent and 
therefore they seem to point at real, important variations in elimination 
mechanisms. Although the shift in f at first sight may be rather small, it 
must be stressed that such differences have profound influences on the 
accumulation characteristics (see for instance figure 15.4). 
E. PHARMACOKINETIC INTERACTIONS 
The fact that the elimination process of salicylates is well-understood in 
detail suggests several interaction possibilities, both on the level of hepatic 
metabolism and on the level of renal excretion. In the following some 
investigations in this field and their possible implications are discussed. 
First it should be defined what kind of kinetic drug interactions may be 
expected. The most understandable approach is to return to the clearance 
function for a single metabolic pathway of elimination 
VCe. = Щ ^ - ( 1 3 · 8 ) 
(The same formula is applicable for tubular secretion processes) 
The equation indicates that two parameters may be modified by other 
drugs. The first is the metabolic capacity (or the tubular transport 
maximum) of the pathway. This metabolic capacity may be increased 
(with enzyme inducers such as phénobarbital etc.) or decreased (by irrevers-
ible enzyme inhibitors, uncouplers of metabolic chains, substances that 
cause tissue damage etc.). Also in various pathological situations the 
metabolic capacity will be subject to alteration. The second parameter, to 
which the further discussion will be restricted, is the apparent Michaelis-
Menten constant Код. Whereas non-competitive interactions will influence 
primarily Q
m
, all competitive interactions (between substances that are 
metabolised or transported by the same system) are reflected in K^j. When 
a second substance is introduced at a concentration I and with an apparent 
Michaelis-Menten constant Kj (I from 'inhibitor'), equation 13.8 obviously 
becomes: 
vCel = ¡ (16.2) 
This implies that any competitive inhibitor will decrease the clearance 
function, provided that its concentration is not very small with respect to 
its corresponding Kj. Clearly this effect is not limited to cases where 
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capacity-limited elimination occurs. Also when С < Код the clearance, 
which then is a concentration-independent constant, is lowered by the 
presence of an inhibitor. Actually possible signs of saturation will become 
less pronounced by the inhibitor, which causes an increased apparent Код 
value. So, whether kinetic interaction via Код takes place or not and to 
what degree, is only dependent on the ratio I/Kj of the inhibitor and not 
on the enzymatic parameters of the drug itself. In the light of these con­
siderations three different types of interaction were investigated. 
a. Benzoic acid 
Benzoic acid is known to be metabolised almost exclusively by conjuga­
tion with glycine, leading to the metabolite hippuric acid, which is extrem­
ely rapidly excreted in urine (Quick, 1931; Williams, 1959;Wuand Elliot, 
1961; Schachter, 1956; Levy, 1965). On basis of detailed analysis of renal 
excretion data the expectation that benzoic acid would inhibit competitiv­
ely the formation of salicyluric acid, the main metabolite of salicylic acid, 
has been confirmed (Levy ad Amsel, 1966; Amsel and Levy, 1969). In this 
plasma cone ( mg/l,log scale) 
100 
sodium salicylate 
+ sodium ben zoate 
750 mg oral 
sub* A L 
Figure 16.7 
Plasma curves after sodium salicylate alone and in combination with sodium ben-
zoate. Benzoate appears to inhibit the elimination o) solleviate. See text ¡or details 
and table 16.3. 
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report we demonstrate the effect of benzoic acid on the plasma curve of 
salicylic acid. The fact that benzoic acid seems to be a tool for affecting 
specifically one of the pathways of salicylate elimination is an extra 
argument in favour of this type of experiments. Of course the interaction 
of benzoic acid with salicylic acid will seldom be encountered in practice, 
since benzoate is only used as a preservative in very small doses. Never­
theless the results obtained are important from the point of view that they 
reflect in general the effects of diminishing the efficiency of glycine con­
jugation on salicylate elimination. In our experiments half an hour before 
the intake of 750 mg of salicylic acid (in the form of sodium salicylate 
solution) 1 g of benzoate in aqueous solution was ingested followed by 
250—500 mg benzoate every hour. A typical experimental result is given in 
figure 16.7, where in the same subject the plasma curves after sodium 
salicylate alone and after sodium salicylate with sodium benzoate are 
given. The inhibition of the elimination of salicylate by benzoate is clearly 
visible. Details of the dosage regimen of benzoate, together with the fitted 
values of the relevant pharmacokinetic parameters are given in table 16.3. 
TABLE 16.3 
Pharmacokinetics of salicylic acid after oral administration of a single dose of 750 mg 
(in the form of sodium salicylate solution) with and without concurrent adminis­
tration of sodium benzoate. In the benzoate trial 1000 mg of sodium benzoate in 
aqueous solution was given half an hour before and 250 mg at 1, 2, 3, 4 and 5 his 
after ingestion of the salicylate solution 
Drag' 
S 
S + B 
S 
S + B 
S 
S + B 
V/F 
0) 
7.7 
7.1 
7.8 
7.7 
7.4 
7.0 
KM 
(mg/1) 
37 
57 
31 
52 
56 
129 
f 
0.72 
0.67 
0.84 
0.84 
0.96 
l.OO 
1. S = salicyuc acid, В = benzoic acid 
2. τ
e
i refers to the ultimate straight part of the plasma curve 
3. Q
r
 = amount of salicylic acid that is excreted in urine unchanged 
4. pH
u r a v
 = weighted average of pH of all urine samples produced during each exper­
iment 
rel2 
(hr) 
4.5 
5.3 
3.1 
4.5 
2.9 
4.3 
Qr' PH'ur,; 
(% dose) 
0.4 
0.3 
5.6 
5.4 
7.3 
5.7 
5.33 
5.42 
5.78 
5.92 
7.00 
6.15 
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The most striking result is the increase in Код, which can be explained on 
basis of the fact that benzoate competes with salicylate for the mechanism 
that couples these drugs with glycine. A concomitantly prolonged time 
constant for elimination т
е
\ is observed. Further f seems to be unaffected, 
as is the case for the total percentage of salicylate excreted unchanged in 
urine. Obviously benzoate does not interfere with renal clearance. The 
results seem to be easily interpretable, but there is a strange aspect in­
volved in this matter, viz. the fact that the rate of elimination of benzoate 
is so high that one is forced to assume that soon after benzoate administra­
tion is stopped the level of this inhibitor falls down to negligible values. As 
an illustration if this figure 16.8 shows the plasma curve of benzoate after 
oral administration of sodium benzoate in solution. In this figure also the 
influence of salicylate of the benzoate curve is indicated and it may be 
noted that benzoate elimination is hardly impaired by concurrent 
administration of large doses of sodium salicylate. These curves confirm 
the observations of Amsel and Levy (1969) that the excretion rate of 
plasma cone ( m g / l , l o g scale) 
200-
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20 
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5 : 
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_ , . „ t ime (mm) 
Figure 16.8 
Plasma curves of benzoic acid after administration of sodium benzoate alone or 
together with sodium salicylate. Benzoate obviously is eliminated in a non-linear way. 
Although salicylate has some influence on the profile of the benzoate curve, it seems 
that the elimination of benzoate is hardly retarded. 
subject RN 
sodtum oenioate 3g oral 
sodium salicylate 1g oral 
sodium salicylate 2g oral 
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hippuric acid after administration of sodium benzoate is independent of 
the simultaneous presence of salicylate in plasma. This means that, al-
though salicylate is present in concentrations that are certainly higher than 
its Michaelis-Menten constant, the expected decrease of benzoate clearance 
fails to turn up. As Amsel and Levy pointed out the only logical explana-
tion is that the formation of hippurate is limited by the rate of supply of 
the co-substrate glycine, which is not the case for salicyluric acid forma-
tion. However, the question remains how it is possible that the influence 
of benzoate administration on salicylate elimination is visible even after 
benzoate has disappeared from the body (which was confirmed by benzoate 
measurements in plasma and urine and of hippurate in urine). Although 
the pharmacokinetic behaviour of benzoic acid in plasma, which we are 
currently investigating in detail, is definitely much more complex than the 
simple picture that arises from urinary excretion data, we tend to ascribe 
the prolonged influence of benzoate to a partial exhaustion of the easily 
mobilized glycine pool in the body. As a matter of fact this implies that 
the salicylate-benzoate interaction described here is only partly com-
petitive whereas after some time a more non-competitive interaction 
occurs. Preliminary calculations which we performed on such mixed inter-
action models indicate that they may lead to plasma curves that are 
formally indiscernable from a purely competitive interaction. One final 
point has to be mentioned. It is well-known that the renal clearance of 
hippuric acid involves tubular secretion. One might think of a possible 
inhibition of the secretion of salicylic acid by hippuric acid as a source of 
kinetic drug interaction. This possibility, however, can be ruled out since 
the excretion of hippurate after administration of this metaboUte itself 
shows only signs of saturation at excretion rates much higher than the 
rates that can occur in the experiments described above. Therefore we may 
assume that for the hippurate formed from benzoic acid the ratio I/K¡ is 
small enough to have no or only minor consequences for the excretion of 
salicylic acid. 
b. Probenecid 
Probenecid was developed as a drug to prolong the action of penicillin by 
retarding the elimination of this antibiotic via competition for the tubular 
secretion process (Beyer et al., 1951). Also active reabsorption processes 
are affected by probenecid as evidenced by the fact that it is an effective 
uricosuric agent (Sirota et al., 1952). Probenecid appears to be a com-
petitive inhibitor of all kinds of active transport processes and is also a 
potent inhibitor of some glycine conjugases (Beyer et al., 1950). In the 
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field of antiinflammatory drugs for instance a strong increase in the plasma 
level of indomethacin has been demonstrated after concomitant adminis­
tration of probenecid (Skieth et al., 1968; Brooks et al., 1974). As far as 
salicylate is concerned, inhibition of the tubular secretion of free salicylic 
acid has been demonstrated (Gutman et al., 1955) and also inhibition of 
salicyluric acid formation may be expected to occur. When probenecid is 
given for uricosuric purposes the concurrent administration of salicylate is 
contraindicated, since salicylate causes a decrease of the uricosuric effect 
of probenecid. The mechanism of this interaction is not exactly known 
but it might be that salicylate inhibits the tubular secretion of probenecid, 
which actually first has to be secreted into the tubuli before it can com­
pete with uric acid for the active reabsorption. On the other hand it seems 
interesting to look after the effect of probenecid on salicylate plasma 
levels and to determine which pharmacokinetic parameters (if any) change 
under the influence of probenecid. In view of the complicated patterns of 
elimination involved it is difficult to predict the net result of such inter­
action. Whereas on the one side inhibition of tubular secretion of free 
salicylate may be expected (as is the case with penicillin-antibiotics) on the 
other hand inhibition of the formation of salicyluric acid might occur. 
Also the formation of other metabolites might be reduced, since probene­
cid is known to impair the hepatic uptake of various drugs (see for in­
stance Kenwright and Levi, 1973). 
In our experiments the volunteers took single doses of 750 mg salicylic 
acid in the form of sodium salicylate solution. In the probenecid trials 
doses of 500 mg probenecid were ingested every 8 hrs over the period of 
32 hrs, starting 9 hrs before salicylate intake. On the basis of the pharma­
cokinetic behaviour of probenecid, which is essentially non-linear (Dayton 
et al., 1963), plasma levels of 25 to 50 mg/1 may be expected throughout 
the period of such a dosage schedule. The plasma curves of salicylate with 
and without probenecid treatment are illustrated by figure 16.9 and 
table 16.4 shows a compilation of the relevant data and fitted parameters. 
The increase in 7
e
j caused by probenecid is obvious, and it seems that this 
is caused by a rise of Код as well as of f. The amount of salicylate that is 
excreted unchanged seems to be diminished under the influence of 
probenecid, but this effect is not very strong. For instance it is remarkable 
that subject ВС excreted more salicylate in urine during the probenecid 
trial than during the control experiment. The reason obviously is the fact 
that the average pH of his urine during the probenecid trial was a full unit 
higher than during the control. So it seems that urinary pH has a much 
more pronounced effect on salicylate excretion than probenecid adminis-
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Influence of probenecid on the elimination of salicylic acid from plasma. Probenecid 
causes a decreased rate of elimination of salicylate. The mechanism of this inter-
ference is discussed in the text. 
TABLE 16.4 
Pharmacokinetics of salicylic acid after oral administration of 750 mg salicylic acid 
(in the form of sodium salicylate solution) with and without concurrent adminis-
tration of repeated oral doses of probenecid 
Subject 
HA 
ВС 
WR 
Drug' 
S 
S + P 
S 
S + P 
S 
S + P 
V/F 
(1) 
8.6 
8.1 
7.7 
7.2 
8.3 
7.8 
KM 
(mg/l) 
33 
65 
37 
48 
56 
88 
f 
0.85 
0.95 
0.72 
0.85 
0 78 
0.90 
' e l ' 
(hr) 
3.1 
4.6 
4.5 
4.7 
2.9 
4.8 
Qr3 PHur,av 
(% dose) 
1.0 
0.6 
0.4 
2.0 
5.3 
3.1 
5.37 
5.74 
5.33 
6.36 
5.78 
6.01 
1. S = salicylic acid, Ρ = probenecid 
2. т
е
і refers to the ultimate straight part of the curve 
3. Qr = amount of salicylic acid excreted in urine unchanged 
4· pHur.av = weighted average of pH of all urine samples during each experiment 
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tration has. Nevertheless figure 16.10 provides some evidence in favour of 
inhibition of tubular secretion of salicylate by the presence of probenecid, 
but at high salicylate levels such inhibition will hardly be appreciable and 
probably even the opposite effect (by inhibition of active reabsorption) 
will prevail. In the light of these considerations it seems unlikely that the 
increase in Код, that is observed, may be attributed to alterations in renal 
elimination characteristics. More likely the variation is caused primarily 
by interaction at the level ot biotransformation. In practice probenecid-
salicylate interaction will not be important for salicylate levels in single 
dose situations. The consequences for salicylate levels after chronic 
administration, however, may be significant in that a substantial increase 
renal excretion rate (ijg/min)-
25 
20-
15-
10 
• sodium salicylate 
Δ + probenecid 
\ ^ 
20 40 60 Θ0 100 
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Figure 16.10 
Renal excretion rate versus plasma concentration of salicylic acid administered alone, 
or concurrently with probenecid. The data suggest an inhibition of the tubular 
secretion of salicylic acid by probenecid. 
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of plateau levels may be brought about by probenecid. Experimental data 
to confirm this are not available. On the other hand it would be more 
profitable to have a drug at one's disposal that enhances salicylate elimina­
tion than one that impairs it, since constant and high plateau levels of 
salicylate can be obtained easily anyway. The following paragraph 
describes some preliminary trials we performed with a substance that 
might be expected to be of value in this respect. 
с D-glucuronolactone* 
Since conjugation with glucuronic acid is a major metabolic route for 
salicylates one might speculate about the possibility that salicylglucuro-
nides, once they have been formed, run the risk of being split again by 
(3-glucuronidase that is known to be present in liver as well as serum. When 
this would be the case, then the administration of an inhibitor of (3-glucu­
ronidase would lead to an enhanced efficiency of the glucuronidation and 
thereby to an increased rate of elimination of salicylate. Such an inhibitor 
might be useful for treatment of salicylate intoxications. 
It is known that D-glucarolactone is a potent inhibitor of j3-glucuronidase 
(Marsh, 1963) and several authors have recommended its use to reduce 
toxic effects of foreign compounds (Boyland and Williams, 1956; 
Brodersen and Hermann, 1953; Hartiala and Häkkinen, 1960). In mice oral 
glucarolactone administration has been shown to result in inhibition of 
^-glucuronidase in liver and kidney (Kiyomoto et al., 1963). Evidence has 
been reported that glucarolactone inhibits intestinal ^-glucuronidase 
thereby reducing the extent of enterohepatic circulation of drugs that are 
excreted into bile in a conjugated form (Marselos et al., 1975). 
In our study we used D-glucuronolactone, which is known to be rapidly 
absorbed and metabolized to D-glucaric acid and its lactone-form and to 
be an innocuous compound when ingested by man (Marsh, 1963). The 
levels of glucaric acid in plasma and urine were determined according to 
the method of Marsh (1963). In three male volunteers (age 20—22 years; 
body weight 71—78 kg) we determined plasma levels and urinary excretion 
of D-glucaric acid after ingestion of D-glucuronolactone in aqueous solu-
tion. The halflife for elimination from plasma was estimated to be 
2.5—4hrs and of the total dose administered 15—20% was recovered in 
* The idea for performing these preliminary investigations orginated from stimulat-
ing discussions with Dr. P.Th. Henderson and Dr. W.R.F. Notten, whose kind co-
operation is gratefully acknowledged. The significance of the glucuronic acid system 
in drug elimination has been discussed for instance by Aarts (1968) and Notten 
(1975). 
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urine in the form of D-glucaric acid. A 2 g dose of D-glucuronolactone 
gives rise to peak levels of D-glucaric acid in plasma within 1 hr 
(15—20 mg/1, corrected for glucaric acid levels in control periods which 
vary from 2—5 me/1). On the basis of these data a dosage regimen for 
D-glucuronolactone was adopted consisting of a first dose of 2 g, after 
1.5 hrs followed by a dose of 0.5 g, which then was repeated every hour. 
In the two volunteers participating in the glucuronolactone-salicylate trial, 
this dosage schedule led to reasonably constant plasma levels of D glucaric 
acid (25-35 mg/1). Salicylic acid (750 mg in the form of sodium salicylate 
solution) was ingested 0.5 hr after the first dose of D-glucuronolactone. 
Table 16.5 gives the results of the comparative pharmacokinetics of sali­
cylate alone and in combination with D-glucuronolactone treatment. 
Although these data should be regarded with due reserve, since only two 
cases have been studied, the outcome of the trials is not encouraging in the 
sense that D-glucuronolactone hardly seems to influence the elimination of 
salicylate. The results are even contrary to what might be expected. For 
instance the fact that we measured an increase in the amount of salicylate 
which is excreted unchanged cannot be reconciled with the expectations 
expressed above. An attractive hypothesis would be that D-glucaric acid, 
like glucose and uric acid, is actively reabsorbed from urine and competes 
with salicylic acid for this reabsorption mechanism. However, no direct 
indications at all can be found for such a mechanism. When the renal 
excretion rate of glucaric acid is plotted against the plasma concentration 
TABLE 16.5 
Pharmacokinetics of salicylic acid after oral administration of a single dose of 750 mg 
salicylic acid (in the form of a sodium salicylate solution) alone and together with 
D-glucuronolactone (repeatedly) 
Subject 
HA 
JM 
Drug1 
S 
S + C 
S 
S + G 
V/F 
(1) 
8.6 
8.3 
8.3 
8.1 
KM 
(mg/1) 
33 
30 
23 
29 
f 
0.85 
0.88 
0.81 
0.76 
xel2 
(hr) 
3.1 
3.2 
2.7 
3.1 
Qr3 PHur,av 
(% dose) 
1.0 
3.2 
2.1 
4.5 
5.37 
5.80 
6.02 
5.97 
1. S = salicylic acid, G = D-glucuronolactone 
2. т
е
і refers to ultimate straight part of the curve 
3. Q
r
 = amount of salicylic acid excreted in urine unchanged 
4. рНцг av « weighted average of pH of all urine samples during each experiment 
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(figure 16.11 ; derived from a typical control experiment where only glucu-
ronolactone and no salicylate is administered), there appears to be no need 
at all for assuming more than purely linear excretion. In conclusion, these 
preliminary investigations suggest that D-glucuronolactone will not be use­
ful for treatment of salicylate intoxications. No significant influence on 
plateau levels of salicylate can be expected, but if any alteration at all 
would occur this presumably would consist of an increase in the level. 
Nevertheless, in view of the literature data mentioned above, studies in 
man on the interaction of glucuronolactone (or glucarolactone) with other 
drugs that are largely glucuronidated seem to be very worthwhile. 
renal e x c r e t i o n r a t e ( m g / m m ) -
2 0 
1.5 
1.0 
0.5-
Ί 
D-glucan'c acid 
subj R Ρ 
10 15 20 
plasma cone ( m g / l ) 
Figure 16.11 
Renal excretion rate of D-glucaric acid as a function of its plasma concentration, 
after oral administration of D-glucuronolactone. The excretion seems to be a purely 
linear process. See text for further details. 
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F. SOME BIOPHARMACEUTICAL ASPECTS 
a. Ascal®, Rhonal®, Enterosalicyl® and sodium salicylate-sodium-
bicarbonate solution. 
For evaluation of analgesic therapy in both acute and chronic situations, 
controlled pharmacokinetic studies may provide important background 
information especially when different pharmaceutical formulations of the 
same drug have to be compared. In this connection we studied in 4 volun-
teers the profile of the plasma curves obtained after single dose adminis-
tration of sodium salicylatf; in the form of solution and in the form of 
enteric coated tablet (Enterosalicyl®) and of acetylsalicylic acid in the 
form of a solution of its water soluble calcium salt (Ascal®) and in the 
form of coated microcrystals (Rhonal®). These formulations are exten-
sively used in the Netherlands. Figure 16.12 gives an illustrative example 
of the plasma curves obtained. Figure 16.13 shows the ranges in which all 
individual curves for the various preparations are lying and table 16.6 con-
tains some indices of the rate and degree of absorption of the four 
products. It should be noted that in case of acetylsalicylic acid containing 
products not the level of the drug itself but only that of its sole metabolite 
plasma cone (mg/ l , log scale) 
100 
sodium salicylate 
500 mg 
subj A R 
acetylsalicylic acid 
5 0 0 mg 
subj. AR 
Figure 16.12 
Comparison of pb'·-'!.· levels o¡ salicylate after oral administration o] two acetyl-
salicylic acid preparations (Rhonal® and Ascal®) and two salicylic acid preparations 
(Enterosalicyl® and sodium salicylate solution) to the same individual. Note that the 
absorption of the aqueous dosage forms is more rapid than that of the tablets. 
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plasma cone (mg / ! ; l og scale) 
Cf. figure 16.12. In this figure the ranges are indicated in which all concentration 
data of 4 subjects are situated. The differences in absorption rate seen in figure 16.12 
are confirmed by these ranges. 
salicylic acid is measured. Nevertheless, this gives useful information on 
the absorption process, in view of the facts that acetylsalicylic acid, which 
is absorbed as such (see introduction), is rapidly deacetylated to salicylic 
add and that all salicylic acid measured must originate from the acetyl-
salicylic acid administered. Therefore we may conclude that absorption 
from Ascal® proceeds definitely faster than from Rhonal®. Because 
acetylsalicylic avid is quickly deacetylated to salicylic acid, which is much 
less effective as an analgesic, we tend to conclude that for general analgesic 
purposes Ascal® should be preferred over Rhonal®. The result of this 
comparison is not very surprising since Leonards (1963) convincingly 
demonstrated that the rate of gastro-intestinal absorption of acetylsalicylic 
acid is markedly increased when water soluble derivatives are applied. 
However, also the degree of gastro-intestinal disturbances of the various 
acetylsalicylic acid formulations should be taken into account. Especially 
gastro-intestinal bleeding is a well-known risk of acetylsalicylic acid 
(Salter, 1968), the degree of which is strongly dependent on the pharma-
ceutical formulation (Wood et al., 1962; Stubbé et al., 1962; Györy and 
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TABLE 16 6 
Time and concentration of the plasmapeak of salicylic acid, obtained after oral admin 
istration of 4 different salicylate preparations 
Subject1 
HF 
VF 
AR 
HR 
Drug2 
Sa sol 
hnterosalicyl® 
Ascal® 
Rhonal® 
SA sol 
Enterosahcyl® 
Ascal® 
Rhonal® 
SA sol 
bnterosalicyl® 
Ascal® 
Rhonal® 
SA sol 
Enterosalicyl® 
Ascal® 
Rhonal® 
ι
 3 
'max 
(hr) 
10 
65 
10 
20 
< 05 
85 
20 
38 
< 05 
85 
1 1 
38 
< 05 
81 
09 
38 
С
 3 
'-max 
(mg/1) 
52 2 
34 3 
59 8 
32 0 
51 55 
310 
48 4 
35 5 
55 60 
20 0 
42 4 
35 5 
43 50 
29 0 
40 1 
38 0 
t'/ì 
(hr) 
27 
24 
21 
30 
1 all subjects male, age 19-24 
2 SA sol = sodium salicylate solution The salicylic acid content of the formulations 
is SA sol 385 mg, Ascal® 385 mg, Rhonal® 385 mg, Enterosahcyl® 431 mg 
3 t m a x and Cmax refer to the highest measured concentration 
Stiel, 1968, Frenkel et al., 1968, Leonards and Levy, 1967, 1969, 1972 
and 1973) It appears that enteric coated formulations have the lowest nsk 
of inducing blood loss but since these usually are quite slowly absorbed 
their analgesic effectiveness is questionable. Fortunately also the water 
soluble preparations especially when these are highly buffered are reason-
ably safe. Therefore these seem to be the most appropriate dosage forms 
to obtain acute analgesia (for instance buffered effervescent preparations) 
Also the kinetic comparison of the two dosage forms, containing sodium 
salicylate comes up to the patterns expected. The solution leads to 
maximal plasma levels of salicylate usually within half an hour whereas the 
enteric coated tablets give these maxima only after 6 5 to 8 5 hrs. These 
last maxima inevitably are lower than those obtained after ingestion of the 
solution On the other hand it should be noticed that from 5—6 hrs after 
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intake the plasma level obtained from Entcrosalicyl® exceeds that from 
the solution substantially. Here we touch an important point with regard 
to the evaluation of the two drug formulations. Since sodium salicylate is 
not suitable for general analgesic purposes, but only for treatment of 
inflammatory disorders, it is very questionable if high peak levels (of short 
duration) are of any advantage at all. More likely constant levels, lasting 
for long periods of time, should be preferred. Furthermore antiinflam-
matory therapy as a rule implies protracted administration of large amounts 
of drug. It is very well conceivable that in such a situation a dosage form 
from which the active substance is slowly released is more satisfactory 
than a solution. As far as the gastro-intestinal side-effects are concerned, 
the pharmaceutical formulation is less critical in case of sodium salicylate 
than in case of acetylsalicylic acid. Gastro-intestinal blood loss after 
sodium salicylate is much less significant than after acetylsalicylic acid and 
is often not observed at all (see references cited above). Especially enteric 
coated tablets can be regarded as safe in this respect. Blood levels on 
chronic administration will be discussed in the following part of this 
chapter (16 G). Our data do not allow definite statements on the bio-
logical availability of the four products under investigation. Nevertheless 
the biological availability of the aqueous solutions (Ascal® and sodium 
salicylate solution) must be practically complete in view of the height of 
the peak levels obtained and the apparent volume of distribution that may 
be derived (4.5-6.5 1). Complete availability of acetylsalicylic acid from 
aqueous solution has been confirmed by Rowland et al. (1972), who also 
showed that this does not imply that the total dose of acetylsalicylic acid 
reaches the general circulation intact (Rowland estimated the fraction that 
was deacetylated before passage into the general circulation at 30%). 
Under the assumption of constant pharmacokinetic behaviour within the 
same individual over the whole period of experimentation (1 month), in 
our study the average bioavailability of Rhonal® and Entcrosalicyl® may 
be estimated at 85% of that of the corresponding water soluble formula-
tions. The difference, however, is not statistically significant. Finally, it 
should be mentioned that the general characteristics, that we considered 
here as determining the absorption process of salicylates, appear to be 
valid in many similar comparative studies (see for instance Bell et al., 
1966; Pütter and Bauer, 1970; Graham and Rowland, 1972; Hollister, 
1972; Frislid et al., 1972). 
b. Salipyrin 
Salipyrin (phenazone salicylate) is a complex molecular compound 
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of phenazone and salicylic acid. It is not a salt, the carboxvlic function 
of salicylic acid is not neutralized (Huckel, 1962). In the Netherlands 
salipyrin is quite extensively used as a weak antipyretic analgesic for the 
relief of less severe types of pain and fever. Although salipyrin should be 
regarded as an administration form of phenazone rather than of salicylic 
acid, we report the results of our investigations into the kinetic behaviour 
of this drug in this chapter since we were primarily interested in the factors 
that modify the absorption characteristics of salicylate. (It must be 
stressed that in view of the large difference in the rate of elimination 
between salicylate and phenazone, salipyrin can never be a suitable dosage 
form for chronic administration of salicylate). This study consisted of the 
administration of three different preparations to four volunteers: 1 g sali­
pyrin in aqueous suspension and equimolar doses of sodium salicylate 
and phenazone in aqueous solution. Figure 16.14 shows an illustrative 
example of the plasma curves obtained in tne same individual after each of 
the three formulations. Table 16.7 gives some relevant pharmacokinetic 
data for all volunteers. Our data reveal no difference between biological 
plasmo cone. ( mg/l : log scole) 
100 
salipyrin 1000mg oral ( · and · ) 
Phenazone 577 mg oral A 
sodium salicylate 490 mg oral Δ 
subj WD 
30 
time ( Mrs) 
Figure 16.14 
Plasma curves of salicylic acid and phenazone after administration of 1 g salipyrin as 
compared with plasma curves after each drug separately in equimolar doses. It may 
be noted that the curves for salicylic acid are practically the same, whereas for 
phenazone the plasma levels differ markedly. This phenomenon is discussed in detail 
in the text. 
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TABLb 16 7 
Pharmacokinetic parameters obtained for salicylic acid and phcnazone alter oral 
administration of 1 g salipynn (SAP) as aqueous suspension and of equimolar amounts 
of sodium sabcylate (SA) or phenazone (P) in aqueous solution 
Subject1 
GB 
WD 
MR 
JS 
Drug 
V/F 
(1) 
SAP 7 6 
SA 7 5 
Ρ 
SAP 7 S 
SA 7 7 
Ρ 
SAP 6 9 
SA 6 9 
Ρ 
SAP 7 0 
SA 7 0 
Ρ 
Salicylic acid2 
kCe|/F 
(ml/min) 
42 
41 
36 
37 
36 
36 
33 
33 
T
el 
(ht) 
30 
3 0 
35 
35 
32 
32 
36 
36 
Ій 
Oir) 
21 
21 
24 
24 
22 
22 
25 
25 
'max 
(hr) 
1 50 
0 75 
125 
< 0 25 
1 25 
< 0 25 
175 
0 75 
V/F 
(1) 
67 
45 
70 
50 
47 
47 
56 
47 
Phenazone 
kCe|/F 
(mi/min) 
84 
32 
43 
31 
50 
50 
49 
42 
T
el 
(hr) 
134 
23 5 
27 1 
27 I 
156 
156 
190 
19 0 
M 
(hr) 
9 3 
163 
188 
188 
108 
108 
132 
132 
'max 
(hr) 
0 75 
100 
100 
100 
100 
0 50 
1 50 
< 0 25 
1 all subjects male, age 20-23 yi, body weight 69-77 kg 
2 parameters calculated on basis of free salicylic acid, assuming linear pharmaco­
kinetics 
availability of salicylic acid from aqueous sodium salicylate solution and 
that from sahpyrin. The only difference appears to be that maximal 
plasma levels are more rapidly reached after mgpstion of the sodium sali­
cylate solution and that these accordingly are somewhat higher than after 
salipynn. A different result anses with regard to phenazone. Here it is not 
so much a time shift in the peak concentration, but a difference in bio­
logical availability that is predominant. In three of the four subjects the 
biological availability of phenazone from salipynn was lower than from 
aqueous phenazone solution, the ratios being 0 85, 0 67 and 0 71 In the 
fourth person no difference was observed. It may be noted that these data 
strongly support the idea that salipynn is split into its components already 
in the gastro-mtestmal tract. The pattern of elimination is remarkably 
constant in all cases, except the elimination of phenazone in subject В 
The enormous variation in the rate of elimination of phenazone in this 
subject (in two weeks time) is totally inexplicable and contrary to the 
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common experience of a very constant kinetic behaviour of phenazone 
(see chapter 10). No attempts were made to characterize the metabolic 
pattern of the subject under consideration in more detail. From a pharma-
cokinetic point of view, the data presented do not provide a rational basis 
for the use of salipyrin as a dosage form of phenazone (or salicylate). Asa 
matter of fact a discouragement of its use would be more justified. On the 
other hand it cannot be excluded that the specific combination as present 
in salipyrin may have beneficial effects in some cases or that it may be 
better tolerated than its components separately by some patients. 
G. REPEATED ADMINISTRATION 
For the treatment of various rheumatic diseases plasma levels of salicylate 
as high as 300 mg/1 are required. These levels are only slightly below the 
level at which centrally mediated side-effects become predominant (see for 
instance Goodman and Gillman, 1970). Since the plasma concentration 
has to be maintained at this slightly subtoxic level for long periods of time, 
the pharmacokinetic behaviour of salicylate on chronic administration 
deserves special attention. In chapter 15 the pharmacokinetic theory of 
the consequences of capacity-limited elimination for chronic drug adminis-
tration has been outlined. Paulus et al. (1971) reported a three-fold in-
crease in plasma sáicylate level after increasing the daily dose of acetyl-
salicylic acid from 65 to 100 mg per kg body weight. Levy and Tsuchiya 
(1972) presented some numerical calculations in order to account for this 
phenomenon. Obviously a qualitative explanation is very simple on basis 
of the capacity-limited features of salicylate elimination. It is likely, how-
ever, that generalized quantitative predictions will be impossible in view of 
the large interindividual variation in the kinetics of salicylate metabolism 
(Gibson et al., 1975; Gupta et al., 1975). In this paragraph we report 
experimental data to illustrate the theory and we will discuss these data 
with special reference to the simple infusion-approach that we proposed in 
chapter 15. 
a. Relationship between dose and plateau level of salicylate 
Figure 16.15 shows the profile of the plasma concentration curve over a 
8 hr dosage interval at a dose of 1 g sodium salicylate (in solution) in a 
steady state situation and the change that is brought about by diminishing 
the dose per interval to 0.5 g. When the average plateau concentration over 
the dosage interval is estimated, these turn out to 142—29 and 109—27 for 
the subjects К and Ζ respectively. So in these cases doubling of the dose 
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plasma cone (mg/l;log scale) 
200-
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200 
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Fîgwe 16.15 
Plasma levels of salicylate over a dosage interval (8 hrsj in plateau situations after a 
daily dose of 3 g (left) and the change that is brought about by halving the dose 
(right). The difference in the average plateau concentration is as much as a factor 
4-5, whereas in linear pharmacokinetics a factor 2 would be expected. 
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results in a 4- to S-fold increase in average steady state level. On basis of 
equation 15.10 it is possible to estimate the values of both Код and f when 
the average plateau levels at two different dosage regimens are measured, 
provided that the maximally attainable total body clearance constant код 
is known. From the profile of the plasma curve during the 0.5 g dosage 
regimen an estimate of код can be made, for the subjects К and Z, 
although the estimates probably will be too low in view of the clear signs 
of non-linear behaviour of the plasma concentration. Assuming that код is 
in the order of 3 l/hr, Код may be estimated at about 50 mg/1 for both 
subjects К and Ζ with f being near to unity. These values seem to be in a 
quite normal range. However, the estimation is very much dependent on 
the average plasma level at the low dosage regimen and it can easily be 
derived that small variations in this average level will profoundly influence 
the calculated Код and f values. More reliable estimates can be made when 
equation 15.10 is applied to experimental data in which higher doses have 
been administered. Table 16.8 shows the average plateau concentrations 
reached in a volunteer who took 0.75 g salicylic acid (as sodium salicylate 
solution) three times daily for a week, followed by three times daily 1 g 
for another week. After the last 1 g dose the decay of the plasma curve 
was followed for 30 hrs in order to be able to calculate the metabolic and 
kinetic parameters. These parameters are also given in table 16.8, together 
with the Код and f value estimated from the average plateau levels accord­
ing to equation 15.10 and using код = 2.4 l/hr. The values for Код and f 
that are calculated by these two procedures agree reasonably well. It 
should be noticed, however, that especially the magnitude of f is very 
critical with regard to the accumulation characteristics (see also 
chapter 15). This implies that only when f could be estimated with high 
precision, predictions may be made concerning the height of the plateau 
TABLE 16.8 
Average plateau concentration (Cpi) in a subject (JBi) who took 750 mg salicylic acid 
three times daily for a week and then a dose of 1000 mg for another week. After the 
last dose the plasma curve was followed and the parameters were calculated. See text 
for further explanation 
D/Ät Cpi KM(mg/l)andf KM (mg/l) and f 
(mg/hr) (mg/l) estimated on basis obtained after last 
of Cpi dose 
750/8 98 KM = 2 5 KM = 38 ± 60% 
1000/8 149 f = 0.76 f = 0.80± 20% 
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level. Unfortunately fis not a constant within one individual. Already in 
part D of this chapter it has been shown that f is very sensitive to changes 
in urinary pH. As a consequence the plateau levels of salicylate during 
chronic therapy are highly dependent on the pH of the urine. An increase 
in this pH will lead inevitably to a decrease in f and decrease in steady 
state plasma level. This phenomenon has been observed by Levy and 
Leonards (1971) and Levy et al., (1975), and is very important for chronic 
therapy. On the one side a slight decrease in the pH of the urine may cause 
toxic plasma levels in a patient on a dosage regimen which first yielded 
therapeutic and subtoxic levels. On the other hand an increase in urinary 
pH may change a dosage regimen from adequately therapeutic into insuf-
ficient. For instance the concomitant use of antacids may have profound 
influence (Gibaldi et al., 1974; Levy et al., 1975). Further alkalinization of 
urine is an important therapeutic measure for the treatment of salicylate 
intoxication (see for instance Morgan and Polak, 1971; Hill, 1973; Bender, 
1975). Infusion of sodiumbicarbonate may enhance the elimination of 
salicylate very effectively, especially in case of very high plasma levels. 
The importance of fluctuations in urine pH, even in relatively short-term 
experiments may be illustrated by figure 16.16 where the plasma curvéis 
depicted as it was obtained in a subject (JBo) after administration of 1 g 
salicylic acid (as sodium salicylate solution) three times daily for 9 days. 
After the last dose again the plasma curve was followed for 24 hrs. The 
average plateau level was about 160 mg/1. In the right part of the figure the 
drawn line represents the result of the curve fitting procedure and the 
parameters are given. When on basis of the fitted parametere the theoreti-
cal mean plateau concentration is calculated (top of right axis) it appears 
that the measured plateau concentration corresponds to an f value of 
about 0.85, whereas the curve on day 10 revealed an f value of 0.97. This 
appears to be the consequence of differences in urinary pH on day 10 
when no further sodiumbicarbonate was ingested, and the days before, 
when sodiumbicarbonate was present in the solution that was taken. 
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Figure 16.16 
Repeated administration of 1 g salicylic acid three times daily. The line in the ¡eft 
part connects plasma concentrations measured just before intake of the following 
dose. Theoretical plateau concentrations for various f values are given (top of right 
axis). The average plateau level measured corresponds with an f value of about 0.85, 
whereas the curve after the last dose reveals an f value of 0.97. This difference is 
probably related to Donations in the pHofthe urine, as discussed in the text. 
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Biopharmaceutical aspects 
Figure 16.16 points at the significance of the dosage form for the 
accumulation characteristics of salicylate. This significance is substantiated 
by fig 16.17 and table 16.9. Figure 16 17 illustrates the difference m 
steady state levels measured in a female patient who was taking 1.5 g 
sodium salicylate (1.3 g salicylic acid) 4 times daily, first in the form of 
Enterosahcyl® tablets and after some weeks m the form of a bicarbonate 
containing aqueous solution. Whereas in case of Enterosahcyl® administra­
tion very constant plateau levels of about 390 mg/1 are reached, the levels 
after salicylate solution are much more fluctuating and much lower (aver­
aging around 220 mg/1). The fluctuating levels in the last case may be 
explained partly by a more rapid absorption of salicylate from the solution 
but will be associated with the non-linear kinetic behaviour of salicylate as 
well. Obviously the capacity-limitation implies a decrease in the rate of 
elimination with increasing plasma levels, so that the plasma curve over 
each interval will exhibit less fluctuation, as the level rises. 
piasrr 
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Figure 16 17 
Plasma levels of salicylic acid in a female subject after chrome administration of 1 5 g 
sodium salicylate 4 dd in the form of enteric coated tablets (left) and aqueous 
solution (right). Different symbols refer to different measuring periods for each form 
Obviously the plateau is reached It is remarkable that the same dose of sodium 
salicylate gives much lower plasma levels when administered as a solution than when 
administered as enteric coated tablets See text for details 
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TABLE 16.9 
Biopharmaceutical aspects of chronic salicylate administration. The drugs were 
administered in equal dosages per interval 
Subject Dosage from 
solution 
Enterosalicyl® 
solution 
Enterosalicyl18 
RhonaJ® 
solution 
Rhonal® 
Daily dose1 
(g) 
5.2 
5.2 
2.6 
2.6 
2.3 
2.6 
2.3 
ΔΙ2 
(hr) 
6 
6 
8 
8 
8 
8 
8 
Cpl3 
(mg/I) 
220 
390 
80 
175 
130 
75 
95 
1. dose expressed in g free salicylic acid 
2. At = dosage interval 
3. Cpi e average plateau concentration of salicylic acid in plasma 
Table 16.9 summarizes some data on the magnitude of the accumulation 
plateau that is obtained on chronic administration of various dosage forms 
of salicylate. As far as salicylate levels are concerned Rhonal® and Entero­
salicyl® seem to be equivalent at least in the few measurements we did. 
Although the average plateau level usually is lower for Rhonal® than for 
Enterosalicyl® the difference can be fully accounted for by the fact that 
Rhonal® contains a lower dose when expressed as salicylic acid (385 mg 
and 431 mg for Rhonal® and Enterosalicyl® respectively). In any case the 
solution is clearly inferior. In view of the non-linear pharmacokinetics of 
salicylate the difference will become more pronounced with increasing 
daily dose. The relatively low salicylate levels that are encountered with 
the solution most probably are caused by the addition of sodiumbicar-
bonate to the solution as argued before. 
The data presented in this paragraph stress the importance of pharma­
ceutical formulation and possible comedication for the evaluation of 
dosage regimens of salicylate, needed for adequate antiinflammatory 
therapy. Our analysis indicates that there are some possibilities for predict­
ing levels after chronic medication but it also points at some weak aspects 
of the theoretical approach, with special reference to the uncertainty of 
urinary pH. Although explanation of the findings afterwards is reasonably 
successful the predictive value is limited in view of inter- and intra-
individual variables that cannot easily be incorporated into a general 
theoretical approach. 
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CHAPTER 17 SUMMARY OF SECTION III 
Pharmacokinetics is the study of the behaviour of drugs in man or animals. 
It includes the kinetic processes of diffusion in and out various compart-
ments, with elimination usually assumed to occur from a central compart-
ment. In general, all kinetic processes are assumed to be first order, so 
that the rate of drug transfer is supposed to be directly proportional to the 
drug concentration in the compartments. The kinetic processes may then 
adequately be described by a set of linear differential equations (linear 
pharmacokinetics, section II). 
In drug elimination, however, there are several processes involved, which 
are in principle saturable (e.g. metabolic transformation and renal tubular 
secretion). Such processes can be expected to lead to deviations from 
first-order pharmacokinetics. Non-linear pharmacokinetics which is the 
topic of section III deals with all processes that cause deviations from 
first-order behaviour. There are, however, only a few mechanisms for 
which a better mathematical description than the first-order approx-
imation is possible. 
In chapter 13 the pharmacokinetic behaviour of foreign substances that 
are completely or partially eliminated via metabolism by saturable enzyme 
systems is analysed. General integrated equations are derived which describe 
the time course of the plasma concentration under the assumption of a 
saturable enzyme system according to Michaelis-Menten kinetics in com-
bination with normal first-order elimination processes. A procedure for the 
estimation of initial values of the elementary kinetic parameters on the 
basis of the models is outlined. These initial values have been used in a 
non-linear curve-fitting program in order to obtain reliable kinetic and 
enzyme parameters from the plasma curves. With these methods, kinetic 
and apparent enzyme parameters are calculated for ethanol, salicylic acid, 
4-hydroxybutyric acid and phenytoin. The same methods were applied for 
the analysis of 4-aminophenazone data in chapter 10 (section II). In 
chapter 13 also the analogy between the mathematical description of 
saturable metabolism and that of tubular secretion is discussed. Further it 
is indicated that the influence of protein binding on the apparent total 
body clearance is opposite to what is found in case of Michaelis-Menten 
kinetics, so that in some cases capacity-limited pharmacokinetics might be 
concealed by protein binding. 
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In chapter 14 the mathematics of the simultaneous occurrence of two 
capacity-limited pathways is outlined. Since for several drugs (salicylic 
acid, ethanol) it is known that at least two potentially saturated metabolic 
pathways are involved such a theoretical discussion is relevant in order to 
find out if, despite of the two combined mechanisms, the mathematical 
description of chapter 13 may be applied. The answer is positive as far as 
salicylic acid is concerned. It is argued that in most cases it is impossible to 
discriminate the two pathways on basis of plasma curves alone and that 
the pooling of the two routes leads to reasonably constant operational 
enzyme parameters, certainly for salicylic acid. 
Chapter 15 deals with the consequences of capacity-limited elimination for 
drug accumulation. Obviously the fact that the rate of elimination of drug 
decreases at increasing plasma concentrations causes a disproportionately 
high accumulation of the drug with increasing dose. This phenomenon is 
very important in practice for instance for phenytoin and salicylates. Simple 
formulas are presented for calculating the average plateau level that can be 
expected when these drugs are administered in a fixed dosage regimen for 
long periods of time. 
Chapter 16 is devoted to several aspects of the pharmacokinetics and 
biopharmaceutics of salicylates in man. The profile of the plasma curve of 
salicylic acid after single doses is concentration-dependent and can be 
characterized according to the methods of chapter 13. The volume of 
distribution is in the same order of magnitude as found for Ibuprofen and 
alclofenac; also the clearance at low doses is comparable to that of these 
drugs. At higher doses, however, the clearance decreases by partial satura-
tion of the enzyme systems responsible for elimination of salicylic acid. 
The factors involved in these processes are discussed in detail. Evidence is 
presented to support the view that also the renal clearance of salicylic acid 
is essentially non-linear. As a matter of fact indications are found for the 
occurrence of tubular secretion as well as active tubular reabsorption. 
This complex renal clearance provides insight in the mechanism of the 
so-called paradox effect of salicylates on uric acid excretion. The excretion 
of unchanged salicylic acid in urine is highly pH dependent. Alkalinization 
of the urine (by administration of sodium bicarbonate) causes a higher 
renal clearance of unchanged salicylic acid and therby less metabolic trans-
formation. This implies that the influence of capacity-limited elimination 
becomes less pronounced. Acidification of the urine (by administering 
ammonium chloride) has the opposite effect. Some paragraphs of 
chapter 16 deal with pharmacokinetic interactions of salicylic acid with 
substances suspected to alter salicylate disposition: benzoic acid, 
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probenecid and D-glucuronolactone. Benzoic acid appears to inhibit the 
metabolism of salicylic acid both competitively and non-competitively. 
Probenecid has an influence on the renal excretion of salicylic acid as well 
as on the metabolism. D-glucuronolactone appears to enhance the renal 
excretion of unchanged salicylic acid, whereas we expected an increase of 
the amount of salicylic acid excreted as glucuronide. 
Further experiments are described on the non-linear kinetics after 
chronic administration of salicylates. It was found for instance that doubl-
ing of the daily dose of sodium salicylate from 1.5 to 3 g led to a four- to 
five-fold increase in the average plasma plateau concentration. Obviously 
such an increase cannot be explained on the basis of linear kinetics, but it 
fits very well within the model of capacity-limited elimination. 
Also some biopharmaceutical aspects were studied. Plasma curves were 
compared after single administration of 500 mg sodium salicylate as a 
solution (containing sodium bicarbonate) and as enteric coated tablet 
(Enterosalicyl®). The absorption from the solution was much faster than 
from the tablets and the biological availability tended to be somewhat 
higher. However, after chronic ingestion of equal doses plateau concentra-
tions were much higher for the tablet form than for the solution. Most 
likely this phenomenon has to be explained by the fact that in the solution 
(and not in the tablets) sodium bicarbonate is present, which increases the 
renal excretion of unchanged salicylic acid, thereby reducing the fraction 
that is metabolized by capacity-limited systems. In chronic dosage 
regimens Rhonal®, which is a formulation of acetylsalicylic acid (coated 
microcrystals), has the same characteristics as the enteric coated tablets, at 
least when the difference in salicylic acid content is taken into account. 
In single dose situations two acetylsalicylic acid formulations were com-
pared: Ascal®, the water soluble calcium acetylsalicylate, and Rhonal®. As 
expected, the water soluble form was more rapidly absorbed and it is 
stated that for acute analgesia only water soluble acetylsalicylic acid 
preparations should be used since only these may provide effective plasma 
levels of the analgetically superior acetylsalicylic acid, whereas less rapidly 
absorbed dosage forms are only salicylic acid formulations with a higher 
risk of side-effects than sodium salicylate itself. Finally the drug salipyrin, a 
molecular compound of salicylic acid and phenazone, has been compared 
with its two consituting drugs. Evidence is presented that the drug is split 
into its components already in the gastro-intestinal tract so that phenazone 
and salicylate are separately absorbed. From a pharmacokinetic point of 
view the use of salipyrin is not sensible, neither as a dosage form of 
salicylic acid, nor as a phenazone formulation. 
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SAMENVATTING 
Dit proefschrift is gewijd aan de farmacokinetiek van een aantal anti-
pyretische en antiflogistische analgetica bij de mens. De verschillende ge-
neesmiddelen worden besproken vanuit een fundamenteel farmacokine-
tisch oogpunt, maar de praktische consequenties van de experimentele 
resultaten worden zoveel mogelijk aangegeven. Het geheel is verdeeld in 
3 secties: 
Sectie I (hoofdstukken 1-3) omvat een algemene inleiding en de be-
schrijving van de voornaamste methodieken die bij de onderzoekingen zijn 
gebruikt. 
Hoofdstuk I bestaat uit een kort overzicht van de hypothesen betref-
fende de werking van antipyretische en antiflogistische analgetica. Tevens 
wordt de plaats van farmacokinetische processen in het geheel van de 
werking van geneesmiddelen besproken. Verder wordt het belang van far-
macokinetische gegevens voor optimalisering van de farmacotherapie aan-
geduid, waarbij speciaal aandacht wordt besteed aan de onderzoekingen 
die in het proefschrift worden beschreven. 
In hoofdstuk 2 wordt een overzicht gegeven van de toegepaste methoden 
voor extractie en kwantitatieve analyse van de verschillende geneesmidde-
len in biologische monsters. De meeste stoffen zijn gaschromatografisch 
bepaald, eventueel na derivatiseren. 
Salicylzuur en flufenaminezuur werden fluorometrisch bepaald. Ook de 
mathematische analyse van plasmacurves volgens bepaalde farmacokine-
tische modellen wordt in dit hoofdstuk besproken. In het algemeen is deze 
analyse uitgevoerd via computerfit m.b.v. het niet-lineaire regressie pro-
gramma Farmfit. 
Hoofdstuk 3 geeft enige fysisch-chemische eigenschappen (verdelings-
coëfficiënt en pKa) voor de onderzochte verbindingen. Ook wordt het 
belang van deze parameters voor het farmacokinetisch gedrag bediscus-
sieerd. Met nadruk wordt gewezen op de noodzaak om bij deze overwegin-
gen de invloed van ionisatie en lipofiliteit in samenhang te beschouwen. 
Sectie II (hoofdstukken 4-12) is gewijd aan de processen van absorptie 
en eliminatie van een aantal analgetica, voor zover deze voldoen aan li-
neaire kinetiek. De eliminatiesnelheid van geneesmiddelen uit het lichaam 
wordt hoofdzakelijk bepaald door twee farmacokinetische parameters: de 
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klaring, die een maat is voor de efficiency waarmee lever en nieren (en 
eventueel andere organen) een bepaalde stof uit het lichaam verwijderen, 
en het verdelingsvolume dat bepaalt hoe groot het (schijnbare) volume is 
waaruit de stof geëlimineerd moet worden. De gebruikelijke benadering is 
om alle kinetische processen als eerste orde te beschouwen, zodat de snel-
heid waarmee een geneesmiddel uit een bepaald compartiment verdwijnt 
recht evenredig is met de concentratie in dat compartiment. In dit geval 
kunnen alle snelheidsprocessen eenvoudig beschreven worden met behulp 
van een stelsel van lineaire differentiaalvergelijkingen en spreekt men van 
lineaire farmacokinetiek. Voor de meeste geneesmiddelen blijkt deze be-
nadering in eerste instantie toereikend. 
In hoofdstuk 4 worden de basale begrippen en de algemene mathema-
tische formuleringen van lineaire farmacokinetische modellen in detail uit-
eengezet. Ook wordt aandacht besteed aan de mogelijkheid van cumulatie 
van geneesmiddelen in het lichaam, wanneer deze chronisch toegediend 
worden volgens bepaalde doseringsschema's. De overige hoofdstukken in 
sectie II zijn gewijd aan de specifieke analgetica afzonderlijk. Ibuprofen 
(Brufen®) en alclofenac (Mirvan®) zijn het onderwerp van hoofdstuk 5 en 
hoofdstuk 8 respectievelijk. Deze beide middelen hebben een klein ver-
delingsvolume (<10 1), kleiner nog dan het volume van de extracellulaire 
vloeistof, hetgeen waarschijnlijk veroorzaakt wordt door binding aan 
plasma-eiwitten. Ook de klaringsconstante van deze stoffen is klein 
(30-50 ml/min), maar vanwege het kleine verdelingsvolume is hun half-
waardetijd toch nog vrij kort (1.5-3 uur). Hoewel de totale klaring van 
Ibuprofen en alclofenac ongeveer gelijk is, bestaan er grote verschillen in de 
relatieve bijdragen van renale en metabole klaring. Ibuprofen wordt nauwe-
lijks onveranderd uitgescheiden in de urine, terwijl van alclofenac soms 
hoeveelheden tot 50% van de dosis onveranderd in de urine verschijnen. 
Deze verschillen hangen samen met verschillen in fysisch-chemische eigen-
schappen (wateroplosbaarheid, vetoplosbaarheid, eiwitbinding). De renale 
klaring van alclofenac neemt sterk toe met toenemende urine-produktie, 
maar lijkt overigens te bestaan uit uitsluitend filtratie en passieve terug-
resorptie. Voor Ibuprofen worden naast deze lineaire processen, duidelijke 
aanwijzingen voor een tubulair secretiemechanisme aangetroffen, hoewel 
dit mechanisme slechts een geringe capaciteit heeft en snel verzadigd is. 
Beide geneesmiddelen worden na orale toediening vrij snel geresorbeerd. 
De beide handelsvormen van alclofenac (Mirvan® tabletten en suppo-
sitoria) zijn praktisch equivalent in dit opzicht. Zoals verwacht op grond 
van de farmacokinetische parameters, blijkt noch Ibuprofen, noch alclo-
fenac aanleiding te geven tot cumulatie bij toediening driemaal daags. 
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In hoofdstuk 6 wordt de farmacokinetiek van de afzonderlijke optische 
isomeren van ibuprofen besproken. De resultaten ondersteunen het idee 
dat in het menselijk lichaam inversie van levo- naar dextro-ibuprofen voor-
komt, terwijl de omgekeerde reactie niet of nauwelijks plaatsvindt. 
Hoofdstuk 7 beschrijft een vergelijking van de farmacokinetiek van ibu-
profen en ibufenac. Het verdelingsvolume van ibufenac lijkt wat groter te 
zijn dan dat van ibuprofen. Ibufenac wordt veel langzamer geresorbeerd en 
doorgaans ook minder snel geëlimineerd dan ibuprofen. Er werden aan-
wijzingen gevonden voor een enterohepatische circulatie van ibufenac. 
Het onderwerp van hoofdstuk 9 is het farmacokinetisch gedrag van 
flufenaminezuur (Arlef®) en mefenaminezuur (Ponstan®). Deze beide fena-
maten vertonen tamelijk onregelmatige plasmacurves in de zin dat het 
onmogelijk bleek de curves redelijk te beschrijven volgens normale 
modellen. Relatieve waarden voor de klaringsconstanten werden verkregen 
m.b.v. het oppervlak onder de plasmacurve. De twee fenamaten zijn op-
vallend weinig wateroplosbaar. Vooral voor mefenaminezuur lijkt dit moei-
lijkheden in het resorptieproces te veroorzaken. De resorptie van deze stof 
wordt bevorderd door voedsel. Een emulgerend effect van de geproduceer-
de gal zal hieraan wellicht ten grondslag liggen. 
Hoofdstuk 10 is gewijd aan een aantal fenazon-derivaten. Typisch voor 
het kinetisch gedrag van fenazon en zijn derivaten is de grote inter-
individuele variatie. Zelfs in de homogene groep van jonge vrijwilligers die 
wij bestudeerden bleek een veel grotere farmacokinetische variatie voor 
fenazon-derivaten dan voor de aromatische zuren. Het verdelingsvolume 
van fenazon-derivaten is ongeveer gelijk aan het volume van het totale 
lichaamswater (30-40 1), maar lijkt iets groter te zijn voor meer lipofiele 
derivaten, zoals 4-isopropylfenazon (propyfenazon). Er komen in deze 
serie grote verschillen in klaringsconstante voor: van 30-50 ml/min voor 
fenazon tot 500 ml/min of meer voor 4-isopropylfenazon of 4-amino-
fenazon (4-aminoantipyrine). De renale klaring is meestal verwaarloosbaar 
(0-6% onveranderd uitgescheiden in de urine). 
Invoering van een isopropyl-groep in fenazon leidt tot een veel snellere 
metabole eliminatie (waarschijnlijk via oxidatie van de isopropyl-groep). 
Dit geldt ook voor substitutie van een dimethylamino-groep, waardoor 
4-dimethylammofenazon (amidopyrine, Pyramiden®) ontstaat. Ook hier is 
de grotere klaring het gevolg van metabole instabiliteit van de substituent, 
omdat het metabolisme vooral via N-demethylering plaatsvindt. De eerste 
gedemethyleerde metaboliet, 4-methylaminofenazon, wordt minder snel 
geëlimineerd dan het dimethylderivaat zelf. Het feit dat 4-isopropylamino-
fenazon (Isopyrin®) weer sneller geëlimineerd wordt dan 4-dimethyl-
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aminofenazon wijst erop dat de isopropyl-groep sneller verwijderd kan 
worden dan een methyl-groep. De klaring van 4-ammofenazon is niet-
lineair. Hoewel de niet-lineaire farmaçokinetiek het onderwerp is van 
sectie III, is deze stof vanwege zijn chemische structuur toch in hoofd-
stuk 10 opgenomen. 4-aminofenazon wordt voor een aanzienlijk deel 
(soms tot 40%) geëlimineerd via renale excretie, hetgeen ongebruikelijk is 
voor fenazon-derivaten, en verder via N-acetylering. De bijdrage van de 
renale en metabole processen aan de totale (niet-lineaire) klaring wordt in 
detail besproken. Speciale aandacht wordt besteed aan de mogelijkheid dat 
ook voor deze stof een genetisch bepaald verschil tussen snelle en langzame 
acetyleerders optreedt. 
In hoofdstuk 11 worden in het kort een aantal farmacokinetische ge-
gevens voor fenacetine en paracetamol besproken. In gebruikelijke dosis (< 
500 mg) leidt fenacetine tot nauwelijks meetbare, zeer lage plasmaspiegels. 
Dit verschijnsel wordt niet veroorzaakt door een groot verdelingsvolume, 
maar door een sterk first-pass effect. Paracetamol vertoont dit verschijnsel 
niet. Mede op basis van biofarmaceutische overwegingen lijkt paracetamol 
voor de pijntherapie waardevoller dan fenacetine. 
Sectie III is geheel gewijd aan de theoretische en praktische aspecten van 
de niet-lineaire farmaçokinetiek. Bij de eliminatie van geneesmiddelen zijn 
duidelijk processen betrokken, die in principe verzadigbaar zijn (enzyma-
tische omzetting en tubulaire secretie bijv.). Onder bepaalde omstandig-
heden zullen daardoor afwijkingen van eerste-orde gedrag optreden. 
In hoofdstuk 13 wordt de kinetiek van stoffen, die geheel of gedeeltelijk 
via metabolisme door verzadigbare enzymsystemen (capaciteitsbeperkte 
kinetiek) worden geëlimineerd, geanalyseerd. Er wordt een grafische proce-
dure beschreven om te komen tot een schatting van de elementaire kine-
tische parameters op basis van modellen met geheel of gedeeltelijk capaci-
teitsbeperkte eliminatie. De aldus gevonden waarden worden gebruikt als 
beginschatting voor computerfit, zoals gedemonstreerd aan de hand van 
een aantal voorbeelden (ethanol, salicylzuur, 4-hydroxyboterzuur en 
Phenytoine). Dezelfde methode werd toegepast op 4-aminofenazon 
(hoofdstuk 10). 
In hoofdstuk 13 wordt ook gewezen op de volkomen analogie tussen 
tubulaire secretie en verzadigbaar metabolisme. Verder wordt aangegeven 
dat eiwitbinding een effect heeft op de klaring dat tegengesteld is aan het 
effect van capaciteitsbeperkte kinetiek. 
In hoofdstuk 14 wordt de theorie van twee gelijktijdig voorkomende 
capaciteitsbeperkte wegen behandeld. Er wordt aangetoond dat in veel 
gevallen (zeker ook voor salicylzuur) de analyse volgens hoofdstuk 13 ge-
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oorloofd is, ondanks het feit dat meerdere verzadigbare mechanismen voor 
eliminatie parallel functioneren. Verder wordt besproken dat het in de 
meeste gevallen onmogelijk zal zijn de verschillende mechanismen experi-
menteel te onderscheiden op basis van plasmametingen alleen. 
Hoofdstuk 15 behandelt de gevolgen van capaciteitsbeperkte eliminatie 
voor cumulatie van geneesmiddelen. Het is duidelijk dat deze capaciteitsbe-
perking, die ertoe leidt dat de eliminatie van de stof met toenemende 
concentratie afneemt, een onevenredig sterke verhoging van de plateau-
concentratie met toenemende dosis veroorzaakt. Speciaal voor salicylaten, 
ethanol en Phenytoine is dit verschijnsel van uitermate groot belang. Een-
voudige formules worden gegeven, die het mogelijk maken om gemiddelde 
plateauconcentraties te berekenen, zonder toepassing van numerieke 
methoden. 
Hoofdstuk 16 beschrijft verschillende aspecten van de farmacokinetiek 
en biofarmacie van salicylaten bij de mens. Het profiel van de plasmacurve 
van salicylzuur na enkelvoudige dosering is concentratie-afhankelijk en kan 
beschreven worden m.b.v. de methoden die zijn aangegeven in hoofd-
stuk 13. Het verdelingsvolume is vergelijkbaar met dat van Ibuprofen en 
alclofenac en ook de klaring bij lage doseringen is in dezelfde orde van 
grootte als die van deze geneesmiddelen. Bij hogere doseringen neemt de 
klaring echter af als gevolg van gedeeltelijke verzadiging van de elimineren-
de enzymen. De factoren, die bepalend zijn voor deze verschijnselen, 
worden in detail besproken. Onder bepaalde omstandigheden blijkt ook de 
renale excretie van salicylzuur duidelijk niet-lineair te zijn. Bij lage urine-
pH worden aanwijzingen gevonden voor zowel tubulaire secretie als actieve 
temgresorptie. Een dergelijk complex patroon is in overeenstemming met 
het paradox effect van salicylzuur op de uraat-excretie. De excretie van 
onveranderd salicylzuur neemt sterk toe met toenemende urine-pH (ver-
mindering van de passieve terugresorptie) zodat bij hoge pH de actieve 
processen overschaduwd worden door de passieve, lineaire processen. Wan-
neer door toediening van natriumbicarbonaat of ammoniumchloride de uri-
ne resp. basisch of zuur gemaakt wordt, blijkt het verschil tussen beide be-
handelingen vooral te bestaan uit een verandering van de hoeveelheid onver-
anderd uitgescheiden salicylzuur en daardoor een verandering in de invloed 
in capaciteitsbeperkt metabolisme. Ook farmacokinetische interacties met 
enige stoffen waarvan verwacht kan worden dat ze de salicylaat-klaring 
zouden beïnvloeden wordt besproken. Benzoezuur lijkt het metabolisme 
van salicylzuur zowel competitief als non-competitiefte remmen. Probene-
cid beïnvloedt de renale excretie én het metabolisme van salicylzuur 
negatief. D-glucuronolactone heeft geen duidelijke invloed, maar neigt tot 
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remming van de eliminatie, terwijl het tegenovergestelde verwacht werd. 
Bij chronische medicatie blijkt een verdubbeling van de dosis van 1.5 tot 
3.0 g per dag te leiden tot een 4- à S-voudige toename van de gemiddelde 
plateauconcentratie, hetgeen in overeenstemming is met de beschouwing in 
hoofdstuk 15. Ook worden een aantal biofarmaceutische aspecten be-
schreven. Bij chronische medicatie met gelijke doseringen blijkt Enterosa-
licyl® (enteric coated natriumsalicylaat) aanzienlijk hogere plateauspiegels 
te geven dan een oplossing van natriumsalicylaat. Het verschil is hoogst 
waarschijnlijk gelegen in de aanwezigheid van natriumbicarbonaat in de 
drank. 
Na enkelvoudige dosering is de resorptie van salicylzuur uit de oplossing 
veel sneller dan uit Enterosalicyl® tabletten. In acute situaties zijn ook 
twee acetylsalicylzuur-preparaten vergeleken: Ascal®, het wateroplosbare 
calciumacetylsalicylaat en Rhonal®, gecoate microkristallen. Het water-
oplosbare Ascal® wordt sneller geresorbeerd en in het algemeen wordt 
gesteld dat alleen wateroplosbare acetylsalicylzuur-preparaten de mogelijk-
heid bieden gebruik te maken van de specifieke analgetische activiteit in 
vergelijking met salicylzuur. Tenslotte worden een aantal experimenten 
beschreven ter vergelijking van salipyrine, een moleculaire verbinding van 
salicylzuur en fenazon, met natriumsalicylaat en fenazon afzonderlijk in 
oplossing. Vanuit een farmacokinetisch oogpunt is salipyrine geen opti-
male doseringsvorm, noch van salicylzuur, noch van fenazon. 
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STELLINGEN 
I 
Op theoretische zowel als praktische gronden veidient de klatingsfunktie de 
voorkeur boven de in de literatuur vrijwel uitsluitend gebruikte snelheids-
constante als de basale parameter voor de eliminatie van farmaca. 
II 
Hoewel de auteurs zelf de mogelijkheid van "dose-dependent kinetics" aandui-
den, gaan de berekeningen van Lund et al. betreffende de biologische beschik-
baarheid en de te verwachten plateauspiegels van fenytoïne geheel voorbij aan 
de implicaties van een dergelijk fenomeen en is hun analyse op beide gebieden 
volstrekt onjuist. 
Lund, L. et al., Europ. J. Ctin. Pharmacol. 7., 81 (1974). 
ΠΙ 
Bepaling van het totale lichaamswater volgens de methode van Huckabee kan 
gemakkelijk tot verkeerde uitkomsten leiden. 
Huckabee, W.E., J. Appi. Physiol. 9., 157 (1956). 
IV 
De verklaring van Botha voor de verlaagde salicylaatspiegels bij gelijktijdig ge­
bruik van acetosal en antacida, nl. verminderde absorptie van acetosa!, is erg 
onwaarschijnlijk. 
Botha, D., Pahlavi Med. J. 5., 29 (1974). 
V 
Hoewel capillaire kolommen in de gaschromatograiïe een waardevolle uitbrei-
ding geven van de mogelijkheden voor kwalitatieve analyse van biologische 
monsters, lijkt hun waarde voor kwantitatieve farmacokinetische studies voor-
alsnog beperkt. 
VI 
De wijze waarop Costali en Naylor de door apomorphine veroorzaakte stereo-
typie kwantificeren, zal onveranderlijk een dosisafhankelijkheid van deze ste-
reotypie laten zien. De curves die zij verkrijgen door de intensiteit van de ste-
reotypie uit te zetten tegen de logarithme van de dosis mogen echter volstrekt 
niet beschouwd worden als dosis-werkingscurves zoals die in de moleculaire 
farmacologie bekend zijn. 
Costali, В. en R.J. Naylor, Europ. J. Pharmacol. 24., 8 (1973). 
VII 
De opmerkingen van Wagner over een artikel van Van Ginneken et al. kunnen 
slechts verklaard wolden door aan te nemen dat hij het betreffende artikel niet 
helemaal gelezen of helemaal niet begrepen heeft. 
Wagner, I.G.,J. Pharmacokin. Biopharm. 3., 457 (1975). 
Van Ginneken, C.A.M, et al.,/. Pharmacokin. Biopharm. 2., 395 (1974). 
VIII 
Duur en intensiteit van verslaving aan narcotische analgetica zijn mede afhan­
kelijk van farmacokinetische factoren. 
IX 
Nu naast de propyl- en methylhomologen van de natuurlijke cannabinoiden in 
cannabis onverwacht ook butylhomologen zijn aangetroffen moet men ver­
wachten dat nog verschillende andere homologe reeksen zullen worden gevon­
den. 
Harvey, D.1.,J. Pharm. Pharmacol. 28., 280 (1976). 
Χ 
Wie in zijn omgeving amateur-tuiniers gebruik ziet maken van herbiciden, kan 
met vreugde constateren dat het spreekwoord: "Onkruid vergaat niet", zowel 
letterlijk als figuurlijk, een kern van waarheid bevat. 
XI 
De hausse in nostalgische kinderboeken valt moeilijk te rijmen met de huidi­
ge emancipatiebeweging. 
C.A.M. VAN GINNEKEN NIJMEGEN, 8 SEPTEMBER 1976 
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